<?xml version="1.0" encoding="utf-8"?>


<DOCUMENT xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dart3.xsd">

<DOCUMENT-HEADER AEXT-CLASS="Y">
<DOCUMENT-NAME ACODE="11011">사업보고서</DOCUMENT-NAME>
<FORMULA-VERSION ADATE="20210122">4.2</FORMULA-VERSION>
<COMPANY-NAME AREGCIK="00842619">(주)레고켐 바이오사이언스</COMPANY-NAME>

<SUMMARY>
<EXTRACTION ACODE="LINK_FLAG" AFEATURE="BOTH">N</EXTRACTION>
<EXTRACTION ACODE="FIN_TYPE" AFEATURE="BOTH">A</EXTRACTION>
<EXTRACTION ACODE="CRP_RGS_NO_TEMP" AFEATURE="BOTH">160111-0206866</EXTRACTION>
</SUMMARY>
</DOCUMENT-HEADER>

<BODY>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆ 정정문서 작성시 『정오표』 삽입</COMMENT>
<LIBRARYLIST>정정신고(보고)-대표이사등의확인.LCommon</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="LCommon">정정신고(보고)-대표이사등의확인</FILENAME>

<CORRECTION>
<TITLE ATOC="Y" AASSOCNOTE="CORRECTION">정 정 신 고 (보고)</TITLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="600" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="600" HEIGHT="30">2021년 05월 31일</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P></P>
<P USERMARK="F-14">1. 정정대상 공시서류 : 사업보고서</P>
<P></P>
<P USERMARK="F-14">2. 정정대상 공시서류의 최초제출일 : 2021.03.23</P>
<P></P>
<P USERMARK="F-14">3. 정정사항</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="794" BORDER="1">

<COLGROUP>
<COL WIDTH="316"></COL>
<COL WIDTH="314"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="64"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="325" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">항  목</TH>
<TH ALIGN="CENTER" WIDTH="323" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">정정사유 </TH>
<TH ALIGN="CENTER" WIDTH="73" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">정 정 전</TH>
<TH ALIGN="CENTER" WIDTH="73" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">정 정 후</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" HEIGHT="30" VALIGN="MIDDLE">6.배당에 관한 사항 등</TD>
<TD WIDTH="323" HEIGHT="30" VALIGN="MIDDLE">과거 배당 이력 추가</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" HEIGHT="30" VALIGN="MIDDLE">XI. 그 밖에 투자자 보호를 위하여 필요한 사항</TD>
<TD WIDTH="323" HEIGHT="30" VALIGN="MIDDLE">특례상장기업 관리종목 지정유예 현황 추가</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" HEIGHT="30" VALIGN="MIDDLE">XI. 그 밖에 투자자 보호를 위하여 필요한 사항</TD>
<TD WIDTH="323" HEIGHT="30" VALIGN="MIDDLE">직접금융자금 중 미사용자금의 운용내역 추가</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" HEIGHT="30" VALIGN="MIDDLE">II. 사업의 내용</TD>
<TD WIDTH="323" HEIGHT="30" VALIGN="MIDDLE">연구개발활동 모범사례 반영</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주4)</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" HEIGHT="30" VALIGN="MIDDLE">IX. 계열회사 등에 관한 사항</TD>
<TD WIDTH="323" HEIGHT="30" VALIGN="MIDDLE">투자기업 상장/비상장 여부 추가</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주5)</TD>
<TD WIDTH="73" HEIGHT="30" VALIGN="MIDDLE">주5)</TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;
<SPAN USERMARK=" B">주1) 기재추가&cr;</SPAN>과거 배당 이력
</P>

<TABLE WIDTH="600" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="300" VALIGN="MIDDLE" HEIGHT="30"></TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 회, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="599" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="140"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">연속 배당횟수</TD>
<TD COLSPAN="2" WIDTH="299" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">평균 배당수익률</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">분기(중간)배당</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">결산배당</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최근 3년간</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">최근 5년간</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>

<P>해당사항 없습니다.&cr;&cr;
<SPAN USERMARK=" B">주2) 기재추가</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="711" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="405"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="79" HEIGHT="30">(기준일 : </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="151" HEIGHT="30">2020년 12월 31일</TD>
<TD VALIGN="MIDDLE" WIDTH="67" HEIGHT="30">)</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="414" HEIGHT="30">(단위 : 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="711" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="86"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="163" HEIGHT="83" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">관리종목 지정요건</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="347" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="3">요건별 회사 현황</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="106" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="2">관리종목&cr;지정유예 여부</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="95" HEIGHT="83" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">항목별&cr;지정유예 &cr;종료시점</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">항목</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="99" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사업연도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">해당</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="55" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">미해당</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="53" VALIGN="MIDDLE">최근 사업연도말&cr;매출액 30억미만</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="53" VALIGN="MIDDLE">최근 사업연도말 매출액(별도)</TD>
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="53" VALIGN="MIDDLE">2020</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="53" VALIGN="MIDDLE">49,393,701,591</TD>
<TD ALIGN="CENTER" WIDTH="51" HEIGHT="53" VALIGN="MIDDLE">-</TD>
<TD ALIGN="CENTER" WIDTH="55" HEIGHT="53" VALIGN="MIDDLE">O</TD>
<TD ALIGN="CENTER" WIDTH="95" HEIGHT="53" VALIGN="MIDDLE">2015년 12월 31일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="120" VALIGN="MIDDLE" ROWSPAN="4">최근 4사업연도 연속 영업손실 발생</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="120" VALIGN="MIDDLE" ROWSPAN="4">최근 4사업연도 &cr;각 영업손익&cr;(별도)</TD>
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="30" VALIGN="MIDDLE">2020</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="30" VALIGN="MIDDLE">-29,761,761,146</TD>
<TD ALIGN="CENTER" WIDTH="51" HEIGHT="120" VALIGN="MIDDLE" ROWSPAN="4">-</TD>
<TD ALIGN="CENTER" WIDTH="55" HEIGHT="120" VALIGN="MIDDLE" ROWSPAN="4">O</TD>
<TD ALIGN="CENTER" WIDTH="95" HEIGHT="120" VALIGN="MIDDLE" ROWSPAN="4">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="30" VALIGN="MIDDLE">2019</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="30" VALIGN="MIDDLE">8,416,841,998</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="30" VALIGN="MIDDLE">2018</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="30" VALIGN="MIDDLE">-15,977,963,887</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="30" VALIGN="MIDDLE">2017</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="30" VALIGN="MIDDLE">-8,099,205,818</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="168" VALIGN="MIDDLE" ROWSPAN="3">자기자본 50%이상(10억원 이상에 한함)의 법인세차감전계속사업손실이 최근 3년간 2회 이상 및 최근 사업연도 법인세차감전계속사업손실 발생</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="168" VALIGN="MIDDLE" ROWSPAN="3">최근&cr;3사업연도&cr;각 법인세차감전&cr; 계속사업손익&cr;(연결)</TD>
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="45" VALIGN="MIDDLE">2020</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="45" VALIGN="MIDDLE">-8,826,761,782</TD>
<TD ALIGN="CENTER" WIDTH="51" HEIGHT="168" VALIGN="MIDDLE" ROWSPAN="3">-</TD>
<TD ALIGN="CENTER" WIDTH="55" HEIGHT="168" VALIGN="MIDDLE" ROWSPAN="3">O</TD>
<TD ALIGN="CENTER" WIDTH="95" HEIGHT="168" VALIGN="MIDDLE" ROWSPAN="3">2015년 12월 31일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="56" VALIGN="MIDDLE">2019</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="56" VALIGN="MIDDLE">13,101,518,704</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="99" HEIGHT="67" VALIGN="MIDDLE">2018</TD>
<TD ALIGN="RIGHT" WIDTH="123" HEIGHT="67" VALIGN="MIDDLE">-26,426,772,928</TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;
<SPAN USERMARK=" B">주3)기재추가&cr;</SPAN>마. 미사용자금의 운용내역
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="598" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="231"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30">(기준일 : </TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30">2020년 12월 31일</TD>
<TD VALIGN="BOTTOM" WIDTH="126" HEIGHT="30">)</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="240" HEIGHT="30">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="110"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">종류</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금융상품명</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">운용금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약기간</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">실투자기간</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="120" HEIGHT="30" VALIGN="MIDDLE">예ㆍ적금</TD>
<TD ALIGN="CENTER" WIDTH="120" HEIGHT="30" VALIGN="MIDDLE">보통예금</TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30" VALIGN="MIDDLE">977,606</TD>
<TD ALIGN="CENTER" WIDTH="120" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD ALIGN="CENTER" WIDTH="119" HEIGHT="30" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="240" HEIGHT="30" VALIGN="MIDDLE" COLSPAN="2">계</TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30" VALIGN="MIDDLE">977,606</TD>
<TD ALIGN="CENTER" WIDTH="239" HEIGHT="30" VALIGN="MIDDLE" COLSPAN="2">-</TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;
<SPAN USERMARK=" B">주4)&cr;<정정전>&cr;</SPAN>
<SPAN USERMARK=" B">9. 경영상의 주요계약</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN>① 신약연구개발</SPAN>
<SPAN></SPAN>
</P>
<P>당사가 체결한 주요 유효 계약내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1054">

<COLGROUP>
<COL WIDTH="115"></COL>
<COL WIDTH="130"></COL>
<COL WIDTH="187"></COL>
<COL WIDTH="362"></COL>
<COL WIDTH="215"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="124" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 과제명</TH>
<TH USERMARK="F-BT" WIDTH="139" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사업화 모델</TH>
<TH USERMARK="F-BT" WIDTH="196" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">업체/단계/시점</TH>
<TH USERMARK="F-BT" WIDTH="371" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약 개요</TH>
<TH USERMARK="F-BT" WIDTH="224" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="124" HEIGHT="631" ROWSPAN="8" ALIGN="CENTER" VALIGN="MIDDLE">
<P USERMARK="F-BT">차세대</P>
<P USERMARK="F-BT">ADC 원천기술</P>
</TD>

<TD WIDTH="139" HEIGHT="631" ROWSPAN="8" ALIGN="CENTER" VALIGN="MIDDLE">
<P USERMARK="F-BT"> 기술이전 및 기술이전 전제 물질평가</P>
</TD>

<TD USERMARK="F-BT" WIDTH="196" HEIGHT="76" VALIGN="MIDDLE">
<SPAN>□</SPAN>
<SPAN>Fosun Pharma</SPAN>
<SPAN>(중국)&cr;</SPAN>
<SPAN>□허셉틴-ADC 후보물질&cr;□2015년 8월</SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">□총규모: 약209억&cr;□중국시장 대상 기술이전 </TD>

<TD USERMARK="F-BT" WIDTH="224" HEIGHT="76" VALIGN="MIDDLE">
<SPAN>□ 임상 1상 진행 중&cr;□ 중국 임상 진행 따른 마일&cr;    스톤 수익 발생 예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□Millenium Pharma(Takeda)&cr;□비공개 타겟&cr;□2019년 3월</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□총규모: </SPAN>
<SPAN>$404mn (Upfront+Milestone) + 로열티   &cr;□레고켐바이오 기술 활용 ADC 면역항암제&cr;   후보물질 발굴 중</SPAN>
</TD>
<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□ 후보물질 발굴 중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="196" HEIGHT="99" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□Iksuda (유럽)&cr;□비공개 타겟&cr;□</SPAN>
<SPAN>2020년 4월</SPAN>
</TD>

<TD WIDTH="371" HEIGHT="99" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$407mn (Upfront+Milestone) + 로열티&cr;  + Revenue sharing(제3자 기술이전시)   &cr;□레고켐바이오 기술 활용 ADC 치료제&cr;   후보물질 발굴예정</SPAN>
</TD>

<TD WIDTH="224" HEIGHT="99" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□ 후보물질 발굴예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□Iksuda (유럽)&cr;</SPAN>
<SPAN>□</SPAN>
<SPAN>CD19-ADC 후</SPAN>
<SPAN>보물질&cr;□</SPAN>
<SPAN>2020년 5월</SPAN>
</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$227mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시)  </SPAN>
<SPAN USERMARK="F-BT">  &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□ 임상 1상 진행예정&cr;□ NovImmune과 공동연구를 &cr;   통해 확보한 후보물질임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□CStone (중국)&cr;</SPAN>
<SPAN>□</SPAN>
<SPAN>ROR1-ADC 후</SPAN>
<SPAN>보물질&cr;□</SPAN>
<SPAN>2020년 10월</SPAN>
</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$363.5mn (Upfront+Milestone) + 로열티&cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시) </SPAN>
<SPAN USERMARK="F-BT"> &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□ 임상 1상 진행예정&cr;□ ABL Bio와 공동연구를 통해&cr;    확보한 후보물질임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□Pyxis (미국)&cr;</SPAN>
<SPAN>□</SPAN>
<SPAN>DLK1-ADC 후</SPAN>
<SPAN>보물질&cr;□</SPAN>
<SPAN>2020년 12월</SPAN>
</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$294mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Option(지분/Revenue Sharing) </SPAN>
<SPAN USERMARK="F-BT">&cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□ 임상 1상 진행예정&cr;□ </SPAN>
<SPAN>와이바이오로직스</SPAN>
<SPAN>와 공동연구를 통해 확보한 후보물질임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□비공개(미국)&cr;□비공개 타겟&cr;□2019년 1분기</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: 미공개 (물질평가 </SPAN>
<SPAN USERMARK="F-BT">계약</SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴 중</SPAN>
</TD>
<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□비공개(일본)&cr;□비공개 타겟&cr;□2020년 4분기</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">□총규모: 미공개 (리서치 라이선스 계약</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴 중</SPAN>
</TD>
<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="124" HEIGHT="122" ALIGN="CENTER" VALIGN="MIDDLE">ATX 저해제</TD>

<TD WIDTH="139" HEIGHT="122" ALIGN="CENTER" VALIGN="MIDDLE">
<P USERMARK="F-BT">기술이전 /&cr;Profit Sharing</P>
</TD>
<TD USERMARK="F-BT" WIDTH="196" HEIGHT="122" VALIGN="MIDDLE">□브릿지바이오&cr;□후보물질&cr;□2017년 5월</TD>

<TD WIDTH="371" HEIGHT="122" VALIGN="MIDDLE">
<P USERMARK="F-BT">□ 후보물질 확정 후 브릿지 바이오 주도 개발 진행&cr;□사업화 모델 : 단계별 마일스톤 + Profit Sharing</P>
<P USERMARK="F-BT">  - Profit Sharing: 제 3자 기술이전 시 개발 단계별&cr;    양사간 기여율에 따른 이익 배분&cr;  - 마일스톤: 300억 (선급금 30억 포함)</P>
</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="122" VALIGN="MIDDLE">□ 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="124" HEIGHT="99" ALIGN="CENTER" VALIGN="MIDDLE">옥사졸리디논계 &cr;항생제</TD>

<TD WIDTH="139" HEIGHT="99" ALIGN="CENTER" VALIGN="MIDDLE">
<P USERMARK="F-BT"> 기술이전</P>
<P USERMARK="F-BT">(시장분할)</P>
</TD>
<TD USERMARK="F-BT" WIDTH="196" HEIGHT="99" VALIGN="MIDDLE">□Haihe Bio(구 RMX Bio)&cr;□임상1상 완료 후&cr;□2016년 12월</TD>

<TD WIDTH="371" HEIGHT="99" VALIGN="MIDDLE">
<P USERMARK="F-BT">□중국 : 약 240억 (Upfront+Milestone) + 로열티&cr;□글로벌 : 임상 2상 데이터 확보 후 기술이전 추진</P>
</TD>

<TD USERMARK="F-BT" WIDTH="224" HEIGHT="99" VALIGN="MIDDLE">
<SPAN>□ 임상 2상 진행 중&cr;</SPAN>
<SPAN>□ FDA 희귀의약품 지정&cr;□ FDA QIDP 승인&cr;</SPAN>
<SPAN>□ FDA Fast Track 지</SPAN>
<SPAN>정</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="124" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE">
<P USERMARK="F-BT">항응혈제 </P>
<P USERMARK="F-BT">(FXa 저해제 )</P>
</TD>
<TD WIDTH="139" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT"> 기술이전 /&cr;  Profit Sharing</TD>
<TD WIDTH="196" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">□ 녹십자&cr;□후보물질&cr;□2009년 6월</TD>

<TD WIDTH="371" HEIGHT="76" VALIGN="MIDDLE">

<P USERMARK="F-BT">
<SPAN>□ </SPAN>
<SPAN>중국시장 : 2018년2월 중국제약사 Lee's Pharma에&cr;   기술이전 ->녹십자와 Profit Sharing  중&cr;</SPAN>
<SPAN>□북미, 유럽 ,일본 등 : sub-L/O시 Profit Sharing </SPAN>
</P>
</TD>

<TD WIDTH="224" HEIGHT="76" VALIGN="MIDDLE" USERMARK="F-BT">
<SPAN>□ 임상 1상 완료(미국)&cr;</SPAN>
<SPAN>□ 임상 1상 진행예정(중국)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN>가. 라이센스 아웃(License-out) 계약&cr;                                           </SPAN>
<SPAN USERMARK=" B"><라이센스 아웃 계약 총괄표>&cr;</SPAN>
<SPAN>                                                                                               </SPAN>
<SPAN USERMARK="F-11">    (단위: 백만원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="1096" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="89"></COL>
<COL WIDTH="233"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="126"></COL>
<COL WIDTH="157"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="196"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">품목</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">계약상대방</TD>
<TD WIDTH="76" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">대상지역</TD>
<TD WIDTH="135" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">계약체결일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">계약종료일</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">총 계약금액</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK=" BC0XD7D7D7">
<SPAN USERMARK="F-BT">수취금액</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7" VALIGN="MIDDLE" ALIGN="CENTER">진행단계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB02-0133</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">녹십자/Lee's Pharm</TD>
<TD WIDTH="76" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">전세계</TD>
<TD WIDTH="135" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">2009년 6월 4일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT">특허만료일</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">비공개 </TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">중국 임상 1상 IND 승인완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB01-0371</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Haihe Biopharma</TD>
<TD WIDTH="76" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">중국</TD>
<TD WIDTH="135" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">2016년 12월 12일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT">상업화 기간 동안 계속</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">24,000</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">중국 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">
<SPAN>LCB14</SPAN>
</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Fosun Pharma</TD>
<TD WIDTH="76" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">중국</TD>
<TD WIDTH="135" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">2015년 8월 17일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT">특허만료일</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">20,842</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">임상 1상 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB17-0877</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">브릿지바이오</TD>
<TD WIDTH="76" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">전세계</TD>
<TD WIDTH="135" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="CENTER">2017년 5월 31일</TD>

<TD WIDTH="166" HEIGHT="30">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">30,000</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">미국 임상 2상 준비중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" HEIGHT="30">
<SPAN USERMARK="F-BT">LCB69</SPAN>
</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Millenium Pharmaceuticals(Takeda)</TD>
<TD WIDTH="76" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">전세계</TD>
<TD WIDTH="135" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">2019년 3월 21일</TD>

<TD WIDTH="166" HEIGHT="30">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="96" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">454,823</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">후보물질 발굴예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="98" HEIGHT="30">
<SPAN USERMARK="F-BT">LCB91</SPAN>
</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Iksuda Therapeutics</TD>
<TD WIDTH="76" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">전세계</TD>
<TD WIDTH="135" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">2020년 4월 14일</TD>

<TD WIDTH="166" HEIGHT="30">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="96" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">496,316</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">후보물질 발굴예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB73</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Iksuda Therapeutics</TD>
<TD WIDTH="76" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">전세계</TD>
<TD WIDTH="135" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">2020년 5월 14일</TD>

<TD WIDTH="166" HEIGHT="30">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="96" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">278,370</TD>

<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">
<SPAN USERMARK="F-BT">비공개</SPAN>
</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">임상 1상 진행예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB71</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">CStone Pharmaceuticals</TD>
<TD WIDTH="76" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">전세계</TD>
<TD WIDTH="135" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">2020년 10월 29일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT">특허 만료일</TD>
<TD WIDTH="96" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">409,883</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">비공개</TD>

<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" HEIGHT="30" USERMARK="F-BT">LCB67</TD>
<TD WIDTH="242" HEIGHT="30" USERMARK="F-BT">Pyxis Oncology</TD>
<TD WIDTH="76" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">전세계</TD>
<TD WIDTH="135" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT">2020년 12월 02일</TD>
<TD WIDTH="166" HEIGHT="30" USERMARK="F-BT">특허 만료일</TD>
<TD WIDTH="96" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">325,487</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK="F-BT">비공개</TD>

<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="5" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="717" HEIGHT="30" USERMARK="F-BT">합계</TD>
<TD WIDTH="96" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">비공개</TD>
<TD WIDTH="78" HEIGHT="30" USERMARK="F-BT" VALIGN="MIDDLE" ALIGN="RIGHT">비공개</TD>
<TD WIDTH="205" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>※ 외화 금액은 체결시점 공시를 통해 안내한 원화금액으로 입력하였습니다.&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">[계약 1]</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="676" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">①계약 상대방</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">녹십자</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">②계약 내용</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">③대상 지역</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">④총 계약금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑤수취 금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑥계약 조건</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="53" USERMARK="F-BT">⑦회계처리 방법</TD>
<TD WIDTH="543" HEIGHT="53" USERMARK="F-BT">계약금 및 중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑧대상 기술</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑨개발 진행경과</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">미국 임상 1상 완료 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑩기타 사항</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 2]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">푸싱제약 (Shanghai Fosun Pharmaceutical Development Co., Ltd.)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">항HER2 항체-약물 복합체 (anti-HER2 ADC)&cr;중국 시장만을(중국, 대만, 홍콩, 마카오 포함) 대상으로 전용실시권 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국(Greater China)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">20,842,050,000원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">계약금 및 중도금(임상시험 및 신약허가 단계별 마일스톤) 10,750천불, 매출 금액별 달성시 받게 되는 sales 마일스톤 7,000천불 등 포함 총 계약규모는 17,750천불, 그리고 별도의 로열티를 수령함.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="99">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="99">
<SPAN USERMARK=" 0X000000">계약금(비공개)은 반환의무 및 추가적인 조건은 없으며, 중도금 수령전까지 &cr;기간인식함.&cr;</SPAN>
<SPAN USERMARK=" 0X000000">중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항HER2 항체-약물 복합체 (anti-HER2 ADC)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 3]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Haihe Biopharma (구 RMX Biopharma)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">LCB01-0371 옥사계 항생제 기술이전&cr;LCB01-0371은 MRSA, VRE 등의 그람양성균 슈퍼박테리아 및 다제내성 결핵 치료제로서 약물 장기복용에 따른 부작용을 최소화 할 수 있는 새로운 슈퍼항생제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">약 240억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="122">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="122">- 계약금 : 6억원(50만불) - 계약 체결 후 30일이내 &cr;- 단계별 마일스톤 : 234억(2,000만불) &cr;  ☞ 각 단계별 임상 개발 및 상업화, 목표 판매수량 달성등에 성공할 경우 받게 되는 조건부 마일스톤임. &cr;- 로열티는  별도임. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">계약금은 반환의무 및 조건이 없고 관련하여 수행할 의무가 완료되는 시점에 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB01-0371 옥사계 항생제 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN USERMARK=" B">[계약 4]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오(300억원)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="191">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="191"> - 기술이전료와 Profit Sharing을 포함하는 계약 &cr;(1) 총계약금액: 300억원 &cr;   - 선급금: 20억원 &cr;   - 단계별 마일스톤: 280억원 &cr;     ☞ 각 단계별 임상 개발 진행과정에 받게 되는 조건부 마일스톤임. &cr;(2) Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">미국 임상 2상 준비중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 5]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>Millenium Pharmaceuticals(Takeda)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,548억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="145">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="145"> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 선급금 및 단기마일스톤: 8,162,050,000원 &cr;   - 마일스톤 : 446,661,150,000원 &cr;  - 총 계약금액 : 454,823,200,000원 &cr;  3) 경상기술료 (Royalty) : 별도 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB69</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">[계약 6]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,963억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="168">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="168"> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 총 계약금액(선급금 및 단기마일스톤): 496,315,575,000원 &cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) 
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB91</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 7]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항CD19 항체-약물 복합체 (anti-CD19 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">2,784억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214"> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 6,131,500,000원&cr;   - 마일스톤 :  272,238,600,000원&cr;     => 총 계약금액 : 278,370,100,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) 
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB73</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">임상 1상 진행예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 8]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">CStone Pharmaceuticals</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항ROR1 항체-약물 복합체 (anti-ROR1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,099억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214"> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 11,276,000,000원&cr;   - 마일스톤 :  398,606,600,000원&cr;     => 총 계약금액 : 409,882,600,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) 
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB71</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 9]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Pyxis Oncology</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항DLK1 항체-약물 복합체 (anti-DLK1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">3,255억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="260">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="260"> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 10,517,450,000원&cr;      1차 : 553,550,000원&cr;      2차 : 9,963,900,000원(2021년  4월 30일 이내)&cr;   - 마일스톤 :  314,969,950,000원&cr;     => 총 계약금액 : 325,487,400,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) Option 포함
<SPAN>&cr;   - 선급금, 단계별 마일스톤과 별도로 옵션행사시 Pyxis사의 지분 및 제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분받을 수 있는 권리확보</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB67</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>의약사업부문이 체결한 주요 판권 관련 계약은 아래와 같습니다.</SPAN>
<SPAN USERMARK=" I"></SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1031">

<COLGROUP>
<COL WIDTH="179"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="133"></COL>
<COL WIDTH="348"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약품목</TH>
<TH USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약상대방</TH>
<TH USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약체결일 </TH>
<TH USERMARK="F-BT" WIDTH="357" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약 내용</TH>
<TH USERMARK="F-BT" WIDTH="215" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">나누리병원 외</TD>
<TD USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2015.10.01 </TD>
<TD USERMARK="F-BT" WIDTH="357" HEIGHT="30" VALIGN="MIDDLE">치료재료, 의료소모품  계약</TD>
<TD USERMARK="F-BT" WIDTH="215" HEIGHT="30" VALIGN="MIDDLE"> 5개 병원</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
<SPAN USERMARK=" 0XFF0000 B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">10. </SPAN>
<SPAN USERMARK=" B">연구개발 관련사항</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>
<P USERMARK=" B">가. 연구개발 조직도&cr;</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="242" ALIGN="CENTER" HSPACE="0">201231 조직도.jpg</IMG>
<IMG-CAPTION ATOC="N">201231 조직도</IMG-CAPTION>
</IMAGE>

<P>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN></SPAN>
<SPAN>당사의 창업멤버인 대표이사를 포함한 경영진은 국내에서 세계적 신약개발을 주도해온 LG생</SPAN>
<SPAN>명과학 등에서 팀장급으로 오랜 경험을 가진 핵심요원들입니다.  창업 이후 국내외 </SPAN>
<SPAN>연구인력을 지속적으로 채용하였습니</SPAN>
<SPAN>다</SPAN>
<SPAN>.</SPAN>
<SPAN> </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>2</SPAN>
<SPAN>020년</SPAN>
<SPAN> 12월 </SPAN>
<SPAN>전체 인원 103명 중, 경영관리, 사업전략 11</SPAN>
<SPAN>명 </SPAN>
<SPAN>및 의약사업부문</SPAN>
<SPAN> 4명을</SPAN>
<SPAN> 제외한</SPAN>
<SPAN> </SPAN>
<SPAN>88명의</SPAN>
<SPAN> 연구진을 </SPAN>
<SPAN>확보하고 있습니다. 전공별로는 </SPAN>
<SPAN>유기합성 전공자가 37명, Biology/약학 전공자 46명, 기</SPAN>
<SPAN>타 5명으로 구성되어 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="752" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="31"></COL>
<COL WIDTH="44"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="308"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">구분</TD>
<TD WIDTH="53" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">성명</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">직급</TD>
<TD WIDTH="118" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">담당업무</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">최종학위</TD>
<TD WIDTH="317" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요 학력 및 경력</TD>
<TD WIDTH="92" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요연구실적</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">1</TD>
<TD WIDTH="53" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">김용주</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">대표이사</TD>
<TD WIDTH="118" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구개발총괄</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">박사</TD>
<TD WIDTH="317" HEIGHT="102" USERMARK="F-8" VALIGN="MIDDLE">한국과학원 유기화학 박사(1983)&cr;LG화학 기술연구원 연구위원(1983-1997)&cr;LG화학 기술연구원 연구소장/LG BMI 법인장(1997-2000)&cr;LG생명과학기술연구원 신약연구소장/연구위원(2000-2006)&cr;현, (주)레고켐바이오 대표이사/CEO</TD>
<TD WIDTH="92" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">2</TD>
<TD WIDTH="53" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">이창선</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">신약연구소장</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="140" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Yale 유기화학 박사(2001)&cr;LG생명과학(1991-1996)&cr;Oregon State Univ. Postdoc/Staff Scientist(2001-2003)&cr;PTC Therapeutics 연구위원(2006-2016)&cr;RaND Biosciences Inc.CTO(2016-2017)&cr;한독 상무(2018)&cr;현, (주)레고켐바이오 신약연구소장</TD>
<TD WIDTH="92" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">3</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">조영락</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">개발본부장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">연세대학교 화학 박사(1999)&cr;The Salk Institute(1999-2000)&cr;The Scripps Research Institute(2000-2001)&cr;LG생명과학 차장(2001-2006)&cr;현, (주)레고켐바이오 개발본부장</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">4</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">안세창</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">연구위원</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">공정센터장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Minnesota 화학과 박사(1991)&cr;Harvard Univ. Post-doc(1991-1993)&cr;LG생명과학(1993-2015)&cr;LG화학(2015-2016)&cr;현, (주)레고켐바이오 연구위원</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">5</TD>
<TD WIDTH="53" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">송호영</TD>
<TD WIDTH="66" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구위원</TD>
<TD WIDTH="118" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">합성센터장</TD>

<TD WIDTH="66" HEIGHT="83" USERMARK=" 0X0000FF" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN USERMARK="F-10 0X000000">박사</SPAN>
</TD>

<TD WIDTH="317" HEIGHT="83" USERMARK="F-8 0X0000FF" VALIGN="MIDDLE">
<SPAN USERMARK=" 0X000000">서울대학교 화학과 박사(2002)&cr;LG생명과학 Post-doc(2002)&cr;LG생명과학(2003-2006)&cr;</SPAN>
<SPAN USERMARK=" 0X000000">현, (주)레고켐바이오 연구위원</SPAN>
</TD>
<TD WIDTH="92" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주5)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-10">주1) 당 연구인력(김용주 대표이사)의 주요 연구실적은 다음과 같습니다.&cr;     - 세</SPAN>
<SPAN USERMARK="F-10">파계 항생제 국내 최초 신약 기술이전(Glaxo)&cr;     - "FACTIVE" 미국 FDA 최초 승인&cr;     - 동탑산업 훈장(대통령상) 수상&cr;     - LG그룹 연구개발상 대상 수장(세파계 항생제)&cr;     - 특허 100여건&cr;</SPAN>
<SPAN USERMARK="F-10">&cr;주2) 당 연구인력(이창선 CTO)의 주요 연구실적은 다음과 같습니다.&cr;     - LG화학 AIDS 치료제팀, 분자설계 및 합성 전략 고안, 전임상 후보 물질 도출&cr;     - Celera Genomics 신약개발팀, 거대세포 관련 천식치료제 개발 &cr;     - HDAC 억제제 임상 후보 물질 발굴&cr;     - Celera, HDAC-8 선택 특이적 억제제단독고안, 특허 출원 및 기술이전&cr;     - PTC Therapeutics, 척추근육증치료제 개발 참여및 기술이전&cr;&cr;주3) 당 연구인력(조영락 개발본부장)의 주요 연구실적은 다음과 같습니다.&cr;     - OXa. 항생제 임상1상 진행  P/L&cr;     - 항응혈제(FXa)녹십자 기술이전&cr;     - 특허15건(해외32개국)&cr;     - 학술지(국내 5, 국외 15)&cr;&cr;주4) 당 연구인력(안세창 공정센터장)의 주요 연구실적은 다음과 같습니다.&cr;     - 신물질 농약 3종 개발 생산(PBX, EBX, FTS)&cr;     - 의약 API 및 임상시료 생산&cr;     - OLED/LCD 핵심재료 생산&cr;     - 국내 특허 등록 11건&cr;     - 논문 11편&cr;&cr;주5) 당 연구인력(송호영 합성센터장)의 주요 연구실적은 다음과 같습니다. &cr;     - Thrombin 저해제연구 개발 (비임상까지진행&cr;     - C형 간염 치료제 연구개발&cr;     - 항응혈제(FXa)녹십자 기술이전 P/L&cr;     - 국내외 학술지 발표 7건&cr;     - 특허 16건&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF">&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" B">나. 연구개발비 집행현황</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="608" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="599"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="608" HEIGHT="30" USERMARK="F-BT">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="610">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="107"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="260" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">15기</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">14기</TH>
<TH WIDTH="116" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">13기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">시약재료비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">1,463,587 </TD>
<TD USERMARK="F-BT" WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">824,799 </TD>
<TD USERMARK="F-BT" WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">826,122 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">인건비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">6,431,541 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,858,154 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,954,448 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">감가상각비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">1,368,955 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,155,660 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">763,713 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기술개발비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">27,068,193 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,035,084 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,280,177 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기타</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">19,807,743 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,744,720 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,029,250 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">연구개발비용 계</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">56,140,020 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">17,618,417 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">17,853,710 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">정부보조금</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">(1,935,742)</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(907,204)</TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(2,348,500)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" HEIGHT="60" ROWSPAN="2" VALIGN="MIDDLE">회계처리</TD>
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">매출원가</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK=" 0X0000FF">- </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">판매비와관리비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">54,204,278 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,711,212 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,505,210 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="53" COLSPAN="2" VALIGN="MIDDLE">연구개발비 / 매출액 비율&cr;[연구개발비용계÷당기매출액×100]</TD>
<TD WIDTH="117" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">113.66%</TD>
<TD WIDTH="117" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">30.64%</TD>
<TD WIDTH="116" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">61.43%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN USERMARK="F-11">주) 연구개발비용은 정부보조금을 차감하기 전의 지출총액 기준으로 산정하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B">다. 연구개발</SPAN>
<SPAN USERMARK=" B">과제 총</SPAN>
<SPAN USERMARK=" B">괄표</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" BI"></SPAN>
<SPAN>당사가 진행중인 주요 연구개발과제의 세부</SPAN>
<SPAN>내용은 아래와 같습니다.</SPAN>
</P>
<P><합성의약품 파이프라인></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="930">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="182"></COL>
<COL WIDTH="209"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="204"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<SPAN>구분</SPAN>
</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">적응증</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">현재 &cr;개발단계</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">Partner</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99">항생제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">Delpazolid&cr;(그람양성균)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">결핵, 다제내성 결핵, &cr;MRSA, VRE</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">임상 2상  &cr;진행중</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">Haihe Biopharma&cr; (중국판권)</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99">- FDA 희귀의약품  &cr;- FDA QIDP  &cr;- Fast Track &cr;- 기술이전(‘16.12)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99">항응혈제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">LCB02-0133&cr;(Nokxaban,  FXa Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">항응혈제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">임상 1상&cr; 완료</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">GC녹십자/&cr; Lee's Pharm</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99">- 글로벌&cr;  (Profit Sharing) &cr;- 제3자 기술이전&cr;   ('18.01, 중국/동남아 권리)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="53">항섬유화제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB17-0877 &cr;(ATX Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">특발성 폐섬유증&cr;간질성 섬유화 폐질환</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">임상 2상&cr;진행예정</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">브릿지바이오</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="53">- 글로벌(Profit Sharing) &cr;- FDA 희귀의약품(19.01) </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="30">항암제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Small molecule Oncology</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">면역항암제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">　</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P><ADC 파이프라인></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="783">

<COLGROUP>
<COL WIDTH="73"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="95"></COL>
<COL WIDTH="95"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">구분</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">적응증/타겟</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">현재&cr;개발단계</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">Antibody &cr;Partner</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">사업화현황</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">Licensee</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="212">ADC&cr;Platform</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB69</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Takeda</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">L/O&cr;(글로벌)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Takeda</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">면역항암제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB91</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Iksuda</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">L/O&cr;(글로벌)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Iksuda</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB91</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">비공개(미국)</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB06A</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">비공개(일본)</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-기술이전 &cr;옵션 포함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="10" WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="415"> ADC&cr;Products</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB14</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">HER2</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">임상 1상</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">L/O&cr;(중국)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">FosunPharma</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB73</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">CD19</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">전임상</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Novimmune</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">L/O&cr;(글로벌)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Iksuda</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB71</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">ROR1</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">전임상</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">ABL Bio</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">L/O&cr;(글로벌)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">CStone</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB67</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">DLK1</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">전임상</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Ybiologigs</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"> L/O&cr;(글로벌)</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Pyxis</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">LCB84</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Diatheva</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> -</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"></TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">LCB02A</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">고형암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Harbour&cr;Biomed</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53"> -</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">LCB04A</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">ImmuneOncia</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">LCB97</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">비공개</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">LCB87</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">비공개</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">LCB05A</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">고형암/혈액암</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Discovery</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">비공개</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="104" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">Collaboration</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN>이 과제 중 당사에서 가장 앞서 </SPAN>
<SPAN>임상 2상 진행 중인 옥</SPAN>
<SPAN>사졸리디논계 항생제(경구)와 항응혈제(FXa저해제), 전임상 단계인 그람음성균 항생제와  차세대 원천기술 후보&cr; ADC 등 5개 과제에 대한 설명은 다음과 같습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
</P>
<P>ㄱ. 옥사졸리디논계 항생제 (Delpazolid, 개발번호 : LCB01-0371)</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="702">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="544"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<SPAN>다제내성 결핵</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">골수독성 등 안전성 우수, 물에 대한 용해도 우수하여 경구/주사 겸용 가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="103" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="103" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 경구용: </SPAN>
<SPAN USERMARK="F-11">다제내성 결핵 대상 국내 2상a 진행 중 &cr;              -> </SPAN>
<SPAN USERMARK="F-11">글로벌 2상b 준비 중 (미국 등 다수국가 예정)</SPAN>
</P>

<P USERMARK="F-12">
<SPAN USERMARK="F-BT11">- </SPAN>
<SPAN USERMARK="F-BT11">주사제: 미국에서 전임상 완료, </SPAN>
<SPAN USERMARK="F-BT11">국내 1상 완료 </SPAN>
<SPAN USERMARK="F-BT11">&cr;- 글로벌 임상: FDA 희귀의약품, QIDP, Fast Track 지정 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">- 중국: 중국시장 대상으로 기술이전 완료 Haihe Bio(구 RMX Bio, &cr;   2016년 12월)&cr;- 글로벌(중국 외): 임상2상 단계에서 기술이전 목표</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<P>ㄴ. 항응혈제 FXa 저해제 (LCB02-0133, 녹십자 개발번호 : GCC-4401C)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">뇌졸중, 협심증, 심근경색, 심부정맥성 혈전증, 페색전증</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">약효, 특히 출혈부작용(bleeding) 개선, 세계최초 경구/주사 겸용가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 녹십자 주도로 미국에서 1상 완료 </P>
<P USERMARK="F-BT">- 임상 2상a 진입 준비 중 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 중국 기술이전 진행 (Lee's Pharm, 2018년 2월)</P>
<P USERMARK="F-BT">- 2차: 임상 2상 단계 글로벌 제약사 기술이전</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P>ㄷ. 항섬유화제 ATX 저해제 (LCB17-0877)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>
<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">항염증, 폐섬유증 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">후보물질 단계에서의 차별적인 ATX 저해력</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 후보물질&cr;- </SPAN>
<SPAN USERMARK="F-11">브릿지바이오 통한 전임상 완료 및 미국 임상 1상 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 개발전문사 기술이전 완료 (브릿지 바이오, 2017년 5월)</P>

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 2</SPAN>
<SPAN USERMARK="F-11">차: 글로벌 임상 진행 단계에서 제 3자 글로벌 기술이전 목표&cr;- 3차: 개발단계 진행에 따른 마일스톤 수령</SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>ㄹ. ADC 원천기술 </SPAN>
</P>

<TABLE BORDER="1" WIDTH="692" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">적응증</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">항체의 선택성과 저분자 약물의 약효의 장점을 결합한 신규 신약개발 기술로 주로 항암제에 적용할 예정.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">차별성</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">기존 1세대 기술의 단점인 혼합물 문제와 불안정한 링커의 단점을 모두 극복한 차세대 원천기술로 기대.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="398" USERMARK="F-BT">
<P USERMARK="F-BT12">개발일정</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="398" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>-</SPAN>
<SPAN>  </SPAN>
<SPAN>중국 푸싱제약( Fosun Pharma) Herceptin ADC 에 대한 중국시장 기술이전&cr;   계약 체결 (2015년 8월) 후</SPAN>
<SPAN> 중국에서 임상1상 진행중&cr;- 밀레니엄 파마수티컬( Takeda ) ADC 플랫폼 기술이전 계약체결(2019년 3월)&cr;   후보물질 발굴예정&cr;- 익수다(Iksuda)에 ADC 플랫폼 및 CD19 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 4월, 5월)&cr;- 시스톤(CStone)에 ROR1 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 10월)&cr;- 픽시스(Pyxis)에 DLK1 ADC에 대한 전세계시장 대상 기술이전 계약체결&cr;  (2020년 12월)&cr;- 원천기술 강화 및 개발후보 확대 위한 국내,외 기관과 신규타겟 적용시험&cr;   진행 중 &cr;   . </SPAN>
<SPAN>복수 글</SPAN>
<SPAN>로벌제약사와 기술이전 전제한 물질평가 진행 중 &cr;   . </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>미국/유럽 등지 여러 항체회사들과 신규 항체 대상&cr;     후보물질 발굴 위한 공동연구 중  </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P USERMARK="F-BT">- 신규 Toxin 플랫폼 발굴 (특허 출원 중)&cr;- Beyond Oncology: ADC이외 분야 원천기술 적용 모색 중</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168" USERMARK="F-BT">
<P USERMARK="F-BT12">사업화 계획</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="168" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>□</SPAN>
<SPAN>원천기술 기술이전</SPAN>
</P>

<P>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">  . </SPAN>
<SPAN USERMARK="F-BT">글로벌제약사 등과 당사 Platform </SPAN>
<SPAN USERMARK="F-BT">기술이전 확대&cr;  . 향후 년 3건 이상 기술이전 목표</SPAN>
</P>
<P USERMARK="F-BT">□Her2-ADC 개발 및 기술이전</P>
<P USERMARK="F-BT">-중국 푸싱제약과 중국시장 대상 기술이전 계약체결 완료(2015.08.17)</P>

<P>
<SPAN USERMARK="F-BT">- 푸싱제약 중국 임상 진행중 -> 임상 결과 활용 및 당사 주도 글로벌 제약사&cr;  대상 기술이전</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>  
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
</P>

<P>&cr;<정정후>&cr;
<SPAN></SPAN>
<SPAN USERMARK=" B">9. 경영상의 주요계약</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN>① 신약연구개발</SPAN>
<SPAN></SPAN>
</P>
<P>당사가 체결한 주요 유효 계약내역은 다음과 같습니다.&cr;가. 라이센스아웃(License-out) 계약                                                                  </P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1506">

<COLGROUP>
<COL WIDTH="133"></COL>
<COL WIDTH="165"></COL>
<COL WIDTH="396"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="406"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="405" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">선급금&cr;(백만원)</P>
</TD>

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액&cr;(백만원)</P>
</TD>

<TD WIDTH="415" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P USERMARK="F-BT">ADC 후보물질</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">Fosun Pharma</SPAN>
<SPAN USERMARK="F-BT">&cr;(중국)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="76">

<P USERMARK="F-BT">
<SPAN>□대상 : 허셉틴-ADC 후보물질&cr;□총규모: 약209억&cr;□중국시장 대상 기술이전 </SPAN>
</P>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">2015년 8월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">20,842</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="76">
<P USERMARK="F-BT">□ 임상 1상 진행 중&cr;□ 중국 임상 진행 따른 마일스톤 수익 발생 예정</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<P USERMARK="F-BT">ADC 원천기술</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">Millenium Pharma&cr;(Takeda)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">

<P USERMARK="F-BT">
<SPAN>□비공개 타겟&cr;</SPAN>
<SPAN>□총규모: </SPAN>
<SPAN>$404mn (Upfront+Milestone) + 로열티   &cr;□레고켐바이오 기술 활용 ADC 면역항암제&cr;   후보물질 발굴 중</SPAN>
</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">2019년 3월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">454,823</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">

<P USERMARK="F-BT">
<SPAN>□ 후보물질 발굴 중</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">ADC 원천기술</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">Iksuda (유럽)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="122">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$407mn (Upfront+Milestone) + 로열티&cr;  + Revenue sharing(제3자 기술이전시)   &cr;□레고켐바이오 기술 활용 ADC 치료제&cr;   후보물질 발굴예정</SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">2020년 4월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">496,316</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="122" USERMARK="F-BT">□ 후보물질 발굴예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Iksuda (유럽)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">CD19-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$227mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시)  </SPAN>
<SPAN USERMARK="F-BT">  &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 5월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">6,132</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">278,370</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ NovImmune과 공동연구를 &cr;   통해 확보한 후보물질임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">CStone (중국)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">ROR1-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$363.5mn (Upfront+Milestone) + 로열티&cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시) </SPAN>
<SPAN USERMARK="F-BT"> &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 10월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">11,276</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">409,883</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ ABL Bio와 공동연구를 통해&cr;    확보한 후보물질임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Pyxis (미국)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">DLK1-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$294mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Option(지분/Revenue Sharing) </SPAN>
<SPAN USERMARK="F-BT">&cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 12월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">10,517</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">325,487</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ </SPAN>
<SPAN USERMARK="F-BT">와이바이오로직스</SPAN>
<SPAN USERMARK="F-BT">와 공동연구를 통해 확보한 후보물질임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">ATX 저해제</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">브릿지바이오</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="145">
<P></P>
<P USERMARK="F-BT">□ 후보물질 확정 후 브릿지 바이오 주도 개발 진행&cr;□사업화 모델 : 단계별 마일스톤 + Profit Sharing</P>
<P USERMARK="F-BT">  - Profit Sharing: 제 3자 기술이전 시 개발 단계별&cr;    양사간 기여율에 따른 이익 배분&cr;  - 마일스톤: 300억 (선급금 30억 포함)</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">2017년 5월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">2,000</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">30,000</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="145" USERMARK="F-BT">□ 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">옥사졸리디논계 &cr;항생제</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">Haihe Bio(구 RMX Bio)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<P USERMARK="F-BT">□중국 : 약 240억 (Upfront+Milestone) + 로열티&cr;□글로벌 : 임상 2상 데이터 확보 후 기술이전 추진</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">2016년 12월</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">상업화 기간 동안 계속</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">600</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">24,000</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□ 임상 2상 진행 중&cr;</SPAN>
<SPAN USERMARK="F-BT">□ FDA 희귀의약품 지정&cr;□ FDA QIDP 승인&cr;</SPAN>
<SPAN USERMARK="F-BT">□ FDA Fast Track 지</SPAN>
<SPAN USERMARK="F-BT">정</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P USERMARK="F-BT">항응혈제 </P>
<P USERMARK="F-BT">(FXa 저해제 )</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">GC녹십자</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="76">

<P USERMARK="F-BT">
<SPAN>□ </SPAN>
<SPAN>중국시장 : 2018년2월 중국제약사 Lee's Pharma에&cr;   기술이전 ->녹십자와 Profit Sharing  중&cr;</SPAN>
<SPAN>□북미, 유럽 ,일본 등 : sub-L/O시 Profit Sharing </SPAN>
</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">2009년 6월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개 </TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□ 임상 1상 완료(미국)&cr;</SPAN>
<SPAN USERMARK="F-BT">□ 임상 1상 진행예정(중국)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>※ 외화 금액은 체결시점 공시를 통해 안내한 원화금액으로 입력하였습니다.&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">[계약 1]</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="676" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">①계약 상대방</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">녹십자</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">②계약 내용</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">③대상 지역</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">④총 계약금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑤수취 금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑥계약 조건</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="53" USERMARK="F-BT">⑦회계처리 방법</TD>
<TD WIDTH="543" HEIGHT="53" USERMARK="F-BT">계약금 및 중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑧대상 기술</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑨개발 진행경과</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">미국 임상 1상 완료 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑩기타 사항</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 2]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">푸싱제약 (Shanghai Fosun Pharmaceutical Development Co., Ltd.)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">항HER2 항체-약물 복합체 (anti-HER2 ADC)&cr;중국 시장만을(중국, 대만, 홍콩, 마카오 포함) 대상으로 전용실시권 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국(Greater China)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">20,842,050,000원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">계약금 및 중도금(임상시험 및 신약허가 단계별 마일스톤) 10,750천불, 매출 금액별 달성시 받게 되는 sales 마일스톤 7,000천불 등 포함 총 계약규모는 17,750천불, 그리고 별도의 로열티를 수령함.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="99">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="99">
<SPAN USERMARK=" 0X000000">계약금(비공개)은 반환의무 및 추가적인 조건은 없으며, 중도금 수령전까지 &cr;기간인식함.&cr;</SPAN>
<SPAN USERMARK=" 0X000000">중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항HER2 항체-약물 복합체 (anti-HER2 ADC)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 3]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Haihe Biopharma (구 RMX Biopharma)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">LCB01-0371 옥사계 항생제 기술이전&cr;LCB01-0371은 MRSA, VRE 등의 그람양성균 슈퍼박테리아 및 다제내성 결핵 치료제로서 약물 장기복용에 따른 부작용을 최소화 할 수 있는 새로운 슈퍼항생제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">약 240억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="122">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="122">- 계약금 : 6억원(50만불) - 계약 체결 후 30일이내 &cr;- 단계별 마일스톤 : 234억(2,000만불) &cr;  ☞ 각 단계별 임상 개발 및 상업화, 목표 판매수량 달성등에 성공할 경우 받게 되는 조건부 마일스톤임. &cr;- 로열티는  별도임. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">계약금은 반환의무 및 조건이 없고 관련하여 수행할 의무가 완료되는 시점에 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB01-0371 옥사계 항생제 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN USERMARK=" B">[계약 4]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오(300억원)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="191">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="191"> - 기술이전료와 Profit Sharing을 포함하는 계약 &cr;(1) 총계약금액: 300억원 &cr;   - 선급금: 20억원 &cr;   - 단계별 마일스톤: 280억원 &cr;     ☞ 각 단계별 임상 개발 진행과정에 받게 되는 조건부 마일스톤임. &cr;(2) Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">미국 임상 2상 준비중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 5]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>Millenium Pharmaceuticals(Takeda)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,548억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="145">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="145"> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 선급금 및 단기마일스톤: 8,162,050,000원 &cr;   - 마일스톤 : 446,661,150,000원 &cr;  - 총 계약금액 : 454,823,200,000원 &cr;  3) 경상기술료 (Royalty) : 별도 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB69</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">[계약 6]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,963억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="168">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="168">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 총 계약금액(선급금 및 단기마일스톤): 496,315,575,000원 &cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB91</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 7]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항CD19 항체-약물 복합체 (anti-CD19 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">2,784억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 6,131,500,000원&cr;   - 마일스톤 :  272,238,600,000원&cr;     => 총 계약금액 : 278,370,100,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB73</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">임상 1상 진행예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 8]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">CStone Pharmaceuticals</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항ROR1 항체-약물 복합체 (anti-ROR1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,099억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 11,276,000,000원&cr;   - 마일스톤 :  398,606,600,000원&cr;     => 총 계약금액 : 409,882,600,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB71</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 9]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Pyxis Oncology</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항DLK1 항체-약물 복합체 (anti-DLK1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">3,255억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="260">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="260">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 10,517,450,000원&cr;      1차 : 553,550,000원&cr;      2차 : 9,963,900,000원(2021년  4월 30일 이내)&cr;   - 마일스톤 :  314,969,950,000원&cr;     => 총 계약금액 : 325,487,400,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) Option 포함</SPAN>
<SPAN>&cr;   - 선급금, 단계별 마일스톤과 별도로 옵션행사시 Pyxis사의 지분 및 제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분받을 수 있는 권리확보</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB67</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>나. 기술제휴 계약(물질평가 계약)
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1077">

<COLGROUP>
<COL WIDTH="103"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="326"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="335" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액</P>
</TD>

<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">ADC 원천기술</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">비공개(미국)</SPAN>
</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: 미공개 (물질평가 </SPAN>
<SPAN USERMARK="F-BT">계약</SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴중</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">2019년 1분기</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="76" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">ADC 원천기술</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">비공개(일본)</SPAN>
</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: 미공개 (리서치 라이선스 계약</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴중</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">2020년 4분기</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="76" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>다. 라이센스인(License-In) 계약</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1077">

<COLGROUP>
<COL WIDTH="103"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="326"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="335" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액</P>
</TD>

<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">항바이러스&cr;치료제</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">한국화학연구원외3개기관</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="53">
<SPAN USERMARK="F-BT">□항바이러스 (코로나바이러스 등) 후보물질</SPAN>
<SPAN USERMARK="F-BT">&cr;</SPAN>
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">총규모: 비공개</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<SPAN USERMARK="F-BT">2020년 5월</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">□ 전임상 준비중</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>의약사업부문이 체결한 주요 판권 관련 계약은 아래와 같습니다.</SPAN>
<SPAN USERMARK=" I"></SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1031">

<COLGROUP>
<COL WIDTH="179"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="133"></COL>
<COL WIDTH="348"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약품목</TH>
<TH USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약상대방</TH>
<TH USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약체결일 </TH>
<TH USERMARK="F-BT" WIDTH="357" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약 내용</TH>
<TH USERMARK="F-BT" WIDTH="215" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">나누리병원 외</TD>
<TD USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2015.10.01 </TD>
<TD USERMARK="F-BT" WIDTH="357" HEIGHT="30" VALIGN="MIDDLE">치료재료, 의료소모품  계약</TD>
<TD USERMARK="F-BT" WIDTH="215" HEIGHT="30" VALIGN="MIDDLE"> 5개 병원</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
<SPAN USERMARK=" 0XFF0000 B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">10. </SPAN>
<SPAN USERMARK=" B">연구개발 관련사항</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>
<P USERMARK=" B">가. 연구개발 조직도&cr;</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="247" ALIGN="CENTER" HSPACE="0">210331 조직도.jpg</IMG>
<IMG-CAPTION ATOC="N">210331 조직도</IMG-CAPTION>
</IMAGE>

<P>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN>당사의 창업멤버인 대표이사를 포함한 경영진은 국내에서 세계적 신약개발을 주도해온 LG생</SPAN>
<SPAN>명과학 등에서 팀장급으로 오랜 경험을 가진 핵심요원들입니다.  창업 이후 국내외 </SPAN>
<SPAN>연구인력을 지속적으로 채용하였습니</SPAN>
<SPAN>다</SPAN>
<SPAN>.</SPAN>
<SPAN> </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>2</SPAN>
<SPAN>021년</SPAN>
<SPAN> 03월 </SPAN>
<SPAN>전체 인원 107명 중, 경영관리, 사업전략 12</SPAN>
<SPAN>명 </SPAN>
<SPAN>및 의약사업부문</SPAN>
<SPAN> 4명을</SPAN>
<SPAN> 제외한</SPAN>
<SPAN> </SPAN>
<SPAN>91명의</SPAN>
<SPAN> 연구진을 </SPAN>
<SPAN>확보하고 있습니다. 전공별로는 </SPAN>
<SPAN>유기합성 전공자가 35명, Biology/약학 전공자 49명, 기</SPAN>
<SPAN>타 8명으로 구성되어 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="752" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="31"></COL>
<COL WIDTH="44"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="308"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">구분</TD>
<TD WIDTH="53" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">성명</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">직급</TD>
<TD WIDTH="118" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">담당업무</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">최종학위</TD>
<TD WIDTH="317" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요 학력 및 경력</TD>
<TD WIDTH="92" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요연구실적</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">1</TD>
<TD WIDTH="53" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">김용주</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">대표이사</TD>
<TD WIDTH="118" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구개발총괄</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">박사</TD>
<TD WIDTH="317" HEIGHT="102" USERMARK="F-8" VALIGN="MIDDLE">한국과학원 유기화학 박사(1983)&cr;LG화학 기술연구원 연구위원(1983-1997)&cr;LG화학 기술연구원 연구소장/LG BMI 법인장(1997-2000)&cr;LG생명과학기술연구원 신약연구소장/연구위원(2000-2006)&cr;현, (주)레고켐바이오 대표이사/CEO</TD>
<TD WIDTH="92" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">2</TD>
<TD WIDTH="53" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">이창선</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">신약연구소장</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="140" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Yale 유기화학 박사(2001)&cr;LG생명과학(1991-1996)&cr;Oregon State Univ. Postdoc/Staff Scientist(2001-2003)&cr;PTC Therapeutics 연구위원(2006-2016)&cr;RaND Biosciences Inc.CTO(2016-2017)&cr;한독 상무(2018)&cr;현, (주)레고켐바이오 신약연구소장</TD>
<TD WIDTH="92" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">3</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">조영락</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">개발본부장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">연세대학교 화학 박사(1999)&cr;The Salk Institute(1999-2000)&cr;The Scripps Research Institute(2000-2001)&cr;LG생명과학 차장(2001-2006)&cr;현, (주)레고켐바이오 개발본부장</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">4</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">안세창</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">연구위원</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">공정센터장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Minnesota 화학과 박사(1991)&cr;Harvard Univ. Post-doc(1991-1993)&cr;LG생명과학(1993-2015)&cr;LG화학(2015-2016)&cr;현, (주)레고켐바이오 연구위원</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">5</TD>
<TD WIDTH="53" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">송호영</TD>
<TD WIDTH="66" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구위원</TD>
<TD WIDTH="118" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">합성센터장</TD>

<TD WIDTH="66" HEIGHT="83" USERMARK=" 0X0000FF" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN USERMARK="F-10 0X000000">박사</SPAN>
</TD>

<TD WIDTH="317" HEIGHT="83" USERMARK="F-8 0X0000FF" VALIGN="MIDDLE">
<SPAN USERMARK=" 0X000000">서울대학교 화학과 박사(2002)&cr;LG생명과학 Post-doc(2002)&cr;LG생명과학(2003-2006)&cr;</SPAN>
<SPAN USERMARK=" 0X000000">현, (주)레고켐바이오 연구위원</SPAN>
</TD>
<TD WIDTH="92" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주5)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-10">주1) 당 연구인력(김용주 대표이사)의 주요 연구실적은 다음과 같습니다.&cr;     - 세</SPAN>
<SPAN USERMARK="F-10">파계 항생제 국내 최초 신약 기술이전(Glaxo)&cr;     - "FACTIVE" 미국 FDA 최초 승인&cr;     - 동탑산업 훈장(대통령상) 수상&cr;     - LG그룹 연구개발상 대상 수장(세파계 항생제)&cr;     - 특허 100여건&cr;</SPAN>
<SPAN USERMARK="F-10">&cr;주2) 당 연구인력(이창선 CTO)의 주요 연구실적은 다음과 같습니다.&cr;     - LG화학 AIDS 치료제팀, 분자설계 및 합성 전략 고안, 전임상 후보 물질 도출&cr;     - Celera Genomics 신약개발팀, 거대세포 관련 천식치료제 개발 &cr;     - HDAC 억제제 임상 후보 물질 발굴&cr;     - Celera, HDAC-8 선택 특이적 억제제단독고안, 특허 출원 및 기술이전&cr;     - PTC Therapeutics, 척추근육증치료제 개발 참여및 기술이전&cr;&cr;주3) 당 연구인력(조영락 개발본부장)의 주요 연구실적은 다음과 같습니다.&cr;     - OXa. 항생제 임상1상 진행  P/L&cr;     - 항응혈제(FXa)녹십자 기술이전&cr;     - 특허15건(해외32개국)&cr;     - 학술지(국내 5, 국외 15)&cr;&cr;주4) 당 연구인력(안세창 공정센터장)의 주요 연구실적은 다음과 같습니다.&cr;     - 신물질 농약 3종 개발 생산(PBX, EBX, FTS)&cr;     - 의약 API 및 임상시료 생산&cr;     - OLED/LCD 핵심재료 생산&cr;     - 국내 특허 등록 11건&cr;     - 논문 11편&cr;&cr;주5) 당 연구인력(송호영 합성센터장)의 주요 연구실적은 다음과 같습니다. &cr;     - Thrombin 저해제연구 개발 (비임상까지진행&cr;     - C형 간염 치료제 연구개발&cr;     - 항응혈제(FXa)녹십자 기술이전 P/L&cr;     - 국내외 학술지 발표 7건&cr;     - 특허 16건&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF">&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" B">나. 연구개발비 집행현황</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="608" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="599"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="608" HEIGHT="30" USERMARK="F-BT">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="610">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="107"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="260" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">16기 1분기</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">15기</TH>
<TH WIDTH="116" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">14기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">시약재료비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">795,404 </TD>
<TD USERMARK="F-BT" WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,463,587 </TD>
<TD USERMARK="F-BT" WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">824,799 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">인건비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">1,744,614 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,431,541 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,858,154 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">감가상각비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">338,727 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,368,955 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,155,660 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기술개발비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">12,350,827 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">27,068,193 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,035,084 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기타</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">891,355 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">19,807,743 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,744,720 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">연구개발비용 계</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">16,120,927 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">56,140,020 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">17,618,417 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">정부보조금</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">(1,935,742)</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,935,742)</TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(907,204)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" HEIGHT="60" ROWSPAN="2" VALIGN="MIDDLE">회계처리</TD>
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">매출원가</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">- </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">판매비와관리비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">14,185,185 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">54,204,278 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,711,212 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="53" COLSPAN="2" VALIGN="MIDDLE">연구개발비 / 매출액 비율&cr;[연구개발비용계÷당기매출액×100]</TD>
<TD WIDTH="117" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">305.43%</TD>
<TD WIDTH="117" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">113.66%</TD>
<TD WIDTH="116" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">30.64%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN USERMARK="F-11">주) 연구개발비용은 정부보조금을 차감하기 전의 지출총액 기준으로 산정하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B">다. 연구개발</SPAN>
<SPAN USERMARK=" B">과제 총</SPAN>
<SPAN USERMARK=" B">괄표</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" BI"></SPAN>
<SPAN>당사가 진행중인 주요 연구개발과제의 세부</SPAN>
<SPAN>내용은 아래와 같습니다.</SPAN>
</P>
<P><합성의약품 연구개발과제 진행현황></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="930">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="182"></COL>
<COL WIDTH="209"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="204"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<SPAN USERMARK="F-BT">구분</SPAN>
</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">적응증</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">현재 &cr;개발단계</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Partner</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99" USERMARK="F-BT">항생제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Delpazolid&cr;(그람양성균)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">결핵, 다제내성 결핵, &cr;MRSA, VRE</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">임상 2상  &cr;진행중</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Haihe Biopharma&cr; (중국판권)</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">- FDA 희귀의약품  &cr;- FDA QIDP  &cr;- Fast Track &cr;- 기술이전(‘16.12)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99" USERMARK="F-BT">항응혈제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">LCB02-0133&cr;(Nokxaban,  FXa Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">항응혈제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">임상 1상&cr; 완료</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">GC녹십자/&cr; Lee's Pharm</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">- 글로벌&cr;  (Profit Sharing) &cr;- 제3자 기술이전&cr;   ('18.01, 중국/동남아 권리)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="53" USERMARK="F-BT">항섬유화제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB17-0877 &cr;(ATX Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">특발성 폐섬유증&cr;간질성 섬유화 폐질환</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">임상 2상&cr;진행예정</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">브릿지바이오</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">- 글로벌(Profit Sharing) &cr;- FDA 희귀의약품(19.01) </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="30" USERMARK="F-BT">항암제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Small molecule Oncology</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">면역항암제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">　</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P><ADC 연구개발과제 진행현황></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="925">

<COLGROUP>
<COL WIDTH="73"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="118"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">구분</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">적응증/타겟</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">현재&cr;개발단계</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Antibody &cr;Partner</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">사업화현황</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Licensee</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="212" USERMARK="F-BT">ADC&cr;Platform</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB69</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Takeda</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Takeda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">면역항암제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB91</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB91</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">비공개(미국)</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB06A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">비공개(일본)</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-기술이전 &cr;옵션 포함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="10" WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="415" USERMARK="F-BT"> ADC&cr;Products</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB14</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">HER2</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">임상 1상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(중국)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">FosunPharma</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB73</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">CD19</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Novimmune</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">21년 4분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB71</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">ROR1</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">ABL Bio</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">CStone</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">21년 4분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB67</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">DLK1</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Ybiologigs</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT"> L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Pyxis</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">22년 1분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB84</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Mediterranea</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Licensed-In</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB87</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Diatheva</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"> -</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"></TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB02A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Harbour&cr;Biomed</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT"> -</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB04A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">ImmuneOncia</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB97</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비공개</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB05A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비공개</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN>이 과제 중 당사에서 가장 앞서 </SPAN>
<SPAN>임상 2상 진행 중인 옥</SPAN>
<SPAN>사졸리디논계 항생제(경구)와 항응혈제(FXa저해제), 전임상 단계인 그람음성균 항생제와  차세대 원천기술 후보&cr; ADC 등 5개 과제에 대한 설명은 다음과 같습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
</P>
<P>ㄱ. 옥사졸리디논계 항생제 (Delpazolid, 개발번호 : LCB01-0371)</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="702">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="544"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<SPAN>다제내성 결핵</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">골수독성 등 안전성 우수, 물에 대한 용해도 우수하여 경구/주사 겸용 가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="103" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="103" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 경구용: </SPAN>
<SPAN USERMARK="F-11">다제내성 결핵 대상 국내 2상a 진행 중 &cr;              -> </SPAN>
<SPAN USERMARK="F-11">글로벌 2상b 준비 중 (미국 등 다수국가 예정)</SPAN>
</P>

<P USERMARK="F-12">
<SPAN USERMARK="F-BT11">- </SPAN>
<SPAN USERMARK="F-BT11">주사제: 미국에서 전임상 완료, </SPAN>
<SPAN USERMARK="F-BT11">국내 1상 완료 </SPAN>
<SPAN USERMARK="F-BT11">&cr;- 글로벌 임상: FDA 희귀의약품, QIDP, Fast Track 지정 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">- 중국: 중국시장 대상으로 기술이전 완료 Haihe Bio(구 RMX Bio, &cr;   2016년 12월)&cr;- 글로벌(중국 외): 임상2상 단계에서 기술이전 목표</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<P>ㄴ. 항응혈제 FXa 저해제 (LCB02-0133, 녹십자 개발번호 : GCC-4401C)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">뇌졸중, 협심증, 심근경색, 심부정맥성 혈전증, 폐색전증</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">약효, 특히 출혈부작용(bleeding) 개선, 세계최초 경구/주사 겸용가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 녹십자 주도로 미국에서 1상 완료 </P>
<P USERMARK="F-BT">- 임상 2상a 진입 준비 중 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 중국 기술이전 진행 (Lee's Pharm, 2018년 2월)</P>
<P USERMARK="F-BT">- 2차: 임상 2상 단계 글로벌 제약사 기술이전</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P>ㄷ. 항섬유화제 ATX 저해제 (LCB17-0877)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>
<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">항염증, 폐섬유증 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">후보물질 단계에서의 차별적인 ATX 저해력</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 후보물질&cr;- </SPAN>
<SPAN USERMARK="F-11">브릿지바이오 통한 전임상 완료 및 미국 임상 1상 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 개발전문사 기술이전 완료 (브릿지 바이오, 2017년 5월)</P>

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 2</SPAN>
<SPAN USERMARK="F-11">차: 글로벌 임상 진행 단계에서 제 3자 글로벌 기술이전 목표&cr;- 3차: 개발단계 진행에 따른 마일스톤 수령</SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>ㄹ. ADC 원천기술 </SPAN>
</P>

<TABLE BORDER="1" WIDTH="692" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">적응증</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">항체의 선택성과 저분자 약물의 약효의 장점을 결합한 신규 신약개발 기술로 주로 항암제에 적용할 예정.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">차별성</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">기존 1세대 기술의 단점인 혼합물 문제와 불안정한 링커의 단점을 모두 극복한 차세대 원천기술로 기대.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="398" USERMARK="F-BT">
<P USERMARK="F-BT12">개발일정</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="398" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>-</SPAN>
<SPAN>  </SPAN>
<SPAN>중국 푸싱제약( Fosun Pharma) Herceptin ADC 에 대한 중국시장 기술이전&cr;   계약 체결 (2015년 8월) 후</SPAN>
<SPAN> 중국에서 임상1상 진행중&cr;- 밀레니엄 파마수티컬( Takeda ) ADC 플랫폼 기술이전 계약체결(2019년 3월)&cr;   후보물질 발굴예정&cr;- 익수다(Iksuda)에 ADC 플랫폼 및 CD19 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 4월, 5월)&cr;- 시스톤(CStone)에 ROR1 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 10월)&cr;- 픽시스(Pyxis)에 DLK1 ADC에 대한 전세계시장 대상 기술이전 계약체결&cr;  (2020년 12월)&cr;- 원천기술 강화 및 개발후보 확대 위한 국내,외 기관과 신규타겟 적용시험&cr;   진행 중 &cr;   . </SPAN>
<SPAN>복수 글</SPAN>
<SPAN>로벌제약사와 기술이전 전제한 물질평가 진행 중 &cr;   . </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>미국/유럽 등지 여러 항체회사들과 신규 항체 대상&cr;     후보물질 발굴 위한 공동연구 중  </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P USERMARK="F-BT">- 신규 Toxin 플랫폼 발굴 (특허 출원 중)&cr;- Beyond Oncology: ADC이외 분야 원천기술 적용 모색 중</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168" USERMARK="F-BT">
<P USERMARK="F-BT12">사업화 계획</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="168" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>□</SPAN>
<SPAN>원천기술 기술이전</SPAN>
</P>

<P>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">  . </SPAN>
<SPAN USERMARK="F-BT">글로벌제약사 등과 당사 Platform </SPAN>
<SPAN USERMARK="F-BT">기술이전 확대&cr;  . 향후 년 3건 이상 기술이전 목표</SPAN>
</P>
<P USERMARK="F-BT">□Her2-ADC 개발 및 기술이전</P>
<P USERMARK="F-BT">-중국 푸싱제약과 중국시장 대상 기술이전 계약체결 완료(2015.08.17)</P>

<P>
<SPAN USERMARK="F-BT">- 푸싱제약 중국 임상 진행중 -> 임상 결과 활용 및 당사 주도 글로벌 제약사&cr;  대상 기술이전</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>  
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
</P>

<P>
<SPAN USERMARK=" B">주5)&cr;<정정전>&cr;</SPAN>타법인출자 현황
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="501" BORDER="1">

<COLGROUP>
<COL WIDTH="492"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="501" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="36">법인명</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" USERMARK="F-10">(주)인투셀 주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" USERMARK="F-10">브릿지바이오테라퓨틱스(주) 주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" USERMARK="F-10">(주)에스알파테라퓨틱스</TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;
<SPAN USERMARK=" B"><정정후></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="501" BORDER="1">

<COLGROUP>
<COL WIDTH="492"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="501" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="36">법인명</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">(주)인투셀 주1)&cr;(비상장)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">브릿지바이오테라퓨틱스(주) 주2)&cr;(코스닥 상장)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="501" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">(주)에스알파테라퓨틱스&cr;(비상장)</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;</P>
<PGBRK></PGBRK>
</CORRECTION>

<SECTION-1 AID="CEO-CERT-COR" ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="TTL_CEO_CERT_COR">【 대표이사 등의 확인 】</TITLE>

<APPENDIX ATYPE="IMAGE">
<COMMENT>◆click◆ 대표이사 등이 서명한 『확인서』 그림파일 삽입</COMMENT>
</APPENDIX>

<IMAGE>
<IMG WIDTH="594" HEIGHT="840" ALIGN="CENTER" HSPACE="0">대표이사등의 확인서_20210531.jpg</IMG>
<IMG-CAPTION ATOC="N">대표이사등의 확인서_20210531</IMG-CAPTION>
</IMAGE>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>
</LIBRARY>
</INSERTION>

<COVER>
<P></P>
<COVER-TITLE ATOC="Y" AASSOCNOTE="COVER">사 업 보 고 서</COVER-TITLE>
<P>&cr;&cr;&cr;</P>
<P USERMARK="F-16">                                    (제 15 기)</P>

<TABLE-GROUP ACLASS="COVER" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="209"></COL>
<COL WIDTH="153"></COL>
<COL WIDTH="211"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD CLASS="NORMAL" ROWSPAN="2" ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="218" HEIGHT="60" AUPDATECONT="N">사업연도</TD>
<TU CLASS="NORMAL" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="162" HEIGHT="30" AUNIT="PERIODFROM" AUNITVALUE="20200101">2020년 01월 01일</TU>
<TD CLASS="NORMAL" VALIGN="MIDDLE" WIDTH="220" HEIGHT="30" AUPDATECONT="N"> 부터</TD>
</TR>

<TR ACOPY="N" ADELETE="N">
<TU CLASS="NORMAL" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="162" HEIGHT="30" AUNIT="PERIODTO" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD CLASS="NORMAL" VALIGN="MIDDLE" WIDTH="220" HEIGHT="30" AUPDATECONT="N"> 까지</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE AFIXTABLE="N" BORDER="0" WIDTH="600" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="391"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">금융위원회</TD>
<TD WIDTH="400" HEIGHT="30" ALIGN="RIGHT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">한국거래소 귀중</TD>
<TD WIDTH="400" HEIGHT="30" ALIGN="RIGHT">2021년 03월 23일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>
</TBODY>
</TABLE>

<TABLE-GROUP ACLASS="PB_VAL" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="391"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="200" HEIGHT="30" AUPDATECONT="N">제출대상법인 유형 :</TD>
<TU WIDTH="400" HEIGHT="30" AUNIT="PB_TYPE" AUNITVALUE="1">주권상장법인</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30" AUPDATECONT="N"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="200" HEIGHT="30" AUPDATECONT="N">면제사유발생 :</TD>
<TU WIDTH="400" HEIGHT="30" AUNIT="PB_CAMNT" AUNITVALUE="-">해당사항 없음</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<TABLE AFIXTABLE="N" BORDER="0" WIDTH="600" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="391"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">회      사      명 :</TD>
<TD WIDTH="400" HEIGHT="30">(주)레고켐 바이오사이언스</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">대   표    이   사 :</TD>
<TD WIDTH="400" HEIGHT="30">김 용 주</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">본  점  소  재  지 :</TD>
<TD WIDTH="400" HEIGHT="30">대전광역시 대덕구 문평서로 8-26</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30">(전  화) 042-861-0688</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30">(홈페이지) http://www.legochembio.com</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">작  성  책  임  자 :</TD>
<TD WIDTH="400" HEIGHT="30">(직  책)  수석부사장       (성  명) 박세진</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30">(전  화)  042-861-0688</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30"></TD>
<TD WIDTH="400" HEIGHT="30"></TD>
</TR>
</TBODY>
</TABLE>
<PGBRK></PGBRK>
</COVER>

<SECTION-1 AID="CEO-CERT" ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="TTL_CEO_CERT">【 대표이사 등의 확인 】</TITLE>

<APPENDIX ATYPE="IMAGE">
<COMMENT>◆click◆ 대표이사 등이 서명한 『확인서』 그림파일 삽입</COMMENT>
</APPENDIX>

<IMAGE>
<IMG WIDTH="594" HEIGHT="840" ALIGN="CENTER" HSPACE="0">대표이사등의 확인서.jpg</IMG>
<IMG-CAPTION ATOC="N">대표이사등의 확인서</IMG-CAPTION>
</IMAGE>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y">I. 회사의 개요</TITLE>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-1-0">1. 회사의 개요</TITLE>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『연결재무제표를작성하는주권상장법인』 삽입</COMMENT>
<LIBRARYLIST>11011#*연결재무제표를작성하는주권상장법인.dsl</LIBRARYLIST>
</INSERTION>

<P>가. 회사의 법적, 상업적 명칭&cr;당사의 명칭은 "주식회사 레고켐 바이오사이언스"라고 표기합니다. 또한, 영문으로는LegoChem Biosciences Inc.라 표기합니다.  단, 약식으로 표기할 경우에는 (주)레고켐 바이오 또는 LegoChem Bio 또는 LCB 라고 표기합니다.&cr;&cr;나. 설립일자 및 존속기간&cr;당사는 합성신약 연구개발 목적으로 2006년 5월 2일에 설립되었습니다. 또
<SPAN>한 </SPAN>
<SPAN> 2012년 12월 20일</SPAN>
<SPAN>에 코스닥시장 상장 승인을 받아 회사 주식이 2013년 5월 10일자</SPAN>로 상장되었습니다. &cr;&cr;다. 본사의 주소, 전화번호 및 홈페이지&cr;주소: 대전광역시 대덕구 문평서로 8-26(문평동) &cr;전화번호: 042-861-0688&cr;홈페이지: http://www.legochembio.com&cr;&cr;라. 중소기업 해당여부&cr;당사는 보고서 제출일 현재 중소기업에 해당됩니다.&cr;&cr;마. 주요사업의 내용&cr;당사는 의약화학(medicinal chemistry)을 기반으로 합성신약을 연구, 개발하고 이를 적정 개발단계 신약후보물질 License-Out 통한 수익 창출하는 분야 그리고 인수, 합병을 통해 추가된 의약품, 의료기기, 의료용 소모품 판매사업을 주요 사업으로 영위하고 있습니다. 주요 사업분야 중  항생제,항응혈제,항암제, ADC(Antibody-Drug Conjugate)분야를 중심으로 세계적 신약개발 후보 창출에 전념하고 있으며 상세한 내용은 동 보고서의 『II. 사업의 내용』을 참조하시기 바랍니다.&cr;
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>&cr;
<SPAN>바</SPAN>
<SPAN>. 계열회사에 관한 사항&cr;</SPAN>
<SPAN>- 당사는 2020년 12월 31일 현재 당사를 제외하고, 1개의 관계기업을 가지고 있습니다. 계열회사에 관한 사항은 동 보고서 'IX. 계열회사 등에 관한 사항'을 참조하시기 바랍니다.&cr;</SPAN>
</P>
<P>사. 회사의 주권상장(또는 등록ㆍ지정)여부 및 특례상장에 관한 사항</P>
<P></P>
<P>회사의 주권상장(또는 등록ㆍ지정)여부 및 특례상장에 관한 사항</P>

<TABLE-GROUP ACLASS="SPC_CRT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="731" BORDER="1">

<COLGROUP>
<COL WIDTH="161"></COL>
<COL WIDTH="161"></COL>
<COL WIDTH="229"></COL>
<COL WIDTH="144"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="170" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">주권상장&cr;(또는 등록ㆍ지정)여부</TH>
<TH WIDTH="170" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">주권상장&cr;(또는 등록ㆍ지정)일자</TH>
<TH WIDTH="238" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">특례상장 등&cr;여부</TH>
<TH WIDTH="153" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">특례상장 등&cr;적용법규</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE WIDTH="170" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="SPC_CHK">코스닥시장</TE>
<TU WIDTH="170" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUNIT="SPC_DATE" AUNITVALUE="20130510">2013년 05월 10일</TU>
<TE WIDTH="238" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="SPC_CHP">기술성장기업의 코스닥시장 상장</TE>
<TE WIDTH="153" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="SPC_LAW">코스닥시장상장규정&cr;제7조2항</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-2-0">2. 회사의 연혁</TITLE>

<P>
<SPAN>가. 회사의 본점소재지 및 그 변경&cr;</SPAN>당사는 2013년 05월 회사의 본점 소재지를 대전광역시 유성구 전민동 461-8 대전바이오벤처타운의 임차 만료로 대전광역시 대덕구 문평서로 8-26번지 DNF 건물로 본점 소재지를 변경하였습니다.&cr;&cr;
<SPAN>나. 경영진의 중요한 변동 및 최대주주의 변동&cr;</SPAN>당사의 현재 대표이사인 김용주는 회사를 설립한 이후 경영권을 행사하고 있으며, 최대주주 또한 설립일 이후 변동이 없습니다.&cr;&cr;다. 상호의 변경 &cr;※ 해당 사항이 없습니다.&cr;&cr;라. 회사가 화의, 회사정리절차 그 밖에 이에 준하는 절차를 밟은 적이 있거나 현재 진행중인 경우 그 내용과 결과&cr;※ 해당 사항이 없습니다.&cr;&cr;마. 회사가 합병등을 한 경우 그 내용&cr;1) 합병&cr;- 2015년 10월 1일 비상장법인 (주)칸메드와 합병계약을 체결하고, 2015년 12월21일(합병등기일) 합병을 완료하였습니다. 
</P>

<TABLE BORDER="1" WIDTH="762" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="116"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="133"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" B">구  분</TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" B">내  역</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="99">1. 합병방법</TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="99">본 합병은 주권상장법인인 주식회사 레고켐바이오사이언스가 주권비상장법인인 주식회사 칸메드를 흡수합병하는 방법으로 하며, 이에 따라 주식회사 레고켐 바이오사이언스는 존속하고 주식회사 칸메드는 소멸되어 해산합니다. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="76">2. 합병목적 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="76">주식회사 레고켐 바이오사이언스와 주식회사 칸메드는 사업다각화와 경영효율성 증대를 통하여 양사의 주주가치 극대화를 추구하기 위함. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="30">3. 합병비율 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">-(주)레고켐 바이오사이언스:(주)칸메드 = 1 : 1.363813 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="1325">4. 합병비율 산출근거 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="1325">합병법인의 기준주가는 자본시장과금융투자업에관한법률시행령 제176조 의5 제1항제1호에 따라 합병을 위한 이사회 결의일(2015년 10월 1일)과 합병계약을 체결한 날(2015년 10월1일) 중 앞서는 날의 전일(2015년 9월 30일)을 기산일로 한 최근 1개월간의 거래량 가중산술평균종가, 최근 1주일간의 거래량 가중산술평균종가, 최근일의종가를 산술평균한 가액을 기준으로 100분의 10(계열회사 간 합병)의 범위에서 할인또는 할증한 가액으로 산정하는바 본 건 합병에서는 할인하지 않은 가액으로 산정하였습니다. &cr;&cr;최근 1개월 가중산술평균종가는 2015년 9월 1일부터 2015년 9월 30일까지의 종가와 거래량을 이용하며 최근 1주일 가중 산술평균종가는 2015년 9월 24일부터 2015년 9월 30일까지의 종가와 거래량을 이용합니다. &cr;&cr;1개월 가중평균주가(2015.09.01 ~ 2015.09.30) : 22,440원 &cr;&cr;1주일 가중평균주가(2015.09.24 ~ 2015.09.30) : 22,888원 &cr;&cr;최종일 주가(2015.09.30) : 22,750원 &cr;&cr;산술평균주가 : 22,693원 &cr;&cr;기준 주가: 22,693원 &cr;&cr;합병법인의 1주당 자산가치는 증권의발행및공시등에관한규정시행세칙 제5조에 따라 주요사항보고서를 제출하는 날이 속하는 사업연도의 직전 사업연도말 현재의 감사받은 재무상태표상의 자본총계에서 일부 조정항목을 가감하여 산정된 순자산가액을 분석기준일 현재의 발행주식총수로 나누어 산정하였습니다. &cr;&cr;순자산가액 : 20,286,417,766원 &cr;&cr;발행주식수 : 7,680,828 주 &cr;&cr;1주당 주식가액 : 2,641원 &cr;&cr;자본시장과금융투자업에관한법률시행령 제176조의5에 의하면, 비상장법인인 피합병법인의 합병가액은 본질가치(자산가치와 수익가치를 각각 1과 1.5의 비율로 가중산술평균한 가액)로 평가하도록 규정하고 있으므로, 본 평가에 있어 합병가액의 산정은 본질가치를 적용하였습니다. &cr;&cr;자산가치(a) : (2,423)원 &cr;수익가치(b) : 49,967원 &cr;본질가치[(a+(b*1.5)]/2.5: 30,949원 &cr;합병가액 : 30,949원 &cr;&cr;산출결과 &cr;&cr;합병법인이 피합병법인을 합병함에 있어서 합병비율의 기준이 되는 양 합병당사회사의 주당평가액은 합병법인과 피합병법인이 각각 22,693원(주당 액면가액 500원)과 30,949원(주당 액면가액 500원)으로 추정되었으며, 이에 따라 합병 당사회사의 합병비율은 1 : 1.363813은 적정한 것으로 판단됩니다. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" ROWSPAN="2" WIDTH="256" VALIGN="MIDDLE" HEIGHT="60">5. 합병신주의 종류와 수 (주) </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">보통주식 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">1,363,813 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">종류주식 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="6" WIDTH="125" VALIGN="MIDDLE" HEIGHT="180">6. 합병상대회사 </TD>
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">회사명 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">주식회사 칸메드 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">주요사업 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">의료기기 소모품, 판매업 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">회사와 관계 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" WIDTH="131" VALIGN="MIDDLE" HEIGHT="90">최근 사업연도 재무내용(백만원) </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">자산총계 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">7,293 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">자본금 </TD>
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">500 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">부채총계 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">4,832 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">매출액 </TD>
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">9,096 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">자본총계 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2,461 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">당기순이익 </TD>
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1,836 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="11" WIDTH="125" VALIGN="MIDDLE" HEIGHT="330">7. 합병일정 </TD>
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">임시 주주총회일자 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">2015-11-16 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="131" VALIGN="MIDDLE" HEIGHT="60">구주권제출기간 </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">시작일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">종료일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="131" VALIGN="MIDDLE" HEIGHT="60">매매거래정지 예정기간 </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">시작일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">종료일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="131" VALIGN="MIDDLE" HEIGHT="60">채권자이의제출기간 </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">시작일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-11-17 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">종료일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-12-18 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">합병기일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-12-21 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">합병등기완료일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-12-21 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">신주권교부일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-12-29 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="231" VALIGN="MIDDLE" HEIGHT="30">신주의 상장일 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2015-12-30 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="30">9. 우회상장 해당 여부 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">아니오 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="30">10. 타법인의 우회상장 요건 충족여부 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">아니오 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="1249">11. 주식매수청구권 사항 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="1249">1. 행사요건 및 절차 &cr;&cr;가.이사회결의 반대의사 표시 &cr;주주총회결의일 전일까지 이사회결의 반대의사표시 통지서를 기재한 후, 명부주주는 주주총회 1영업일 전일까지 해당법인 본사에 제출하고, 실질주주는 주주총회 3영업일 전일까지 거래증권회사에 제출하여야 함. &cr;&cr;나.행사 요건 &cr;권리주주 확정기준일(2015.10.16) 현재 주주명부에 등재된 주주를 대상으로하여 주주총회결의일 전일까지 이사회결의 반대의사를 통지하고, 주주명부폐쇄 기준일부터 매수청구권 행사일까지 주식을 계속보유하여야 함. &cr;&cr;단, 반대의사를 통지한 주식의 범위내에서 주주총회결의일부터20일이내 주식매수선택권을 행사한 주식에 한해 주식매수대금이 지급되며, 매각 후 재취득한 주식에 대해서는 매수청구권이 없음. &cr;&cr;&cr;나.이사회결의 반대의사 표시 &cr;주주총회결의일 전일까지 이사회결의 반대의사표시 통지서를 기재한 후, 명부주주는 주주총회 1영업일 전일까지 해당법인 본사에 제출하고, 실질주주는 주주총회 3영업일 전일까지 거래증권회사에 제출하여야 함. &cr;&cr;2.주식매수청구기간 &cr;상법 제522조의3 및 자본시장과 금융투자업에 관한 법률 제165조의5에 의거하여 주주총회 전에 회사에 대하여 서면으로 합병에 관한 이사회 결의에 반대하는 의사를 통지한 주주는 주주총회 결의일부터 20일이내에 매수청구를 할 수 있습니다. &cr;&cr;3.주식매수청구서의 주식매수 예정가격 &cr;1)협의를 위한 회사의 제시가격 &cr;  23,679원 &cr;  a. 최근 2개월 거래량 가중평균 &cr;  25,710원 &cr;  b. 최근 1개월 거래량 가중평균 &cr;  22,440원 &cr;  c. 최근 1주일 거래량 가중평균 &cr;  22,888원 &cr;  d.기준매수가격:[a+b+c/3]=23,679 원 &cr;&cr;2)산출근거 &cr;자본시장과 금융투자업에 관한 법률 제165조의5 및 동법 시행령 제176조의7 에 따른 매수가격 산정방법에 의한 가액 &cr;&cr;3)협의가 성립되지 아니할경우 처리방법 &cr;자본시장과 금융투자업에 관한 법률 제165조의5 제3항에 따라 당해 회사 또는 매수를 청구하는 주주가 협의를 위한 회사의 제시가격에 반대하는 경우에는 법원에 매수가격의 결정을 청구할 수 있습니다. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="30">12. 이사회결의일(결정일) </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">2015-10-01 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" ROWSPAN="2" WIDTH="256" VALIGN="MIDDLE" HEIGHT="60">-사외이사 참석여부 </TD>
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">참석(명) </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">1 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="100" VALIGN="MIDDLE" HEIGHT="30">불참(명) </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="30">-감사(감사위원)참석여부 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="30">참석 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="3" WIDTH="356" VALIGN="MIDDLE" HEIGHT="651">13. 기타 투자판단에 참고할 사항 </TD>
<TD COLSPAN="3" WIDTH="406" VALIGN="MIDDLE" HEIGHT="651">가. 본 합병은 합병법인인 주식회사 레고켐 바이오사이언스와 피합병법인인 주식회사 칸메드의 합병계약 승인을 위한 임시주주총회에서 각각 참석주주의 의결권의 3분의 2 이상의 수와 발행주식총수의 3분의 1 이상의 수의 승인을 얻지 못할 경우 합병이 무산될 수 있음 &cr;(주)칸메드가 인수를 추진하고 있는 법정 관리중인 "A" 제약회사의 인수 또는 이에 준하는 대안을 확보하는 것을 전제로 함. &cr;&cr;나. 합병의 주요 일정 &cr; - 주주확정 기준일: 2015.10.16 &cr; - 주주명부 폐쇄기간: 2015.10.19~2015.10.20 &cr; - 합병 반대주주 의사 접수: 2015.10.30~2015.11.13 &cr; - 임시주주총회 예정일: 2015.11.16 &cr; - 주식매수청구권행사기간: 2015.11.16~2015.12.07 &cr; - 채권자 이의 제출기간: 2015.11.17~2015.12.18 &cr; - 합병기일: 2015.12.21 &cr;&cr;다. 상기 나. 합병의 주요 일정은 관계법령상의 인허가, 승인 및 관계기관과의 협의 등에 의해 변경 될 수 있음. &cr;&cr;라. 본건 합병과 관련하여 합병법인 주식매수청구권이 행사된 주식에 대한 각 주식매수가액의 합계액이 각 주식매수청구권 행사기간 만료시점을 기준으로 금오십억원(5,000,000,000)원을 초과하는 경우 본 계약을 해제할 수 있음 &cr;&cr;바. 기타 세부사항은 2015년 10월 01일 및 10월 16일(정정) 공시하는 주요사항보고서(합병결정) 참조 </TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;바. 회사의 업종 또는 주된 사업의 변화&cr;당사는 설립 이후 의약화학(medicinal chemistry)을 기반으로 합성신약을 연구, 개발하고 이를 적정 개발단계 신약후보물질 License-Out 통한 수익 창출을 주요사업으로 하고 있으며, 2015년 12월 21일(합병등기일) 합병으로 인해  의약품, 의료기기, 의료용 소모품 판매사업을 추가로 영위하고 있습니다.&cr;</P>

<P>사. 그 밖에 경영활동과 관련된 중요한 사항의 발생내용&cr;&cr;2013년 02월 그람음성균 항생제-범부처 전주기 신약개발사업 선정&cr;2013년 03월 증권신고서 제출&cr;2013년 05월 코스닥 시장 상장, 매매개시&cr;                    본점 소재지 변경(대전 대덕구 문평서로 8-26)&cr;2013년 07월  제3회차 사모전환사채 발행(10억)&cr;                    (KB12-1벤처조합)(업무집행조합원:KB 인베스트먼트)&cr;2013년 08월  2013년도 중소기업 기술혁신 개발사업중 글로벌 전략기술 개발사업&cr;                    (투자연계) 과제 선정 (중소기업청) &cr;                    그람음성균 항생제 비임상 개시(영국)&cr;                    녹십자 FXa 저해제 임상 1상(b) 개시(미국)&cr;2013년
<SPAN></SPAN>
<SPAN> 11월 차세대 Oxa.항생제 기술이전 변경계약(중국 Medicilon사->Longthera)&cr; </SPAN>
<SPAN>&cr;2014년 </SPAN>
<SPAN>01월  </SPAN>
<SPAN>그람음성균 항생제 단독투여방식 대상  추가 기술이전&cr;                    계약 체결(AstraZeneca)&cr;                 </SPAN>
<SPAN USERMARK=" 0X0000FF">  </SPAN>
<SPAN USERMARK="F-11 0X0000FF"> </SPAN>
<SPAN USERMARK="F-11">☞ </SPAN>
<SPAN USERMARK="F-11">2012년 12월 및 2014년 1월 AstraZeneca와 체결한 그람음성균 &cr;                     항생제 기술이전 계약은 2014년 4월 30일 공시한 바와 같이 계약 해지 &cr;                     되었음.&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN>2014년 04월 벤처기업 확인(6차) → 벤처투자기업 (한국벤처캐피탈협회)&cr;</SPAN>
<SPAN USERMARK="F-11 0X0000FF"></SPAN>
<SPAN>2014년 08월 산업통상자원부 두뇌역량우수전문기업 선정(2년)&cr;2014년 09월 LCB02-0133 FXa 저해제 임상 1상 미국에서 완료&cr;                   Delpazolid (LCB01-0371) (IV) 주사제 미국 비임상 개시&cr;                   LCB01-0699 차세대 옥사계항생제 중국 Medicilon 비임상 개시&cr;                  신규항암제(Sanofi와 공동연구) In-vivo 개시&cr;2014년 10월 Delpazolid (LCB01-0371) 옥사계 항생제, 식품의약품안전처 &cr;                   제품화 내비게이터(“팜나비”) 2호 선정&cr;2014년 11월 3개 창투사 190억 투자 유치&cr;</SPAN>
<SPAN>2015년 08월 </SPAN>
<SPAN>Anti-HER2 ADC, 중국시장 대상으로 Fosun Pharma에 기술이전</SPAN>
<SPAN USERMARK="F-11">&cr;</SPAN>
<SPAN>           10월 레고켐바이오의 칸메드 흡수합병 계약 체결(10월 1일)&cr;           11월 2015년도 국제공동기술개발사업(한-프랑스) 선정 (산업통상자원부) &cr;</SPAN>
<SPAN>           12월 칸메드 인수완료, 레고켐제약(구.한불제약) 종속회사 편입&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN>2016년 04월 벤처기업 확인(7차) → 벤처투자기업 (한국벤처캐피탈협회)&cr;           05월 다제내성 결핵치료제인 LCB01-0371 임상2상 시험계획 승인&cr;          </SPAN>
<SPAN> 06월 고유 ADC 링커 특허 취득&cr;           07월 LCB10-0200 그람음성균 항생제 글로벌 임상을 위한 JV 설립&cr;           08월 Delpazolid (LCB01-0371)옥사계 항생제(주사제), 한국 식품의약품&cr;                  안전처 임상 1상 시험 승인&cr;                 산업통상자원부 두뇌역량우수전문기업 재선정(2년)&cr;           09월 4개 창투사 350억 투자 유치&cr;           12월 Delpazolid (LCB01-0371) 옥사계항생제, 중국시장 대상으로 &cr;                    Haihe Bio(구 RMX Bio)사에 기술이전&cr;</SPAN>
<SPAN>2017년 01월 Takeda와 ADC 리서치 라이선스 계약 체결           &cr;        </SPAN>           ADC 항체 구조 및 제조방법 특허 취득&cr;
<SPAN USERMARK=" 0X9D3272">           </SPAN>
<SPAN>04월 고</SPAN>
<SPAN>유 ADC 플랫폼 기술 ConjuALL 미국 특허 등록&cr;           05월 LCB17-0877 ATX 저해제, 브릿지바이오에 기술이전&cr;    </SPAN>
<SPAN>       07월 Delpazolid (LCB01-0371) 그람양성균 항생제 미국 FDA 희귀의약품 &cr;                   지정&cr;           </SPAN>
<SPAN>08월 고</SPAN>
<SPAN>유 ADC 플랫폼 기술 ConjuALL 일본 특허 등록&cr;</SPAN>
<SPAN>         </SPAN>
<SPAN></SPAN>
<SPAN>  09월 LCB10-0200 그람음성균 항생제 미국 NIH 국책과제 선정&cr;</SPAN>
<SPAN>          </SPAN>
<SPAN>        </SPAN>
<SPAN> </SPAN>
<SPAN>LCB01-0371 그람양성균 항생제 미국 FDA QIDP 선정</SPAN>
<SPAN></SPAN>
<SPAN>&cr;                   LCB18-0055 베타락탐 저해제 Geom Therapeutics 기술이전&cr;</SPAN>
<SPAN></SPAN>
<SPAN>2018년 01월 Delpazolid (LCB01-0371) 미국 FDA 신속심사 (Fast Track) 선정        &cr;        </SPAN>           LCB02-0133 중국판권 Lee's Pharm 기술이전&cr;
<SPAN></SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN>      </SPAN>
<SPAN USERMARK=" 0X0000FF">     </SPAN>
<SPAN> 04월 벤처기업 확인(8차) → 벤처투자기업 (한국벤처캐피탈협회)&cr;            08월 산업통상자원부 두뇌역량우수전문기업 재선정(2년)&cr;            11월 '월드 ADC 어워즈 2018'에서 '베스트 ADC플랫폼 테크놀로지' 수상&cr;</SPAN>
<SPAN>2019년 03월 Takeda와 ADC 기술이전 계약 체결   </SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>            06월 </SPAN>
<SPAN>고</SPAN>
<SPAN>유 ADC 플랫폼 기술 ConjuALL 미국 특허 등록&cr;        </SPAN>
<SPAN>    10월 '월드 ADC 어워즈 2019'에서 2년 연속 '베스트 ADC플랫폼 &cr;                    테크놀로지' 수상&cr;</SPAN>
<SPAN>2020년 04월 Iksuda와 ADC 원천기술이전 계약 체결</SPAN>
<SPAN></SPAN>
<SPAN>&cr;           05월 </SPAN>
<SPAN>Iksuda와 Anti-CD19 ADC 기술이전 계약 체결</SPAN>
<SPAN></SPAN>
<SPAN>&cr;           06월 신종바이러스(CEVI)융합사업단과 COVID-19치료제 후보물질 &cr;                   기술도입 계약체결&cr;           10월 '월드 ADC 어워즈 2020'에서 3년 연속 '베스트 ADC플랫폼 &cr;                    테크놀로지' 수상&cr;           10월 CStone과 Anti-ROR1 ADC 기술이전 계약 체결&cr;           12월 Pyxis와 Anti-DLK1 ADC 기술이전 계약 체결&cr;           12월</SPAN> 일본기업과 ADC 리서치 라이선스 계약 체결 &cr;
</P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-3-0">3. 자본금 변동사항</TITLE>
<P>증자(감자)현황</P>

<TABLE-GROUP ACLASS="INC_STAT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="914" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="608"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="617" HEIGHT="30" AUNIT="WONSTOCK" AUNITVALUE="1">(단위 : 원, 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="916" BORDER="1">

<COLGROUP>
<COL WIDTH="83"></COL>
<COL WIDTH="149"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="299"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식발행&cr;(감소)일자</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">발행(감소)&cr;형태</TH>
<TH COLSPAN="5" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="666" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">발행(감소)한 주식의 내용</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식의 종류</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">수량</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주당&cr;액면가액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="90" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주당발행&cr;(감소)가액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="308" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20130507">2013.05.07</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="01">유상증자(일반공모)</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">1,400,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">15,500</TE>

<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">
<SPAN>코스닥 시장 상장 공모주 </SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20130514">2013.05.14</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">우선주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">985,798</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">-</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 우선주의 감소</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20130514">2013.05.14</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">1,131,632</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">-</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20130516">2013.05.16</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">31,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">2,333</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20131104">2013.11.04</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">우선주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">166,666</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">-</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 우선주의 감소</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20131104">2013.11.04</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">199,999</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">-</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20140715">2014.07.15</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">27,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">3,333</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20140916">2014.09.16</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">79,681</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">12,550</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">전환사채</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20141110">2014.11.10</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="04">유상증자(제3자배정)</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">415,298</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">18,300</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20150318">2015.03.18</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">24,468</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">8,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20151221">2015.12.21</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="-">-</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">1,363,813</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">22,693</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">합병으로 인한 신주발행</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20160418">2016.04.18</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">20,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">8,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20160418">2016.04.18</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">19,108</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">12,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20160418">2016.04.18</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">231,884</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">20,700</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20160908">2016.09.08</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="04">유상증자(제3자배정)</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">615,574</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">39,800</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20161005">2016.10.05</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">13,700</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20170404">2017.04.04</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">13,380</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">24,650</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20180131">2018.01.31</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">318,839</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">20,700</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20180131">2018.01.31</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">290,856</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">36,100</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20180227">2018.02.27</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">4,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">18,050</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20180227">2018.02.27</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">21,100</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">19,150</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20181124">2018.11.24</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="04">유상증자(제3자배정)</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">우선주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">1,408,447</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20190320">2019.03.20</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">9,680</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">27,450</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20191210">2019.12.10</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">83,535</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20191212">2019.12.12</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">38,842</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">3,642</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">27,450</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">3,640</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">31,850</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">2,240</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">33,150</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">690</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">12,300</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">900</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">35,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200213">2020.02.13</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">27,270</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">33,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200422">2020.04.22</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="07">주식매수선택권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">6,780</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">33,000</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200507">2020.05.07</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">3,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200602">2020.06.02</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">39,905</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200604">2020.06.04</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">16,132</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200605">2020.06.05</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">895,228</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200609">2020.06.09</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="05">전환권행사</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">120,537</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">42,600</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">우선주의 보통주전환에 따른 보통주의 증가</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200617">2020.06.17</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="10">무상증자</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">11,841,903</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">500</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" AUNIT="INC_DT" AUNITVALUE="20200617">2020.06.17</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="158" HEIGHT="30" AUNIT="INC_DR_KND" AUNITVALUE="10">무상증자</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="98" HEIGHT="30" ACODE="INC_STK_KND">우선주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="INC_CNT">211,268</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACODE="INC_PAR_AMT">500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACODE="INC_SL_AMT">500</TE>
<TD VALIGN="MIDDLE" WIDTH="308" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆ 『미상환 전환사채 발행현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*미상환전환사채발행현황.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆ 『미상환 신주인수권부사채 등 발행현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*미상환신주인수권부사채등발행현황.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆ 『미상환 전환형 조건부자본증권 등 발행현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*미상환전환형조건부자본증권등발행현황.dsl</LIBRARYLIST>
</INSERTION>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-4-0">4. 주식의 총수 등</TITLE>
<P>주식의 총수 현황</P>

<TABLE-GROUP ACLASS="TOT_STK" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="712" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="365"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="106" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="374" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="712" BORDER="1">

<COLGROUP>
<COL WIDTH="83"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="184"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="243" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구  분</TH>
<TH COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="276" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" AUPDATECONT="N">주식의 종류</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="193" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACOPYCOL="N" ACODE="STK_KND_TOT" ADELETECOL="N" AMOVECOL="N">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACOPYCOL="Y" ACODE="STK_KND_TOT" ADELETECOL="Y" AMOVECOL="N">종류주식</TE>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅰ. 발행할 주식의 총수</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK1">40,000,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK1">10,000,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_ISU_STK1">50,000,000</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅱ. 현재까지 발행한 주식의 총수</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK2">23,683,806</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK2">1,619,715</TE>

<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_ISU_STK2">25,303,521
<SPAN USERMARK=" 0X0000FF"></SPAN>
</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE1">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅲ. 현재까지 감소한 주식의 총수</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="TOT_RST">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="TOT_RST">1,197,179</TE>

<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_RST">1,197,179
<SPAN USERMARK=" 0X0000FF"></SPAN>
</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="4" VALIGN="MIDDLE" WIDTH="92" HEIGHT="120" AUPDATECONT="N"></TD>
<TD VALIGN="MIDDLE" WIDTH="151" HEIGHT="30" AUPDATECONT="N"> 1. 감자</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="RDC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="RDC_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_RDC_CNT">-</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE3">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="MIDDLE" WIDTH="151" HEIGHT="30" AUPDATECONT="N"> 2. 이익소각</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="DST_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="DST_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_DST_CNT">-</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE4">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="MIDDLE" WIDTH="151" HEIGHT="30" AUPDATECONT="N"> 3. 상환주식의 상환</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="RFD_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="RFD_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_RFD_CNT">-</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE5">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="MIDDLE" WIDTH="151" HEIGHT="30" AUPDATECONT="N"> 4. 기타</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ETC_CNT">-</TE>

<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ETC_CNT">1,197,179
<SPAN USERMARK=" 0X0000FF"></SPAN>
</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_ETC_CNT">1,197,179</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE6">전환우선주의 보통주 전환</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅳ. 발행주식의 총수 (Ⅱ-Ⅲ)</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK3">23,683,806</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="ISU_STK3">422,536</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_ISU_STK3">24,106,342</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE7">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅴ. 자기주식수</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="TRS_STK">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="TRS_STK">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_TRS_STK">-</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE8">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" AUPDATECONT="N"> Ⅵ. 유통주식수 (Ⅳ-Ⅴ)</TD>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="FLT_STK">23,683,806</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="FLT_STK">422,536</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="92" HEIGHT="30" ACODE="SUM_FLT_STK">24,106,342</TE>
<TE VALIGN="MIDDLE" WIDTH="193" HEIGHT="30" ALIGN="CENTER" ACODE="NOTE9">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<P>
<SPAN USERMARK="F-11">주1) 당사 정관상 발행할 주식 총수는 50,000,000주이며, 발행할 주식 총수 중 종류 주식의 발행한도는 10,000,000주입니다.&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11">주2) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 기존주식에 무상증자분을 추가하여 작성하였습니다.</SPAN>
</P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆ 『자기주식 취득 및 처분 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*자기주식취득및처분현황.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="LE0" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆ 『종류주식(명칭) 발행현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*종류주식발행현황.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">24_종류주식발행현황</FILENAME>
<P>종류주식(명칭) 발행현황</P>

<TABLE-GROUP ACLASS="ISS_CURR" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="63"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="3" AUPDATECONT="N">발행일자</TD>
<TU WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="ISS_DATE" AUNITVALUE="20181123" COLSPAN="2">2018년 11월 23일</TU>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="3" AUPDATECONT="N">주당 발행가액(액면가액)</TD>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_PRC">42,600</TE>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_PRCK">500</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="3" AUPDATECONT="N">발행총액(발행주식수)</TD>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_TOT">59,999,842,200</TE>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_TOTK">1,408,447</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="3" AUPDATECONT="N">현재 잔액(현재 주식수)</TD>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_PNT">9,000,016,800</TE>

<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ISS_PNTK">211,268
<SPAN USERMARK=" 0X0000FF"></SPAN>
</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="72" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="475" ROWSPAN="12" AUPDATECONT="N">주식의&cr;내용</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2" AUPDATECONT="N">이익배당에 관한 사항</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_BET" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2" AUPDATECONT="N">잔여재산분배에 관한 사항</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_PRO" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="85" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="173" ROWSPAN="5" AUPDATECONT="N">상환에&cr;관한 사항</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">상환조건</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_REP" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">상환방법</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_WAY" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">상환기간</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_DAT" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">주당 상환가액</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_PRC" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">1년 이내&cr;상환 예정인 경우</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="STK_ONE" COLSPAN="2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="85" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="212" ROWSPAN="4" AUPDATECONT="N">전환에&cr;관한 사항</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" AUPDATECONT="N">전환조건&cr;(전환비율 변동여부 포함)</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" ACODE="STK_CHA" COLSPAN="2">전환가격 : 발행가와 동일 &cr;전환비율 : 1 대 1</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">전환청구기간</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_CDA" COLSPAN="2">2019년 11월 23일 ~ 2023년 11월 22일</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">전환으로 발행할&cr;주식의 종류</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="STK_KID" COLSPAN="2">기명식 보통주</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">전환으로&cr;발행할 주식수</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="STK_CHT" COLSPAN="2">1,408,447</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2" AUPDATECONT="N">의결권에 관한 사항</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="STK_VOT" COLSPAN="2">우선주 1주당 1 의결권</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" COLSPAN="3" AUPDATECONT="N">기타 투자 판단에 참고할 사항&cr;(주주간 약정 및 재무약정 사항 등)</TD>
<TE WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="ISS_ETC" COLSPAN="2">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주) 상기 주당 발행가액과 현재 잔액(현재 주식수)는 2020년 6월 1일 무상증자결정에 따라 각각 21,300원과 422,536주로 변경되었습니다.</P>
</LIBRARY>
</INSERTION>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-5-0">5. 의결권 현황</TITLE>

<TABLE-GROUP ACLASS="VOT_STK" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="294"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="303" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="229"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="136"></COL>
<COL WIDTH="115"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구     분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식의 종류</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">발행주식총수(A)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISU_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISU_STK">23,683,806</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISU_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISU_STK">422,536</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">의결권없는 주식수(B)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISN_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISN_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE1">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISN_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISN_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE1">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">정관에 의하여 의결권 행사가 배제된 주식수(C)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISQ_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISQ_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE2">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISQ_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISQ_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">기타 법률에 의하여&cr;의결권 행사가 제한된 주식수(D)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISJ_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISJ_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE3">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISJ_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISJ_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE3">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">의결권이 부활된 주식수(E)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISB_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISB_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE4">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISB_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISB_STK">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE4">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="238" HEIGHT="60" AUPDATECONT="N">의결권을 행사할 수 있는 주식수&cr;(F = A - B - C - D + E)</TD>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISH_STK_KND">보통주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISH_STK">23,683,806</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE5">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="30" ACODE="ISH_STK_KND">종류주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="145" HEIGHT="30" ACODE="ISH_STK">422,536</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="124" HEIGHT="30" ACODE="VOT_NOTE5">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-6-0">6. 배당에 관한 사항 등</TITLE>
<P>1) 배당 정책&cr;당사는 향후 순이익 발생에 따라 배당가능이익이 확보되면 정관 제 57 조 (이익배당)에 따라 배당을 실시할 예정입니다.&cr;</P>
<P>☞ 정관 제 57조(이익배당)  </P>
<P>- 이익의 배당은 금전, 또는 금전 외의 재산으로 할 수 있다.</P>
<P>- 이익의 배당을 주식으로 하는 경우 회사가 수종의 주식을 발행한 때에는 주주총회의 결의로 그와 다른 종류의 주식으로도 할 수 있다.</P>
<P>- 1항의 배당은 매 결산기말 현재의 주주명주에 기재된 주주 또는 등록된 질권자에게 지급한다.</P>
<P>- 이익배당은 주주총회의 결의로 정한다. 다만, 제54조제6항에 따라 재무제표를 이사회가 승인하는 경우 이사회 결의로 이익배당을 정한다.</P>
<P>&cr;2) 최근 3사업연도 배당에 관한 사항 </P>
<P></P>
<P>주요배당지표</P>

<TABLE-GROUP ACLASS="DIVIDEND" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="607" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="152"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="102"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="161" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">구   분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="113" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">주식의 종류</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">당기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">전기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">전전기</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">제15기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">제14기</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">제13기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">주당액면가액(원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X23" ADELIM="1" VALIGN="MIDDLE">500</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X23" ADELIM="2" VALIGN="MIDDLE">500</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X23" ADELIM="3" VALIGN="MIDDLE">500</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">(연결)당기순이익(백만원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X01" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X01" ADELIM="2" VALIGN="MIDDLE">12,476</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X01" ADELIM="3" VALIGN="MIDDLE">-26,073</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">(별도)당기순이익(백만원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X35" ADELIM="1" VALIGN="MIDDLE">-6,986</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X35" ADELIM="2" VALIGN="MIDDLE">16,004</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X35" ADELIM="3" VALIGN="MIDDLE">-24,897</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">(연결)주당순이익(원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X02" ADELIM="1" VALIGN="MIDDLE">-307</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X02" ADELIM="2" VALIGN="MIDDLE">1,281</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X02" ADELIM="3" VALIGN="MIDDLE">-2,446</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">현금배당금총액(백만원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X24" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X24" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X24" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">주식배당금총액(백만원)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X25" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X25" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X25" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="2" VALIGN="MIDDLE" WIDTH="274" HEIGHT="30" AUPDATECONT="N" ALIGN="CENTER">(연결)현금배당성향(%)</TD>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X05" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X05" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X05" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" VALIGN="MIDDLE" WIDTH="161" HEIGHT="60" AUPDATECONT="N" ALIGN="CENTER">현금배당수익률(%)</TD>
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X31" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" VALIGN="MIDDLE" WIDTH="161" HEIGHT="60" AUPDATECONT="N" ALIGN="CENTER">주식배당수익률(%)</TD>
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X32" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" VALIGN="MIDDLE" WIDTH="161" HEIGHT="60" AUPDATECONT="N" ALIGN="CENTER">주당 현금배당금(원)</TD>
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X33" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" VALIGN="MIDDLE" WIDTH="161" HEIGHT="60" AUPDATECONT="N" ALIGN="CENTER">주당 주식배당(주)</TD>
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ4" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="113" HEIGHT="30" ACODE="XQ4" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="111" HEIGHT="30" ACODE="X34" ADELIM="3" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주) 주당 순이익은 기본주당 순이익 입니다.&cr;※ 기본주당이익 산출근거는 III. 재무에 관한 사항의 5.재무제표 주석 중 주당이익 항목을 참조하십시오.&cr;주1) 당사는 당기 중 ㈜바스칸바이오제약에 대한 지배력을 상실하여, 해당 기업을 &cr; 연결대상 종속기업에서 제외하였으며, 당기말 현재 연결대상 기업은 없습니다.&cr;</P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆ 『과거배당이력』 삽입</COMMENT>
<LIBRARYLIST>11011#*과거배당이력.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">48_과거배당이력</FILENAME>
<P>과거 배당 이력</P>

<TABLE-GROUP ACLASS="DIVIDEND_BCK" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" HEIGHT="30" AUPDATECONT="N" VALIGN="MIDDLE"></TD>
<TD WIDTH="300" HEIGHT="30" AUPDATECONT="N" VALIGN="MIDDLE" ALIGN="RIGHT">(단위: 회, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="140"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="300" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">연속 배당횟수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="299" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">평균 배당수익률</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">분기(중간)배당</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">결산배당</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최근 3년간</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="149" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최근 5년간</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="RIGHT" WIDTH="150" HEIGHT="30" ACODE="DIV_QUA" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="150" HEIGHT="30" ACODE="DIV_END" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="150" HEIGHT="30" ACODE="DIV_THR" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="149" HEIGHT="30" ACODE="DIV_FIV" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>해당사항 없습니다.</P>
</LIBRARY>
</INSERTION>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-1-7-0">7. 정관에 관한 사항</TITLE>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆ 『정관변경이력』 삽입</COMMENT>
<LIBRARYLIST>11011#*정관변경이력.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">49_정관변경이력</FILENAME>
<P>1) 정관 변경 이력</P>

<TABLE-GROUP ACLASS="ART_BCK" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="882" BORDER="1">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="155"></COL>
<COL WIDTH="266"></COL>
<COL WIDTH="297"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="137" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">정관변경일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="164" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">해당주총명</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="275" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주요변경사항</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="306" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">변경이유</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="53" AUNIT="ART_DATE" AUNITVALUE="20190326" VALIGN="MIDDLE">2019년 03월 26일</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="53" ACODE="ART_NAME" VALIGN="MIDDLE">제 13기 정기주주총회</TE>
<TE WIDTH="275" HEIGHT="53" ACODE="ART_CHN" VALIGN="MIDDLE">제8조(주권의 발행과 종류)</TE>
<TE WIDTH="306" HEIGHT="53" ACODE="ART_RSN" VALIGN="MIDDLE">주권 전자등록의무화에 따라 삭제 (전자증권법 §25 ①)</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="76" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="76" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="76" ACODE="ART_CHN" VALIGN="MIDDLE">제8조의2(주식 등의 전자등록)</TE>
<TE WIDTH="306" HEIGHT="76" ACODE="ART_RSN" VALIGN="MIDDLE">상장법인의 경우 전자증권법에 따라 발행하는 모든 주식 등에 대하여 전자등록이 의무화됨에 따라 근거를 신설</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="53" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="53" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="53" ACODE="ART_CHN" VALIGN="MIDDLE">제 11 조 (주식매수선택권)</TE>
<TE WIDTH="306" HEIGHT="53" ACODE="ART_RSN" VALIGN="MIDDLE">행사일 연장&cr;장기근속유도</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="53" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="53" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="53" ACODE="ART_CHN" VALIGN="MIDDLE">제14조(명의개서대리인)</TE>
<TE WIDTH="306" HEIGHT="53" ACODE="ART_RSN" VALIGN="MIDDLE">주식 등의 전자등록에 따른 주식사무처리 변경내용 반영</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="76" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="76" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="76" ACODE="ART_CHN" VALIGN="MIDDLE">제15조(주주 등의 주소, 성명 및 인감 또는 서명 등 신고)</TE>
<TE WIDTH="306" HEIGHT="76" ACODE="ART_RSN" VALIGN="MIDDLE">주식 등이 전자등록에 따른 명의개서 대리인에게 별도 신고할 필요가 없으므로 &cr;조항 삭제</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="30" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="30" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="30" ACODE="ART_CHN" VALIGN="MIDDLE">제 18 조 (전환사채의 발행)</TE>
<TE WIDTH="306" HEIGHT="30" ACODE="ART_RSN" VALIGN="MIDDLE">한도 증액</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="30" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="30" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="30" ACODE="ART_CHN" VALIGN="MIDDLE">제 19 조 (신주인수권부사채의 발행)</TE>
<TE WIDTH="306" HEIGHT="30" ACODE="ART_RSN" VALIGN="MIDDLE">한도 증액</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="30" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="30" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="30" ACODE="ART_CHN" VALIGN="MIDDLE">제22조(사채발행에 관한 준용규정)</TE>
<TE WIDTH="306" HEIGHT="30" ACODE="ART_RSN" VALIGN="MIDDLE">제15조의 삭제에 따른 문구정비</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="30" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="30" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="30" ACODE="ART_CHN" VALIGN="MIDDLE">제 35 조 (이사의 수)</TE>
<TE WIDTH="306" HEIGHT="30" ACODE="ART_RSN" VALIGN="MIDDLE">자산총액 1천억원 이상 사외이사 선임</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="30" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="30" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="30" ACODE="ART_CHN" VALIGN="MIDDLE">제 47 조 (감사의 수)</TE>
<TE WIDTH="306" HEIGHT="30" ACODE="ART_RSN" VALIGN="MIDDLE">자산총액 1천억원 이상 상근감사 선임</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="53" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="53" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="53" ACODE="ART_CHN" VALIGN="MIDDLE">제 55 조 (외부감사인 선임)</TE>
<TE WIDTH="306" HEIGHT="53" ACODE="ART_RSN" VALIGN="MIDDLE">[주식회사 등의 외부감사에 관한 법률] 개정으로 변경</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="61" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="61" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="61" ACODE="ART_CHN" VALIGN="MIDDLE">제 17 조 (주주명부의 폐쇄 및 기준일)</TE>

<TE WIDTH="306" HEIGHT="61" ACODE="ART_RSN" VALIGN="MIDDLE">
<P USERMARK="F-GL11">기간을 의미하는 경우 개월로 표현 수정</P>
<P USERMARK="F-GL11">중복문구 삭제</P>
</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="61" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="61" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>
<TE WIDTH="275" HEIGHT="61" ACODE="ART_CHN" VALIGN="MIDDLE">제 23 조 (소집시기)</TE>

<TE WIDTH="306" HEIGHT="61" ACODE="ART_RSN" VALIGN="MIDDLE">
<P USERMARK="F-GL11">기간을 의미하는 경우</P>
<P USERMARK="F-GL11">개월로 표현 수정</P>
</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TU ALIGN="CENTER" WIDTH="137" HEIGHT="224" AUNIT="ART_DATE" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="164" HEIGHT="224" ACODE="ART_NAME" VALIGN="MIDDLE">상 동</TE>

<TE WIDTH="275" HEIGHT="224" ACODE="ART_CHN" VALIGN="MIDDLE">
<P>부      칙</P>
<P USERMARK="F-GL11">이 정관은 2019년 3월 26일부터 &cr;시행한다.</P>
<P USERMARK="F-GL11">다만, 제8조, 제8조의 2, 제14조, 제15조 및 제22조의 개정 규정은 [주식/사채 등의 전자등록에 관한 법률 시행령]이 시행되는 2019년 9월 16일부터 &cr;시행한다.</P>
</TE>
<TE WIDTH="306" HEIGHT="224" ACODE="ART_RSN" VALIGN="MIDDLE">부칙 신설</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P>&cr;※ 2021년 03월 31일 제 15기 정기주주총회의 안건으로 상정될 정관 일부 변경의 건은 아래와 같습니다.&cr;</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="630">

<COLGROUP>
<COL WIDTH="184"></COL>
<COL WIDTH="192"></COL>
<COL WIDTH="227"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>현 행</P>
</TH>

<TH WIDTH="201" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>개 정(안)</P>
</TH>

<TH WIDTH="236" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>개 정 이 유</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="306">
<P>제 8 조의 2 (주식 등의 전자등록)</P>
<P> </P>
<P>회사는 「주식·사채 등의 전자등록에 관한법률」제2조 제1호에 따른 주식 등을 발행하는 경우에는 전자등록기관의 전자등록계좌부에 주식 및 신주인수권증서에 표시된 권리 등을 전자등록하여야 한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="306">
<P>제 8 조의 2 (주식등의 전자등록)</P>
<P> </P>
<P>본 회사는 「주식·사채 등의 전자등록에 관한법률」 제2조 제1호에 따른 주식등을 발행하는 경우에는 전자등록기관의 전자등록계좌부에 주식등을 전자등록하여야 한다. 다만, 회사가 법령에 따른 등록의무를 부담하지 않는 주식등의 경우에는 그러하지 아니할 수 있다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="306">
<P>비상장 사채 등 의무등록 대상이 아닌 주식 등에 대해서는 전자등록을 하지 않을 수 있도록 함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="329">
<P>제 9 조의 3 </P>
<P>(이익배당 및 주식의 전환에 관한 종류주식)</P>
<P> </P>
<P>⑧ 기타 종류주식의 발행, 전환의 청구, 기타 전환에 대한 사항은 상법 제346조 내지 제351조의 규정을 따른다. 다만, 전환권을 행사한 주식 의 이익이나 이자의 배당에 관하여는 그 청구를 한 때가 속하는 영업연도 말에 전환된 것으로 본다.</P>
</TD>

<TD WIDTH="201" HEIGHT="329">
<P>제 9 조의 3 </P>
<P>(이익배당 및 주식의 전환에 관한 종류주식)</P>
<P> </P>
<P>⑧ 기타 종류주식의 발행, 전환의 청구, 기타 전환에 대한 사항은 상법 제346조 내지 제351조 의 규정을 따른다. </P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="329">
<P>배당 기준일이 언제인지와 관계 없이 영업년도 중간에 발행된 신주에 대하여 구주와 동등 배당 하는 취지로 정비</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="237">
<P>제 12 조 (신주의 배당기산일)</P>
<P> </P>
<P>본 회사가 유상증자, 무상증자 및 주식배당에 의하여 발행한 신주에 대한 이익의 배당에 관하여는 신주를 발행한 때가 속하는 영업년도의 직전 영업년도말에 발행된 것으로 본다.</P>
</TD>

<TD WIDTH="201" HEIGHT="237">
<P>제12조 (신주의 동등배당)</P>
<P> </P>
<P>본 회사는 배당기준일 현재 발행(전환된 경우를 포함)된 동등 주식에 대하여 발행일에 관계없이 모두 동등하게 배당한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="237">
<P>상법 개정으로 정관이 정하는 바에 따라 배당에 있어서 직전영업연도말 에 발행된 것으로 볼 수 있도록 한 규정이 삭제됨에 따라 배당기준일이 언제인지와 관계 없이 영업년도 중간에 발행된 신 주에 대하여 구주와 동등 배당하는 취지로 정비</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="191">
<P>제 14 조 (명의개서 대리인)</P>
<P> </P>
<P>① ② ③ 생략</P>
<P> </P>
<P>④ 제3항의 사무취급에 관한 절차는 명의개서대리인의 증권 명의개서대행업무 규정에 따른다.</P>
</TD>

<TD WIDTH="201" HEIGHT="191">
<P>제 14 조 (명의개서 대리인)</P>
<P> </P>
<P>① ② ③ 생략</P>
<P> </P>
<P>④ 제3항의 사무취급에 관한 절차는 명의개서대리인이 정한 관련업무 규정에 따른다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="191">
<P>전자등록제도 도입에 따라 증권에 대한 명의개서 대행 업무 없어짐에 따라 정비</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="467">
<P>제 16 조 (주주명부)</P>
<P> </P>
<P>회사의 주주명부는 상법 제352조의2에 따라 전자문서로 작성한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="467">
<P>제 16 조 (주주명부의 작성 및 비치)</P>
<P> </P>
<P>① 본 회사는 전자등록기관으로부터 소유자 명세를 통지 받은 경우 통지 받은 사항과 통지 연원일을 기재하여 주주명부를 작성·비치하여야 한다.</P>
<P> </P>
<P>② 본 회사는 5% 이상 지분을 보유한 주주(특수관계인 포함)의 현황에 변경이 있는 등 필요한 경우에 전자 등록기관에 소유자 명세의 작성을 요청할 수 있다. </P>
<P> </P>
<P>③ 회사의 주주명부는 상법 제352조의2에 따라 전자문서로 작성한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="467">
<P>전자증권법 제37조 제6항의 규정 내용을 반영, 전자증권법 시행령 제31조 제4항 제3호 가목에 의거 회사가 소유자 명세의 작성을 요청 가능하도록 근거규정 마련</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" VALIGN="MIDDLE" HEIGHT="766">
<P>제 17 조 (주주명부의 폐쇄 및 기준일)</P>
<P> </P>
<P>① 본 회사는 매년 1월 1일부터 1월 15일까지 주주의 권리에 관한 주주명부의 기재변경을 정지한다.</P>
<P> </P>
<P>② 본 회사는 매년 12월 31일 현재 주주명부에 기재되어 있는 주주를 그 결산기에 관한 정기주주 총회에서 권리를 행사할 주주로 한다.</P>
<P> </P>
<P>③ 본 회사는 임시주주총회의 소집 기타 필요한 경우 이사회의 결의로 3월을 경과하지 아니하는 일정한 기 간을 정하여 권리에 관한 주주명부 의 기재변경을 정지하거나, 이사회의 결의로 3개월내로 정한 날에 주주 명부에 기재되어 있는 주주를 그 권리를 행사할 주주로 할 수 있다. 이 경우 이사회가 필요 하다고 인정 하는 때에는 주주명부의 기재 변경 정지와 기준일의 지정을 함께 할 수 있다. 이 경우 회사는 주주명주 폐쇄 기간 또는 기준일의 2주간 전에 공고하여야 한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="766">
<P> 제 17 조 (주주명부의 폐쇄 및 기준일)</P>
<P> </P>
<P>① 회사는 의결권을 행사하거나 배당을 받을 자 기타 주주 또는 질권자로서 권리를 행사할 자를 정하기 위하여 이사회 결의로 일정한 기간을 정하여 주주명부의 기재변경을 정지하거나 일정한 날에 주주명부에 기재된 주주 또는 질권자를 그 권리를 행사할 주주 또는 질권자로 볼 수 있다.</P>
<P> </P>
<P>② 회사가 제1항의 기간 또는 날을 정하는 경우 3개월을 경과하지 아니하는 일정한 기간을 정하여 권리에 관한 주주명부의 기재변경을 정지하거나, 3개월내로 정한 날에 주주명부에 기재되어 있는 주주를 그 권리를 행사할 주주로 할 수 있다.</P>
<P> </P>
<P>③ 회사가 제1항의 기간 또는 날을 정한 때에는 그 기간 또는 날의 2주전에 이를 공고하여야 한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="766">
<P>전자증권법상 주주명부폐쇄 절차 불필요하여 삭제</P>
<P> </P>
<P>상법 개정에 따라 기준일을 결산 기말이 아닌 날로 정할 수 있어서 </P>
<P>기준일 12월 31일 삭제하여 정기주주총회 개최 시기의 유연성을 확보하기 위하여 조문을 정비함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="237">
<P>제 18 조 (전환사채의 발행)</P>
<P> </P>
<P>①②③ 생략</P>
<P> </P>
<P>④전환으로 인하여 발행하는 신주에 대한 이익의 배당과 전환 사채에 대한 이자의 지급에 대하여 는 제12조(신주의 배당기산일)의 규정을 준용한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="237">
<P>제 18 조 (전환사채의 발행)</P>
<P> </P>
<P>①②③ 생략</P>
<P> </P>
<P>④ 전환으로 인하여 발행하는 신주에 대한 이익의 배당에 대하여 는 제12조의 규정을 준용한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="237">
<P>전환사채를 주식으로 전환하는 경우 이자의 지급에 관한 내용을 삭제함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" VALIGN="MIDDLE" HEIGHT="260">
<P>제 19 조 (신주인수권부사채의 발행)</P>
<P> </P>
<P>①②③④ 생략</P>
<P> </P>
<P>⑤전환으로 인하여 발행하는 신주에 대한 이익의 배당과 전환 사채에 대한 이자의 지급에 대하여 는 제12조(신주의 배당기산일)의 규정을 준용한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="260">
<P> 제 19 조 (신주인수권부사채의 발행)</P>
<P> </P>
<P>①②③④ 생략</P>
<P> </P>
<P>⑤ 전환으로 인하여 발행하는 신주에 대한 이익의 배당에 대하여 는 제12조의 규정을 준용한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="260">
<P>신주인수권부사채를 주식으로 전환하는 경우 이자의 지급에 관한 내용 을 삭제함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="214">
<P>제 23 조 (소집시기)</P>
<P> </P>
<P>① 생략</P>
<P> </P>
<P>② 정기주주총회는 매사업년도 종료 후 3개월 이내에, 임시주주 총회는 필요에 따라 소집한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="214">
<P>제 23 조 (소집시기)</P>
<P> </P>
<P>① 생략</P>
<P> </P>
<P>② 정기주주총회는 제17조 제1항에서 정한 기준일로부터 3개월 이내에, 임시주주총회는 필요에 따라 소집한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="214">
<P>상법 개정에 따라 정기총회 의결권 행사 기준일을 결산기말이 아닌 날 로 정할 수 있게 됨에 따라 </P>
<P>기준일로부터 3개월 이내에 개최하는 것으로 통일.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="996">
<P>제 48 조 (감사의 선임)</P>
<P> </P>
<P>① 감사는 주주총회에서 선임한다.</P>
<P> </P>
<P>② 감사의 선임을 위한 의안은 이사의 선임을 위한 의안과는 별도 로 상정하여 의결하여야 한다.</P>
<P> </P>
<P>③ 감사의 선임은 출석한 주주의 의결권의 과반수로 하되 발행주식 총수의 4분의 1 이상의 수로 하여야 한다. 그러나 의결권 있는 발행주식 총수의 100분의 3을 초과하는 수의 주식을 가진 주주는 그 초과하는 주식에 관하여 감사의 선임에는 의결권을 행사하지 못한다. 다만, 소 유주식의 산정에 있어 최대주주와 그 특수관계인, 최대주주 또는 그 특수관계인의 계산으로 주식을 보유하는 자, 최대주주 또는 그 특수관계인에게 의결권을 위임한 자가 소유하는 의결권 있는 주식의 수는 합산한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="996">
<P>제48조(감사의 선임·해임) </P>
<P> </P>
<P>① 감사는 주주총회에서 선임·해임한다. </P>
<P> </P>
<P>② 감사의 선임 또는 해임을 위한 의안은 이사의 선임 또는 해임을 위한 의안과는 별도로 상정하여 의결하여야 한다.</P>
<P> </P>
<P>③ 감사의 선임은 출석한 주주의 의결권의 과반수로 하되 발행주식 총수의 4분의 1 이상의 수로 하여야 한다. 다만, 상법 제368조의4제1항 에 따라 전자적 방법으로 의결권을 행사할 수 있도록 한 경우에는 출석 한 주주의 의결권의 과반수로써 감사의 선임을 결의할 수 있다. </P>
<P> </P>
<P>④ 감사의 해임은 출석한 주주의 의결권의 3분의 2 이상의 수로 하되, 발행주식총수의 3분의 1 이상 의 수로 하여야 한다.</P>
<P> </P>
<P>⑤ 제3항·제4항의 감사의 선임 또는 해임에는 의결권 있는 발행주 식총수 의 100분의 3을 초과하는 수의 주식을 가진 주주(최대주주인 경우에는 그의 특수관계인, 최대주주 또는 그 특수 관계인의 계산으로 주식을 보유하는 자, 최대주주 또는 그 특수관계인에게 의결권을 위임한 자가 소유하는 의결권 있는 주식의 수를 합산한다)는 그 초과하는 주식 에 관하여 의결권을 행사하지 못한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="996">
<P>전자투표 도입 시 감사선임의 주주 총회 결의요건 완화에 관한 내용을 반영함.</P>
<P> </P>
<P> </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="375">
<P>제 54 조 (재무제표 등의 작성 등)</P>
<P> </P>
<P>① 생략 (재무제표)</P>
<P> </P>
<P>② 대표이사(사장)는 정기주주총회 회일의 6주간 전에 제1항의 서류를 감사에게 제출하여야 한다.</P>
<P> </P>
<P>③ 감사는 정기주주총회일의 1주전까지 감사보고서를 대표이사 (사장)에게 제출하여야 한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="375">
<P>제 54 조 (재무제표 등의 작성 등)</P>
<P> </P>
<P>① 생략 (재무제표)</P>
<P> </P>
<P>② 대표이사(사장)는 정기주주총회 회일 또는 사업보고서 제출기한의 6주간 전에 제1항의 서류를 감사 에게 제출하여야 한다.</P>
<P> </P>
<P>③ 감사는 정기주주총회일 또는 사업보고서 제출기한의 1주 전까지 감사보고서를 대표이사(사장)에게 제출하여야 한다.</P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="375">
<P>※ 회사는 "주식회사 등의 외부감사에 관한 법률"의 규정에 따라 재무제표를 사업보고서 제출기한 6주 전(연결 재무제표는 4주 전)까지 외부 감사 인에게 제출하여야 함. </P>
<P> </P>
<P>※ 사업보고서 제출기한 1주전까지 “감사의 감사 보고서”를 대표이사(사장)에게 제출하여야함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="193" HEIGHT="214">
<P>제 57 조 (이익배당)</P>
<P> </P>
<P>①② 생략</P>
<P> </P>
<P>③ 1항의 배당은 매 결산기말 현재의 주주명부에 기재된 주주 또는 등록된 질권자에게 지급한다.</P>
</TD>

<TD WIDTH="201" HEIGHT="214">
<P>제 57 조 (이익배당)</P>
<P> </P>
<P>①② 생략</P>
<P> </P>
<P>③ 제1항의 배당은 이사회 결의로 정하는 배당기준일 현재의 주주명부 에 기재된 주주 또는 등록된 질권자에게 지급한다. </P>
</TD>

<TD WIDTH="236" VALIGN="MIDDLE" HEIGHT="214">
<P>배당 기준일을 이사회 결의로 정하는 날로 함.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="3" WIDTH="630" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="375">
<P>부 칙</P>
<P> </P>
<P>제1조(시행일) </P>
<P> </P>
<P>본 정관은 제15기 정기 주주총회에서 승인한 2021년 3월 31일부터 시행한다. </P>
<P> </P>
<P>제2조(감사 선임에 관한 적용례) </P>
<P> </P>
<P>제50조제3항·제5항의 개정규정(선임에 관한 부분에 한한다)은 이 정관 시행 이후 선임하는 감사부터 적용한다.</P>
<P> </P>
<P>제3조(감사 해임에 관한 적용례) </P>
<P> </P>
<P>제50조제4항·제5항의 개정규정(해임에 관한 부분에 한한다)은 이 정관 시행 당시 종전 규정에 따라 선임된 </P>
<P>감사를 해임하는 경우에도 적용한다.</P>
</TD>
</TR>
</TBODY>
</TABLE>
<PGBRK></PGBRK>
</SECTION-2>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-2-0-0">II. 사업의 내용</TITLE>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『수주상황』 삽입</COMMENT>
<LIBRARYLIST>11011#*_수주상황.dsl</LIBRARYLIST>
</INSERTION>
<P USERMARK=" B">1. 사업의 개요  </P>

<P>
<SPAN>가. 제약산업의 특성&cr;</SPAN>
<SPAN>제약 산업의 특징은 아래와 같이 4개</SPAN>로 요약할 수 있습니다. 
<SPAN>&cr;</SPAN>
<SPAN>① 고위험, 고부가가치 (high risk, high return) </SPAN>
<SPAN>&cr;</SPAN>
<SPAN>  하나의 신약을 상품화하는데 소요되는 비용은 실패비용 및 개발 기간 등을 감안하면 평균 26억$ 정도입니다 (중도 실패 없이 성공적으로 수행할 경우는 개발비용은 훨씬 적어짐). 또한 첫 물질의 발굴에서부터 FDA 승인까지는 길게는 평균 12년~15년의 개발기간이 필요합니다. 신약개발은 이와 같은 고위험이 따르지만, 성공적으로 상업화되는 경우는 단 한 제품만으로도 세계적 제약회사가 될 수 있고, 특허 만료기간(출원으로부터 20년, 미국의 경우는 등록으로부터 17년)동안 물질특허를 인정 받아 안정적으로 사업을 영위할 수 있습니다. &cr;</SPAN>
</P>

<P USERMARK=" B">
<SPAN USERMARK=" !B">② 연구 집약적</SPAN>
<SPAN USERMARK=" !B">&cr;</SPAN>
<SPAN USERMARK=" !B">신약개발을 위해서는 기초연구부터 허가과정까지 의학, 약학, 화학, 생물학 등 제반 기능이 유기적으로 결합되어야 하며 10여 년의 개발과정을 거쳐야 하므로 그 어떤 산업보다 연구개발 비중이 높습니다. 제약, 바이오를 포함한 헬스케어산업은 2018년기준 전세계 모든 산업의 R&D비용 중 2번째로 높은 21.7%를 차지하고 있습니다. </SPAN>
</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="395" ALIGN="CENTER" HSPACE="0">r&d.jpg</IMG>
<IMG-CAPTION ATOC="N">r&d</IMG-CAPTION>
</IMAGE>

<P USERMARK=" B">
<SPAN USERMARK=" !B">③ 지적 재산권 확보가 경쟁력의 핵심</SPAN>
</P>
<P> 제약 산업은 물질특허의 확보가 사업의 핵심 성공 요인으로, 이 물질 특허를 얻지 못하면 원천적으로 사업이 불가능하거나 물질특허 소유자로부터 기술이전을 받아야 합니다. 임상개발을 수행하기 어려운 중소규모 제약사나 벤처는 임상2상 단계 이전에 글로벌제약사에 기술이전을 함으로써 수익을 창출할 수 있습니다. 특허가 가장 중요한 경쟁요소이기 때문에 대부분의 국가에서는 특허기간을 최대한 보호하기 위한 다양한 전략 및 정책을 도입하고 있습니다. 미국은 특허 등록 후 17년이고, 그 외의 국가는 특허 출원 후 20년까지가 특허 보호기간입니다.</P>
<P></P>

<P>
<SPAN>④ 허가과정 상의 엄격한 정부규제</SPAN>
<SPAN> </SPAN>
<SPAN>&cr;</SPAN>
<SPAN> 제약 산업은 인간의 생명에 직접적인 영향을 미치므로 신약의 안전성 확보를 위해 각국 정부가 엄격하게 규제하는 특징을 갖고 있습니다. 이에 따라 새로운 치료제를 개발한 후 판매하기 위해서는 정부가 정하는 여러 단계의 임상실험을 하여야 하며 식품의약품 안전처에 모든 자료를 제출한 후에 판매승인을 받아야 합니다. </SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" 0X1814FF B"></SPAN>
<SPAN USERMARK=" 0X1814FF B"></SPAN>
<SPAN USERMARK=" B">나. 제약산업의 성장성</SPAN>
</P>

<P>2020년 글로벌 의약품시장의 규모는 약 $940bn 이며, 고령화 및 복지사회 진입으로 고성장이 전망되어 2026년에는 약 $1,432bn 까지 성장할 것으로 전망됩니다. 그리고 전통적인 의약화학기반의 합성의약품의 비중이 점차 하락하고 있으며, 바이오의약품 시장이 점차 확대되고 있습니다. 2020년 이밸류에이트파마에 따르면, 2026년까지 전체 의약품중에 바이오의약품의 비중이 35%까지 상승할 것으로 예상되며, 높은 가격을 고려할 때 글로벌 제약시장의 규모는 앞으로도 제약시장의 공성장세가 지속될 것으로 예상됩니다.
<SPAN></SPAN>
</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="470" ALIGN="CENTER" HSPACE="0">바이오의약품 성장추세.jpg</IMG>
<IMG-CAPTION ATOC="N">바이오의약품 성장추세</IMG-CAPTION>
</IMAGE>

<P>
<SPAN USERMARK=" B">다. 경기변동 및 계절성 관련&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN></SPAN>
<SPAN>① 신약연구개발&cr;일반적으로 신약연구개발 부분은 경기변동 및 계절적 요인이 적은 분야 입니다. 신약에 대한 수요는 인류의 수명연장과 건강에 대한 높아진 관심 또한 소득 수준이 향상됨에 따라 다른 어떤 소비보다도 우선적으로 지출되는 속성을 가지고 있습니다.&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>② 의약사업 부문&cr;</SPAN>
<SPAN>의료기기 산업역시 </SPAN>
<SPAN>경기변동 요인이 적은 분야로서  가장 큰 위험 요소는 건강보험 수가 인하입니다. </SPAN>
<SPAN>이는 건강보험 당연지정제도하에서는 필연적인 이슈이며 모든 관련 회사들이 공통적으로 갖는 이슈로 당사만의 위험요소는 아닙니다. 현재 당사는 의료기기, 의료소모품 2개영역의 사업활동을 영위하고 있으며, 안정적인 매출처 확보를 통해 지속적인 수익창출를 이어가고 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B">라. 시</SPAN>
<SPAN USERMARK=" B">장 여건&cr;</SPAN>
<SPAN>당사의 주요 사업영역은 연구개발 분야에서 합성신약과 ADC(Antibody-Drug Conjugates:항체약물복합체)분야 그리고 의약품, 의료기기, 의료용 소모품 판매사업 입니다.&cr;</SPAN>
<SPAN>&cr;① 합성신약&cr;</SPAN>의약화학(Medicinal Chemistry)을 핵심기술로 글로벌 합성신약을 연구개발하여 개발초기단계(후보물질 ~ 임상2상)에서 기술이전을 통해 수익을 창출하는 주 사업모델을 가진 신약연구개발 전문업체는 국내의 경우 소수 업체에 불과합니다. 각 사별로 지닌 고유기술이 각각 다르고 추진전략도 다르지만 기술이전을 통한 수익창출이란 같은 사업모델을 가진 업체를 경쟁업체라 할 수 있겠습니다. 물론 글로벌제약사에 신약을 기술이전 하려는 사업계획을 가진 제약업체나 화학연구원, 생명공학연구원처럼 신약을 연구하는 국공립연구소나 대학 등도 크게 보면 경쟁상대라 할 수 있습니다. 또한 같은 모델을 가진 전세계의 많은 신약개발 업체도 모두 경쟁상대에 포함 됩니다.&cr;
</P>
<P>글로벌제약사들은 주로 개발후기(임상2상b~임상3상) 단계의 개발후보들을 In-licensing하여 부족한 파이프라인을 채우는 전략을 추진 중이며 그 비율을 점차 확대해 나가고 있습니다. 따라서 글로벌 스탠다드에 맞는 신약후보물질을 발굴하면 기술이전 가능성은 매우 높으므로, 이러한 질 높은 신약후보를 찾아낼 수 있는 경쟁력을 확보하는 것이 경쟁력의 핵심이라 할 수 있습니다.</P>

<P>
<SPAN>&cr;② ADC &cr;</SPAN>
<SPAN>항암제 치료제 분야를 주도할 것으로 전망되는 ADC는  Antibody라는  </SPAN>
<SPAN>바이오약물과 합성약물(Toxin)을 링커라는 연결물질을 </SPAN>
<SPAN>통해 결합한 새로운 신약제조 방법입니다. ImmunoGen과 Seagen이라는 미국의 2개 회사가 1세대 ADC 원천기술을 확보하고 시장을 독점적으로 주도하고 있는 가운데,  1세대 기술의 단점인 단일물질제조 및 링커의 안정성을, 그리고 암세포 특이적 약효를 개선한 톡신 등 2세대 원천기술을 개발하기 위해 수십개의 회사가 치열하게 경쟁을 벌이고 있는 상황입니다. &cr;&cr;</SPAN>
<SPAN>ADC분야는 2011년에 Seagen의 Adcetris가 미국 FDA 승인을 시작으로 현재 총 9개의 신약이 승인되어 판매되고 있습니다. 그리고 Takeda, Merck, BMS 등 글로벌제약사들은 당사와 같은 플랫폼을 보유한 회사의 기술을 도입하여 각사가 선정한 특정 항체타겟 및 다양한 적응증으로 확장하여 임상개발을 진행중으로 ADC의약품시장의 확대가 기대되고 있는 상황입니다.</SPAN>
</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="335" ALIGN="CENTER" HSPACE="0">승인된 adc 의약품 리스트.jpg</IMG>
<IMG-CAPTION ATOC="N">승인된 adc 의약품 리스트</IMG-CAPTION>
</IMAGE>

<P>
<SPAN>2019년 10월 출시된 Genentech의 폴리비와 12월에 출시된 Astellas/Seagen의 Padcev, Astrazeneca/Daiichi sankyo의 Enhertu가 블록버스터로 성장할 전망입니다. 특히 Enhertu는 Kadcyla보다 우수한 효능으로 2025년 매출액 3조원을 상회할 것으로 예상됩니다. 이 밖에 작년 하반기 FDA에 허가를 신청한 Seagen과  Immunomedics의 ADC와 GSK의 다발성골수종 치료ADC가 올해 승인되어 출시되었습니다. 글로벌데이터에 따르면 ADC시장은 2019년 26억달러에서 2025년 136억 달러까지 커질 젓으로 예상되며 연평균 성장률은 31.6%에 달할 것으로 예상됩니다.</SPAN>
</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="311" ALIGN="CENTER" HSPACE="0">adc시장 규모 추이.jpg</IMG>
<IMG-CAPTION ATOC="N">adc시장 규모 추이</IMG-CAPTION>
</IMAGE>

<P>
<SPAN USERMARK=" 0X0000FF"> </SPAN>
<SPAN>ADC 수익모델은 원천기술을 </SPAN>
<SPAN>항체</SPAN>
<SPAN> 타겟별로 기술이전 하거나 특정항체를 적용한 ADC 치료제를 기술이전(Product 기술이전) 하는  것으로</SPAN>
<SPAN> 1세대 기술보유회사의 경우 한 회</SPAN>
<SPAN>사가 각각 </SPAN>
<SPAN>다수의 </SPAN>
<SPAN>기술이전 실적을 가지고 있습니다. 1세대 기술의 </SPAN>
<SPAN>최근 </SPAN>
<SPAN>평균 기술이전료는</SPAN>
<SPAN> Platform의</SPAN>
<SPAN> 경우는 항체 타겟당 1억$ 전후, 치료제 후보물질의 경우는 전임상단계에서 2~3억$</SPAN>
<SPAN> </SPAN>
<SPAN>규모로 파악되며, 임상단계가 올라감에 따라 가치는 기하급수적으로 상향되고 있습니다. 따라서 1세대 기술의 한계를 개선한 2세대 원천기술을 조기 확보하면 매우 큰 수익을 창출할 수 있는 기회가 열려 있습니다.  </SPAN>
<SPAN></SPAN>
<SPAN>당사는 특허출원한 고유한 링커 및 단일물질로 만드는 방법을 포함 2세대 기술로서의 장점을 보유하고 있고 또한 최근 고유한 톡신도 자체발굴함으로써 다양한 수익 모델을 통해 향후 기술이전 등을 통한 수익창출을 기대하고 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>③ 의약사업 부문&cr;</SPAN>
<SPAN> 사회의 고령화로 인하여 노년층의 수술 및 시술 건수가 증가 하고 있으며, 주 52시간근무제로 인하여 여가 생활 특히 스포츠를 즐기는 인구가 증가하여 스포츠 손상이 증가 하고 있습니다. 따라서 근골격계 수술 환자가 증가하며 관련된 의료기기의 수요가증가 하고 있습니다.&cr; 당사는 기 확보된 안정적인 수요처를 기반으로 정형외과등 수술 및 재활에 필요한 의료기기와 소모품 중심의 사업을 운영하고 있습</SPAN>
<SPAN>니다.&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">마. 회사의 경쟁력&cr;</SPAN>
<SPAN>① 신약연구개발_연구진의 풍부한 경험과 능력</SPAN>
</P>

<P>
<SPAN> </SPAN>
<SPAN>당사의 대표이사인 김용주 박사는 ㈜LG생명과학 기술연구원에서 23년 동안 재직하면서 신약연구 그룹장, 신약연구소장으로서 신약후보물질 발굴을 진두지휘 하였습니다. 1991년 세파계 항생제 후보물질을 Glaxo Wellcome(당시)사에 국내 최초로 기술수출하여, 국내에서도 신약연구 개발의 가능성을 제고시켰고, 그 후 ㈜LG생명과학의 신약개발 사업 확대의 초석이 되었습니다. 재직 중에 항생제(세파계, 퀴놀론계), 항응혈제(트롬빈, FXa 저해제), 항암제, 항바이러스제(B형 간염치료제, HCV, AIDS), 당뇨병치료제, 간질환 치료제(캐스패이즈 저해제) 등의 다양한 질환군에서 15개의 신약후보물질을 발굴하였습니다, 이 중 퀴놀론계 항생제인 "팩티브 (FACTIVE)”는 미국 FDA의 승인을 받았고 7개의 후보물질을 다국적 제약사를 포함한 외국계 제약사에 기술이전 한 바 있습니다. 또한 재직 중에 다국적 제약사인 GSK, 일본의 Yamanouchi, 미국의 Elitra 등 외국 제약사 및 바이오벤처와의 신약 후보발굴을 위한 공동연구도 수행한 바 있습니다. 이러한 초기 Lead 발굴~미국 FDA 승인까지 전 과정 경험 및 세계적 제약사들과의 기술이전, 공동연구, 협상 경험 등을 통해 대표이사는 신약개발의 맥을 짚을 수 있는 능력과 국제적 감각 및 네트워크를 보유하고 있습니다. </SPAN>
<SPAN></SPAN>
<SPAN>또한 연구소장을 비롯한 팀장급 핵심인력들과 </SPAN>
<SPAN>경영관리 및 사업개발을 담당하고 있</SPAN>
<SPAN>는 </SPAN>
<SPAN>CFO, 사업개발 담당 </SPAN>
<SPAN>등의</SPAN>
<SPAN> 연구진 및 경영진이 보유한 풍부한 경험과 역량이 당사의 강점입니다. </SPAN>
</P>
<P> </P>

<P>
<SPAN>② 신약연구개발_핵심기술의 우수성</SPAN>
</P>

<P>
<SPAN> </SPAN>
<SPAN>당사는 Conjuall과 LegoChemistry란 2가지 핵심기술을 보유하고 있습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>Conjuall</SPAN>
<SPAN>(</SPAN>
<SPAN>ADC 원천기술)은</SPAN>
<SPAN> 기</SPAN>
<SPAN>존 1세대 ADC 기술의 문제점을 극복한 단일물질 구현과 링커의 안정성을 개선한 차세대 원천기술로 당사의 미래성장 동력이 될 것으로 기대 됩니다. </SPAN>
<SPAN> </SPAN>
<SPAN>당사가 보유한 차세대  ADC 원천기술은 다양한 항체를 활용하여 구현되고 있으며, 기존 기술들과 비교 데이타를 통해  차별성이 검증되고 있습니다.  2015년 허셉틴-ADC 후보 물질을 중국</SPAN>
<SPAN> </SPAN>
<SPAN>최고 제약사 중의 하나인 </SPAN>
<SPAN>Fosun Pharma에 중국시장 대상으로 기술이전 하여 현재 임상1상이 진행중이며, 2019년 3월에는 ADC분야 글로벌 리딩 기업인 Takeda에 플</SPAN>
<SPAN>랫폼기술을 이전하였으며, 다케다는 당사의 기술을 사용하여 면역항암제를 개발중에 있습니다. 2020년 4월과 5월에는 글로벌 임상개발능력을 보유한 ADC전문개발사인 Iksuda에 ADC플랫폼과 후보물질에 대한 2건의 기술이전 그리고 10월 중국의 대표적인 바이오기업은 CStone사 그리고 12월 미국의 Pyxis사에 후보물질을 이전하여 ADC부문에 총 6건의 기술실적을 달성하였습니다. 또한, 글로벌제약사를 포함한 국내, 외 다수 제약사들과 기술이전 논의 및 공동연구가 활발히 진행되고 있습니다. </SPAN>
<SPAN></SPAN>
<SPAN>당사는 또한 기존 PBD 톡신의 문제점을 개선하여  정상세포에 대한 독성발현을 최소화 시키는 독자적인 톡신도 자체개발 하였습니다. 또한 기존 항암제 분야에만 국한하지 않고 면역항암제나 항생제 등의 영역으로도 확장하는 연구도 시작하였습니다&cr;&cr;</SPAN>
<SPAN>LegoChemistry는</SPAN>
<SPAN> 특정한 구조를 갖는 핵심중간체를 활용하여 신약후보물질을 효율적으로 발굴하는 고유구조 접</SPAN>
<SPAN>근방식(Novel Scaffold Approach)입</SPAN>
<SPAN>니</SPAN>
<SPAN>다. 당사가 개발한 그람양성균 항생제(Delpazolid), 항응혈제(Nokxaban), 항섬유화제(BBT-877)를 비롯하여 ADC 플랫폼 기술은 LegoChemistry의 중간핵심구조를 활용한 결과들입니다.</SPAN>
<SPAN>  당사는 이러한 중간핵심구조를 활용하여 지속적으로 </SPAN>
<SPAN>새로운 pipeline을 확장할 예정입니다.&cr;</SPAN>
<SPAN>&cr;당사는 차별성을 보유한 링커 및 톡신을 당사 고유의 ADC 제조방법원천기술인 ConjuALL과 결합하여 ADC 분야의 세계적인 경쟁력을 가진 회사로 성장한다는 비전을 가지고 있습니다.</SPAN>
<SPAN> </SPAN>
<SPAN> &cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>③</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN> </SPAN>
<SPAN>의약사업부문_안정적 수요처와 신규사업 </SPAN>
<SPAN>의약사업부문은 의료용품 및  의료기기  사업을 주요 기반으로 사업을 진행하고 있습니다. </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>의료기기 사업의 경우, 수도권 소재 5개 병원의 치료재료와 의료소모품 등 의료기기를 납품하고 있으며, </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>비용대비 효과가 우수한 제품을 지속적으로 영업, 마케팅 하여 매출 증대를 일으키고 있습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">바. 요약 재무현황  </SPAN>
<SPAN USERMARK=" 0X1814FF BIU">&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF BIU"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN>2020년 제15기</SPAN>
<SPAN></SPAN>
<SPAN>를</SPAN>
<SPAN> 포함한 과거 3년간의 요약 재무현황은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="624">

<COLGROUP>
<COL WIDTH="615"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="624" HEIGHT="30" ALIGN="RIGHT">(단위 : 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="627">

<COLGROUP>
<COL WIDTH="216"></COL>
<COL WIDTH="125"></COL>
<COL WIDTH="125"></COL>
<COL WIDTH="125"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">　과목</TD>

<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" 0X0000FF BC0XD7D7D7">
<SPAN USERMARK=" 0X000000">제</SPAN>
<SPAN USERMARK=" 0X000000"> 15 기</SPAN>
</TD>

<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<SPAN>제</SPAN>
<SPAN> 14 기</SPAN>
</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제 13 기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">자산</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　유동자산</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">100,010,638,124 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">111,419,272,490 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">93,378,850,696 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　비유동자산</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">35,901,709,939 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">30,058,180,591 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">28,307,433,051 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　자산총계</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">135,912,348,063 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">141,477,453,081 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">121,686,283,747 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">부채</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　유동부채</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">14,009,297,856 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,423,972,628 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,945,687,495 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　비유동부채</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,776,865,961 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,144,134,739 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,445,867,208 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　부채총계</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,786,163,817 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,568,107,367 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,391,554,703 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">자본</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　자본금</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,053,171,000 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,004,004,500 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,999,164,500 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　자본잉여금</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">180,889,858,521 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">185,180,023,251 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">184,478,809,168 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　기타자본구성요소</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,245,694,338 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,471,712,833 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,012,929,571 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　기타포괄손익누계액</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,075,072,000 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(94,894,800)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">468,289,087 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　이익잉여금(결손금)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(86,137,611,613)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(78,811,545,647)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(90,294,405,224)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">   비지배지분</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,160,045,577 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,629,941,942 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">　자본총계</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">112,126,184,246 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">115,909,345,714 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">105,294,729,044 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">자본과부채총계</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">135,912,348,063 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">141,477,453,081 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">121,686,283,747 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">영업수익</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">49,393,701,591 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">57,500,138,690 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,240,301,764 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">영업비용</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">79,155,462,737 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">49,083,296,692 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">41,218,265,651 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">영업이익(손실)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(29,761,761,146)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,416,841,998 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(15,977,963,887)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">법인세비용차감전순이익(손실)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(8,826,761,782)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,101,518,704 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(26,426,772,928)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">법인세비용(수익)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,840,500,563)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">626,010,911 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(354,090,242)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">당기순이익(손실)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,986,261,219)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,475,507,793 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(26,072,682,686)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">기본주당순이익(손실)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(307)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">641 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,446)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="225" VALIGN="MIDDLE" HEIGHT="30">희석주당순이익(손실)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(307)</TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">566 </TD>
<TD WIDTH="134" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,446)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
</P>

<P USERMARK="F-16 0XFF0000 B">
<SPAN USERMARK="F-12"></SPAN>
<SPAN USERMARK="F-12 0X000000">2. 주요 제품 등에 관한 사항&cr;</SPAN>
<SPAN USERMARK="F-12 0X000000"></SPAN>
<SPAN USERMARK="F-12 0X000000"></SPAN>
<SPAN USERMARK="F-12 0X000000"></SPAN>
<SPAN USERMARK="F-12 0X000000"></SPAN>
<SPAN USERMARK="F-12 0X000000">가. 주요 제품 등의 현황</SPAN>
<SPAN USERMARK="F-12 0X000000 !B"> &cr;</SPAN>
<SPAN USERMARK="F-12 0X000000 !B"></SPAN>
<SPAN USERMARK="F-12 0X000000 !B"></SPAN>
<SPAN USERMARK="F-12 0X000000 !B"></SPAN>
<SPAN USERMARK="F-12 0X000000 !B">① 신약연구개발 </SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="706" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="697"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="706" HEIGHT="31" USERMARK="F-BT12">(단위: 천원, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="706">

<COLGROUP>
<COL WIDTH="77"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="284"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="86" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분 </TH>
<TH USERMARK="F-BT" WIDTH="115" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년</TH>
<TH USERMARK="F-BT" WIDTH="106" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2019년</TH>
<TH USERMARK="F-BT" WIDTH="106" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2018년</TH>
<TH USERMARK="F-BT" WIDTH="293" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제품 설명</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="86" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">기술이전 </TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">29,956,979&cr;(96.4)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">31,370,973&cr;(98.7)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">2,135,649&cr;(85.7)</TD>
<TD USERMARK="F-BT" WIDTH="293" HEIGHT="53" VALIGN="MIDDLE">당사가 보유한 신약후보물질 및 &cr;원천기술의 권리이전, 사용료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="86" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">공동연구 </TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">0&cr;(0.0)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">0&cr;(0.0)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">0&cr;(0.0)</TD>
<TD USERMARK="F-BT" WIDTH="293" HEIGHT="53" VALIGN="MIDDLE">특정 프로젝트를 매출처와 공동으로 &cr;연구하는 목적으로 연구비 수령</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="86" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">연구용역 </TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">1,134,707&cr;(3.6)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">417,892&cr;(1.3)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">355,334&cr;(14.3)</TD>
<TD USERMARK="F-BT" WIDTH="293" HEIGHT="53" VALIGN="MIDDLE">화합물 합성용역 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="86" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">합 계 </TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">31,091,686&cr;(100.0)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">31,788,865&cr;(100.0)</TD>
<TD USERMARK="F-BT" WIDTH="106" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">2,490,983&cr;(100.0)</TD>
<TD USERMARK="F-BT" WIDTH="293" HEIGHT="53" VALIGN="MIDDLE">-</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN>② 의약사업부문</SPAN>
<SPAN> </SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="661">

<COLGROUP>
<COL WIDTH="652"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="661" HEIGHT="31" ALIGN="RIGHT">(단위: 천원, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="666">

<COLGROUP>
<COL WIDTH="88"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="215"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="97" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH USERMARK="F-BT" WIDTH="115" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년</TH>
<TH USERMARK="F-BT" WIDTH="115" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2019년</TH>
<TH USERMARK="F-BT" WIDTH="115" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2018년</TH>
<TH USERMARK="F-BT" WIDTH="224" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제품 설명</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">8,196,650&cr;(44.8)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">10,540,492&cr;(41.0)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">9,483,548&cr;(41.7)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">임플란트 수술용 재료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">의료소모품</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">10,110,108&cr;(55.2)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">9,738,722&cr;(37.88)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">8,973,828&cr;(39.5)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">수술, 진료용 일회성 소모품</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">전문의약품</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">4,072,907&cr;(15.84)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">2,295,133&cr;(10.1)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">일반의약품</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">2,404,983&cr;(9.35)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">1,669,051&cr;(7.3)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">용역수수료</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">(1,008,333)&cr;(-3.92)</TD>

<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>357,605 &cr;(1.6)</SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">의약품 판매 수수료,포장용역</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">상품매출&cr;(백조이 등)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">0&cr;(0)</TD>

<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>1,969&cr;(0.01)</SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">매출할인</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">(4,742)&cr;(-0.03)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">(37,497)&cr;(-0.15)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">(31,784)&cr;(-0.1)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="97" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">합계</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">18,302,016&cr;(100)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">25,711,274&cr;(100)</TD>
<TD USERMARK="F-BT" WIDTH="115" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">22,749,320&cr;(100)</TD>
<TD USERMARK="F-BT" WIDTH="224" HEIGHT="53" VALIGN="MIDDLE">　</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" B">나. 주요 제품 등의 가격변동추이&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN>① 신약연구개발 </SPAN>
<SPAN>&cr; 당사의 주요제품은 기술이전을 목적으로 연구개발 중인 과제들로서 가격변동추이를 기재하기에 적합하지 않습니다. 또한 각 과제별 기술이전에 대한 기대가치는 당사 후보물질의 약효 및 안전성 등에 대한 차별적 장점 보유 여부, 글로벌제약사의 수요 정도, 경쟁상태, 시장규모, 예상 시장점유율 등의 다양한 요인에 의하여 결정되므로 쉽게 예측하기는</SPAN> 어려우며, 파이프라인의 경쟁력 및 시장의 Unmet needs에 따라 가격이 결정되는 것이지, 가격 변동의 계절성 및 분석할 만한 추세가 있지는 않습니다.&cr;  &cr;일반적으로 개발단계가 진행될수록 성공확률이 높아지며 계약규모가 기하급수적으로 커지게 되는데 각 단계별 가치를 표로 정리해 보면 다음과 같습니다.
</P>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="600" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="600" HEIGHT="259">

<IMAGE>
<IMG WIDTH="574" HEIGHT="208" ALIGN="CENTER" HSPACE="0">[개발단계별 기술이전 계약규모 변화 추이].jpg</IMG>
<IMG-CAPTION ATOC="N">[개발단계별 기술이전 계약규모 변화 추이]</IMG-CAPTION>
</IMAGE>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0X0000FF I"></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="840">

<COLGROUP>
<COL WIDTH="831"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="840" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위: 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="842">

<COLGROUP>
<COL WIDTH="82"></COL>
<COL WIDTH="472"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="69"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구  분</TH>
<TH USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 품  목</TH>
<TH USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년</TH>
<TH USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2019년</TH>
<TH USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2018년</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료소모품</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">Accufuser plus/P2015M [2.0ml/15min]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">52,110</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">51,090</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">   50,060 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">GSS PEDICLE SCREW(CEDAR) [POLY]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">254,380</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">249,400</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  244,410 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">SEXTANT MULTI-AXIAL SCREW SET</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">254,380</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">249,400</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  244,410 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">ANYPLUS POLY Cannula [tedscrew(self)]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">254,380</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">249,400</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  244,410 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">VANGUARD FEMORAL COMPONENTS</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">926,160</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">908,000</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  889,840 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">ANYPLUS PLIF PEEK CAGE</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">360,230</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">353,170</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  346,100 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">I-BEAM TIBIAL TRAY</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">742,620</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">728,060</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  713,490 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">ANYPLUS ALIF PEEK CAGE</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">608,140</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">596,220</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  584,290 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">DISPOSABLE CANNULA</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">42,870</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">42,030</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">    41,180</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">ARTHREX BIOCOMPOSITE SUTURE ANCHOR</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">214,890</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">210,680</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  206,460 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">CAPSTONE [32/36]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">608,140</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">596,220</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  584,290 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">NEXGEN LPS FLEX FEMORAL COMPONENT</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">926,160</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">908,000</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  889,840 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">BIOSUTURETAK SUTURE ANCHOR W/FIBERWIRE [AR-1322BNF]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">214,890</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">210,680</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  206,460 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">VANGUARD TIBIAL BEARING</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">379,720</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">372,280</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  364,830 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">NEXGEN TIBIAL PLATE</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">740,300</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">725,790</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  711,270 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">ANYPLUS T-PLIF PEEK CAGE</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">608,140</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">596,220</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  584,290 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">Y-Knot All Suture Anchor(With One ＃2(5 Metric) Hi-Fi Suture) [Y1301]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">193,720</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">189,930</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  186,130 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">CD HORIZON M8(M10) SCREW SET</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">254,380</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">249,400</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">  244,410 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">GSS ROD</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">97,070</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">95,170</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">   93,260 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료소모품</TD>
<TD USERMARK="F-BT" WIDTH="481" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">VAC, HEMO 100ML [SS100M]</TD>
<TD USERMARK="F-BT" WIDTH="100" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">16,510</TD>
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">16,190</TD>
<TD USERMARK="F-BT" WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">   15,860 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN>(1) 산출 기준&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN>의</SPAN>
<SPAN>료</SPAN>
<SPAN>보험수가 기준 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(2) 주요 가</SPAN>
<SPAN>격변동원인</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>2020년은 환율변동사항을 반영하여 의료보험수가가 전기 대비 2%의 상승이 있었습니다.</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">3. 주요 원재료에 관한 사항&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">가. 원재료 매입 현황&cr;</SPAN>
<SPAN>① 신약연구개발 </SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="727">

<COLGROUP>
<COL WIDTH="718"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="727" HEIGHT="30" ALIGN="RIGHT">
<SPAN USERMARK="F-BT"> (단위 : 천원</SPAN>
<SPAN>)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="731">

<COLGROUP>
<COL WIDTH="62"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="45"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="71" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">매입&cr; 유형 </TH>
<TH WIDTH="126" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">품 목 </TH>
<TH WIDTH="54" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">구분 </TH>
<TH WIDTH="118" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">2020년도&cr;(제15기)</TH>
<TH WIDTH="121" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">2019년도&cr;(제14기)</TH>
<TH WIDTH="121" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">2018년도&cr;(제13기)</TH>
<TH WIDTH="120" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="12" WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="360" USERMARK="F-BT">시약&cr; 재료비 </TD>
<TD ROWSPAN="3" WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" USERMARK="F-BT">화합물 합성 </TD>
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">753,506 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">     460,056 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          352,284 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">수입 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">              - </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                   - </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">소계 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">753,506 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">       460,056 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          352,284 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" USERMARK="F-BT">평가 </TD>
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">680,105 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        407,551 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          431,187 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">수입 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,073 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">               - </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                   - </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">소계 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">681,179 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        407,551 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          431,187 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" USERMARK="F-BT">공통 </TD>
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">43,454 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          71,780 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">            43,035 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">수입 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                - </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                   - </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">소계 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">43,454 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          71,780 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">            43,035 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" WIDTH="126" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" USERMARK="F-BT">시약재료비 합계</TD>
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,477,066 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        939,388 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          826,507 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">수입 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,073 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                - </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                   - </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">소계 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,478,140 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        939,388 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          826,507 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" ROWSPAN="3" WIDTH="197" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" USERMARK="F-BT">합 계 </TD>
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,477,066 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        939,388 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          826,507 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">수입 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,073 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                - </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">                   - </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">소계 </TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,478,140 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">        939,388 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">          826,507 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="730" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="36"></COL>
<COL WIDTH="676"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="45" HEIGHT="30" USERMARK="F-BT">주1)</TD>
<TD WIDTH="685" HEIGHT="30" USERMARK="F-BT">상기 매입액은 당사의 연구성격 상 화합물 합성과 평가로 구분하였습니다.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="45" HEIGHT="53" USERMARK="F-BT">주2)</TD>
<TD WIDTH="685" HEIGHT="53" USERMARK="F-BT">상기 시약재료의 메이커는 국외인 경우가 많지만 당사는 국내의 대리점을 통하여 원화로 매입하고 있습니다.</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">② 의약사업부문 </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>의약사업부문은 제품을 구입하여 판매하므로, 원재료가 발생하지 않습니다.</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN>&cr;</SPAN>
<SPAN>나</SPAN>
<SPAN>. 원재료 가격변동 추이 &cr;</SPAN>
<SPAN></SPAN>
<SPAN>① 신약연구개발 </SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="828" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="819"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="828" HEIGHT="30" USERMARK="F-BT"> (단위: 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="825">

<COLGROUP>
<COL WIDTH="87"></COL>
<COL WIDTH="281"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="45"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="96" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매입&cr;유형</TH>
<TH USERMARK="F-BT" WIDTH="290" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">품목</TH>

<TH WIDTH="48" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<SPAN>구분</SPAN>
</TH>
<TH USERMARK="F-BT" WIDTH="113" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2020년&cr;(제15기)</TH>
<TH USERMARK="F-BT" WIDTH="112" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2019년&cr;(제14기)</TH>
<TH USERMARK="F-BT" WIDTH="112" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2018년&cr;(제13기)</TH>
<TH USERMARK="F-BT" WIDTH="54" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="96" HEIGHT="150" ROWSPAN="5" ALIGN="CENTER" VALIGN="MIDDLE">화합물 합성</TD>
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">Aceton 99.5% </TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">33,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">33,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">29,700</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">Dichloromethane 99% </TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">35,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">35,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">35,000</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">Hexanes </TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">31,300</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">31,300</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">28,170</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">Trifluoroacetic acid</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">45,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">45,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">45,000</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">N,N-Dimethylformamide anhydrous, 99.8%</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">182,200</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">156,240</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">156,240</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="96" HEIGHT="120" ROWSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE">평가</TD>
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">SD Rat(8주령)</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">29,200</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">25,300</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">25,300</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">DMEM, high glucose, pyruvate</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">27,810</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">27,000</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">26,190</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">Minimum Essential Medium (MEM)</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">28,440</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">27,540</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">26,730</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="290" HEIGHT="30" VALIGN="MIDDLE">RPMI 1640 Medium, HEPES</TD>
<TD USERMARK="F-BT" WIDTH="48" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국내</TD>
<TD USERMARK="F-BT" WIDTH="113" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">390,600</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">378,900</TD>
<TD USERMARK="F-BT" WIDTH="112" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">367,200</TD>
<TD USERMARK="F-BT" WIDTH="54" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="729">

<COLGROUP>
<COL WIDTH="38"></COL>
<COL WIDTH="673"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="47" HEIGHT="30">주)</TD>
<TD USERMARK="F-BT" WIDTH="682" HEIGHT="30">당사가 사용하고 있는 주요 시약의 품목을 기재하였으며, 원화 기준으로 구매하고 있습니다.</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>② </SPAN>
<SPAN>의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN>의약사업부문은 제품을 구입하여 판매하므로, 원재료가 발생하지 않</SPAN>
<SPAN>습니다</SPAN>
<SPAN>.</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">4. 생산 및 생산설비에 관한 사항</SPAN>
</P>

<P>
<SPAN USERMARK=" B">가. 생산능력 및 생산실적 &cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>당사는 연구기업의 특성상 생산능력(당사의 경우는 프로젝트 수행능력)은 연구원의 기본자질과 풍부한 경험의 정도에 의해서 좌우되므로 생산능력이 실험기계나 연구실의 단순한 인프라의 규모로 산정되지는 않으며, 연구의 단계별로 일정한 부분에 대해서는 언제든지 연구 네트워킹을 통한 외부의 전문 연구기관과의 협력을 통해 협업이 가능하므로, 생산능력이 물적 조건에 의해 제약되기 보다는 회사의 연구전략에 의해서 정해지는 특성이 있습니다.&cr;&cr;또한  당사는 실제 신약후보물질의 샘플 등을 생산과 의약사업부문에서 판매하고 있는 제품에 있어 일정 기준을 충족하는 CMO를 활용하고 있기 때문에, 당사 자체의 생산능력 및 가동률을 산정할 수 없습니다.&cr;
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">나. 생산설비에 관한 사항</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="1026" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1017"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="1026" HEIGHT="30" USERMARK="F-BT">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1026">

<COLGROUP>
<COL WIDTH="52"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="136"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="69"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">사업소</TD>
<TD ROWSPAN="2" WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">소유형태</TD>
<TD ROWSPAN="2" WIDTH="145" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">소재지</TD>
<TD ROWSPAN="2" WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">구분</TD>
<TD ROWSPAN="2" WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">기초 장부가액</TD>
<TD COLSPAN="2" WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">당기증감</TD>
<TD ROWSPAN="2" WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">당기상각</TD>
<TD ROWSPAN="2" WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">기말 장부가액</TD>
<TD ROWSPAN="2" WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">증가</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">감소</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="8" WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="240" USERMARK="F-BT">본사</TD>
<TD ROWSPAN="8" WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="240" USERMARK="F-BT">소유</TD>
<TD ROWSPAN="8" WIDTH="145" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="240" USERMARK="F-BT">대전광역시 대덕구 문평서로 8-26</TD>
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비품</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">237,431 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">299,371 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">520 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">105,871 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">430,410 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국고보조금</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(8,000)</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(267)</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(7,733)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">건설중인자산</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">2,577,147 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">2,693,759 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">5,270,905 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국고보조금</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(867,000)</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(867,000)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">연구설비</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">2,299,703 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">709,401 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">849,789 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">2,159,315 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국고보조금</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(44,001)</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(15,730)</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(28,271)</TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">시설장치</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">316,367 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">33,419 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">119,895 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">229,891 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">사용권자산</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">313,229 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">621,753 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">74,936 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">429,914 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">430,132 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="4" WIDTH="405" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">합계</TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">5,699,876 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">3,482,703 </TD>
<TD WIDTH="109" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">75,456 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">1,489,473 </TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">7,617,650 </TD>
<TD WIDTH="78" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">　-</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1025">

<COLGROUP>
<COL WIDTH="25"></COL>
<COL WIDTH="982"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="34" HEIGHT="37">주)</TD>
<TD USERMARK="F-BT" WIDTH="991" HEIGHT="37">당사는 연구설비를 국고보조금 재원에 의해 매입할 경우, 재무제표에 국고보조금을 유형자산의 차감계정으로 기재하고 있습니다.</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0X0000FF">&cr;&cr;</SPAN>
<SPAN USERMARK=" B">5. 매출에 관한 사항</SPAN>
</P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">가. 매출 실적&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF B"></SPAN>
<SPAN>①</SPAN>
<SPAN> </SPAN>
<SPAN>신약연구개발</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="711" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="702"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="711" HEIGHT="30" USERMARK="F-BT">(단위: 천원, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="708" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="53"></COL>
<COL WIDTH="174"></COL>
<COL WIDTH="37"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="37"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="37"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="62" HEIGHT="83" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">매출&cr;유형</TH>
<TH ROWSPAN="2" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="229" HEIGHT="83" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">품 목</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="153" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">2020년도&cr;(제15기)</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="136" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">2019년도&cr;(제14기)</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="128" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">2018년도&cr;(제13기)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">비중</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">비중</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="15" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="62" HEIGHT="450" USERMARK="F-BT">기술&cr;이전</TD>
<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90" USERMARK="F-BT">항응혈제&cr;(FXa저해제)</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">19,402 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">0.1 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">335,951</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">1.1</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">293,399</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">11.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">19,402 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">0.1 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">335,951</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">1.1</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">293,399</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">11.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90" USERMARK="F-BT">
<SPAN>항섬유화제&cr;(ATX 저해제)</SPAN>
<SPAN></SPAN>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">1,237,302 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">4.0 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">26,584,706</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">83.6</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">1,000,000</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">40.1</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">1,237,302 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">4.0 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">26,584,706</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">83.6</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">1,000,000</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">40.1</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90" USERMARK="F-BT">항생제 &cr;(차세대 옥사졸리디논계)</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90" USERMARK="F-BT">항생제&cr;(옥사졸리디논계)</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90" ROWSPAN="3">
<SPAN USERMARK="F-BT">ADC원천기술</SPAN>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">28,700,275 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">92.9 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">4,214,016</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">13.3</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">842,250</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">33.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">28,700,275 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">92.9 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">4,214,016</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">13.3</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">842,250</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">33.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="6" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="62" HEIGHT="180" USERMARK="F-BT">공동&cr;연구</TD>

<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90">
<P USERMARK="F-BT">항염증치료제</P>
<P USERMARK="F-BT">(PAR2길항제)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="183" HEIGHT="90">
<P USERMARK="F-BT">항암제</P>
<P USERMARK="F-BT">(신규항암제)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="245" HEIGHT="90" USERMARK="F-BT">연구용역</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">904,707 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">2.3 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">591,992</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">1.9</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">158,670</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">6.4</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">230,000 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">0.7 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">57,000</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">0.2</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">196,364</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">7.9</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">1,134,707 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">3.1 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">648,992</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">2.0</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">355,034</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">14.3</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="245" HEIGHT="90" USERMARK="F-BT">기타</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">5,200</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">300</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">- </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">5,200</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">300</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="3" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="245" HEIGHT="90" USERMARK="F-BT">합계</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">수출</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">29 ,604,982 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">95.2 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">4,806,008</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">15.1</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">1,000,920</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">40.2</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">내수</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">1,486,704 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">4.8 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">26,982,857</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">84.9</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">1,490,063</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">59.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">소계</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="95" HEIGHT="30" USERMARK="F-BT">31,091,686 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="58" HEIGHT="30" USERMARK="F-BT">100.0 </TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="90" HEIGHT="30" USERMARK="F-BT">31,788,865</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">100</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="82" HEIGHT="30" USERMARK="F-BT">2,490,983</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="46" HEIGHT="30" USERMARK="F-BT">100</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="710">

<COLGROUP>
<COL WIDTH="32"></COL>
<COL WIDTH="660"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="41" HEIGHT="30">주1)</TD>

<TD USERMARK="F-BT" WIDTH="669" HEIGHT="30">
<SPAN></SPAN>
<SPAN>재무수치는 K-IFRS기준입니다.</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN>② 의약사업부문 </SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="692">

<COLGROUP>
<COL WIDTH="683"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="692" HEIGHT="30" ALIGN="RIGHT">(단위: 천원, %</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="692">

<COLGROUP>
<COL WIDTH="53"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="37"></COL>
<COL WIDTH="95"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="95"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="85"></COL>
<COL WIDTH="53"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="62" HEIGHT="106" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출&cr;유형</TH>
<TH USERMARK="F-BT" WIDTH="142" HEIGHT="106" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">품 목</TH>

<TH USERMARK="F-BT 0X0000FF" WIDTH="166" HEIGHT="53" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<SPAN USERMARK=" 0X000000">2020년도&cr;</SPAN>
<SPAN USERMARK=" 0X000000">(제15</SPAN>
<SPAN USERMARK=" 0X000000">기)</SPAN>
</TH>

<TH WIDTH="166" HEIGHT="53" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<SPAN>2019년도&cr;</SPAN>
<SPAN>(제14</SPAN>
<SPAN>기)</SPAN>
</TH>

<TH USERMARK="F-BT" WIDTH="156" HEIGHT="53" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<SPAN>2018년도&cr;</SPAN>
<SPAN>(제13</SPAN>
<SPAN>기)</SPAN>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="104" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액</TH>
<TH USERMARK="F-BT" WIDTH="62" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비중&cr;(%)</TH>
<TH WIDTH="104" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">금액</TH>
<TH WIDTH="62" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT">비중&cr;(%)</TH>
<TH USERMARK="F-BT" WIDTH="94" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금액</TH>
<TH USERMARK="F-BT" WIDTH="62" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비중&cr;(%)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="540" ROWSPAN="18" ALIGN="CENTER" VALIGN="MIDDLE">상품&cr;매출</TD>

<TD USERMARK="F-BT" WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>의료기기</SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,196,650</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">44.8</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">10,540,492 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">41.00</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,483,548</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">41.7</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,196,650</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">44.8</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">10,540,492 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">41.00</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,483,548</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">41.7</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD USERMARK="F-BT" WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>의료소모품 </SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,110,108</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">55.2</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT"> 9,738,722 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">37.88</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,973,828</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">39.4</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,110,108</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">55.2</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">  9,738,722 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">37.88</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,973,828</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">39.4</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">전문의약품</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">              - </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">194,549</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">0.9</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">  4,072,907 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">15.84</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,100,584</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9.2</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">   4,072,907 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">15.84</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,295,133</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10.1</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">일반의약품</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">     345,758 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">1.34</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">123,705</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">0.5</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">   2,059,225 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">8.01</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,545,346</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6.8</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">   2,404,983 </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">9.35</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,669,051</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">7.3</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT">용역수수료</SPAN>
</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">              - </TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(1,008,333)</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(3.92)</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">     357,605</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1.6</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(1,008,333)</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(3.92)</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">     357,605</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1.6</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="96" HEIGHT="90" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">상품</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">                -</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">-</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(4,742)</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(0.03)</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(37,497)</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(0.15)</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(29,845)</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(0.1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(4,742)</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(0.03)</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(37,497)</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">(0.15)</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(29,845)</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(0.1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="158" HEIGHT="90" COLSPAN="2" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">합계</TD>
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">수출</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">       345,758</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">1.34</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">318,254</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1.4</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">내수</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">18,302,016</TD>

<TD USERMARK="F-BT 0X0000FF" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN USERMARK=" 0X000000">100.00</SPAN>
</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT"> 25,365,516</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">98.66</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">22,431,066</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">98.6</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="46" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-BT" WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">18,302,016</TD>

<TD USERMARK="F-BT 0X0000FF" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN USERMARK=" 0X000000">100.00</SPAN>
</TD>
<TD WIDTH="104" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">25,711,274</TD>
<TD WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-BT">100.00</TD>
<TD USERMARK="F-BT" WIDTH="94" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">22,749,320</TD>
<TD USERMARK="F-BT" WIDTH="62" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">100.0</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">                                                                   </SPAN>
<SPAN USERMARK=" B">         </SPAN>
<SPAN USERMARK=" B">                       </SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK=" B">나. 판매경로 및 판매전략&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>① 신약연구개발</SPAN>
<SPAN>&cr;당사의 매출은 기술</SPAN>
<SPAN>이전과 공동연구, 그리고 연구용역으로 구성되며 대부분 당사와 고객간 직접 거래 형태로, 해외 기술이전의 경우는 지역별 Agent를 통해 이루어지고 있습니다. 당사가 현재까지 체결한 기술이전 Agent 계약은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="601">

<COLGROUP>
<COL WIDTH="189"></COL>
<COL WIDTH="394"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="198" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기   관 </TH>
<TH USERMARK="F-BT" WIDTH="403" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제 휴 내 역 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD USERMARK="F-BT" WIDTH="198" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>MEDCI </SPAN>
</TD>

<TD USERMARK="F-BT" WIDTH="403" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN>일본, 미국 </SPAN>
<SPAN USERMARK="F-GL">Agentship</SPAN>
<SPAN> (2014년 10월) </SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-12" WIDTH="198" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">Zenith Pharm </TD>

<TD USERMARK="F-BT" WIDTH="403" HEIGHT="31" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN>중국 </SPAN>
<SPAN USERMARK="F-GL">Agentship</SPAN>
<SPAN> (2011년 5월) </SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">Pullan</TD>

<TD WIDTH="403" HEIGHT="31" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN USERMARK="F-BT">미국</SPAN>
<SPAN USERMARK="F-BT"> </SPAN>
<SPAN></SPAN>
<SPAN>Agentship</SPAN>
<SPAN USERMARK="F-BT"> (2019년 3월) </SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" BI"></SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>당사는 글로벌 전문성을 갖춘 인재로 구성된 사업개발팀을 운영하고 있으며, 국내 및 해외 기술이전 및 공동연구 등의 사업화를 적극 추진하고 있습니다. 매년 전세계 각국에서 개최하는 주요 전문 컨퍼런스 참여 통한 파트너링 미팅 및  각 지역별 기술이전 Agent들을 통한 상시 파트너 발굴 등의 활동으로  매년 수백건 이상의 사업화 관련 미팅을  진행하고 있습니다. 조인트벤처 설립, 지역별 분할기술이전, 공동개발 등 다양한 사업모델을 발굴하여 사업화를 추진 중에 있습니다. 당사는 주 수익원인 글로벌 기술이전을 조기 가시화 하기 위해 사업개발 활동에 최선의 노력과 역량을 집중하고 있습니다. &cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>&cr;
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>현재까지 당사의 의약</SPAN>
<SPAN>사업부문은 </SPAN>
<SPAN>수도권 소재 5개의</SPAN>
<SPAN> 외과수술 전문병원을 중심으로 치료재료와 의료소모품  등 의료기기를 납품 하고 있습</SPAN>
<SPAN>니다. 또한, 관계기업인 주식회사 바스칸바이오제약과의 협업으로 병원의 영업 및 마케팅활동을 통하여 새로운 제품 도입 및 매출 수익이</SPAN>
<SPAN> 증대될 전망으로 보입니다.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">6. 수주 상황</SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>① 신약연구개발</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>당사와 같은 기술이전을 주 수익모델로 하는 신약연구개발 회사의 경우 일반 제조업이나 용역업체와 같은 수주는 발생하지 않습니다. 기술이전 계약의 경우 일종의 계약금에 해당하는 Upfront와 </SPAN>중도금에 해당하는 Milestone fee, 그리고 신약개발 후보가 기술이전한 회사(Licensee)에 의해 출시되면 받게되는 Royalty로 구성되어 있습니다. 이런 측면에서 이미 체결된 기술이전 계약의 경우 임상 및 전임상 단계를 성공
<SPAN>하면 마일스톤을 받는다는 점에서 수주라 할 수도 있습니다. </SPAN>
<SPAN>&cr;&cr;당사는 현</SPAN>
<SPAN>재 ADC분야 6건, 합성신약분야 3건 총 9건의 기술이전계약으로 약 2조원의 마일스톤을 확하하고 있어 파트너사의 연구개발이 진행됨에 따라 지속적인 마일스톤 유입이 기대되고 있습니다.&cr;&cr;당사는 가장 주력하고 있는 ADC 분야에서 글로벌제약사를 포함한 다수의 회사들과 기술이전 논의 및 공동연구가 활발히 진행 중에 있습니다.</SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>&cr;
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN>② 의약사업부문</SPAN>
<SPAN> </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>의약사업부문은 수도권 소재 </SPAN>
<SPAN>외과수술 전문병원에 대한 지속적인  매출을</SPAN>
<SPAN> 기반으로 안정적인 매출구조를 </SPAN>
<SPAN>보유하고 있</SPAN>
<SPAN></SPAN>
<SPAN>습</SPAN>
<SPAN>니다.&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF">&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">7. 시장위험과 위험관리</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>① 신약연구개발</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>당사는 신약후보물질을 발굴하여 이를 기술이전하는 것을 주 사업으로 하는 회사로서 원재료 비율이 타 제조업에</SPAN> 비해 낮아 금리, 원재료 가격, 환율 및 기타 시장 변수에 의한 자산이나 손익 등에 예상치 못한 손실을 일으킬 가능성이 미미합니
<SPAN>다. </SPAN>
<SPAN>당사는 신약연구개발의 본질적 속성인  실패 가능성을 고려 모든 연구개발비를 당기비용으로 처리하고 있습니다.&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" 0XFF0000"></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN> 의료기기 산업은</SPAN>
<SPAN> </SPAN>
<SPAN>경기변동 요인이 적은 분야로서  가장 큰 위험 요소는 건강보험 수가 인하입니다. </SPAN>
<SPAN>이는 건강보험 당연지정제도하에서는 필연적인 이슈이며 </SPAN>
<SPAN>모든 관련 회사들이 공통적으로 갖는 이슈로 당사만의 위험요소는 아닙니다.</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" B">8. 파생상품 거래 현황&cr;</SPAN>
<SPAN></SPAN>
<SPAN>당사는  현재 보유하고 있는 파생상품이 없습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN USERMARK=" B">9. 경영상의 주요계약</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN>① 신약연구개발</SPAN>
<SPAN></SPAN>
</P>
<P>당사가 체결한 주요 유효 계약내역은 다음과 같습니다.&cr;가. 라이센스아웃(License-out) 계약                                                                  </P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1506">

<COLGROUP>
<COL WIDTH="133"></COL>
<COL WIDTH="165"></COL>
<COL WIDTH="396"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="406"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="405" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">선급금&cr;(백만원)</P>
</TD>

<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액&cr;(백만원)</P>
</TD>

<TD WIDTH="415" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P USERMARK="F-BT">ADC 후보물질</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">Fosun Pharma</SPAN>
<SPAN USERMARK="F-BT">&cr;(중국)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="76">

<P USERMARK="F-BT">
<SPAN>□대상 : 허셉틴-ADC 후보물질&cr;□총규모: 약209억&cr;□중국시장 대상 기술이전 </SPAN>
</P>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">2015년 8월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">20,842</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="76">
<P USERMARK="F-BT">□ 임상 1상 진행 중&cr;□ 중국 임상 진행 따른 마일스톤 수익 발생 예정</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<P USERMARK="F-BT">ADC 원천기술</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">Millenium Pharma&cr;(Takeda)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">

<P USERMARK="F-BT">
<SPAN>□비공개 타겟&cr;</SPAN>
<SPAN>□총규모: </SPAN>
<SPAN>$404mn (Upfront+Milestone) + 로열티   &cr;□레고켐바이오 기술 활용 ADC 면역항암제&cr;   후보물질 발굴 중</SPAN>
</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">2019년 3월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">454,823</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">

<P USERMARK="F-BT">
<SPAN>□ 후보물질 발굴 중</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">ADC 원천기술</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">Iksuda (유럽)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="122">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$407mn (Upfront+Milestone) + 로열티&cr;  + Revenue sharing(제3자 기술이전시)   &cr;□레고켐바이오 기술 활용 ADC 치료제&cr;   후보물질 발굴예정</SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">2020년 4월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">496,316</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="122" USERMARK="F-BT">□ 후보물질 발굴예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Iksuda (유럽)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">CD19-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$227mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시)  </SPAN>
<SPAN USERMARK="F-BT">  &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 5월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">6,132</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">278,370</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ NovImmune과 공동연구를 &cr;   통해 확보한 후보물질임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">CStone (중국)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">ROR1-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$363.5mn (Upfront+Milestone) + 로열티&cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Revenue sharing(제3자 기술이전시) </SPAN>
<SPAN USERMARK="F-BT"> &cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 10월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">11,276</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">409,883</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ ABL Bio와 공동연구를 통해&cr;    확보한 후보물질임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">ADC 후보물질</TD>
<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Pyxis (미국)</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">DLK1-ADC 후</SPAN>
<SPAN USERMARK="F-BT">보물질&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: </SPAN>
<SPAN USERMARK="F-BT">$294mn (Upfront+Milestone) + 로열티 &cr;  </SPAN>
<SPAN USERMARK="F-BT">+ Option(지분/Revenue Sharing) </SPAN>
<SPAN USERMARK="F-BT">&cr;</SPAN>
<SPAN USERMARK="F-BT">□전세계시장 대상 기술이전 </SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">2020년 12월</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">10,517</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">325,487</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□ 임상 1상 진행예정&cr;□ </SPAN>
<SPAN USERMARK="F-BT">와이바이오로직스</SPAN>
<SPAN USERMARK="F-BT">와 공동연구를 통해 확보한 후보물질임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">ATX 저해제</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">브릿지바이오</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="145">
<P></P>
<P USERMARK="F-BT">□ 후보물질 확정 후 브릿지 바이오 주도 개발 진행&cr;□사업화 모델 : 단계별 마일스톤 + Profit Sharing</P>
<P USERMARK="F-BT">  - Profit Sharing: 제 3자 기술이전 시 개발 단계별&cr;    양사간 기여율에 따른 이익 배분&cr;  - 마일스톤: 300억 (선급금 30억 포함)</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">2017년 5월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">2,000</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145" USERMARK="F-BT">30,000</TD>
<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="145" USERMARK="F-BT">□ 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">옥사졸리디논계 &cr;항생제</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">Haihe Bio(구 RMX Bio)</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="99">
<P USERMARK="F-BT">□중국 : 약 240억 (Upfront+Milestone) + 로열티&cr;□글로벌 : 임상 2상 데이터 확보 후 기술이전 추진</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99">
<SPAN USERMARK="F-BT">2016년 12월</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">상업화 기간 동안 계속</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">600</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">24,000</TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="99">
<SPAN USERMARK="F-BT">□ 임상 2상 진행 중&cr;</SPAN>
<SPAN USERMARK="F-BT">□ FDA 희귀의약품 지정&cr;□ FDA QIDP 승인&cr;</SPAN>
<SPAN USERMARK="F-BT">□ FDA Fast Track 지</SPAN>
<SPAN USERMARK="F-BT">정</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<P USERMARK="F-BT">항응혈제 </P>
<P USERMARK="F-BT">(FXa 저해제 )</P>
</TD>

<TD WIDTH="174" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">GC녹십자</SPAN>
</TD>

<TD WIDTH="405" VALIGN="MIDDLE" HEIGHT="76">

<P USERMARK="F-BT">
<SPAN>□ </SPAN>
<SPAN>중국시장 : 2018년2월 중국제약사 Lee's Pharma에&cr;   기술이전 ->녹십자와 Profit Sharing  중&cr;</SPAN>
<SPAN>□북미, 유럽 ,일본 등 : sub-L/O시 Profit Sharing </SPAN>
</P>
</TD>

<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">2009년 6월</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">특허만료일</SPAN>
</TD>
<TD WIDTH="92" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">비공개 </TD>

<TD WIDTH="415" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□ 임상 1상 완료(미국)&cr;</SPAN>
<SPAN USERMARK="F-BT">□ 임상 1상 진행예정(중국)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>※ 외화 금액은 체결시점 공시를 통해 안내한 원화금액으로 입력하였습니다.&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B">[계약 1]</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="676" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">①계약 상대방</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">녹십자</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">②계약 내용</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">③대상 지역</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">④총 계약금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑤수취 금액</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑥계약 조건</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="53" USERMARK="F-BT">⑦회계처리 방법</TD>
<TD WIDTH="543" HEIGHT="53" USERMARK="F-BT">계약금 및 중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑧대상 기술</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">LCB02-0133 항응혈제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑨개발 진행경과</TD>
<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT">미국 임상 1상 완료 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="133" HEIGHT="30" USERMARK="F-BT">⑩기타 사항</TD>

<TD WIDTH="543" HEIGHT="30" USERMARK="F-BT 0XFF0000">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 2]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">푸싱제약 (Shanghai Fosun Pharmaceutical Development Co., Ltd.)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">항HER2 항체-약물 복합체 (anti-HER2 ADC)&cr;중국 시장만을(중국, 대만, 홍콩, 마카오 포함) 대상으로 전용실시권 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국(Greater China)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">20,842,050,000원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">계약금 및 중도금(임상시험 및 신약허가 단계별 마일스톤) 10,750천불, 매출 금액별 달성시 받게 되는 sales 마일스톤 7,000천불 등 포함 총 계약규모는 17,750천불, 그리고 별도의 로열티를 수령함.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="99">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="99">
<SPAN USERMARK=" 0X000000">계약금(비공개)은 반환의무 및 추가적인 조건은 없으며, 중도금 수령전까지 &cr;기간인식함.&cr;</SPAN>
<SPAN USERMARK=" 0X000000">중도금(비공개)은 반환의무 및 조건이 없고 관련하여 수행할 추가적인 의무가 존재하지 않아 일시에 기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항HER2 항체-약물 복합체 (anti-HER2 ADC)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 3]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Haihe Biopharma (구 RMX Biopharma)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="76">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="76">LCB01-0371 옥사계 항생제 기술이전&cr;LCB01-0371은 MRSA, VRE 등의 그람양성균 슈퍼박테리아 및 다제내성 결핵 치료제로서 약물 장기복용에 따른 부작용을 최소화 할 수 있는 새로운 슈퍼항생제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">약 240억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="122">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="122">- 계약금 : 6억원(50만불) - 계약 체결 후 30일이내 &cr;- 단계별 마일스톤 : 234억(2,000만불) &cr;  ☞ 각 단계별 임상 개발 및 상업화, 목표 판매수량 달성등에 성공할 경우 받게 되는 조건부 마일스톤임. &cr;- 로열티는  별도임. </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="53">계약금은 반환의무 및 조건이 없고 관련하여 수행할 의무가 완료되는 시점에 일시에 기술이전 수익으로 인식함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB01-0371 옥사계 항생제 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">중국 임상 1상 완료</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT 0XEEAE00" WIDTH="543" HEIGHT="30">
<SPAN USERMARK=" 0X000000">비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN USERMARK=" B">[계약 4]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제 기술이전</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">브릿지바이오(300억원)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="191">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="191"> - 기술이전료와 Profit Sharing을 포함하는 계약 &cr;(1) 총계약금액: 300억원 &cr;   - 선급금: 20억원 &cr;   - 단계별 마일스톤: 280억원 &cr;     ☞ 각 단계별 임상 개발 진행과정에 받게 되는 조건부 마일스톤임. &cr;(2) Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB17-0877 항섬유화제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">미국 임상 2상 준비중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 5]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>Millenium Pharmaceuticals(Takeda)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,548억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="145">⑥계약 조건</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="145"> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 선급금 및 단기마일스톤: 8,162,050,000원 &cr;   - 마일스톤 : 446,661,150,000원 &cr;  - 총 계약금액 : 454,823,200,000원 &cr;  3) 경상기술료 (Royalty) : 별도 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB69</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">[계약 6]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">항체-약물 복합체(ADC) 원천기술 이전계약(라이선스) 체결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,963억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="168">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="168">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 원천기술(3타겟 대상) &cr; (2) 계약금액 &cr;   - 총 계약금액(선급금 및 단기마일스톤): 496,315,575,000원 &cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB91</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">후보물질 발굴 진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 7]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Iksuda Therapeutics</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항CD19 항체-약물 복합체 (anti-CD19 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">2,784억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 6,131,500,000원&cr;   - 마일스톤 :  272,238,600,000원&cr;     => 총 계약금액 : 278,370,100,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB73</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">임상 1상 진행예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;[계약 8]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">CStone Pharmaceuticals</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항ROR1 항체-약물 복합체 (anti-ROR1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">4,099억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="214">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="214">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 11,276,000,000원&cr;   - 마일스톤 :  398,606,600,000원&cr;     => 총 계약금액 : 409,882,600,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) </SPAN>
<SPAN>Profit Sharing &cr;   - 선급금, 단계별 마일스톤과 별도로 &cr;     제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분할 예정임</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB71</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B">[계약 9]</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="124"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">①계약 상대방</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">Pyxis Oncology</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">②계약 내용</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>항DLK1 항체-약물 복합체 (anti-DLK1 ADC)</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">③대상 지역</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">전세계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">④총 계약금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">3,255억원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑤수취 금액</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">비공개</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="260">⑥계약 조건</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="260">
<SPAN> (1) 계약기술 : 항체-약물 복합체(ADC) 후보물질 &cr; (2) 계약금액 &cr;   - 선급금 : 10,517,450,000원&cr;      1차 : 553,550,000원&cr;      2차 : 9,963,900,000원(2021년  4월 30일 이내)&cr;   - 마일스톤 :  314,969,950,000원&cr;     => 총 계약금액 : 325,487,400,000원&cr; (3) 경상기술료 (Royalty) : 별도 &cr; (4) Option 포함</SPAN>
<SPAN>&cr;   - 선급금, 단계별 마일스톤과 별도로 옵션행사시 Pyxis사의 지분 및 제3자 대상 기술이전시 양사는 합의된 비율에 따라 이윤을 배분받을 수 있는 권리확보</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="53">⑦회계처리 방법</TD>

<TD USERMARK="F-BT 0XFF0000" WIDTH="543" HEIGHT="53">
<SPAN USERMARK=" 0X000000">계약금은 반환의무 및 조건이 없으며, 관련하여 수행할 의무가 완료되는 시점에기술이전 수익으로 인식함</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑧대상 기술</TD>
<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">LCB67</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑨개발 진행경과</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>임상 1상 진행예정</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="133" HEIGHT="30">⑩기타 사항</TD>

<TD USERMARK="F-BT" WIDTH="543" HEIGHT="30">
<SPAN>비공개</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>나. 기술제휴 계약(물질평가 계약)
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1077">

<COLGROUP>
<COL WIDTH="103"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="326"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="335" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액</P>
</TD>

<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">ADC 원천기술</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">비공개(미국)</SPAN>
</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: 미공개 (물질평가 </SPAN>
<SPAN USERMARK="F-BT">계약</SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴중</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">2019년 1분기</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="76" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">ADC 원천기술</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76">
<SPAN USERMARK="F-BT">비공개(일본)</SPAN>
</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">□비공개 타겟&cr;</SPAN>
<SPAN USERMARK="F-BT">□총규모: 미공개 (리서치 라이선스 계약</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">)&cr;□레고켐바이오 기술 활용 ADC 후보물질 발굴중</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" HEIGHT="76">
<SPAN USERMARK="F-BT">2020년 4분기</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="76" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="76" USERMARK="F-BT">□ 기술이전 전제한 물질평가 &cr;    진행중</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>다. 라이센스인(License-In) 계약</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1077">

<COLGROUP>
<COL WIDTH="103"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="326"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">품 목</P>
</TD>

<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약상대방</P>
</TD>
<TD WIDTH="335" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">계약의 개요</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약체결일</P>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약종료일</P>
</TD>

<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">계약금액</P>
</TD>

<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P USERMARK="F-BT">진행경과 등 비고</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">항바이러스&cr;치료제</TD>
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">한국화학연구원외3개기관</TD>

<TD WIDTH="335" VALIGN="MIDDLE" HEIGHT="53">
<SPAN USERMARK="F-BT">□항바이러스 (코로나바이러스 등) 후보물질</SPAN>
<SPAN USERMARK="F-BT">&cr;</SPAN>
<SPAN USERMARK="F-BT">□</SPAN>
<SPAN USERMARK="F-BT">총규모: 비공개</SPAN>
</TD>

<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<SPAN USERMARK="F-BT">2020년 5월</SPAN>
</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="229" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">□ 전임상 준비중</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN>② 의약사업부문 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>의약사업부문이 체결한 주요 판권 관련 계약은 아래와 같습니다.</SPAN>
<SPAN USERMARK=" I"></SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1031">

<COLGROUP>
<COL WIDTH="179"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="133"></COL>
<COL WIDTH="348"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약품목</TH>
<TH USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약상대방</TH>
<TH USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약체결일 </TH>
<TH USERMARK="F-BT" WIDTH="357" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계약 내용</TH>
<TH USERMARK="F-BT" WIDTH="215" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="188" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">의료기기</TD>
<TD USERMARK="F-BT" WIDTH="129" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">나누리병원 외</TD>
<TD USERMARK="F-BT" WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2015.10.01 </TD>
<TD USERMARK="F-BT" WIDTH="357" HEIGHT="30" VALIGN="MIDDLE">치료재료, 의료소모품  계약</TD>
<TD USERMARK="F-BT" WIDTH="215" HEIGHT="30" VALIGN="MIDDLE"> 5개 병원</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
<SPAN USERMARK=" 0XFF0000 B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">10. </SPAN>
<SPAN USERMARK=" B">연구개발 관련사항</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>
<P USERMARK=" B">가. 연구개발 조직도&cr;</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="247" ALIGN="CENTER" HSPACE="0">210331 조직도.jpg</IMG>
<IMG-CAPTION ATOC="N">210331 조직도</IMG-CAPTION>
</IMAGE>

<P>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
<SPAN>당사의 창업멤버인 대표이사를 포함한 경영진은 국내에서 세계적 신약개발을 주도해온 LG생</SPAN>
<SPAN>명과학 등에서 팀장급으로 오랜 경험을 가진 핵심요원들입니다.  창업 이후 국내외 </SPAN>
<SPAN>연구인력을 지속적으로 채용하였습니</SPAN>
<SPAN>다</SPAN>
<SPAN>.</SPAN>
<SPAN> </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>2</SPAN>
<SPAN>021년</SPAN>
<SPAN> 03월 </SPAN>
<SPAN>전체 인원 107명 중, 경영관리, 사업전략 12</SPAN>
<SPAN>명 </SPAN>
<SPAN>및 의약사업부문</SPAN>
<SPAN> 4명을</SPAN>
<SPAN> 제외한</SPAN>
<SPAN> </SPAN>
<SPAN>91명의</SPAN>
<SPAN> 연구진을 </SPAN>
<SPAN>확보하고 있습니다. 전공별로는 </SPAN>
<SPAN>유기합성 전공자가 35명, Biology/약학 전공자 49명, 기</SPAN>
<SPAN>타 8명으로 구성되어 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="752" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="31"></COL>
<COL WIDTH="44"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="308"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">구분</TD>
<TD WIDTH="53" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">성명</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">직급</TD>
<TD WIDTH="118" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">담당업무</TD>
<TD WIDTH="66" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">최종학위</TD>
<TD WIDTH="317" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요 학력 및 경력</TD>
<TD WIDTH="92" HEIGHT="28" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주요연구실적</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">1</TD>
<TD WIDTH="53" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">김용주</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">대표이사</TD>
<TD WIDTH="118" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구개발총괄</TD>
<TD WIDTH="66" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">박사</TD>
<TD WIDTH="317" HEIGHT="102" USERMARK="F-8" VALIGN="MIDDLE">한국과학원 유기화학 박사(1983)&cr;LG화학 기술연구원 연구위원(1983-1997)&cr;LG화학 기술연구원 연구소장/LG BMI 법인장(1997-2000)&cr;LG생명과학기술연구원 신약연구소장/연구위원(2000-2006)&cr;현, (주)레고켐바이오 대표이사/CEO</TD>
<TD WIDTH="92" HEIGHT="102" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">2</TD>
<TD WIDTH="53" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">이창선</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">신약연구소장</TD>
<TD WIDTH="66" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="140" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Yale 유기화학 박사(2001)&cr;LG생명과학(1991-1996)&cr;Oregon State Univ. Postdoc/Staff Scientist(2001-2003)&cr;PTC Therapeutics 연구위원(2006-2016)&cr;RaND Biosciences Inc.CTO(2016-2017)&cr;한독 상무(2018)&cr;현, (주)레고켐바이오 신약연구소장</TD>
<TD WIDTH="92" HEIGHT="140" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">3</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">조영락</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">부사장</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">개발본부장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">연세대학교 화학 박사(1999)&cr;The Salk Institute(1999-2000)&cr;The Scripps Research Institute(2000-2001)&cr;LG생명과학 차장(2001-2006)&cr;현, (주)레고켐바이오 개발본부장</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">4</TD>
<TD WIDTH="53" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">안세창</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">연구위원</TD>
<TD WIDTH="118" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">공정센터장</TD>
<TD WIDTH="66" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">박사</TD>
<TD WIDTH="317" HEIGHT="102" VALIGN="MIDDLE" USERMARK="F-8">Univ. of Minnesota 화학과 박사(1991)&cr;Harvard Univ. Post-doc(1991-1993)&cr;LG생명과학(1993-2015)&cr;LG화학(2015-2016)&cr;현, (주)레고켐바이오 연구위원</TD>
<TD WIDTH="92" HEIGHT="102" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-10">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="40" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">5</TD>
<TD WIDTH="53" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">송호영</TD>
<TD WIDTH="66" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">연구위원</TD>
<TD WIDTH="118" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">합성센터장</TD>

<TD WIDTH="66" HEIGHT="83" USERMARK=" 0X0000FF" VALIGN="MIDDLE" ALIGN="CENTER">
<SPAN USERMARK="F-10 0X000000">박사</SPAN>
</TD>

<TD WIDTH="317" HEIGHT="83" USERMARK="F-8 0X0000FF" VALIGN="MIDDLE">
<SPAN USERMARK=" 0X000000">서울대학교 화학과 박사(2002)&cr;LG생명과학 Post-doc(2002)&cr;LG생명과학(2003-2006)&cr;</SPAN>
<SPAN USERMARK=" 0X000000">현, (주)레고켐바이오 연구위원</SPAN>
</TD>
<TD WIDTH="92" HEIGHT="83" USERMARK="F-10" VALIGN="MIDDLE" ALIGN="CENTER">주5)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-10">주1) 당 연구인력(김용주 대표이사)의 주요 연구실적은 다음과 같습니다.&cr;     - 세</SPAN>
<SPAN USERMARK="F-10">파계 항생제 국내 최초 신약 기술이전(Glaxo)&cr;     - "FACTIVE" 미국 FDA 최초 승인&cr;     - 동탑산업 훈장(대통령상) 수상&cr;     - LG그룹 연구개발상 대상 수장(세파계 항생제)&cr;     - 특허 100여건&cr;</SPAN>
<SPAN USERMARK="F-10">&cr;주2) 당 연구인력(이창선 CTO)의 주요 연구실적은 다음과 같습니다.&cr;     - LG화학 AIDS 치료제팀, 분자설계 및 합성 전략 고안, 전임상 후보 물질 도출&cr;     - Celera Genomics 신약개발팀, 거대세포 관련 천식치료제 개발 &cr;     - HDAC 억제제 임상 후보 물질 발굴&cr;     - Celera, HDAC-8 선택 특이적 억제제단독고안, 특허 출원 및 기술이전&cr;     - PTC Therapeutics, 척추근육증치료제 개발 참여및 기술이전&cr;&cr;주3) 당 연구인력(조영락 개발본부장)의 주요 연구실적은 다음과 같습니다.&cr;     - OXa. 항생제 임상1상 진행  P/L&cr;     - 항응혈제(FXa)녹십자 기술이전&cr;     - 특허15건(해외32개국)&cr;     - 학술지(국내 5, 국외 15)&cr;&cr;주4) 당 연구인력(안세창 공정센터장)의 주요 연구실적은 다음과 같습니다.&cr;     - 신물질 농약 3종 개발 생산(PBX, EBX, FTS)&cr;     - 의약 API 및 임상시료 생산&cr;     - OLED/LCD 핵심재료 생산&cr;     - 국내 특허 등록 11건&cr;     - 논문 11편&cr;&cr;주5) 당 연구인력(송호영 합성센터장)의 주요 연구실적은 다음과 같습니다. &cr;     - Thrombin 저해제연구 개발 (비임상까지진행&cr;     - C형 간염 치료제 연구개발&cr;     - 항응혈제(FXa)녹십자 기술이전 P/L&cr;     - 국내외 학술지 발표 7건&cr;     - 특허 16건&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF">&cr;</SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" B">나. 연구개발비 집행현황</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="608" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="599"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="608" HEIGHT="30" USERMARK="F-BT">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="610">

<COLGROUP>
<COL WIDTH="128"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="107"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="260" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">16기 1분기</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">15기</TH>
<TH WIDTH="116" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">14기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">시약재료비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">795,404 </TD>
<TD USERMARK="F-BT" WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,463,587 </TD>
<TD USERMARK="F-BT" WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">824,799 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">인건비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">1,744,614 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,431,541 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,858,154 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">감가상각비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">338,727 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,368,955 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,155,660 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기술개발비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">12,350,827 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">27,068,193 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,035,084 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">기타</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">891,355 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">19,807,743 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,744,720 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">연구개발비용 계</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">16,120,927 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">56,140,020 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">17,618,417 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="30" COLSPAN="2" VALIGN="MIDDLE">정부보조금</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">(1,935,742)</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,935,742)</TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(907,204)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="137" HEIGHT="60" ROWSPAN="2" VALIGN="MIDDLE">회계처리</TD>
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">매출원가</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">- </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">판매비와관리비</TD>
<TD WIDTH="117" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">14,185,185 </TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">54,204,278 </TD>
<TD WIDTH="116" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,711,212 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="260" HEIGHT="53" COLSPAN="2" VALIGN="MIDDLE">연구개발비 / 매출액 비율&cr;[연구개발비용계÷당기매출액×100]</TD>
<TD WIDTH="117" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">305.43%</TD>
<TD WIDTH="117" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">113.66%</TD>
<TD WIDTH="116" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">30.64%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN USERMARK="F-11">주) 연구개발비용은 정부보조금을 차감하기 전의 지출총액 기준으로 산정하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B">다. 연구개발</SPAN>
<SPAN USERMARK=" B">과제 총</SPAN>
<SPAN USERMARK=" B">괄표</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" B">&cr;</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" BI"></SPAN>
<SPAN>당사가 진행중인 주요 연구개발과제의 세부</SPAN>
<SPAN>내용은 아래와 같습니다.</SPAN>
</P>
<P><합성의약품 연구개발과제 진행현황></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="930">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="182"></COL>
<COL WIDTH="209"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="204"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK=" BC0XD7D7D7">
<SPAN USERMARK="F-BT">구분</SPAN>
</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">적응증</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">현재 &cr;개발단계</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Partner</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99" USERMARK="F-BT">항생제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Delpazolid&cr;(그람양성균)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">결핵, 다제내성 결핵, &cr;MRSA, VRE</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">임상 2상  &cr;진행중</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">Haihe Biopharma&cr; (중국판권)</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">- FDA 희귀의약품  &cr;- FDA QIDP  &cr;- Fast Track &cr;- 기술이전(‘16.12)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="99" USERMARK="F-BT">항응혈제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">LCB02-0133&cr;(Nokxaban,  FXa Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">항응혈제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">임상 1상&cr; 완료</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">GC녹십자/&cr; Lee's Pharm</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">- 글로벌&cr;  (Profit Sharing) &cr;- 제3자 기술이전&cr;   ('18.01, 중국/동남아 권리)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="53" USERMARK="F-BT">항섬유화제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB17-0877 &cr;(ATX Inhibitor)</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">특발성 폐섬유증&cr;간질성 섬유화 폐질환</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">임상 2상&cr;진행예정</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">브릿지바이오</TD>
<TD WIDTH="213" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">- 글로벌(Profit Sharing) &cr;- FDA 희귀의약품(19.01) </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="93" HEIGHT="30" USERMARK="F-BT">항암제</TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Small molecule Oncology</TD>
<TD WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">면역항암제</TD>
<TD WIDTH="86" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">　</TD>
<TD WIDTH="213" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P><ADC 연구개발과제 진행현황></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="925">

<COLGROUP>
<COL WIDTH="73"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="118"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">구분</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">프로젝트</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">적응증/타겟</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">현재&cr;개발단계</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Antibody &cr;Partner</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">사업화현황</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">Licensee</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="212" USERMARK="F-BT">ADC&cr;Platform</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB69</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Takeda</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Takeda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">면역항암제</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB91</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB91</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">비공개(미국)</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB06A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">비공개(일본)</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">MTA&cr;(링커 & 톡신)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-기술이전 &cr;옵션 포함</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="10" WIDTH="82" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="415" USERMARK="F-BT"> ADC&cr;Products</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB14</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">HER2</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">임상 1상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(중국)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">FosunPharma</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB73</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">CD19</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Novimmune</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Iksuda</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">21년 4분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB71</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">ROR1</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">ABL Bio</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">CStone</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">21년 4분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB67</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">DLK1</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">전임상</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Ybiologigs</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT"> L/O&cr;(글로벌)</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Pyxis</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">22년 1분기&cr;IND제출예정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB84</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Mediterranea</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Licensed-In</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB87</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Diatheva</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"> -</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"></TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">LCB02A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">고형암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Harbour&cr;Biomed</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT"> -</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB04A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">ImmuneOncia</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB97</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비공개</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB05A</TD>
<TD WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">고형암/혈액암</TD>
<TD WIDTH="133" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Discovery</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비공개</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="118" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="127" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">Collaboration</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN>이 과제 중 당사에서 가장 앞서 </SPAN>
<SPAN>임상 2상 진행 중인 옥</SPAN>
<SPAN>사졸리디논계 항생제(경구)와 항응혈제(FXa저해제), 전임상 단계인 그람음성균 항생제와  차세대 원천기술 후보&cr; ADC 등 5개 과제에 대한 설명은 다음과 같습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
</P>
<P>ㄱ. 옥사졸리디논계 항생제 (Delpazolid, 개발번호 : LCB01-0371)</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="702">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="544"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<SPAN>다제내성 결핵</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">골수독성 등 안전성 우수, 물에 대한 용해도 우수하여 경구/주사 겸용 가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="103" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="103" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 경구용: </SPAN>
<SPAN USERMARK="F-11">다제내성 결핵 대상 국내 2상a 진행 중 &cr;              -> </SPAN>
<SPAN USERMARK="F-11">글로벌 2상b 준비 중 (미국 등 다수국가 예정)</SPAN>
</P>

<P USERMARK="F-12">
<SPAN USERMARK="F-BT11">- </SPAN>
<SPAN USERMARK="F-BT11">주사제: 미국에서 전임상 완료, </SPAN>
<SPAN USERMARK="F-BT11">국내 1상 완료 </SPAN>
<SPAN USERMARK="F-BT11">&cr;- 글로벌 임상: FDA 희귀의약품, QIDP, Fast Track 지정 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="553" VALIGN="MIDDLE" HEIGHT="79" USERMARK="F-BT">
<P USERMARK="F-BT">- 중국: 중국시장 대상으로 기술이전 완료 Haihe Bio(구 RMX Bio, &cr;   2016년 12월)&cr;- 글로벌(중국 외): 임상2상 단계에서 기술이전 목표</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<P>ㄴ. 항응혈제 FXa 저해제 (LCB02-0133, 녹십자 개발번호 : GCC-4401C)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">뇌졸중, 협심증, 심근경색, 심부정맥성 혈전증, 폐색전증</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">약효, 특히 출혈부작용(bleeding) 개선, 세계최초 경구/주사 겸용가능</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 녹십자 주도로 미국에서 1상 완료 </P>
<P USERMARK="F-BT">- 임상 2상a 진입 준비 중 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 중국 기술이전 진행 (Lee's Pharm, 2018년 2월)</P>
<P USERMARK="F-BT">- 2차: 임상 2상 단계 글로벌 제약사 기술이전</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P>ㄷ. 항섬유화제 ATX 저해제 (LCB17-0877)</P>

<TABLE BORDER="1" WIDTH="698" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">적응증</P>
</TD>
<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">항염증, 폐섬유증 등</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">차별성</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="31" USERMARK="F-BT">
<P USERMARK="F-BT">후보물질 단계에서의 차별적인 ATX 저해력</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">
<P USERMARK="F-BT">개발일정</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="53" USERMARK="F-BT">

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 후보물질&cr;- </SPAN>
<SPAN USERMARK="F-11">브릿지바이오 통한 전임상 완료 및 미국 임상 1상 완료</SPAN>
</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">사업화 계획</P>
</TD>

<TD WIDTH="549" VALIGN="MIDDLE" HEIGHT="99" USERMARK="F-BT">
<P USERMARK="F-BT">- 1차: 개발전문사 기술이전 완료 (브릿지 바이오, 2017년 5월)</P>

<P USERMARK="F-BT12">
<SPAN USERMARK="F-11">- 2</SPAN>
<SPAN USERMARK="F-11">차: 글로벌 임상 진행 단계에서 제 3자 글로벌 기술이전 목표&cr;- 3차: 개발단계 진행에 따른 마일스톤 수령</SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>ㄹ. ADC 원천기술 </SPAN>
</P>

<TABLE BORDER="1" WIDTH="692" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="534"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">적응증</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">항체의 선택성과 저분자 약물의 약효의 장점을 결합한 신규 신약개발 기술로 주로 항암제에 적용할 예정.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT12">차별성</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="55" USERMARK="F-BT">
<P USERMARK="F-BT">기존 1세대 기술의 단점인 혼합물 문제와 불안정한 링커의 단점을 모두 극복한 차세대 원천기술로 기대.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="398" USERMARK="F-BT">
<P USERMARK="F-BT12">개발일정</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="398" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>-</SPAN>
<SPAN>  </SPAN>
<SPAN>중국 푸싱제약( Fosun Pharma) Herceptin ADC 에 대한 중국시장 기술이전&cr;   계약 체결 (2015년 8월) 후</SPAN>
<SPAN> 중국에서 임상1상 진행중&cr;- 밀레니엄 파마수티컬( Takeda ) ADC 플랫폼 기술이전 계약체결(2019년 3월)&cr;   후보물질 발굴예정&cr;- 익수다(Iksuda)에 ADC 플랫폼 및 CD19 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 4월, 5월)&cr;- 시스톤(CStone)에 ROR1 ADC에 대한 전세계시장 대상 기술이전&cr;   계약체결(2020년 10월)&cr;- 픽시스(Pyxis)에 DLK1 ADC에 대한 전세계시장 대상 기술이전 계약체결&cr;  (2020년 12월)&cr;- 원천기술 강화 및 개발후보 확대 위한 국내,외 기관과 신규타겟 적용시험&cr;   진행 중 &cr;   . </SPAN>
<SPAN>복수 글</SPAN>
<SPAN>로벌제약사와 기술이전 전제한 물질평가 진행 중 &cr;   . </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>미국/유럽 등지 여러 항체회사들과 신규 항체 대상&cr;     후보물질 발굴 위한 공동연구 중  </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>
<P USERMARK="F-BT">- 신규 Toxin 플랫폼 발굴 (특허 출원 중)&cr;- Beyond Oncology: ADC이외 분야 원천기술 적용 모색 중</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168" USERMARK="F-BT">
<P USERMARK="F-BT12">사업화 계획</P>
</TD>

<TD WIDTH="543" VALIGN="MIDDLE" HEIGHT="168" USERMARK="F-BT">

<P USERMARK="F-BT">
<SPAN>□</SPAN>
<SPAN>원천기술 기술이전</SPAN>
</P>

<P>
<SPAN USERMARK="F-BT"></SPAN>
<SPAN USERMARK="F-BT">  . </SPAN>
<SPAN USERMARK="F-BT">글로벌제약사 등과 당사 Platform </SPAN>
<SPAN USERMARK="F-BT">기술이전 확대&cr;  . 향후 년 3건 이상 기술이전 목표</SPAN>
</P>
<P USERMARK="F-BT">□Her2-ADC 개발 및 기술이전</P>
<P USERMARK="F-BT">-중국 푸싱제약과 중국시장 대상 기술이전 계약체결 완료(2015.08.17)</P>

<P>
<SPAN USERMARK="F-BT">- 푸싱제약 중국 임상 진행중 -> 임상 결과 활용 및 당사 주도 글로벌 제약사&cr;  대상 기술이전</SPAN>
<SPAN USERMARK="F-BT"></SPAN>
</P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>  
<SPAN USERMARK=" 0XFF0000 B"></SPAN>
</P>

<P>
<SPAN USERMARK=" B">11. 그밖에 투자의사결정에 필요한 사항</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN USERMARK=" B">가. 지적재산권 현황</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>회사의 국내외특허는 항생제, 항응혈제, ADC, 항염증제 등을 포함하여 총 217건입니다. 연구분야 별, 국내외별로 내역을 정리하면 아래와 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="606" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="597"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="606" HEIGHT="30" USERMARK="F-BT"> [분야별/국내외별 특허출원 내역]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="625">

<COLGROUP>
<COL WIDTH="72"></COL>
<COL WIDTH="167"></COL>
<COL WIDTH="52"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="27"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="42"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="81" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="83" USERMARK="F-BT">구 분 </TH>
<TH ROWSPAN="2" WIDTH="176" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="83" USERMARK="F-BT">과 제 명 </TH>
<TH COLSPAN="3" WIDTH="148" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">국내 특허</TH>
<TH WIDTH="52" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="83" USERMARK="F-BT" ROWSPAN="2">PCT</TH>
<TH COLSPAN="3" WIDTH="168" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">해외 특허</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="61" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">심사중</TH>
<TH WIDTH="51" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">등록 </TH>
<TH WIDTH="36" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">계 </TH>
<TH WIDTH="62" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">심사중 </TH>
<TH WIDTH="55" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" USERMARK="F-BT">등록 </TH>
<TH WIDTH="51" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">항생제 </TD>
<TD WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB01-0371</TD>

<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">-</P>
</TD>

<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">5</P>
</TD>

<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">5</P>
</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">4</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">1</P>
</TD>

<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">13</P>
</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">14</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">항응혈제 </TD>
<TD WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">FⅩa 억제제 </TD>

<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">1</P>
</TD>

<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">5</P>
</TD>

<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">6</P>
</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">5</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">16</TD>

<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">32</P>
</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">48</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">항염증제 </TD>
<TD WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">LCB17-0877</TD>

<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">-</P>
</TD>

<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">1</P>
</TD>

<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">1</P>
</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">1</TD>

<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">25</P>
</TD>

<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">-</P>
</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">25</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT" ROWSPAN="2">ADC</TD>
<TD WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">ADC Platform</TD>
<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">7</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">3</TD>
<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">10</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">9</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">60</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">18</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">78</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="176" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">ADC Products</TD>
<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">4</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>

<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">4</P>
</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">5</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">24</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">2</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">26</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="257" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<SPAN>합    계 </SPAN>
</TD>
<TD WIDTH="61" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">12</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">14</TD>

<TD WIDTH="36" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">
<P USERMARK="F-BT">26</P>
</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">24</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">126</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">65</TD>
<TD WIDTH="51" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">191</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-0-0">III. 재무에 관한 사항</TITLE>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-1-0">1. 요약재무정보</TITLE>
<P>(1) 개별요약재무제표</P>

<TABLE ACLASS="NORMAL" WIDTH="614" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="605"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="614" HEIGHT="191">당사는 당기 중 ㈜바스칸바이오제약에 대한 지배력을 상실하여, 해당 기업을 연결대상 종속기업에서 제외하였으며, 당기말 현재 연결대상 기업은 없습니다.&cr;이에 따라, 제15기는 개별재무제표이고 비교식으로 표시되는 제14기 및 제13기는 연결재무제표입니다.&cr;&cr;제15기 개별재무제표와 제14기 및 제13기 연결재무제표는 외부감사인의 감사를 받아 한국채택국제회계기준에 따라 작성되었으며, 회계 감사인으로 부터 적정의견을 받은 감사받은 재무제표입니다.</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="634">

<COLGROUP>
<COL WIDTH="625"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="634" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="638">

<COLGROUP>
<COL WIDTH="238"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="121"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK=" BC0XD7D7D7" WIDTH="247" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">과목</TD>
<TD USERMARK=" BC0XD7D7D7" WIDTH="133" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">제 15 기</TD>
<TD USERMARK=" BC0XD7D7D7" WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">제 14 기</TD>
<TD USERMARK=" BC0XD7D7D7" WIDTH="130" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">제 13 기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK=" BC0XD7D7D7" WIDTH="133" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">(2020년 12월말)</TD>
<TD USERMARK=" BC0XD7D7D7" WIDTH="128" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">(2019년 12월말)</TD>
<TD USERMARK=" BC0XD7D7D7" WIDTH="130" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">(2018년 12월말)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">I. 자산</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(1) 유동자산</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">100,010,638</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">111,419,272</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">93,378,851</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(2) 비유동자산</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">35,901,710</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">30,058,181</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">28,307,433</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">자산총계</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">135,912,348</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">141,477,453</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">121,686,284</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">II. 부채</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(1) 유동부채</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,009,298</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,423,973</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,945,687</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(2) 비유동부채</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,776,866</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,144,135</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,445,867</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">부채총계</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">23,786,164</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">25,568,107</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,391,555</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">III. 자본</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK=" 0X0000FF">　</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(1) 자본금</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,053,171</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,004,005</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,999,165</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(2) 자본잉여금</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">180,889,859</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">185,180,023</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">184,478,809</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(3) 기타자본</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,245,694</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,471,713</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,012,930</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(4)기타포괄손익누계액</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,075,072</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(94,895)</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">468,289</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(5) 이익잉여금(결손금)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(86,137,612)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(78,811,546)</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(90,294,405)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">(6) 비지배지분</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK=" 0X0000FF">　-</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,160,046</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,629,942</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">자본총계</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">112,126,184</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">115,909,346</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">105,294,729</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">자본과부채총계</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">135,912,348</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">141,477,453</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">121,686,284</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="53" VALIGN="MIDDLE"></TD>
<TD WIDTH="133" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">2020-01-01 ~ &cr;2020-12-31</TD>
<TD WIDTH="128" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">2019-01-01 ~ &cr;2019-12-31</TD>
<TD WIDTH="130" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">2018-01-01 ~ &cr;2018-12-31</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">I. 영업수익</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">49,393,702</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">57,500,139</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">25,240,302</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">II. 영업비용</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">79,155,463</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">49,083,297</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">41,218,266</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">III. 영업이익(손실)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(29,761,761)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,416,842</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(15,977,964)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">IV. 법인세비용차감전순이익(손실)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(8,826,762)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">13,101,519</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(26,426,773)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">V. 법인세비용</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,840,501)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">626,011</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(354,090)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">VI. 당기순이익(손실)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(6,986,261)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,475,508</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(26,072,683)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">    지배기업의 소유주지분</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(6,986,261)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">13,586,124</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(25,770,425)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">    비지배지분</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,110,616)</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(302,258)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">VII. 주당손익(손실)(단윈:원)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">    기본주당순이익(손실)(단위:원)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(307)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">641 </TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(2,446)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">    희석주당순이익(손실)(단위:원)</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(307)</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">566 </TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(2,446)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="247" HEIGHT="30" VALIGN="MIDDLE">연결에 포함된 회사수</TD>
<TD WIDTH="133" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="128" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<WARNING>※ 아래 『재무제표』단위서식을 클릭하여 해당사항을 선택하면,&cr;    2.연결재무제표 ~ 5.재무제표주석 항목을 삽입할 수 있습니다.</WARNING>
</SECTION-2>

<INSERTION ABASISNUMBER="E1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『재무제표』 삽입</COMMENT>
<LIBRARYLIST>11011#*재무제표_*.*</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dslx:1616475748">20210323_2020년(개별)_15기사업보고서_ 레고켐바이오사이언스_v2.ixd</FILENAME>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-2-0">2. 연결재무제표</TITLE>
<P>- 해당 사항 없음.</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-3-0">3. 연결재무제표 주석</TITLE>
<P>- 해당 사항 없음.</P>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-4-0">4. 재무제표</TITLE>

<TABLE-GROUP ACLASS="{XBRL}BS_S" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="701" BORDER="0">

<COLGROUP>
<COL WIDTH="692"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="701" HEIGHT="31" AUPDATECONT="N">
<P USERMARK="F-12 B">재무상태표</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="701" HEIGHT="30" AUPDATECONT="N">
<P>제 15 기          2020.12.31 현재</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="701" HEIGHT="30" AUPDATECONT="N">
<P>제 14 기          2019.12.31 현재</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="701" HEIGHT="30" AUPDATECONT="N">
<P>제 13 기          2018.12.31 현재</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="701" HEIGHT="30" AUPDATECONT="N">
<P>(단위 : 원)</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="703" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="295"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="304">　</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 15 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 14 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 13 기</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>자산</P>
</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　유동자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>100,010,638,124</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>111,419,272,490</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>93,378,850,696</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　현금및현금성자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>54,648,759,258</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>66,888,373,396</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,221,422,881</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　매출채권</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>20,568,675,667</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>11,119,771,887</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>17,667,222,883</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타유동금융자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>23,556,604,970</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>29,310,848,238</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>61,573,463,640</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　당기법인세자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>172,396,980</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>798,897,912</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>294,870,655</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타유동자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>778,754,609</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,280,008,641</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,867,168,537</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　재고자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>285,446,640</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,021,372,416</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>754,702,100</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　비유동자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>35,901,709,939</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>30,058,180,591</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>28,307,433,051</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　지분법적용 투자지분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,173,545,975</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타비유동금융자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>968,342,799</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>280,606,613</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,397,496,400</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　당기손익-공정가치 측정 금융자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>4,910,625,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,457,500,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,468,475,000</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타포괄손익-공정가치 측정 금융자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>5,432,393,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>868,340,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,716,830,625</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　유형자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>7,617,650,215</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>12,143,892,423</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,274,659,524</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　무형자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>8,149,909,303</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>8,988,456,702</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,109,576,387</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타비유동자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,649,243,647</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,319,384,853</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,340,395,115</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　자산총계</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>135,912,348,063</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>141,477,453,081</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>121,686,283,747</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>부채</P>
</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　유동부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>14,009,297,856</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>15,423,972,628</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>9,945,687,495</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　매입채무</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,554,798,036</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>7,691,811,366</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>8,178,121,965</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타유동금융부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,137,495,110</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>5,562,544,603</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>963,038,728</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　유동리스부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>78,081,202</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>111,180,115</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타유동부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,238,923,508</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,058,436,544</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>804,526,802</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　비유동부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>9,776,865,961</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,144,134,739</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,445,867,208</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　장기차입금</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,612,000,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,900,000,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　확정급여부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>4,373,986,452</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,922,169,394</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,061,498,587</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　이연법인세부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,253,143,489</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,880,745,398</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,413,581,225</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　기타비유동금융부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>240,580,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,267,225,762</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>970,787,396</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　　비유동리스부채</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>297,156,020</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>173,994,185</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　부채총계</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>23,786,163,817</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>25,568,107,367</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>16,391,554,703</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>자본</P>
</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　지배지분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>112,126,184,246</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>113,749,300,137</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>101,664,787,102</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　자본금</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>12,053,171,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,004,004,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>5,999,164,500</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　자본잉여금</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>180,889,858,521</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>185,180,023,251</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>184,478,809,168</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　기타자본구성요소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,245,694,338</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,471,712,833</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,012,929,571</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　기타포괄손익누계액</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,075,072,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(94,894,800)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>468,289,087</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　이익잉여금(결손금)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(86,137,611,613)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(78,811,545,647)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(90,294,405,224)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　비지배지분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,160,045,577</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,629,941,942</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>　자본총계</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>112,126,184,246</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>115,909,345,714</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>105,294,729,044</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="304">
<P>자본과부채총계</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>135,912,348,063</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>141,477,453,081</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>121,686,283,747</P>
</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE-GROUP ACLASS="{XBRL}IS_S1" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="789" BORDER="0">

<COLGROUP>
<COL WIDTH="780"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="789" HEIGHT="31" AUPDATECONT="N">
<P USERMARK="F-12 B">포괄손익계산서</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="789" HEIGHT="30" AUPDATECONT="N">
<P>제 15 기 2020.01.01 부터 2020.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="789" HEIGHT="30" AUPDATECONT="N">
<P>제 14 기 2019.01.01 부터 2019.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="789" HEIGHT="30" AUPDATECONT="N">
<P>제 13 기 2018.01.01 부터 2018.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="789" HEIGHT="30" AUPDATECONT="N">
<P>(단위 : 원)</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="790" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="390"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="399">　</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 15 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="125">
<P>제 14 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 13 기</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>영업수익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>49,393,701,591</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>57,500,138,690</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>25,240,301,764</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>영업비용</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>79,155,462,737</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>49,083,296,692</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>41,218,265,651</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　매출원가</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>13,828,975,461</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>22,689,053,824</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>19,331,863,208</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　대손상각비(환입)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,462,501,035)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>1,945,160,378</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>58,861,519</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　연구개발비</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>54,204,278,760</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>16,711,212,651</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>15,505,210,563</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　판매비와일반관리비</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>12,584,709,551</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>7,737,869,839</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>6,322,330,361</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>영업이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(29,761,761,146)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>8,416,841,998</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(15,977,963,887)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>기타수익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>554,934,294</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>29,667,067</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>45,062,665</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>기타비용</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>27,029,695</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>263,776,223</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>11,468,726,507</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>이자수익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,001,396,561</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>1,498,902,637</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>425,047,806</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>금융수익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>21,021,055,293</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>4,158,813,147</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>692,537,146</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>금융비용</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,397,414,797</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>781,675,915</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>142,730,151</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>리스이자수익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>37,191,051</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>42,745,993</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>지분법이익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,744,866,657</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>법인세비용차감전순이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(8,826,761,782)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>13,101,518,704</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(26,426,772,928)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>법인세비용</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,840,500,563)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>626,010,911</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(354,090,242)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>당기순이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,986,261,219)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>12,475,507,793</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(26,072,682,686)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>기타포괄손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,830,162,053</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(2,670,854,312)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>228,806,666</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　당기손익으로 재분류되지 않는항목(세후기타포괄손익)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,830,162,053</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(2,670,854,312)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>228,806,666</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　　확정급여제도의 재측정손익(세후기타포괄손익)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(333,189,815)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(981,210,425)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(239,482,421)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　　기타포괄손익-공정가치평가손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,169,966,800</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(1,689,643,887)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>468,289,087</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　　지분법자본변동</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,614,932)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>총포괄손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(4,156,099,166)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>9,804,653,481</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(25,843,876,020)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　지배기업지분포괄이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(4,156,099,166)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>10,939,218,860</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(25,537,189,745)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　비지배기업지분포괄이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(1,134,565,379)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(306,686,175)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>주당이익</P>
</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">　</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　기본주당이익(손실) (단위 : 원)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(307)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>641</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(2,446)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="399">
<P>　희석주당이익(손실) (단위 : 원)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(307)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>566</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(2,446)</P>
</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE-GROUP ACLASS="{XBRL}EF_S" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="1338" BORDER="0">

<COLGROUP>
<COL WIDTH="1329"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="1338" HEIGHT="31" AUPDATECONT="N">
<P USERMARK="F-12 B">자본변동표</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="1338" HEIGHT="30" AUPDATECONT="N">
<P>제 15 기 2020.01.01 부터 2020.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="1338" HEIGHT="30" AUPDATECONT="N">
<P>제 14 기 2019.01.01 부터 2019.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="1338" HEIGHT="30" AUPDATECONT="N">
<P>제 13 기 2018.01.01 부터 2018.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="1338" HEIGHT="30" AUPDATECONT="N">
<P>(단위 : 원)</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="1340" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="249"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="129"></COL>
<COL WIDTH="144"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="258" ROWSPAN="2">　</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="1082" COLSPAN="8">
<P>자본</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="121">
<P>자본금</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="129">
<P>자본잉여금</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="138">
<P>기타자본구성요소</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="153">
<P>기타포괄손익누계액</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="150">
<P>이익잉여금(결손금)</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>지배지분 합계</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="125">
<P>비지배지분</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>자본  합계</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2018.01.01 (기초자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>4,977,293,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>107,068,983,259</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>449,077,006</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(64,288,926,292)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>48,206,427,473</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>1,258,568,221</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>49,464,995,694</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>당기순이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(25,770,424,807)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(25,770,424,807)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(302,257,879)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(26,072,682,686)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>확정급여제도의 재측정요소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(235,054,125)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(235,054,125)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(4,428,296)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(239,482,421)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>468,289,087</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>468,289,087</P>
</TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">　</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>468,289,087</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가제거</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지분법자본변동</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>무상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>유상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>704,223,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>59,276,896,340</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>59,981,119,840</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>59,981,119,840</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>우선주의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 행사</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>12,800,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>591,133,100</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(119,270,200)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>484,662,900</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>484,662,900</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 부여</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>754,849,522</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>754,849,522</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>754,849,522</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 취소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(71,726,757)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(71,726,757)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(71,726,757)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>종속기업의 지분변동으로 인한 증감</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>1,799,654,214</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,799,654,214</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>2,678,059,896</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>4,477,714,110</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지배력의 상실</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>기타</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>전환사채의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>304,847,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>15,742,142,255</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>16,046,989,755</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>16,046,989,755</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2018.12.31 (기말자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>5,999,164,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>184,478,809,168</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>1,012,929,571</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>468,289,087</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(90,294,405,224)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>101,664,787,102</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>3,629,941,942</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>105,294,729,044</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2019.01.01 (기초자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>5,999,164,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>184,478,809,168</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>1,012,929,571</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>468,289,087</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(90,294,405,224)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>101,664,787,102</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>3,629,941,942</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>105,294,729,044</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>당기순이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>13,586,123,504</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>13,586,123,504</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(1,110,615,711)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>12,475,507,793</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>확정급여제도의 재측정요소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(957,260,757)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(957,260,757)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(23,949,668)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(981,210,425)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>(1,689,643,887)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,689,643,887)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,689,643,887)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가제거</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>1,126,460,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(1,126,460,000)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지분법자본변동</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>무상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>유상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>우선주의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>(632,480)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(632,480)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(632,480)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 행사</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>4,840,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>346,745,700</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(86,490,800)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>265,094,900</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>265,094,900</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 부여</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>878,122,606</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>878,122,606</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>226,707</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>878,349,313</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 취소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(332,848,544)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(332,848,544)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(332,848,544)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>종속기업의 지분변동으로 인한 증감</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지배력의 상실</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>기타</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>355,100,863</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(19,543,170)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>335,557,693</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(335,557,693)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>전환사채의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2019.12.31 (기말자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>6,004,004,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>185,180,023,251</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>1,471,712,833</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>(94,894,800)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(78,811,545,647)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>113,749,300,137</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>2,160,045,577</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>115,909,345,714</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2020.01.01 (기초자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>6,004,004,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>185,180,023,251</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>1,471,712,833</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>(94,894,800)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(78,811,545,647)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>113,749,300,137</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>2,160,045,577</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>115,909,345,714</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>당기순이익(손실)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(6,986,261,219)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,986,261,219)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,986,261,219)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>확정급여제도의 재측정요소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(333,189,815)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(333,189,815)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(333,189,815)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가손익</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>3,169,966,800</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,169,966,800</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,169,966,800</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>금융자산평가제거</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지분법자본변동</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(6,614,932)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,614,932)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(6,614,932)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>무상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>6,026,585,500</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>(6,069,478,380)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(42,892,880)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(42,892,880)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>유상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>우선주의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>(13,716,200)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(13,716,200)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(13,716,200)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 행사</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>22,581,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>1,793,029,850</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(343,162,050)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,472,448,800</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,472,448,800</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 부여</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>1,126,793,995</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,126,793,995</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,126,793,995</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>주식매수선택권의 취소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>(9,650,440)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(9,650,440)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(9,650,440)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>종속기업의 지분변동으로 인한 증감</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>지배력의 상실</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>(2,160,045,577)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(2,160,045,577)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>기타</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>전환사채의 보통주 전환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="258">
<P>2020.12.31 (기말자본)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="121">
<P>12,053,171,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="129">
<P>180,889,858,521</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="138">
<P>2,245,694,338</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="153">
<P>3,075,072,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="150">
<P>(86,137,611,613)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>112,126,184,246</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="125">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>112,126,184,246</P>
</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE-GROUP ACLASS="{XBRL}CF_S" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="790" BORDER="0">

<COLGROUP>
<COL WIDTH="781"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="790" HEIGHT="31" AUPDATECONT="N">
<P USERMARK="F-12 B">현금흐름표</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="790" HEIGHT="30" AUPDATECONT="N">
<P>제 15 기 2020.01.01 부터 2020.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="790" HEIGHT="30" AUPDATECONT="N">
<P>제 14 기 2019.01.01 부터 2019.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="790" HEIGHT="30" AUPDATECONT="N">
<P>제 13 기 2018.01.01 부터 2018.12.31 까지</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="790" HEIGHT="30" AUPDATECONT="N">
<P>(단위 : 원)</P>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="789" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="381"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
<COL WIDTH="124"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="390">　</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 15 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 14 기</P>
</TH>

<TH ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" WIDTH="133">
<P>제 13 기</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>영업활동현금흐름</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(14,893,363,011)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>24,113,461,209</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(12,758,192,506)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　영업활동으로 인한 현금흐름</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(15,994,736,720)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>23,201,455,697</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(13,055,657,022)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　이자수취</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,100,761,180</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,416,032,769</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>457,681,626</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　이자지급</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(37,069,581)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(93,600,704)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　법인세납부 환급(지급)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>37,682,110</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(504,027,257)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(66,616,406)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>투자활동현금흐름</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>349,128,968</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>29,971,498,846</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(50,584,646,931)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　기타금융자산의 처분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>51,994,467,596</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>66,935,727,773</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>21,634,909,887</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　기타금융자산의 취득</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(46,497,940,596)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(33,476,715,573)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(68,250,893,245)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　기타비유동자산의 증가</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,880,146,676)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　기타금융부채의 감소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(13,000,000)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　유형자산의 처분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>875,000,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>231,080</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>14,055,294</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　유형자산의 취득</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(3,614,465,214)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(3,370,403,713)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(3,756,645,064)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　무형자산의 처분</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>869,593</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>3,537,397</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　무형자산의 취득</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(480,098,152)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(120,878,118)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(213,073,803)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　종속기업에 대한 지배력 상실로 인한 감소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(48,557,583)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>재무활동현금흐름</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,632,910,924</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>2,601,275,914</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>64,939,668,350</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　리스부채의 지급</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>436,813,494</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　주식발행비용</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(58,660,180)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(1,253,580)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(3,828,500)</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　주식매선택권 행사</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,474,499,900</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>265,716,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>484,662,900</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　리스부채의 상환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(396,770,430)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　종속기업의 순현금 유입</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>4,477,714,110</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　유상증자</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>59,981,119,840</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　장기차입금의 증가</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,712,000,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,900,000,000</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　장기차입금의 상환</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　장기미지급금의 증가</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>48,141,634</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>　장기미지급금의 감소</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(146,300,000)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>0</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>환율변동효과 반영전 현금및현금성자산의 순증가(감소)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(11,911,323,119)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>56,686,235,969</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,596,828,913</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>기초현금및현금성자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>66,888,373,396</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,221,422,881</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>8,622,873,067</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>현금및현금성자산에 대한 환율변동효과</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(328,291,019)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>(19,285,454)</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>1,720,901</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="390">
<P>기말현금및현금성자산</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>54,648,759,258</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>66,888,373,396</P>
</TD>

<TD ALIGN="RIGHT" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N" WIDTH="133">
<P>10,221,422,881</P>
</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-5-0">5. 재무제표 주석</TITLE>
<P></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="600" HEIGHT="30">제 15 기 2020년 1월 1일 부터 2020년 12월 31일 까지</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="600" HEIGHT="30">제 14 기 2019년 1월 1일 부터 2019년 12월 31일 까지</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="600" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="600" HEIGHT="30">주식회사 레고켐 바이오사이언스</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>1. 일반사항 :&cr;</P>
<P>주식회사 레고켐 바이오사이언스(이하 '당사')는 2006년 5월 2일자에 설립되었으며, 의약품개발, 생산, 판매업을 사업목적으로 하고 있습니다.&cr;</P>
<P>당사는 2013년 5월 10일에 공모방식으로 코스닥시장에 상장하였고, 당사의 본점은 대전광역시 대덕구 문평서로 8-26(문평동)에 소재하고 있습니다.&cr;&cr;당사는 주식회사 칸메드와 2015년 10월 1일자 이사회 결의 및 2015년 11월 16일자 주주총회 합병승인을 통해 2015년 12월 21일자로 합병하였습니다. 합병은 법률적으로  합병회사인  당사가  피합병회사인  주식회사 칸메드를  흡수합병하는 형식으로 2015년 12월 21일 주식회사 칸메드의 주주명부에 기재된 주주에게 당사의 기명식 보통주식(액면금액 금500원) 총 1,363,813주를 주주별 지분율에 비례하여 합병신주로 발행하였습니다.&cr;&cr;보고기간말 현재 당사의 자본금은 보통주 11,841,903천원, 우선주 211,268천원이며, 주주현황은 다음과 같습니다. </P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="617">

<COLGROUP>
<COL WIDTH="164"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="79"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="173" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주주명</TH>
<TH WIDTH="178" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">보통주</TH>
<TH WIDTH="178" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">우선주</TH>
<TH WIDTH="88" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수</TH>
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수</TH>
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="173" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">김용주</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,479,028</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">10.3%</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">대표이사</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="173" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">대표이사의 특수관계자</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">542,988</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2.3%</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="173" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기타</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">20,661,790</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">85.7%</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">422,536</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">1.7%</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="173" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합계</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">23,683,806</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">98.3%</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">422,536</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">1.7%</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<PGBRK></PGBRK>
<P>1.1 종속회사 현황&cr;&cr;보고기간종료일 현재 당사의 연결대상 종속회사는 없으며, 전기말 연결대상 종속회사 현황은 다음과 같습니다.&cr;</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="784">

<COLGROUP>
<COL WIDTH="313"></COL>
<COL WIDTH="453"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="322" HEIGHT="30" VALIGN="MIDDLE">전기말</TD>
<TD WIDTH="462" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="784">

<COLGROUP>
<COL WIDTH="143"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="133"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기업명</TH>
<TH WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>
<TH WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">소재지</TH>
<TH WIDTH="131" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">보고기간말</TH>
<TH WIDTH="116" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">업종</TH>
<TH WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지배력판단근거</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="152" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">
<P>바스칸바이오제약</P>
<P>(구, (주)레고켐제약)</P>
</TD>
<TD WIDTH="112" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">68.52%</TD>
<TD WIDTH="131" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">한국</TD>
<TD WIDTH="131" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">2019.12.31</TD>
<TD WIDTH="116" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">제약</TD>
<TD WIDTH="142" HEIGHT="64" ALIGN="CENTER" VALIGN="MIDDLE">의결권과반수보유</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="784" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="313"></COL>
<COL WIDTH="453"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="322" HEIGHT="56" VALIGN="MIDDLE">&cr;전기말과 전기</TD>
<TD ALIGN="RIGHT" WIDTH="462" HEIGHT="56" VALIGN="BOTTOM">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="785" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="140"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="149" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">기업명</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">자산</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">부채</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">자본</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">매출</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">당기순이익&cr;(손실)</TH>
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53" ALIGN="CENTER">총포괄손익</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="149" HEIGHT="60" VALIGN="MIDDLE" ALIGN="CENTER">
<P>바스칸바이오제약</P>
<P>(구, (주)레고켐제약)</P>
</TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">9,568,643 </TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">2,710,622 </TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">6,858,021 </TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">4,213,072 </TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">(3,653,232)</TD>
<TD WIDTH="106" ALIGN="CENTER" HEIGHT="60" VALIGN="MIDDLE">(3,729,315)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(*) 종속기업의 요약재무정보는 지배기업과의 회계정책 차이조정 등을 반영한 후의금액이며, 다만 내부거래는 제거하기 전의 금액입니다.&cr;</SPAN>
</P>
<P>1.2 종속기업의 변동내용&cr;&cr;당사는 당기 중 주식회사 바스칸바이오제약(구, (주)레고켐제약)에 대한 지배력을 상실하여, 해당 기업을 연결대상 종속기업에서 제외하고, 동 주식의 공정가치 금액을 지분법적용투자주식으로 분류하였습니다.&cr;&cr;당기말 현재 당사는 종속기업을 보유하고 있지 않으며, 이러한 변화로 당사는 당기부터 연결재무제표를 작성하지 않습니다. 따라서 당기의 재무제표는 개별재무제표이며, 비교표시되는 2019년과 12월 31일로 종료하는 보고기간에 대한 재무제표는 연결기준으로 작성하였습니다.&cr;</P>
<PGBRK></PGBRK>
<P>주식회사 바스칸바이오제약(구, (주)레고켐제약) 투자 지분에 대한 지배력이 상실되어 계산된 처분 손익은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="313"></COL>
<COL WIDTH="269"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="322" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="278" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="658" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="331"></COL>
<COL WIDTH="309"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="340" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">구  분</TH>
<TH WIDTH="318" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">금  액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="340" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">취득 주식의 공정가치(A)</TD>
<TD WIDTH="318" ALIGN="RIGHT" HEIGHT="30">4,437,160</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="340" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">지배력 상실 시점의 순자산(B)</TD>
<TD WIDTH="318" ALIGN="RIGHT" HEIGHT="30">6,858,021</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="340" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">비지배지분(C)</TD>
<TD WIDTH="318" ALIGN="RIGHT" HEIGHT="30">2,160,045</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="340" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">당기손익으로 재분류되는 포괄손익(D)</TD>
<TD WIDTH="318" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="340" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">종속기업투자손익(A-B+C+D)</TD>
<TD WIDTH="318" ALIGN="RIGHT" HEIGHT="30">(260,816)</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN>2. 중요한 회계처리 방침 &cr;</SPAN>
</P>
<P>다음은 재무제표 작성에 적용된 중요한 회계정책입니다. 이러한 정책은 별도의 언급이 없다면, 표시된 회계기간에 계속적으로 적용됩니다.</P>

<P>
<SPAN>&cr;</SPAN>
<SPAN>2.1 재무제표 작성기준&cr;</SPAN>
</P>
<P>당사의 재무제표는 한국채택국제회계기준(이하 기업회계기준)에 따라 작성됐습니다.한국채택국제회계기준은 국제회계기준위원회("IASB")가 발표한 기준서와 해석서 중대한민국이 채택한 내용을 의미합니다.&cr;</P>
<P>재무제표는 다음을 제외하고는 역사적 원가에 기초하여 작성하였습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="722" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="18"></COL>
<COL WIDTH="686"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="27" HEIGHT="30">- </TD>
<TD WIDTH="695" HEIGHT="30">특정 금융자산과 금융부채(파생상품 포함), 공정가치로 측정하는 특정 유형자산과 투자부동산 유형</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="27" HEIGHT="30">- </TD>
<TD WIDTH="695" HEIGHT="30">순공정가치로 측정하는 매각예정자산</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="27" HEIGHT="30">- </TD>
<TD WIDTH="695" HEIGHT="30">확정급여제도와 공정가치로 측정하는 사외적립자산</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>한국채택국제회계기준은 재무제표 작성 시 중요한 회계추정의 사용을 허용하고 있으며, 회계정책을 적용함에 있어 경영진의 판단을 요구하고 있습니다. 보다 복잡하고 높은 수준의 판단이 필요한 부분이나 중요한 가정 및 추정이 필요한 부분은 주석3에서 설명하고 있습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>
<P>2.2 회계정책과 공시의 변경</P>
<P></P>
<P>2.2.1 당사가 채택한 제ㆍ개정 기준서 및 해석서</P>
<P></P>
<P>당사는 2020년 1월 1일로 개시하는 회계기간부터 다음의 제 ·개정 기준서 및 해석서를 신규로 적용하였습니다.&cr;</P>
<P>(1) 기업회계기준서 제1001호 '재무제표 표시', 제1008호 '회계정책, 회계추정의 변경 및 오류' 개정 - 중요성의 정의</P>
<P></P>

<P>
<SPAN>중요성의 정의를 명확히 하였습니다. 정보를 누락하거나 잘못 기재하거나 불분명하게 하여 주요 이용자의 의사결정에 영향을 줄 것으로 합리적으로 예상할 수 있다면 그 정보는 중요합니다. </SPAN>
<SPAN>해당 기준서의 개정이 재무제표에 미치는 중요한 영향은 없습니다.</SPAN>
</P>
<P></P>
<P>(2) 기업회계기준서 제1103호 '사업결합' 개정 - 사업의 정의</P>

<P>
<SPAN> </SPAN>
<SPAN>사업의 정의를 충족하기 위해서는 산출물의 창출에 유의적으로 기여하는 투입물과 실질적인 과정이 반드시 포함되어야 하며, 산출물에서 원가 감소에 따른 경제적 효익은 제외하였습니다. 또한, 취득한 총자산의 대부분의 공정가치가 식별가능한 단일 자산 또는 비슷한 자산의 집합에 집중되어 있는 경우에는 사업의 취득이 아니라고 간주할 수 있는 선택적 집중테스트가 추가되었습니다. </SPAN>
<SPAN>해</SPAN>
<SPAN>당 기준서의 개정이 재무제표에 미치는 중요한 영향은 없습니다.</SPAN>
</P>
<P></P>
<P>(3) 기업회계기준서 제1109호 '금융상품', 제1039호 '금융상품: 인식과 측정', 제1107호 '금융상품: 공시' 개정 - 이자율지표 개혁</P>

<P>
<SPAN> </SPAN>
<SPAN>이자율지표 개혁으로 인한 불확실성이 존재하는 동안 위험회피회계 적용과 관련하여예외규정을 추가하였습니다. 예외규정에서는 예상현금흐름의 발생가능성이 매우 높은지, 위험회피대상항목과 위험회피수단 사이의 경제적 관계가 있는지, 양자간에 높은 위험회피효과가 있는지를 평가할 때, 위험회피대상항목과 위험회피수단이 준거로하고 있는 이자율지표는 이자율지표 개혁의 영향으로 바뀌지 않는다고 가정합니다. </SPAN>
<SPAN>해당 기준서의 개정이 재무제표에 미치는 중요한 영향은 없습니다</SPAN>
</P>
<P></P>
<PGBRK></PGBRK>
<P>2.2.2 당사가 적용하지 않은 제ㆍ개정 기준서 및 해석서</P>
<P> </P>
<P>제정 또는 공표되었으나 시행일이 도래하지 않아 적용하지 아니한 제ㆍ개정 기준서 및 해석서는 다음과 같습니다.&cr;</P>
<P>(1) 기업회계기준서 제 1116호 '리스' 개정 - 코로나19 (COVID-19) 관련 임차료 면제ㆍ할인ㆍ유예에 대한 실무적 간편법</P>
<P> 실무적 간편법으로, 리스이용자는 코로나19의 직접적인 결과로 발생한 임차료 할인 등(Rent concession)이 리스변경에 해당하는지 평가하지 않을 수 있으며, 이로 인해 당기손익으로 인식된 금액을 공시해야 합니다. 동 개정사항은 2020년 6월 1일 이후 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. 당사는 동 개정으로 인해 재무제표에 중요한 영향은 없을 것으로 예상하고 있습니다.</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<P>
<SPAN>(2) 기업회계기준서 제1109호 '금융상품', 제1039호 '금융상품: 인식과 측정', 제1107호 '금융상품: 공시', 제 1104호 '보험계약' 및 제 1116호 '리스' 개정 - 이자율지표 개혁</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>이자율지표 개혁과 관련하여 상각후원가로 측정되는 금융상품의 이자율지표 대체시 장부금액이 아닌 유효이자율을 조정하고, 위험회피관계에서 이자율지표 대체가 발생한 경우에도 중단 없이 위험회피회계를 계속할 수 있도록 하는 등의 예외규정을 포함하고 있습니다. 동 개정사항은 2021년 1월 1일 이후에 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. </SPAN>
<SPAN>당사는 동 개정으로 인해 재무제표에 중요한 영향은 없을 것으로 예상하고 있습니다.</SPAN>
<SPAN></SPAN>
</P>
<P></P>

<P>
<SPAN>(3) 기업회계기준서 제1103호 '사업결합' 개정 - 개념체계의 인용&cr;</SPAN>
<SPAN>인식할 자산과 부채의 정의를 개정된 재무보고를 위한 개념체계를 참조하도록 개정되었으나, 기업회계기준서 제1037호 '충당부채, 우발부채 및 우발자산' 및 해석서제2121호 '부담금'의 적용범위에 포함되는 부채 및 우발부채에 대해서는 해당 기준서를 적용하도록 예외를 추가하고, 우발자산이 취득일에 인식되지 않는다는 점을 명확히 하였습니다. 동 개정사항은 2022년 1월 1일 이후 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. 당사는 동 개정으로 인해 재무제표에 중요한 영향은 없을 것으로 예상하고 있습니다.&cr;</SPAN>
</P>

<P>
<SPAN>(4) 기업회계기준서 제1016호 '유형자산' 개정 - 의도한 사용 전의 매각금액</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>기업이 자산을 의도한 방식으로 사용하기 전에 생산된 품목의 판매에서 발생하는 수익을 생산원가와 함께 당기손익으로 인식하도록 요구하며, 유형자산의 취득원가에서차감하는 것을 금지하고 있습니다. 동 개정사항은 2022년 1월 1일 이후 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. 당사는 동 개정으로 인한 재무제표의 영향을 검토 중에 있습니다.&cr;</SPAN>
</P>

<P>
<SPAN>(5) 기업회계기준서 제1037호 '충당부채, 우발부채 및 우발자산' 개정 - 손실부담계약: 계약이행원가</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>손실부담계약을 식별할 때 계약이행원가의 범위를 계약 이행을 위한 증분원가와 계약 이행에 직접 관련되는 다른 원가의 배분이라는 점을 명확히 하였습니다. 동 개정사항은 2022년 1월 1일 이후 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. 당사는 동 개정으로 인해 재무제표에 중요한 영향은 없을 것으로 예상하고 있습니다. &cr;</SPAN>
</P>

<P>
<SPAN>(6) 한국채택국제회계기준 연차개선 2018-2020</SPAN>
<SPAN></SPAN>
</P>
<P> 한국채택국제회계기준 연차개선 2018-2020은 2022년 1월 1일 이후 시작하는 회계연도부터 적용되며, 조기적용이 허용됩니다. 당사는 동 개정으로 인해 재무제표에 중요한 영향은 없을 것으로 예상하고 있습니다.</P>
<P>· 기업회계기준서 제1101호 '한국채택국제회계기준의 최초 채택' : 최초채택기업    인 종속기업</P>
<P>· 기업회계기준서 제1109호 '금융상품' : 금융부채 제거 목적의 10% 테스트 관련    수수료</P>
<P>· 기업회계기준서 제1116호 '리스' : 리스 인센티브</P>
<P>· 기업회계기준서 제1041호 '농립어업' : 공정가치 측정&cr;</P>

<P>
<SPAN>(7) 기업회계기준서 제1001호 '재무제표 표시' 개정 - 부채의 유동/비유동 분류</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>보고기간말 현재 존재하는 실질적인 권리에 따라 유동 또는 비유동으로 분류되며, 부채의 결제를 연기할 수 있는 권리의 행사가능성이나 경영진의 기대는 고려하지 않습니다. 또한, 부채의 결제에 자기지분상품의 이전도 포함되나, 복합금융상품에서 자기지분상품으로 결제하는 옵션이 지분상품의 정의를 충족하여 부채와 분리하여 인식된경우는 제외됩니다. 동 개정사항은 2023년 1월 1일 이후 시작하는 회계연도부터 적용하며, 조기적용이 허용됩니다. 당사는 동 개정으로 인한 재무제표의 영향을 검토 중에 있습니다.</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>2.3 연결</SPAN>
</P>
<P> </P>
<P>당사는 기업회계기준서 제1110호 '연결재무제표'에 따라 전기까지 연결재무제표를 작성하였으며 당기는 종속회사에 대한 지배력의 상실로 인해 개별재무제표를 작성하였습니다.&cr;</P>
<P>(1) 종속기업</P>
<P>종속기업은 지배기업이 지배하고 있는 모든 기업입니다. 당사가 투자한 기업에 관여해서 변동이익에 노출되거나 변동이익에 대한 권리가 있고, 투자한 기업에 대해 자신의 힘으로 그러한 이익에 영향을 미칠 능력이 있는 경우, 해당 기업을 지배한다고 판단합니다. 종속기업은 당사가 지배하게 되는 시점부터 연결재무제표에 포함되며, 지배력을 상실하는 시점에 연결재무제표에서 제외됩니다.</P>
<P>&cr;당사의 사업결합은 취득법으로 회계처리 됩니다. 이전대가는 취득일의 공정가치로 측정하고, 사업결합으로 취득한 식별가능한 자산ㆍ부채 및 우발부채는 취득일의 공정가치로 최초 측정하고 있습니다. 당사는 청산 시 순자산의 비례적 몫을 제공하는 비지배지분을 사업결합 건별로 판단하여 피취득자의 순자산 중 비례적 지분 또는 공정가치로 측정합니다. 그밖의 비지배지분은 다른 기준서의 요구사항이 없다면 공정가치로 측정합니다. 취득관련 원가는 발생 시 당기비용으로 인식됩니다. &cr;</P>
<P>영업권은 이전대가, 피취득자에 대한 비지배지분의 금액과 취득자가 이전에 보유하고 있던 피취득자에 대한 지분의 취득일의 공정가치 합계액이 취득한 식별가능한 순자산을 초과하는 금액으로 인식됩니다. 이전대가 등이 취득한 종속기업 순자산의 공정가액보다 작다면, 그 차액은 당기손익으로 인식됩니다.&cr;&cr;당사 내의 기업간에 발생하는 거래로 인한 채권, 채무의 잔액, 수익과 비용 및 미실현이익 등은 제거됩니다. 또한 종속기업의 회계정책은 당사에서 채택한 회계정책을 일관성 있게 적용하기 위해 차이가 나는 경우 수정됩니다.&cr;&cr;지배력의 상실을 발생시키지 않는 비지배지분과의 거래는 비지배지분의 조정금액과 지급 또는 수취한 대가의 공정가치의 차이를 지배기업의 소유주에게 귀속되는 자본으로 직접 인식합니다.  &cr;&cr;당사가 종속기업에 대해 지배력을 상실하는 경우, 보유하고 있는 해당 기업의 잔여 지분은 동 시점에 공정가치로 재측정되며, 관련 차액은 당기손익으로 인식됩니다. </P>
<P></P>
<P>(2) 관계기업</P>
<P>관계기업은 당사가 유의적 영향력을 보유하는 기업이며, 관계기업 투자는 최초에 취득원가로 인식하며 이후 지분법을 적용합니다. 당사와 관계기업 간의 거래에서 발생한 미실현이익은 당사의 관계기업에 대한 지분에 해당하는 부분만큼 제거됩니다. 관계기업의 손실 중 당사의 지분이 관계기업에 대한 투자지분(순투자의 일부를 구성하는 장기투자지분 포함)과 같거나 초과하는 경우에는 지분법 적용을 중지합니다. 단, 당사의 지분이 영(0)으로 감소된 이후 추가 손실분에 대하여 당사에 법적-의제의무가 있거나, 관계기업을 대신하여 지급하여야 하는 경우, 그 금액까지만 손실과 부채로 인식합니다. 또한 관계기업 투자에 대한 객관적인 손상의 징후가 있는 경우 관계기업 투자의 회수가능액과 장부금액과의 차이는 손상차손으로 인식됩니다. &cr;&cr;당사는 지분법을 적용하기 위하여 관계기업의 재무제표를 이용할 때, 유사한 상황에서 발생한 동일한 거래나 사건에 대하여 당사가 적용하는 회계정책과 동일한 회계정책이 적용되었는지 검토하여 필요한 경우 관계기업의 재무제표를 조정합니다.</P>
<P></P>
<P>(3) 공동약정</P>
<P>둘 이상의 당사자들이 공동지배력을 보유하는 공동약정은 공동영업 또는 공동기업으로 분류됩니다. 공동영업자는 공동영업의 자산과 부채에 대한 권리와 의무를 보유하며, 공동영업의 자산과 부채, 수익과 비용 중 자신의 몫을 인식합니다. 공동기업참여자는 공동기업의 순자산에 대한 권리를 가지며, 지분법을 적용합니다.</P>

<P>
<SPAN></SPAN>
</P>
<P>2.4 외화환산</P>
<P> </P>
<P>(1) 기능통화와 표시통화</P>
<P>당사는 재무제표에 포함되는 항목들을 각각의 영업활동이 이뤄지는 주된 경제 환경에서의 통화("기능통화")를 적용하여 측정하고 있습니다. 당사의 기능통화는 대한민국 원화이며, 재무제표는 대한민국 원화로 표시되어 있습니다.</P>

<P>
<SPAN></SPAN>
</P>
<P>(2) 외화거래와 보고기간말의 환산</P>
<P>외화거래는 거래일의 환율 또는 재측정되는 항목인 경우 평가일의 환율을 적용한 기능통화로 인식됩니다.  외화거래의 결제나 화폐성 외화 자산ㆍ부채의 환산에서 발생하는 외환차이는 당기손익으로 인식됩니다. 다만, 조건을 충족하는 현금흐름위험회피나 순투자의 위험회피의 효과적인 부분과 관련되거나 보고기업의 해외사업장에 대한 순투자의 일부인 화폐성항목에서 생기는 손익은 기타포괄손익으로 인식합니다.</P>
<P> </P>

<P>
<SPAN>외환차이는 </SPAN>
<SPAN>금융수익 또는 금융비용</SPAN>
<SPAN>에 표시됩니다.</SPAN>
</P>
<P> </P>
<P>비화폐성 금융자산ㆍ부채로부터 발생하는 외환차이는 공정가치 변동손익의 일부로 보아 당기손익-공정가치 측정 지분상품으로부터 발생하는 외환차이는 당기손익으로, 기타포괄손익-공정가치 측정 지분상품의 외환차이는 기타포괄손익에 포함하여 인식됩니다.</P>
<P></P>

<P>
<SPAN>2.5 금융자산&cr;</SPAN>
</P>
<P>(1) 분류</P>
<P>당사는 다음의 측정 범주로 금융자산을 분류합니다.</P>
<P>- 당기손익-공정가치 측정 금융자산</P>
<P>- 기타포괄손익-공정가치 측정 금융자산</P>
<P>- 상각후원가 측정 금융자산</P>
<P> </P>
<P>금융자산은 금융자산의 관리를 위한 사업모형과 금융자산의 계약상 현금흐름 특성에근거하여 분류합니다.</P>
<P> </P>
<P>공정가치로 측정하는 금융자산의 손익은 당기손익 또는 기타포괄손익으로 인식합니다. 채무상품에 대한 투자는 해당 자산을 보유하는 사업모형에 따라 그 평가손익을 당기손익 또는 기타포괄손익으로 인식합니다. 당사는 금융자산을 관리하는 사업모형을 변경하는 경우에만 채무상품을 재분류합니다. </P>
<P> </P>
<P>단기매매항목이 아닌 지분상품에 대한 투자는 최초 인식시점에 후속적인 공정가치 변동을 기타포괄손익으로 표시할 것을 지정하는 취소불가능한 선택을 할 수 있습니다. 지정되지 않은 지분상품에 대한 투자의 공정가치 변동은 당기손익으로 인식합니다.&cr;</P>
<P>(2) 측정</P>
<P>당사는 최초 인식시점에 금융자산을 공정가치로 측정하며, 당기손익-공정가치 측정 금융자산이 아닌 경우에 해당 금융자산의 취득과 직접 관련되는 거래원가는 공정가치에 가산합니다. 당기손익-공정가치 측정 금융자산의 거래원가는 당기손익으로 비용처리합니다. &cr;&cr;내재파생상품을 포함하는 복합계약은 계약상 현금흐름이 원금과 이자로만 구성되어 있는지를 결정할 때 해당 복합계약 전체를 고려합니다.</P>

<P>
<SPAN></SPAN>
</P>
<P>① 채무상품</P>
<P>금융자산의 후속적인 측정은 금융자산의 계약상 현금흐름 특성과 그 금융자산을 관리하는 사업모형에 근거합니다. 당사는 채무상품을 다음의 세 범주로 분류합니다.&cr; &cr;(가) 상각후원가&cr;계약상 현금흐름을 수취하기 위해 보유하는 것이 목적인 사업모형 하에서 금융자산을 보유하고, 계약상 현금흐름이 원리금만으로 구성되어 있는 자산은 상각후원가로 측정합니다. 상각후원가로 측정하는 금융자산으로서 위험회피관계의 적용 대상이 아닌 금융자산의 손익은 해당 금융자산을 제거하거나 손상할 때 당기손익으로 인식합니다. 유효이자율법에 따라 인식하는 금융자산의 이자수익은 ‘금융수익’에 포함됩니다.&cr; </P>
<P>(나) 기타포괄손익-공정가치 측정 금융자산&cr;계약상 현금흐름의 수취와 금융자산의 매도 둘 다를 통해 목적을 이루는 사업모형 하에서 금융자산을 보유하고, 계약상 현금흐름이 원리금만으로 구성되어 있는 금융자산은 기타포괄손익-공정가치로 측정합니다. 손상차손(환입)과 이자수익 및 외환손익을 제외하고는, 공정가치로 측정하는 금융자산의 평가손익은 기타포괄손익으로 인식합니다. 금융자산을 제거할 때에는 인식한 기타포괄손익누계액을 자본에서 당기손익으로 재분류합니다.&cr;</P>

<P>
<SPAN>(다) 당기손익-공정가치 측정 금융자산&cr;상각후원가 측정이나 기타포괄손익-공정가치 측정 금융자산이 아닌 채무상품은 당기손익-공정가치로 측정됩니</SPAN>
<SPAN>다. 위험회피관계가 적용되지 않는 당기손익-공정가치 측정 채무상품의 손익은 당기손익으로 인식하고 발생한 기간에 손익계산서에 </SPAN>
<SPAN>'금융수익' 또는 '금융비용'</SPAN>
<SPAN>으로 표시합니다.</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>② 지분상품</P>
<P>당사는 모든 지분상품에 대한 투자를 후속적으로 공정가치로 측정합니다. 공정가치 변동을 기타포괄손익으로 표시할 것을 선택한 장기적 투자목적 또는 전략적 투자목적의 지분상품에 대해 기타포괄손익으로 인식한 금액은 해당 지분상품을 제거할때에도 당기손익으로 재분류하지 않습니다. 이러한 지분상품에 대한 배당수익은 당사가 배당을 받을 권리가 확정된 때 '금융수익'으로 당기손익으로 인식합니다.</P>
<P> </P>

<P>
<SPAN>당기손익-공정가치로 측정하는 금융자산의 공정가치 변동은 손익계산서에 </SPAN>
<SPAN>'금융수익' 또는 '금융비용'</SPAN>
<SPAN> 으로 표시합니다.  기타포괄손익-공정가치로 측정하는 지분상품에 대한 손상차손(환입)은 별도로 구분하여 인식하지 않습니다.</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>(3) 손상</P>
<P>당사는 미래전망정보에 근거하여 상각후원가로 측정하거나 기타포괄손익-공정가치로 측정하는 채무상품에 대한 기대신용손실을 평가합니다. 손상 방식은 신용위험의 유의적인 증가 여부에 따라 결정됩니다. 단, 매출채권 및 리스채권에 대해 당사는 채권의 최초 인식시점부터 전체기간 기대신용손실을 인식하는 간편법을 적용합니다.</P>

<P>
<SPAN></SPAN>
</P>
<P>(4) 인식과 제거</P>
<P>금융자산의 정형화된 매입 또는 매도는 매매일에 인식하거나 제거합니다. 금융자산은 현금흐름에 대한 계약상 권리가 소멸하거나 금융자산을 양도하고 소유에 따른 위험과 보상의 대부분을 이전한 경우에 제거됩니다.</P>
<P> </P>

<P>
<SPAN>당사가 금융자산을 양도한 경우라도 채무자의 채무불이행시의 소구권 등으로 양도한금융자산의 소유에 따른 위험과 보상의 대부분을 당사가 보유하는 경우에는 이를 제거하지 않고 그 양도자산 전체를 계속하여 인식하되, 수취한 대가를 금융부채로인식합니다.</SPAN>
<SPAN></SPAN>
</P>
<P>&cr;(5) 금융상품의 상계</P>
<P>금융자산과 부채는 인식한 자산과 부채에 대해 법적으로 집행가능한 상계권리를 현재 보유하고 있고, 순액으로 결제하거나 자산을 실현하는 동시에 부채를 결제할 의도를 가지고 있을 때 상계하여 재무상태표에 순액으로 표시합니다. 법적으로 집행가능한 상계권리는 미래사건에 좌우되지 않으며, 정상적인 사업과정의 경우와 채무불이행의 경우 및 지급불능이나 파산의 경우에도 집행가능한 것을 의미합니다.</P>
<P></P>
<P>2.6 매출채권</P>
<P></P>

<P>
<SPAN>매출채권은 유의적인 금융요소를 포함하지 않는 경우에는 무조건적인 대가의 금액으로, 유의적인 금융요소를</SPAN>
<SPAN> 포함하는 경우에는 공정가치로 최초 인식합니다. 매출채권은 후속적으로 유효이자율법을 적용한 상각후원가에 손실충당금을 차감하여 측정됩니다. (당사의 매출채권 회계처리에 대한</SPAN>
<SPAN> 추가적인 사항은 </SPAN>
<SPAN>주석</SPAN>
<SPAN>9</SPAN>
<SPAN>, 손상에</SPAN>
<SPAN> 대한 회계정책은 </SPAN>
<SPAN>주석 2.5</SPAN>
<SPAN> 참조)</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>2.7 재고자산 </P>
<P> </P>
<P>재고자산은 원가와 순실현가능가치 중 작은 금액으로 표시되고, 재고자산의 원가는 총평균법에 따라 결정됩니다.</P>

<P>
<SPAN>&cr;2.8 유형자산 &cr;</SPAN>
</P>
<P>유형자산은 역사적원가에서 감가상각누계액과 손상차손누계액을 차감하여 표시됩니다. 역사적원가는 자산의 취득에 직접적으로 관련된 지출을 포함합니다. &cr;  </P>
<PGBRK></PGBRK>

<P>
<SPAN>토지 및 건설중인자산을</SPAN>
<SPAN> 제</SPAN>
<SPAN>외한 자산은 취득원가에서 잔존가치를 제외하고, 다음의 추정 경제적 내용연수에 걸쳐 정액법으로 상각됩니다.  &cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="597">

<COLGROUP>
<COL WIDTH="290"></COL>
<COL WIDTH="289"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="299" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">구     분</TD>
<TD WIDTH="298" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">추정 경제적 내용연수</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="299" HEIGHT="30">비     품</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="298" HEIGHT="30">5년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="299" HEIGHT="30">연구설비</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="298" HEIGHT="30">5년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="299" HEIGHT="30">시설장치</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="298" HEIGHT="30">5년</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN>유형자산의 감가상각방법과 잔존가치 및 경제적 내용연수는 매 회계연도 말에 재검토되고 필요한 경우 추정의 변경으로 회계처리 됩니다.</SPAN>
<SPAN>&cr;&cr;</SPAN>
<SPAN>2.9 차입원가 &cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>적격자산을 취득 또는 건설하는데 발생한 차입원가는 해당 자산을 의도된 용도로 사용할 수 있도록 준비하는 기간 동안 자본화되고, 적격자산을 취득하기 위한 특정목적차입금의 일시적 운용에서 발생한 투자수익은 당 회계기간 동안 자본화 가능한 차입원가에서 차감됩니다. 기타 차입원가는 발생기간에 비용으로 인식됩니다.  </SPAN>
</P>

<P>
<SPAN>&cr;2.10 무형자산&cr; </SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>무형자산을 최초로 인식할 때는 원가로 측정하며, 최초 인식 후에 내용연수가 유한한기타 무형자산은 상각누계액과 손상차손누계액을 차감한 원가를 장부금액으로 하고 있습니다.</SPAN>
</P>

<P>
<SPAN>&cr;영업권을 제외한 무형자산은 사용가능한 시점부터 잔존가치를 영("0")으로 하여 추정내용연수 동안 정액법으로 상각하고 있습니다. 내용연수가 유한한 무형자산의 상각기간과 상각방법은 매 회계연도 말에 재검토하고, 내용연수가 비한정인 무형자산에 대해서는 그 자산의 내용연수가 비한정이라는 평가를 계속하여 정당화하는지를 매 회계기간에 재검토합니다. 재검토 결과, 이를 변경하는 것이 적절하다고 판단되는 경우 회계추정의 변경으로 처리하고 있습니다.&cr;&cr;취득이나 완성 후의 후속 지출은 기존 무형자산으로부터 기대되는 미래 경제적 효익을 증가시키는 경우에 한하여 자본화하고 있으며, 내부적으로 창출한 영업권 및 브랜드와 관련한 지출을 포함한 기타 후속 지출은 모두 발생시점에 당기손익으로 인식하고 있습니다.&cr;&cr;무형자산의 추정내용연수는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="615">

<COLGROUP>
<COL WIDTH="299"></COL>
<COL WIDTH="298"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="308" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구     분</TH>
<TH WIDTH="307" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">추정내용연수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30">  산업재산권 </TD>
<TD WIDTH="307" HEIGHT="30" ALIGN="CENTER">10년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30">  고객관계 </TD>
<TD WIDTH="307" HEIGHT="30" ALIGN="CENTER">10년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30">  소프트웨어</TD>
<TD WIDTH="307" HEIGHT="30" ALIGN="CENTER">5년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="308" HEIGHT="30">  영업권 </TD>
<TD WIDTH="307" HEIGHT="30" ALIGN="CENTER">비한정</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<P>2.11 비금융자산의 손상</P>
<P> </P>
<P>영업권이나 내용연수가 비한정인 무형자산에 대하여는 매년, 상각대상 자산에 대하여는 자산손상을 시사하는 징후가 있을 때 손상검사를 수행하고 있습니다. 손상차손은 회수가능액(사용가치 또는 처분부대원가를 차감한 공정가치 중 높은 금액)을 초과하는 장부금액만큼 인식되고 영업권 이외의 비금융자산에 대한 손상차손은 매 보고기간말에 환입가능성이 검토됩니다.</P>

<P>
<SPAN>&cr;</SPAN>
<SPAN>2.12 복합금융상품&cr;&cr;복합금융상품의 부채요소는 최초에 동일한 조건의 전환권이 없는 금융부채의 공정가치로 인식하고 있습니다. 자본요소는 복합금융상품 전체의 공정가치와 부채요소의 공정가치의 차이로 최초에 인식됩니다. 복합금융상품의 발행과 직접적으로 관련된 거래원가는 부채요소와 자본요소의 최초 인식 금액에 비례하여 배분하고 있습니다. </SPAN>
<SPAN>당사는 금융감독원 질의회신 "회제이-00094"에 의하여 전환권대가는 자본으로 인식하였습니다.</SPAN>
<SPAN>&cr;</SPAN>
</P>
<P>2.13 매입채무와 기타채무</P>
<P> </P>

<P>
<SPAN>매입채무와 기타 채무는 당사가 보고기간말 전에 재화나 용역을 제공받았으나 지급되지 않은 부채입니다. 해당 채무는 무담보이며, 보통 월 마감 후 </SPAN>
<SPAN>1개월~8개월</SPAN>
<SPAN> 이내에 지급됩니다. 매입채무와 기타 채무는 지급기일이 보고기간 후 12개월 후가 아니라면 유동부채로 표시되었습니다. 해당 채무들은 최초에 공정가치로 인식되고 후속적으로 유효이자율법을 적용한 상각후원가로 측정됩니다.</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>2.14 금융부채</P>
<P> </P>
<P>(1)  분류 및 측정</P>
<P>당사의 당기손익-공정가치 측정 금융부채는 단기매매목적의 금융상품입니다. 주로 단기간 내에 재매입할 목적으로 부담하는 금융부채는 단기매매금융부채로 분류됩니다. 또한, 위험회피회계의 수단으로 지정되지 않은 파생상품이나 금융상품으로부터 분리된 내재파생상품도 단기매매금융부채로 분류됩니다.</P>
<P> </P>
<P>당기손익-공정가치 측정 금융부채, 금융보증계약, 금융자산의 양도가 제거조건을 충족하지 못하는 경우에 발생하는 금융부채를 제외한 모든 비파생금융부채는 상각후원가로 측정하는 금융부채로 분류되고 있으며, 재무상태표 상 '매입채무', '기타금융부채', '차입금' 등으로 표시됩니다.</P>
<P> </P>
<P>(2)  제거</P>
<P>금융부채는 계약상 의무가 이행, 취소 또는 만료되어 소멸되거나 기존 금융부채의 조건이 실질적으로 변경된 경우에 재무상태표에서 제거됩니다. 소멸하거나 제3자에게 양도한 금융부채의 장부금액과 지급한 대가(양도한 비현금자산이나 부담한 부채를 포함)의 차액은 당기손익으로 인식합니다.</P>
<P></P>
<P>2.15 충당부채</P>
<P> </P>
<P>과거사건의 결과로 현재의 법적의무나 의제의무가 존재하고, 그 의무를 이행하기 위한 자원의 유출가능성이 높으며, 당해 금액의 신뢰성 있는 추정이 가능한 경우 충당부채를 인식하고 있습니다. 충당부채는 의무를 이행하기 위하여 예상되는 지출액의 현재가치로 측정되며, 시간경과로 인한 충당부채의 증가는 이자비용으로 인식됩니다.&cr;</P>
<P>2.16 당기법인세 및 이연법인세</P>
<P> </P>
<P>법인세비용은 당기법인세와 이연법인세로 구성됩니다. 법인세는 기타포괄손익이나 자본에 직접 인식된 항목과 관련된 금액은 해당 항목에서 직접 인식하며, 이를 제외하고는 당기손익으로 인식됩니다.</P>
<P>&cr;당기법인세비용은 보고기간말 현재 제정되었거나 실질적으로 제정된 세법에 근거하여 측정합니다. 경영진은 적용 가능한 세법 규정이 해석에 따라 달라질 수 있는 상황에 대하여 당사가 세무신고 시 적용한 세무정책에 대하여 주기적으로 평가하고 있으며, 세무당국이 불확실한 법인세 처리를 수용할 가능성이 높은지 고려합니다. 당사는법인세 측정 시 가장 가능성이 높은 금액 또는 기댓값 중 불확실성의 해소를 더 잘 예측할 것으로 예상되는 방법을 사용하여 불확실성의 영향을 반영합니다. &cr;&cr;이연법인세는 자산과 부채의 장부금액과 세무기준액의 차이로 발생하는 일시적차이에 대하여 장부금액을 회수하거나 결제할 때의 예상 법인세효과로 인식됩니다. 다만,사업결합 이외의 거래에서 자산 ·부채를 최초로 인식할 때 발생하는 이연법인세 자산과 부채는 그 거래가 회계이익이나 과세소득에 영향을 미치지 않는다면 인식되지 않습니다.&cr;&cr;이연법인세자산은 차감할 일시적차이가 사용될 수 있는 미래 과세소득의 발생가능성이 높은 경우에 인식됩니다.&cr;&cr;종속기업, 관계기업 및 공동기업 투자지분과 관련된 가산할 일시적차이에 대해 소멸시점을 통제할 수 있고 예측가능한 미래에 일시적차이가 소멸하지 않을 가능성이 높은 경우를 제외하고 이연법인세부채를 인식하고 있습니다. 또한 이러한 자산으로부터 발생하는 차감할 일시적차이에 대하여 일시적차이가 예측가능한 미래에 소멸할 가능성이 높고 일시적차이가 사용될 수 있는 과세소득이 발생할 가능성이 높은 경우에만 이연법인세자산을 인식하고 있습니다.&cr;&cr;이연법인세 자산과 부채는 법적으로 당기법인세자산과 당기법인세부채를 상계할 수 있는 권리를 당사가 보유하고 있고, 이연법인세 자산과 부채가 동일한 과세당국에 의해서 부과되는 법인세와 관련된 경우에 상계합니다. 당기법인세 자산과 부채는 법적으로 상계할 수 있는 권리를 당사가 보유하고 있고, 순액으로 결제할 의도가 있거나 자산을 실현하는 동시에 부채를 결제하려는 의도가 있는 경우에 상계합니다.&cr;</P>
<P>2.17 종업원급여</P>
<P> </P>
<P>(1) 퇴직급여</P>

<P>
<SPAN>퇴직연금제도는 </SPAN>
<SPAN>확정기여제도</SPAN>
<SPAN>와 </SPAN>
<SPAN>확정급여제도</SPAN>
<SPAN>로 구분되며, 당사는 퇴직연금제도로 확정급여제도를 운영하고 있습니다.&cr;</SPAN>
<SPAN>&cr;확정기여제도는 당사가 고정된 금액의 기여금을 별도 기금에 지급하는 퇴직연금제도이며, 기여금은 종업원이 근무 용역을 제공했을 때 비용으로 인식됩니다.&cr;&cr;확정급여제도는 확정기여제도를 제외한 모든 퇴직연금제도입니다. 일반적으로 확정급여제도는 연령, 근속연수나 급여수준 등의 요소에 의하여 종업원이 퇴직할 때 지급받을 퇴직연금급여의 금액이 확정됩니다. 확정급여제도와 관련하여 재무상태표에 계상된 부채는 보고기간말 현재 확정급여채무의 현재가치에서 사외적립자산의 공정가치를 차감한 금액입니다. 확정급여채무는 매년 독립된 보험계리인에 의해 예측단위적립방식에 따라 산정되며, 확정급여채무의 현재가치는 그 지급시점과 만기가 유사한 우량연결회사채의 이자율로 기대미래현금유출액을 할인하여 산정됩니다. 한편, 순확정급여부채와 관련한 재측정요소는 기타포괄손익으로 인식됩니다.&cr;&cr;제도개정, 축소 또는 정산이 발생하는 경우, 과거근무원가 또는 정산으로 인한 손익은 당기손익으로 인식됩니다. &cr;</SPAN>
</P>
<P>(2) 주식기준보상 &cr;종업원에게 부여한 주식결제형 주식기준보상은 부여일에 지분상품의 공정가치로 측정되며, 가득기간에 걸쳐 종업원 급여비용으로 인식됩니다. 가득될 것으로 예상되는 지분상품의 수량은 매 보고기간말에 비시장성과조건을 고려하여 재측정되며, 당초 추정치로부터의 변동액은 당기손익과 자본으로 인식됩니다.</P>
<P> </P>
<P>주식선택권의 행사시점에 신주를 발행할 때 직접적으로 관련되는 거래비용을 제외한순유입액은 자본금(명목가액)과 주식발행초과금으로 인식됩니다. </P>
<PGBRK></PGBRK>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>2.18 </SPAN>
<SPAN>고객과의 계약에서 생기는 수익&cr;</SPAN>
</P>
<P>(1) 수익인식모형</P>

<P>
<SPAN>당사의 고객과의 계약에서 생기는 수익은 </SPAN>
<SPAN>상품매출, 용역수익 및 기술이전수익 등으로 구성되어 있습니다.</SPAN>
<SPAN> 당사는 고객과의 계약이 개시되는 단계에서부터 통제가 고객에게 이전되는 시점 또는 통제가 고객에게 이전되는 기간에 걸쳐 다음의 5단계 수익인식모형에 따라 수익을 인식하고 있습니다.</SPAN>
</P>
<P> </P>
<P>① 계약의 식별</P>
<P>고객과의 사이에서 집행가능한 권리와 의무가 생기게 하는 합의를 계약으로 식별하고 계약으로 식별된 경우에는 수행의무의 식별 등 이후 단계를 추가 검토하여 수익인식여부를 판별하며, 계약으로 식별되지 못하였으나 고객에게서 대가를 받은 경우에는 부채로 인식하고 있습니다.</P>
<P> </P>
<P>② 수행의무의 식별</P>
<P>수행의무는 고객과의 계약에서 '구별되는 재화나 용역'이나 '실질적으로 서로 같고 고객에게 이전하는 방식도 같은 일련의 구별되는 재화나 용역'을 고객에게 이전하기로 한 약속을 의미합니다. 당사는 계약 개시시점에 고객과의 계약에서 약속한 재화나용역을 검토하여 수행의무를 식별하고 있습니다.</P>
<P> </P>
<P>③ 거래가격의 산정</P>
<P>거래가격은 고객에게 약속한 재화나 용역을 이전하고 그 대가로 기업이 받을 권리를 갖게 될 것으로 예상하는 금액으로서 추정치의 제약을 고려한 변동대가, 유의적인 금융요소, 비현금대가 및 고객에게 지급할 대가 등을 고려하여 산정하고 있습니다. 당사는 반품가능성을 과거의 경험률에 근거하여 합리적으로 추정하여 변동대가에 반영하고, 수행의무를 이전하는 시점과 고객이 그에 대한 대가를 지급하는 시점 간의 기간이 12개월 이내이므로 유의적인 금융요소는 없다고 판단하고 있습니다.</P>
<P> </P>
<P>④ 거래가격의 배분</P>
<P>당사는 하나의 계약에서 식별된 여러 수행의무에 상대적 개별판매가격을 기초로 거래가격을 배분하고 있습니다. 각 수행의무의 개별판매가격이 없는 경우에는 시장평가조정접근법 등을 고려하여 개별판매가격을 적절하게 추정하고 있습니다. </P>
<PGBRK></PGBRK>
<P>⑤ 수익인식</P>
<P>당사는 계약개시 시점에 해당 계약과 관련하여 수행의무를 이행할 때 수익을 인식할지 또는 수행의무를 이행하는 기간에 걸쳐 수익을 인식할지 여부를 판단하고 있습니다. 의무를 수행하는 대로 고객이 동시에 효익을 얻고 소비하는 경우, 의무를 수행하여 자산이 만들어지거나 가치가 높아지는 것과 비례하여 고객이 그 자산을 통제하는 경우, 또는 의무를 수행하여 만든 자산이 당사 자체에는 대체용도가 없으나 현재까지수행을 완료한 부분에 대해 집행가능한 지급청구권은 있는 경우에는 수행의무를 이행하는 기간에 걸쳐 수익을 인식합니다. </P>
<P> </P>
<P>용역수익은 고객과의 요청에 따른 연구 등의 용역을 제공하는 것으로서 기업이 의무를 수행하여 만든 자산이 기업자체에는 대체용도가 없고, 지금까지 의무수행을 완료한 부분에 대해 집행가능한 지급청구권이 기업에 있는 경우에 기간에 걸쳐서 수익을 인식합니다. 한편, 기술이전수익은 독자적인 원천기술을 바탕으로 파트너 제약사 등에 라이선스 제공에 따른 기술료 등의 대가를 수취하고 있으며 라이선스의 성격을 파악하여 사용권의 경우에는 수행의무를 충족하는 시점에 수익을 인식하며 접근권의 경우에는 이행의무를 충족하는 기간에 걸쳐 수익을 인식합니다. 당사의 기술이전 라이선스 제공은 사용권으로 판단하여 수익을 인식하고 있습니다. 상품매출은 자산에 대한 통제가 고객에게 이전되는 시점(국내거래의 경우 인도시점, 해외수출의 경우 선적시점)에 수익을 인식하고 있습니다. &cr;</P>
<P>수행의무를 이행하는 기간에 걸쳐 수익을 인식하는 경우에는 투입법에 따라 산정된 진행률을 적용하여 수익과 원가를 측정하고 수행정도를 나타내지 못하는 투입물의 영향은 투입법에서 적절히 제외하고 있습니다.</P>
<P> </P>
<P>(2) 본인과 대리인의 구분</P>
<P>매출과 관련된 거래에서는 '본인'의 역할을 수행하므로 수행의무의 이행결과로 이전되는 대가의 총액을 수익으로 인식하고있습니다.</P>
<P> </P>
<P>(3) 환불부채와 반환자산</P>
<P>수행의무이행의 대가로서 받을 금액 중 반품에 의해 받을 권리가 상실되는 부분은 고객에게 제품을 이전할 때 수익으로 인식하지 않고 환불부채로 인식하며 매 보고기간말 반품 예상량의 변동에 따라 환불부채를 재측정하고 있습니다.  </P>
<PGBRK></PGBRK>
<P>한편, 반품으로 회수되는 반환자산은 판매시점의 재고자산의 장부금액에서 그 재고자산의 회수에 예상되는 원가를 차감하여 측정하고 매 보고기간말 재측정하고 있습니다.</P>
<P> </P>
<P>(4) 계약체결 증분원가와 계약이행원가</P>
<P>회수가 가능한 계약체결 증분원가 및 조건을 충족하는 계약이행원가에 대해 자산으로 인식하고 있습니다. 이러한 자산은 관련된 재화나 용역을 고객에게 이전하는 방식과 일치하는 체계적 기준으로 상각하며, 자산과 관련된 재화나 용역의 대가로 당사가받을 것으로 예상하는 잔액과 향후 비용으로 인식될 직접원가와의 차액이 당해 자산의 장부가액보다 작은 경우 그 장부금액과의 차이를 손상차손으로 인식하고 있습니다.&cr;</P>

<P>
<SPAN>2.19 정부보조금&cr;&cr;정부보조금은 보조금의 수취와 정부보조금에 부가된 조건의 준수에 대한 합리적인 확신이 있을 때 공정가치로 인식됩니다. 자산관련보조금은 자산의 장부금액을 계산할 때 차감하여 표시되며, 수익관련보조금은 이연하여 정부보조금의 교부 목적과 관련된 비용에서 차감하여 표시됩니다</SPAN>
</P>
<P> </P>

<P>
<SPAN>2.20 영업부문&cr;&cr;</SPAN>
<SPAN>영업부문별 정보는 당사의 경영진에게 보고되는 사업본부별로 공시됩니다(주석 38 참조). 당사의 경영진은 영업부문에 배부될 자원과 영업부문의 성과를 평가하는데 책임이 있습니다.</SPAN>
</P>
<P></P>
<P>2.21 리스</P>
<P></P>
<P>(1) 리스제공자</P>
<P>당사가 리스제공자인 경우 운용리스에서 생기는 리스수익은 리스기간에 걸쳐 정액기준으로 인식합니다. 운용리스 체결 과정에서 부담하는 리스개설직접원가를 기초자산의 장부금액에 더하고 리스료 수익과 같은 기준으로 리스기간에 걸쳐 비용으로 인식합니다. 각 리스된 자산은 재무상태표에서 그 특성에 기초하여 표시하였습니다. </P>
<PGBRK></PGBRK>
<P>(2) 리스이용자</P>
<P>당사는 다양한 사무실, 장비, 자동차 등을 리스하고 있습니다. 리스계약은 일반적으로 고정 기간으로 체결되지만 아래에서 설명하는 연장선택권이 있을 수 있습니다.</P>
<P></P>

<P>
<SPAN>계약에는 리스요소와 비리스요소가 모두 포함될 수 있습니다. 당사</SPAN>
<SPAN>는 상대적 개별 가격에 기초하여 계약 대가를 리스요소와 비리스요소에 배분하였습니다. </SPAN>
<SPAN>그러나 당사가 리스이용자인 부동산 리스의 경우 리스요소와 비리스요소를 분리하지 않고 하나의 리스요소로 회계처리하는 실무적 간편법을 적용하였습니다.</SPAN>
<SPAN></SPAN>
</P>
<P></P>
<P>당사는 계약이 집행가능한 기간 내에서 해지불능기간에 리스이용자가 연장선택권을 행사할 것이 상당히 확실한 경우의 그 대상기간과 종료선택권을 행사하지 않을 것이 상당히 확실한 경우의 그 대상기간을 포함하여 리스기간을 산정합니다. 당사는 리스이용자와 리스제공자가 각각 다른 당사자의 동의 없이 종료할 수 있는 권리가 있는 경우 계약을 종료할 때 부담할 경제적 불이익을 고려하여 집행가능한 기간을 산정합니다. </P>
<P> </P>
<P>리스에서 생기는 자산과 부채는 최초에 현재가치기준으로 측정합니다. 리스부채는 다음 리스료의 순현재가치를 포함합니다.&cr;· 받을 리스 인센티브를 차감한 고정리스료(실질적인 고정리스료 포함)</P>
<P>· 개시일 현재 지수나 요율을 사용하여 최초 측정한, 지수나 요율(이율)에 따라 달라    지는 변동리스료</P>
<P>· 잔존가치보증에 따라 당사(리스이용자)가 지급할 것으로 예상되는 금액</P>
<P>· 당사(리스이용자)가 매수선택권을 행사할 것이 상당히 확실한 경우에 그 매수    선택권의 행사가격</P>
<P>· 리스기간이 당사(리스이용자)의 종료선택권 행사를 반영하는 경우에 그 리스     를 종료하기 위하여 부담하는 금액</P>
<P> </P>
<P>리스의 내재이자율을 쉽게 산정할 수 있는 경우 그 이자율로 리스료를 할인합니다. 내재이자율을 쉽게 산정할 수 없는 경우에는 리스이용자가 비슷한 경제적 환경에서 비슷한 기간에 걸쳐 비슷한 담보로 사용권자산과 가치가 비슷한 자산을 획득하는 데 필요한 자금을 차입한다면 지급해야 할 이자율인 리스이용자의 증분차입이자율을 사용합니다.</P>
<P> </P>
<P>당사는 증분차입이자율을 다음과 같이 산정합니다.</P>
<P>· 가능하다면 개별 리스이용자가 받은 최근 제3자 금융 이자율에 제3자 금융을 받       은 이후 재무상태의 변경을 반영</P>
<P>· 최근 제3자 금융을 받지 않은 경우 무위험이자율에 신용위험을 조정하는 상향 접     근법을 사용</P>
<P>· 국가, 통화, 담보, 보증과 같은 리스에 특정한 조정을 반영</P>
<P></P>
<P>각 리스료는 리스부채의 상환과 금융원가로 배분합니다. 금융원가는 각 기간의 리스부채 잔액에 대하여 일정한 기간 이자율이 산출되도록 계산된 금액을 리스기간에 걸쳐 당기손익으로 인식합니다. </P>
<P> </P>
<P>사용권자산은 다음 항목들로 구성된 원가로 측정합니다. </P>
<P>· 리스부채의 최초 측정금액</P>
<P>· 받은 리스 인센티브를 차감한 리스개시일이나 그 전에 지급한 리스료</P>
<P>· 리스이용자가 부담하는 리스개설직접원가</P>
<P>· 복구원가의 추정치</P>
<P> </P>
<P>사용권자산은 리스개시일부터 사용권자산의 내용연수 종료일과 리스기간 종료일 중 이른 날까지의 기간동안 감가상각합니다. 당사가 매수선택권을 행사할 것이 상당히 확실한(Reasonably certain) 경우 사용권자산은 기초자산의 내용연수에 걸쳐 감가상각합니다.</P>
<P> </P>

<P>
<SPAN>단기리스와 소액자산 리스와 관련된 리스료는 정액 기준에 따라 당기손익으로 인식합니다. 단기리스는 매수선택권 없이 리스기간이 12개월 이하인 리스이며</SPAN>
<SPAN>, 소액리스자산은</SPAN>
<SPAN> IT기기</SPAN>
<SPAN>로 구성되어 있습니다.</SPAN>
</P>
<P></P>
<P>3. 중요한 회계추정 및 가정</P>
<P> </P>

<P>
<SPAN>재무제표 작성에는 미래에 </SPAN>
<SPAN>대한 가정 및 추정이 요구되며 경영진은 당사의 회계정책을 적용하기 위해 판단이 요구됩니다. 추정 및 가정은 지속적으로 평가되며, 과거 경험과 현재의 상황에 비추어 합리적으로 예측가능한 미래의 사건을 고려하여 이루어집니다. 회계추정의 결과가 실제 결과와 동일한 경우는 드물 것이므로 중요한 조정을 유발할 수 있는 유의적인 위험을 내포하고 있습니다.</SPAN>
</P>
<P> </P>
<P>다음 회계연도에 자산 및 부채 장부금액의 조정에 영향을 미칠 수 있는 경영진 판단과 유의적 위험에 대한 추정 및 가정은 다음과 같습니다. 일부 항목에 대한 유의적인 판단 및 추정에 대한 추가적인 정보는 개별 주석에 포함되어 있습니다.</P>

<P>
<SPAN></SPAN>
</P>
<P>(1) 법인세</P>

<P>
<SPAN>당사의 과세소득에 대한 법인세는 다양한 국가의 세법 및 과세당국의 결정을 적용하여 산정되므로 최종 세효과를 산정하는 데에는 불확실성이 존재합니다</SPAN>
<SPAN></SPAN>
<SPAN>(주석 34 참조).</SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>(2) 순확정급여부채</P>

<P>
<SPAN> </SPAN>
<SPAN>순확정급여부채의 현재가치는 보험수리적방식에 의해 결정되는 다양한 요소들 특히 할인율의 변동에 영향을 받습니다</SPAN>
<SPAN>(주석</SPAN>
<SPAN> </SPAN>
<SPAN>22 </SPAN>
<SPAN></SPAN>
<SPAN>참조)</SPAN>
<SPAN>.&cr;</SPAN>
</P>

<P>
<SPAN>4. 재무위험 관리 &cr;&cr;4.1 재무위험관리요소 &cr;&cr;당사는 다양한 활동들로 인하여 시장위험(외환위험, 공정가치 이자율위험, 현금흐름이자율위험), 신용위험 및 유동성위험과 같은 다양한 금융 위험에 노출되어 있습니다. 당사의 전반적인 위험관리 </SPAN>
<SPAN>정책</SPAN>
<SPAN>은 경영진이 승인한 정책에 따라 당사의 재무부서에 의해 이루어지고 있습니다. 당사의 재무부서는 </SPAN>
<SPAN>현업</SPAN>
<SPAN>부서들과 긴밀히 협력하여 재무위험을 식별, 평가 및 회피하고 있습니다.&cr;&cr;당사는 차입금으로 이한 이자율 변동위험이 재무제표에 미치는 영향이 중요하지 않으므로 시장위험에 대한 민감도 분석도 표시하지 아니하였습니다.&cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>(1) </SPAN>
<SPAN>외환</SPAN>
<SPAN>위</SPAN>
<SPAN>험&cr;</SPAN>
<SPAN>당사는 기능통화인 원화 외의 통화로 표시되는 판매 및 구매 등에 대해 환위험에 노출되어 있습니다. </SPAN>
<SPAN>이러한 거래들이 표시되는 주된 통화는 </SPAN>
<SPAN>USD, </SPAN>
<SPAN>EUR</SPAN>
<SPAN> 입니다.</SPAN>
</P>
<P></P>

<P>
<SPAN>당기말 및 전기말 현재 외화자산 및 부채의 내역은 다음과 같습니다. </SPAN>
<SPAN>&cr;                                                                                                       (단위: 천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1122">

<COLGROUP>
<COL WIDTH="149"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="127"></COL>
<COL WIDTH="127"></COL>
<COL WIDTH="127"></COL>
<COL WIDTH="49"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="138"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="158" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60"> 구분 </TH>
<TH COLSPAN="4" WIDTH="466" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 당기말 </TH>
<TH COLSPAN="4" WIDTH="498" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 전기말 </TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH COLSPAN="2" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="194" HEIGHT="30"> 외화금액 </TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="136" HEIGHT="30"> 환율 </TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="136" HEIGHT="30"> 원화금액 </TH>
<TH COLSPAN="2" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="205" HEIGHT="30"> 외화금액 </TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="146" HEIGHT="30"> 환율 </TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="147" HEIGHT="30"> 원화금액 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="158" HEIGHT="60"> 현금 및 현금성자산 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">12,704,405 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,088.00 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">13,822,393 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">12,452,679</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,157.80</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">14,417,712</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> EUR </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">312,827 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,338.24 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">418,638 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> EUR </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">286,453</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,297.43</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">371,653</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="158" HEIGHT="30"> 매출채권 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">9,784,375 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,088.00 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">10,645,400 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">100,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,157.80</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">115,780</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="158" HEIGHT="60"> 외화자산 계 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">22,488,780 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,088.00 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">24,467,793 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">12,552,679</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,157.80</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">14,533,492</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> EUR </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">312,827 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1338.24 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">10,645,400 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> EUR </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">286,453</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,297.43</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">371,653</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="158" HEIGHT="30"> 기타유동금융부채 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">411,244 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,088.00 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">447,433 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">35,268</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,157.80</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">40,833</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="158" HEIGHT="30"> 외화부채 계 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">411,244 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">1,088.00 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="136" HEIGHT="30">447,433 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="58" HEIGHT="30"> USD </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">35,268</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="146" HEIGHT="30">1,157.80</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="147" HEIGHT="30">40,833</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>당기말과 전기말 현재 </SPAN>
<SPAN>외화자산 및 부채</SPAN>
<SPAN>에 대한 원화 환율변동이 손익에 미치는 영향은 다음과 같습니다. </SPAN>
</P>

<P>
<SPAN>                                                                                                        (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="715">

<COLGROUP>
<COL WIDTH="134"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="134"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="143" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>

<TH USERMARK="F-12" WIDTH="286" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<SPAN USERMARK="F-11">당</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11">기</SPAN>
</TH>
<TH WIDTH="286" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">5%P 상승시</TH>
<TH WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">5%P 하락시</TH>
<TH WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">5%P 상승시</TH>
<TH WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">5%P 하락시</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">USD</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">1,201,018 </TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">(1,201,018)</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">724,911</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">(724,911)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">EUR</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">20,932 </TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">(20,932)</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">18,583</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">(18,583)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="143" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>계</SPAN>
</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">1,221,950 </TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">(1,221,950)</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT">743,494</TD>
<TD WIDTH="143" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(743,494)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN></SPAN>
<SPAN>&cr;(2)</SPAN>
<SPAN> 신용위험&cr;신용위험은 당사 차원에서 관리되고 있습니다. 신용위험은 보유하고 있는 수취채권 및 확정계약을 포함한 도소매 거래처에 대한 신용위험 뿐 아니라 현금및현금성자산, 은행 및 금융기관 예치금으로부터 발생하고 있습니다. 은행 및 금융기관의 경우, 독립적인 신용평가기관으로부터의 신용등급이 일정수준 이상인 경우에 한하여 거래를 하고 있습니다.&cr;&cr;당사는 국민은행, 우리은행, 하나은행 등의 금융기관에 현금및현금성자산과 금융자산을 예치하고 있으며, 신용등급이 우수한 금융기관과 거래하고 있으므로 금융기관으로부터의 신용위험은 제한적입니다.&cr;&cr;신용위험으로 인한 최대 노출금액은 금융기관에 예치된 현금및현금성자산(주석7), 매출채권 및 기타금융자산(</SPAN>
<SPAN>주석9, 10</SPAN>
<SPAN>)을 포함한 모든 금융자산의 장부금액입니다.&cr;&cr;(3) 유동성위험&cr;유동성 위험은 당사가 금융부채와 관련된 의무를 충족하는 데 어려움을 겪게 될 위험입니다.&cr;&cr;당사는 보유현금을 적정수준으로 유지하고 영업 자금 수요를 충족시킬 수 있도록 유동성에 대한 예측을 항시 검토하여, 당사의 자금조달 계획, 약정 준수, 당사 내부의 목표재무비율 및 통화에 대한 제한과 같은 외부 법규나 법률 요구사항이 있는 경우 그러한 요구사항을 고려하고 있습니다. &cr;</SPAN>
</P>
<P>당사의 유동성 위험 분석 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="709" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="301"></COL>
<COL WIDTH="390"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="310" HEIGHT="30" VALIGN="MIDDLE"><당기말></TD>
<TD ALIGN="RIGHT" WIDTH="399" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="709">

<COLGROUP>
<COL WIDTH="150"></COL>
<COL WIDTH="85"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="159" HEIGHT="53" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER">구 분</TH>
<TH WIDTH="94" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월&cr;미만</TH>
<TH WIDTH="92" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월에서&cr;1년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1년에서&cr;2년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2년에서&cr;3년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3년 초과</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30">매입채무</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">3,111,018 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">3,443,780 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">6,554,798 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30">기타금융부채-유동</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">6,137,495 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">6,137,495 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30">기타금융부채-비유동</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">240,580 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">240,580 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30">장기차입금(*)</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">28,053 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">2,726,786 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">916,267 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">3,671,106 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30">리스부채</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">68,368 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">138,464 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">78,660 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">64,273 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">50,545 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">400,310 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30" VALIGN="MIDDLE">금융보증계약(**)</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">828,991 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">12,456,015 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">13,285,006 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="159" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합     계</TD>
<TD WIDTH="94" HEIGHT="30" ALIGN="RIGHT">10,145,872 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">16,066,312 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">2,805,446 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">980,540 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">291,125 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">30,289,295 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*)향후 지급할 이자가 포함된 금액입니다.&cr;</SPAN>
<SPAN>(**) 재무상태표상 지급보증 부채가 아니며, 계약금액 총액이 표시되어 있습니다.&cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="712" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="301"></COL>
<COL WIDTH="393"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="310" HEIGHT="30" VALIGN="MIDDLE"><전기말></TD>
<TD ALIGN="RIGHT" WIDTH="402" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="709">

<COLGROUP>
<COL WIDTH="152"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="161" HEIGHT="53" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER">구 분</TH>
<TH WIDTH="92" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월&cr;미만</TH>
<TH WIDTH="92" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월에서&cr;1년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1년에서&cr;2년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">2년에서&cr;3년이하</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3년 초과</TH>
<TH WIDTH="91" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30">매입채무</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">4,158,020 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">3,532,561 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,230 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT"> -</TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">7,691,811 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30">기타금융부채-유동</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">5,562,545 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">5,562,545 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30">기타금융부채-비유동</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,267,226 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,267,226 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30">장기차입금</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,900,000 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,900,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30">리스부채</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">71,987 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">128,935 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">58,321 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">30,542 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">27,181 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">316,966 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30" VALIGN="MIDDLE">금융보증계약</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">419,079 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">6,264,300 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">30,000 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">- </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">6,713,379 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="161" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합     계</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">10,211,631 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT">9,925,796 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">59,551 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,960,542 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">1,294,407 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT">23,451,927 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>위의 분석에 포함된 비파생금융부채는 보고기간말로부터 계약 만기일까지의 잔여 기간에 따라 만기별로 구분되었습니다. 계약 만기일까지의 잔여기간에 따른 만기별 구분에 포함된 현금흐름은 현재가치 할인을 하지 않은 금액이며, 금융보증계약은 계약상 지급을 요구받을 수 있는 계약금액 총액입니다.&cr;</P>
<P>(4) 자본위험관리&cr;당사의 자본관리 목적은 계속기업으로서 주주 및 이해당사자들에게 이익을 지속적으로 제공할 수 있는 능력을 보호하고 자본비용을 절감하기 위해 최적 자본구조를 유지하는 것입니다. &cr;</P>
<P>산업내의 타사와 마찬가지로 회사는 자본조달비율에 기초하여 자본을 관리하고 있습니다. 자본조달비율은 순부채를 총자본으로 나누어 산출하고 있습니다. 순부채는 총부채에서 현금및현금성자산을 차감한 금액이며 총자본은 재무상태표의 "자본"에 순부채를 가산한 금액입니다.</P>
<P>&cr;보고기간말 현재의 당사의 자본조달비율은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="600" HEIGHT="30">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="597" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="214"></COL>
<COL WIDTH="178"></COL>
<COL WIDTH="178"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="223" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="187" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="187" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" HEIGHT="30">총부채</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">23,786,164 </TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">25,568,107</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" HEIGHT="30">차감 : 현금및현금성자산</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">54,648,759 </TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">66,888,373</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" HEIGHT="30">순부채(A)</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(30,862,595)</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(41,320,266)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" HEIGHT="30">자본총계(B)</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">112,126,184 </TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">115,909,346</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" VALIGN="BOTTOM" HEIGHT="30">총자본(C=A+B)</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">81,263,589 </TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">74,589,080</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="223" VALIGN="BOTTOM" HEIGHT="30">자본조달비율(D=A/C)</TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="187" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<PGBRK></PGBRK>

<P>
<SPAN>5. 공정가치&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(1) </SPAN>
<SPAN>공정가치 서열체계&cr;</SPAN>
<SPAN></SPAN>
<SPAN>공정가치로 측정되거나 공정가치가 공시되는 금융상품은 공정가치 서열체계에 따라 구분되며 정의된 수준들은 다음과 같습니다.&cr;&cr;- 동일한 자산이나 부채에 대한 활성시장의(조정되지 않은) 공시가격(수준 1)&cr;- 직접적으로(예: 가격) 또는 간접적으로(예: 가격에서 도출되어) 관측가능한, &cr;   자산이나 부채에 대한 투입변수. 단, 수준 1에 포함된 공시가격은 제외함(수준 2)&cr;- 관측가능한 시장자료에 기초하지 않은, 자산이나 부채에 대한 투입변수&cr;  (관측가능 하지 않은 투입변수)를 이용하여 산정한 공정가치(수준 3)&cr;&cr;</SPAN>
<SPAN>당사의 공정가치로 측정되거나 공정가치가 공시되는 금융상품</SPAN>
<SPAN>은 다음과 같습니다.</SPAN>
</P>

<TABLE WIDTH="694" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="389"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD WIDTH="398" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="696" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="262"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="271" ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="107" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 1</TH>
<TH WIDTH="106" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 2</TH>
<TH WIDTH="106" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 3</TH>
<TH WIDTH="106" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="271" HEIGHT="30">
<SPAN>당기손익-공정가치측정 금융자산</SPAN>
</TD>
<TD WIDTH="107" HEIGHT="30"></TD>
<TD WIDTH="106" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT"></TD>
<TD WIDTH="106" HEIGHT="30"></TD>
<TD WIDTH="106" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">  브릿지바이오테라퓨틱스(주)</TD>
<TD WIDTH="107" ALIGN="RIGHT" HEIGHT="30">4,910,625</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">4,910,625</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="271" HEIGHT="30">
<SPAN>기타포괄손익-공정가치측정 금융자산</SPAN>
</TD>
<TD WIDTH="107" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">  (주)인투셀</TD>
<TD WIDTH="107" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">4,932,400</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">4,932,400</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">  (주)에스알파테라퓨틱스</TD>
<TD WIDTH="107" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">499,993</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">499,993</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합      계</TD>
<TD WIDTH="107" ALIGN="RIGHT" HEIGHT="30">4,910,625</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">5,432,393</TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="106" ALIGN="RIGHT" HEIGHT="30">10,343,018</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<TABLE WIDTH="692" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="387"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><전기></TD>
<TD WIDTH="396" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="696">

<COLGROUP>
<COL WIDTH="262"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
<COL WIDTH="97"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="271" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="107" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 1</TH>
<TH WIDTH="106" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 2</TH>
<TH WIDTH="106" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 3</TH>
<TH WIDTH="106" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">당기손익-공정가치 금융자산</TD>
<TD WIDTH="107" HEIGHT="30"></TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="106" HEIGHT="30">　           </TD>
<TD WIDTH="106" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">  브릿지바이오테라퓨틱스(주)</TD>
<TD WIDTH="107" HEIGHT="30" ALIGN="RIGHT">6,457,500</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">6,457,500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">기타포괄손익-공정가치 금융자산</TD>
<TD WIDTH="107" HEIGHT="30" ALIGN="RIGHT"></TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT"></TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT"></TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30">  (주)인투셀</TD>
<TD WIDTH="107" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">868,340</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">868,340</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="271" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합   계</TD>
<TD WIDTH="107" HEIGHT="30" ALIGN="RIGHT">6,457,500</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">868,340</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">　-</TD>
<TD WIDTH="106" HEIGHT="30" ALIGN="RIGHT">7,325,840</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(2)</SPAN>
<SPAN> 반복적인 공정가치 측정치의 수준3의 변동 내용&cr;</SPAN>
<SPAN>당사는 공정가치 서열체계의 수준 간 이동을 보고기간 말에 인식합니다. </SPAN>
<SPAN>당기 및 전기 중 </SPAN>
<SPAN></SPAN>
<SPAN>반복적인 측정치의 수준 1과 수준 2간의 이동 내역은 없습니다.</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>6. 범주별 금융상품 &cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(1) </SPAN>
<SPAN>보고기간말 현재 당사의 범주별 금융상품의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="747" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="313"></COL>
<COL WIDTH="416"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="322" HEIGHT="30" VALIGN="MIDDLE">
<SPAN><</SPAN>
<SPAN></SPAN>
<SPAN>당기></SPAN>
</TD>
<TD ALIGN="RIGHT" WIDTH="425" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="745">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="151"></COL>
<COL WIDTH="161"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">재무상태표 상 자산</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">상각후원가 측정 &cr;금융자산</TH>
<TH WIDTH="160" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기손익-공정가치&cr;측정 금융자산</TH>
<TH WIDTH="170" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기타포괄손익-공정가치측정 금융자산</TH>
<TH WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">현금및현금성자산</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">54,648,759</TD>
<TD ALIGN="RIGHT" WIDTH="160" HEIGHT="30" VALIGN="MIDDLE">-   </TD>
<TD ALIGN="RIGHT" WIDTH="170" HEIGHT="30">-   </TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30">54,648,759</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">매출채권</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">20,568,676</TD>
<TD ALIGN="RIGHT" WIDTH="160" HEIGHT="30" VALIGN="MIDDLE">-   </TD>
<TD ALIGN="RIGHT" WIDTH="170" HEIGHT="30">-   </TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30">20,568,676</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">기타금융자산-유동</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">23,556,605</TD>
<TD ALIGN="RIGHT" WIDTH="160" HEIGHT="30" VALIGN="MIDDLE">-   </TD>
<TD ALIGN="RIGHT" WIDTH="170" HEIGHT="30">-   </TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30">23,556,605</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">기타금융자산-비유동</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">968,343</TD>
<TD ALIGN="RIGHT" WIDTH="160" HEIGHT="30" VALIGN="MIDDLE">4,910,625</TD>
<TD ALIGN="RIGHT" WIDTH="170" HEIGHT="30">5,432,393</TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30">11,311,361</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="30" VALIGN="MIDDLE">합     계</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">99,742,383</TD>
<TD ALIGN="RIGHT" WIDTH="160" HEIGHT="30" VALIGN="MIDDLE">4,910,625</TD>
<TD ALIGN="RIGHT" WIDTH="170" HEIGHT="30">5,432,393</TD>
<TD ALIGN="RIGHT" WIDTH="120" HEIGHT="30">110,085,401</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" WIDTH="735" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="726"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="735" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="735">

<COLGROUP>
<COL WIDTH="175"></COL>
<COL WIDTH="175"></COL>
<COL WIDTH="175"></COL>
<COL WIDTH="174"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="184" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">재무상태표 상 부채</TH>
<TH WIDTH="184" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">상각후원가측정 &cr;금융부채</TH>
<TH WIDTH="184" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기손익-공정가치&cr;측정금융부채</TH>
<TH WIDTH="183" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" HEIGHT="30">매입채무</TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">6,554,798 </TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="183" HEIGHT="30">6,554,798 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" HEIGHT="30">기타금융부채-유동</TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">6,137,495 </TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="183" HEIGHT="30">6,137,495 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" HEIGHT="30">기타금융부채-비유동</TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">240,580 </TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="183" HEIGHT="30">240,580 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" HEIGHT="30">장기차입금</TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">3,612,000 </TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="183" HEIGHT="30">3,612,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="184" HEIGHT="30" ALIGN="CENTER">합     계</TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">16,544,873 </TD>
<TD ALIGN="RIGHT" WIDTH="184" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="183" HEIGHT="30">16,544,873 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="743" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="313"></COL>
<COL WIDTH="412"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="322" HEIGHT="30" VALIGN="MIDDLE">
<SPAN><</SPAN>
<SPAN> </SPAN>
<SPAN>전기></SPAN>
</TD>
<TD ALIGN="RIGHT" WIDTH="421" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="744">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="162"></COL>
<COL WIDTH="123"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">재무상태표 상 자산</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">상각후원가 측정 &cr;금융자산</TH>
<TH WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기손익-공정가치측정 금융자산</TH>
<TH WIDTH="171" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기타포괄손익-공정가치&cr;측정 금융자산</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">현금및현금성자산</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">66,888,373</TD>
<TD ALIGN="RIGHT" WIDTH="146" HEIGHT="30" VALIGN="MIDDLE">　-</TD>
<TD ALIGN="RIGHT" WIDTH="171" HEIGHT="30">　-</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">66,888,373</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">매출채권</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">11,119,772</TD>
<TD ALIGN="RIGHT" WIDTH="146" HEIGHT="30" VALIGN="MIDDLE">　-</TD>
<TD ALIGN="RIGHT" WIDTH="171" HEIGHT="30">　-</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">11,119,772</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">기타금융자산-유동</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">29,310,848</TD>
<TD ALIGN="RIGHT" WIDTH="146" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD ALIGN="RIGHT" WIDTH="171" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">29,310,848</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="163" HEIGHT="30">기타금융자산-비유동</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">280,607</TD>
<TD ALIGN="RIGHT" WIDTH="146" HEIGHT="30" VALIGN="MIDDLE">6,457,500</TD>
<TD ALIGN="RIGHT" WIDTH="171" HEIGHT="30">868,340</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">7,606,447</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="30" VALIGN="MIDDLE">합     계</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">107,599,600</TD>
<TD ALIGN="RIGHT" WIDTH="146" HEIGHT="30" VALIGN="MIDDLE">6,457,500</TD>
<TD ALIGN="RIGHT" WIDTH="171" HEIGHT="30">868,340</TD>
<TD ALIGN="RIGHT" WIDTH="132" HEIGHT="30">114,925,440</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" WIDTH="737" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="728"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="737" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="741">

<COLGROUP>
<COL WIDTH="177"></COL>
<COL WIDTH="176"></COL>
<COL WIDTH="176"></COL>
<COL WIDTH="176"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="186" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">재무상태표 상 부채</TH>
<TH WIDTH="185" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">상각후원가측정 &cr;금융부채</TH>
<TH WIDTH="185" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기손익-공정가치&cr;측정금융부채</TH>
<TH WIDTH="185" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="186" HEIGHT="30">매입채무</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">7,691,811</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">7,691,811</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="186" HEIGHT="30">기타금융부채-유동</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">5,673,725</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">5,673,725</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="186" HEIGHT="30">기타금융부채-비유동</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">1,441,220</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">1,441,220</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="186" HEIGHT="30" VALIGN="MIDDLE">장기차입금</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">1,900,000</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">1,900,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="186" HEIGHT="30" ALIGN="CENTER">합     계</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">16,706,756</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">　-</TD>
<TD ALIGN="RIGHT" WIDTH="185" HEIGHT="30">16,706,756</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(2) </SPAN>
<SPAN>보고기간 중에 발생한 금융상품 범주별 순손익은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="572" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="563"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="572" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="573">

<COLGROUP>
<COL WIDTH="268"></COL>
<COL WIDTH="139"></COL>
<COL WIDTH="139"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="277" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 구 분 </TH>
<TH WIDTH="148" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 당기 </TH>
<TH WIDTH="148" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 전기 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">상각후원가로 측정하는 금융자산 </TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  대손충당금환입 (대손상각비)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">1,462,501</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(1,945,160)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  이자수익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">1,001,397</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">1,498,903</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  외환차익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">963,786</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">136,600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  외화환산이익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">12,161</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">33,189</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="277" HEIGHT="30"> 소     계 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">3,439,845</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">276,468</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">당기손익-공정가치측정 금융자산 </TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  평가이익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">3,989,025</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  평가손실</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(1,546,875)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="277" HEIGHT="30"> 소     계 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(1,546,875)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">3,989,025</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">기타포괄손익-공정가치측정 금융자산 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  평가이익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">3,169,967</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">파생상품 </TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  평가이익 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">20,045,108</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">상각후원가로 측정하는 금융부채 </TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="148" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  이자비용 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(25,803)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  외환차손 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(1,178,370)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(702,298)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="277" HEIGHT="30">  외화환산손실 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(411,355)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(53,574)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="277" HEIGHT="30"> 소     계 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(1,589,725)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="148" HEIGHT="30">(781,675)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>7. 현금및현금성자산 &cr;&cr;(1)</SPAN>
<SPAN> 보고기간말 현재 당사의 현금및현금성자산은 다음과 같습니다.          (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="747">

<COLGROUP>
<COL WIDTH="240"></COL>
<COL WIDTH="240"></COL>
<COL WIDTH="240"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="249" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="249" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="249" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">보통예금</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">5,380,815</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">            12,910,906</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">MMT</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">4,124,118</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">CMA</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">-</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">3,043,320</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">외화예금</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">14,241,031</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">14,789,364</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">단기채권</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">10,410,778</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">14,020,665</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">정기예금</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">24,616,135</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">18,000,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="249" HEIGHT="30" ALIGN="CENTER">합 계</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">54,648,759</TD>
<TD WIDTH="249" HEIGHT="30" ALIGN="RIGHT">66,888,373</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>(2) </SPAN>
<SPAN>현금및현금성자산은 만기가 짧고 현행시장이자율을 반영하는 변동이자율 조건으로서 장부금액과 공정가치와의 차이가 중요하지 아니하며, 신용위험의 최대 노출정도는 장부금액과 일치합니다.&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>8. 사용이 제한된 금융자산&cr;당기말 및 전기말 현재 사용이 제한된 금융자산의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="723">

<COLGROUP>
<COL WIDTH="714"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="723" HEIGHT="30" ALIGN="RIGHT">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="723">

<COLGROUP>
<COL WIDTH="184"></COL>
<COL WIDTH="126"></COL>
<COL WIDTH="126"></COL>
<COL WIDTH="126"></COL>
<COL WIDTH="116"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="193" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 구 분 </TH>
<TH WIDTH="135" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 내역 </TH>
<TH WIDTH="135" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 당기 </TH>
<TH WIDTH="135" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 전기 </TH>
<TH WIDTH="125" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 비고(*)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 기타유동금융자산 </TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 정기예금 등 </TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,170,000</TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,873,250</TD>
<TD WIDTH="125" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 질권설정</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 합 계 </TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,170,000</TD>
<TD WIDTH="135" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,873,250</TD>
<TD WIDTH="125" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 당사의 신축사옥 차입금 관련하여 12,000백만원, 직원 대출 관련하여 3,170백만원이 담보로 제공되어 있습니다(주석37(2), 39(5)참조).</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;9. 매출채권 &cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>(1)</SPAN>
<SPAN> </SPAN>
<SPAN>보</SPAN>
<SPAN>고기간말 현재 당사의 매출채권의 내역은 다음과 같습니다.            (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="687">

<COLGROUP>
<COL WIDTH="220"></COL>
<COL WIDTH="220"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="229" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="229" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="229" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" HEIGHT="30" ALIGN="CENTER">매출채권</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">21,250,212 </TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">13,276,706 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" HEIGHT="30" ALIGN="CENTER">대손충당금</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">(681,536)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">(2,156,934)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" HEIGHT="30" ALIGN="CENTER">합 계</TD>

<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">
<SPAN>20,568,676 </SPAN>
</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">11,119,772 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(2) </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>보</SPAN>
<SPAN>고기간말  </SPAN>
<SPAN>현재 매출채권의 연령분석은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="596" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="292"></COL>
<COL WIDTH="286"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="301" HEIGHT="30" VALIGN="MIDDLE"><당기>                     </TD>
<TD WIDTH="295" HEIGHT="30" ALIGN="RIGHT">   (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="601">

<COLGROUP>
<COL WIDTH="143"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월 이하</TH>
<TH WIDTH="84" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4~6개월</TH>
<TH WIDTH="83" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">7~12개월</TH>
<TH WIDTH="99" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">12개월 초과</TH>
<TH WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 매출채권</TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,766,866 </TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,127,045 </TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">356,301 </TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">21,250,212 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 기대신용손실율(*)</TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1%</TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3%</TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">100%</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 손실충당금</TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">157,550</TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">167,685</TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">356,301</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">681,536</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 집합평가 매출채권에 대해 기대신용손실률(실무적 간편법)을 고려하여 전체기간 기대신용손실금액을 산정하였습니다.&cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="603" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="292"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="301" HEIGHT="30" VALIGN="MIDDLE"><전기>               </TD>
<TD WIDTH="302" HEIGHT="30" ALIGN="RIGHT">       (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="601">

<COLGROUP>
<COL WIDTH="143"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="91" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">3개월 이하</TH>
<TH WIDTH="84" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">4~6개월</TH>
<TH WIDTH="83" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">7~12개월</TH>
<TH WIDTH="99" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">12개월 초과</TH>
<TH WIDTH="92" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 매출채권 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">7,438,250</TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">5,487,465</TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">279,050</TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">71,942</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">13,276,707</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 기대신용손실율(*) </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2%</TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">34%</TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">26%</TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">100%</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 손실충당금 </TD>
<TD WIDTH="91" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">159,765</TD>
<TD WIDTH="84" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,851,475</TD>
<TD WIDTH="83" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">73,752</TD>
<TD WIDTH="99" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">71,942</TD>
<TD WIDTH="92" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,156,934</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 집합평가 매출채권에 대해 기대신용손실률(실무적 간편법)을 고려하여 전체기간 기대신용손실금액을 산정하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN>(3) 손실충당금의 변동내용은 다음과 같습니다.</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="603" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="292"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="301" HEIGHT="30" VALIGN="MIDDLE"><당기>    </TD>
<TD WIDTH="302" HEIGHT="30" ALIGN="RIGHT">                          (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="604">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="242" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전체기간 기대신용손실</TH>
<TH WIDTH="121" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">12개월&cr;기대신용손실</TH>
<TH WIDTH="120" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출채권&cr;(집합평가)</TH>
<TH WIDTH="121" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출채권&cr;(개별평가)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기초 손실충당금</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,156,934 </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,156,934 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">위험대체(*1)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(21,814)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">21,814 </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">설정(환입)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,500,918)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">38,417 </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,462,501)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기타(*2)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(12,897)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(12,897)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기말 손실충당금</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">621,305 </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">60,231 </TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">681,536 </TD>
</TR>
</TBODY>
</TABLE>
<P>(*1) 집합평가 대상 채권에서 개별평가 대상 채권으로의 대체를 의미합니다.&cr;(*2) 당기 중 종속회사에 대한 지배력 상실로 장부에서 제거되었습니다.&cr;</P>
<PGBRK></PGBRK>

<TABLE ACLASS="NORMAL" WIDTH="603" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="292"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="301" HEIGHT="30" VALIGN="MIDDLE"><전기>      </TD>
<TD WIDTH="302" HEIGHT="30" ALIGN="RIGHT">  (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="604">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="242" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전체기간 기대신용손실</TH>
<TH WIDTH="121" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">12개월&cr;기대신용손실</TH>
<TH WIDTH="120" HEIGHT="83" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합계</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출채권&cr;(개별평가)</TH>
<TH WIDTH="121" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출채권&cr;(집합평가)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기초 손실충당금</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">211,774</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">211,774</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">설정(환입)</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,945,160</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,945,160</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">제거</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">기말 손실충당금</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,156,934</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="121" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="120" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,156,934</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>10. 기타금융자산 </SPAN>
<SPAN>&cr;&cr;</SPAN>
<SPAN>보</SPAN>
<SPAN>고기간말 현</SPAN>
<SPAN>재 당사의 기타금융자산의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="614">

<COLGROUP>
<COL WIDTH="292"></COL>
<COL WIDTH="304"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="301" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD WIDTH="313" HEIGHT="30" ALIGN="RIGHT">  (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="615">

<COLGROUP>
<COL WIDTH="297"></COL>
<COL WIDTH="146"></COL>
<COL WIDTH="145"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="306" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="155" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="154" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">유동 :</TD>
<TD WIDTH="155" VALIGN="MIDDLE" HEIGHT="30">　</TD>
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  금융기관예치금(*)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="155" HEIGHT="30">22,170,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="154" HEIGHT="30">27,873,250</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  단기대여금</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="155" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="154" HEIGHT="30">100,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  미수수익</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">118,768</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">216,116</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  미수금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">868,273</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">262,708</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  보증금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">405,000</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">875,477</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  현재가치할인차금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(5,436)</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(16,703)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">소 계</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,556,605</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,310,848</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">비유동 :</TD>
<TD WIDTH="155" VALIGN="MIDDLE" HEIGHT="30"></TD>
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  보증금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,018,345</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">297,438</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  현재가치할인차금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(50,002)</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(16,831)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">  장기대여금</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">소 계</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">968,343</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">280,607</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="306" VALIGN="MIDDLE" HEIGHT="30">합 계</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">24,524,948</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,591,455</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN>(*) </SPAN>
<SPAN>금융기관예치금은 정기예금으로 구성되어 있으며, </SPAN>
<SPAN>일</SPAN>
<SPAN>부 금액은 사용이 제한되어 있습니다(주석8 참조).</SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>11. 공정가치측정 금융자산&cr;&cr;(1) 보고기간</SPAN>
<SPAN>말 </SPAN>
<SPAN>현재 당기손익-공정가치측정 금융자산의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="947">

<COLGROUP>
<COL WIDTH="938"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="947" HEIGHT="30" ALIGN="RIGHT">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="947">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="119"></COL>
<COL WIDTH="119"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH ROWSPAN="2" WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>회사명</P>
</TH>
<TH ROWSPAN="2" WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수</TH>
<TH ROWSPAN="2" WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>

<TH COLSPAN="2" WIDTH="256" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>당기</P>
</TH>
<TH COLSPAN="2" WIDTH="256" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>취득원가</P>
</TH>

<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>장부금액</P>
</TH>
<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">취득원가</TH>
<TH WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">장부금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>비유동항목</P>
</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">브릿지바이오테라퓨틱스(주)</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">337,500</TD>
<TD WIDTH="114" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">1.76%</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1,800,000</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">4,910,625</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1,800,000</TD>
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">     6,457,500 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1) 당기에 공정가치 평가로 인해 당기손익인식금융자산평가손실 1,546,875천원(전기 당기손익인식금융자산평가이익 3,989,025천원)을 인식하였습니다.&cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>(2) 보고기간</SPAN>
<SPAN>말 </SPAN>
<SPAN>현재 기타포괄손익-공정가치측정 금융자산의 내역은 다음과 같습니다.                                                                                                    (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="948">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="193"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="102"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="2" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH ROWSPAN="2" WIDTH="202" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>과목</P>
</TH>
<TH ROWSPAN="2" WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수</TH>
<TH ROWSPAN="2" WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>
<TH COLSPAN="2" WIDTH="223" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH COLSPAN="2" WIDTH="222" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>취득원가</P>
</TH>

<TH WIDTH="111" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>장부금액</P>
</TH>
<TH WIDTH="111" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">취득원가</TH>
<TH WIDTH="111" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">장부금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P>비유동항목</P>
</TD>
<TD WIDTH="202" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">(주)인투셀(*1)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">440,000</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">4.29%</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">990,000</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,932,400</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">990,000</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">868,340</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="202" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">(주)에스알파테라퓨틱스(*2)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">38,461</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">6.70%</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">499,993</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">499,993</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="202" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<SPAN>Geom Therapeutics(*3)</SPAN>
<SPAN></SPAN>
</TD>

<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<SPAN>-</SPAN>
</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,126,460</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="4" WIDTH="503" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P>합계</P>
</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,489,993</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,432,393</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,116,460</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">868,340</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1) 당기 중 회사는 보유중인 (주)인투셀 비상장주식에서 4,064백만원의 기타포괄손익-공정가치측정 금융자산 평가이익을 인식하였으며, 시장접근법에 의해 주가순자산비율 및 주가매출액비율을 변수로 사용하여 가치평가 되었습니다.&cr;(*2) 당기 중 회사는 (주)에스알파테라퓨틱스가 발행한</SPAN>
<SPAN> </SPAN>
<SPAN>보통주</SPAN>
<SPAN> 38,461</SPAN>
<SPAN>주를 500백만원에 취득하였으며 당기말 현재 해당 주식의 공정가치는 취득원가와 유의적인 차이가 없습니다.&cr;</SPAN>
<SPAN>(*3) Geom Therapeutics는 2020년 3월 중에 청산이 완료되었습니다.</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;회사는 지분상품에 대한 투자목적이 적극적인 매매를 통한 이익실현이 아니며, 해당 지분상품의 공정가치 변동으로 인한 당기손익의 변동성이 클 경우 당사의 영업성과에 대한 비교가능성을 저해한다고 판단하여 기타포괄손익-공정가치측정금융상품으로 지정하였습니다. </SPAN>
<SPAN></SPAN>
<SPAN> 한편, 금융자산을 처분하는 경우 관련 기타포괄손익누계액은 이익잉여금으로 재분류되며 당기손익으로 재분류되지 않습니다.  </SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>12. 기타자산&cr;&cr;보</SPAN>
<SPAN>고기간</SPAN>
<SPAN>말 </SPAN>
<SPAN></SPAN>
<SPAN>현재 당사의 기타자산의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="595" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="586"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="595" HEIGHT="32">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="616">

<COLGROUP>
<COL WIDTH="197"></COL>
<COL WIDTH="196"></COL>
<COL WIDTH="196"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="206" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="205" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="205" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30">유동:</TD>
<TD WIDTH="205" HEIGHT="30">　</TD>
<TD WIDTH="205" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30">선급비용</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">504,302</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">737,659</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30">선급금</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">274,453</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">542,349</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">소 계</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">778,755</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">1,280,008</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE">비유동:</TD>
<TD WIDTH="205" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD WIDTH="205" HEIGHT="30" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE">장기선급금</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">1,163,168</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">1,174,930 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE">(정부보조금)</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">(56,102)</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">(57,322)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE">장기선급비용</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">1,542,177</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">201,777 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">소 계</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">2,649,243</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">1,319,385 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="206" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">3,427,998</TD>
<TD ALIGN="RIGHT" WIDTH="205" HEIGHT="30">2,599,393 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>13. 재고자산&cr;&cr;</SPAN>
<SPAN USERMARK="F-16"></SPAN>
<SPAN>보고기간말 현재 재고자산의 저</SPAN>
<SPAN>가법 평가내용은</SPAN>
<SPAN> 다음과 같습니다.</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="618" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="300"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><당기>        </TD>
<TD ALIGN="RIGHT" WIDTH="309" HEIGHT="30" VALIGN="MIDDLE">  (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="620" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="83"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="133"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">구분</TH>
<TH ROWSPAN="2" WIDTH="114" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">평가전금액</TH>
<TH ROWSPAN="2" WIDTH="129" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">순실현가능가치</TH>
<TH COLSPAN="2" WIDTH="285" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">평가충당금</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="143" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">당기</TH>
<TH WIDTH="142" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">당기 누계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="92" HEIGHT="30" ALIGN="CENTER">상품</TD>
<TD WIDTH="114" ALIGN="RIGHT" HEIGHT="30">149,894</TD>
<TD WIDTH="129" ALIGN="RIGHT" HEIGHT="30">149,894</TD>
<TD WIDTH="143" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="142" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="92" HEIGHT="30" ALIGN="CENTER">원부재료</TD>
<TD WIDTH="114" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="129" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="143" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="142" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="92" HEIGHT="30" ALIGN="CENTER">제품</TD>
<TD WIDTH="114" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="129" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="143" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="142" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="92" HEIGHT="30" ALIGN="CENTER">반품자산(*)</TD>
<TD WIDTH="114" ALIGN="RIGHT" HEIGHT="30">135,552</TD>
<TD WIDTH="129" ALIGN="RIGHT" HEIGHT="30">135,552</TD>
<TD WIDTH="143" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="142" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="92" HEIGHT="30" ALIGN="CENTER">계</TD>
<TD WIDTH="114" ALIGN="RIGHT" HEIGHT="30">285,446</TD>
<TD WIDTH="129" ALIGN="RIGHT" HEIGHT="30">285,446</TD>
<TD WIDTH="143" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="142" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P>(*)  최근 3년 반품율과 매출원가율을 고려하여 산정하였습니다.&cr;</P>
<PGBRK></PGBRK>

<TABLE ACLASS="NORMAL" WIDTH="619" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="301"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><전기>  </TD>
<TD ALIGN="RIGHT" WIDTH="310" HEIGHT="30" VALIGN="MIDDLE">                                        (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="620" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="85"></COL>
<COL WIDTH="101"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="139"></COL>
<COL WIDTH="127"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="94" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">구분</TH>
<TH ROWSPAN="2" WIDTH="110" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">평가전금액</TH>
<TH ROWSPAN="2" WIDTH="132" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="60" ALIGN="CENTER">순실현가능가치</TH>
<TH COLSPAN="2" WIDTH="284" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">평가충당금</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="148" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">전기</TH>
<TH WIDTH="136" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30" ALIGN="CENTER">전기 누계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="94" HEIGHT="30" ALIGN="CENTER">상품</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">837,555</TD>
<TD WIDTH="132" ALIGN="RIGHT" HEIGHT="30">837,555</TD>
<TD WIDTH="148" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="136" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="94" HEIGHT="30" ALIGN="CENTER">원부재료</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">624,296</TD>
<TD WIDTH="132" ALIGN="RIGHT" HEIGHT="30">624,296</TD>
<TD WIDTH="148" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="136" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="94" HEIGHT="30" ALIGN="CENTER">제품</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">320,145</TD>
<TD WIDTH="132" ALIGN="RIGHT" HEIGHT="30">320,145</TD>
<TD WIDTH="148" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="136" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="94" HEIGHT="30" ALIGN="CENTER">반품자산(*)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">239,376</TD>
<TD WIDTH="132" ALIGN="RIGHT" HEIGHT="30">239,376</TD>
<TD WIDTH="148" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="136" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="94" HEIGHT="30" ALIGN="CENTER">계</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">2,021,372</TD>
<TD WIDTH="132" ALIGN="RIGHT" HEIGHT="30">2,021,372</TD>
<TD WIDTH="148" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="136" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*)  최근 3년 반품율과 매출원가율을 고려하여 산정하였습니다.&cr;</SPAN>
<SPAN></SPAN>
</P>
<P>14. 관계기업&cr;&cr;(1) 보고기간말 현재 관계기업 투자의 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="652">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="334"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><당기말>  </TD>
<TD WIDTH="343" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">                                        (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="652" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="66"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="96"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="112"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">기업명</TD>

<TD ROWSPAN="2" WIDTH="75" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">
<P>소재지</P>
</TD>

<TD ROWSPAN="2" WIDTH="77" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">
<P>결산월</P>
</TD>

<TD ROWSPAN="2" WIDTH="105" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">
<P>주요 &cr;영업활동</P>
</TD>

<TD COLSPAN="2" WIDTH="232" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P>당기말</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P>소유지분율</P>
</TD>

<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">
<P>장부금액</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="163" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> (주)바스칸바이오제약&cr;(구.레고켐제약)</P>
</TD>

<TD WIDTH="75" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> 한국</P>
</TD>

<TD WIDTH="77" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P> 12월</P>
</TD>

<TD WIDTH="105" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">
<P>의약품 제조 </P>
</TD>

<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">
<P>32.52% </P>
</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,173,546</TD>
</TR>
</TBODY>
</TABLE>
<P>(*1) (주)바스칸바이오제약(구.레고켐제약)은 2019년 12월 31일 기준 당사의 지분이 68.52%로 종속기업이었으나, 당기 중 종속기업의 타 법인과의 합병 및 유상증자를 통해 당사의 지분이 32.52%로 하락하였습니다. 이에 지배력을 상실한 것으로 판단하여 종속기업에서 제외하고 관계기업으로 분류하였습니다.&cr;</P>
<P>(2) 당기말의 관계기업의 요약 재무정보와 경영성과는 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="723">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="405"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><당기말>  </TD>
<TD WIDTH="414" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">                                        (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="723" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="156"></COL>
<COL WIDTH="88"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="88"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="84"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">기업명</TD>
<TD WIDTH="97" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">자산</TD>
<TD WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">부채</TD>
<TD WIDTH="97" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">자본</TD>
<TD WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">매출</TD>
<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기순손익</TD>
<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">총포괄손익</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">(주)바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="97" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">25,234,756 </TD>
<TD WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,220,676 </TD>
<TD WIDTH="97" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">19,014,081 </TD>
<TD WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">19,765,507 </TD>
<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">(441,852)</TD>
<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">(467,931)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 상기 재무정보는 2020년 12월 31일을 기준으로 감사 받은 재무제표를 이용하였습니다. 또한, 관계기업의 요약재무정보는 당사와의 회계정책 차이조정 등을 반영한 후의 금액이며, 다만 내부거래는 제거하기 전의 금액입니다.</SPAN>
<SPAN> &cr;</SPAN>
</P>
<PGBRK></PGBRK>
<P>(3) 당기말의 관계기업에 대한 지분법 평가 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="884">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="566"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><당기말>  </TD>
<TD WIDTH="575" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">                                        (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="885" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="147"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="137"></COL>
<COL WIDTH="136"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="156" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">기업명</TD>
<TD ROWSPAN="2" WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">기초</TD>
<TD ROWSPAN="2" WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">대체</TD>
<TD COLSPAN="2" WIDTH="292" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기지분법평가</TD>
<TD ROWSPAN="2" WIDTH="145" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">당기말</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">지분법손익</TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">지분법자본변동</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="156" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">㈜바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">-</TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">4,437,160</TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1,744,867</TD>
<TD WIDTH="146" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">(8,481)</TD>
<TD WIDTH="145" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,173,546</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(4) 당기말의 관계기업의 재무정보금액을 관계기업에 대한 지분의 장부금액으로 조정한 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="898">

<COLGROUP>
<COL WIDTH="300"></COL>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="309" HEIGHT="30" VALIGN="MIDDLE"><당기말>  </TD>
<TD WIDTH="589" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">                                        (단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="900" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="153"></COL>
<COL WIDTH="139"></COL>
<COL WIDTH="139"></COL>
<COL WIDTH="139"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="138"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">기업명</TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기말 순자산</TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">지분율</TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">순자산 지분금액</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">주식선택권</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">장부금액</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">㈜바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">19,014,081 </TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">32.52%</TD>
<TD WIDTH="148" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,183,323 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">(860)</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">6,173,546 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN></SPAN>
<SPAN>15. 유형자산 </SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;(1) 보고기간 중 유형자산 변동내역은 다음과 같습니다. </SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="1041" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="286"></COL>
<COL WIDTH="737"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD ALIGN="RIGHT" WIDTH="746" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1045">

<COLGROUP>
<COL WIDTH="144"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="94"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="94"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="87"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="153" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 구 분 </TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 토지 </TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 건물 </TH>
<TH WIDTH="103" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 차량운반구 </TH>
<TH WIDTH="83" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 비 품 </TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 연구설비 </TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 시설장치 </TH>
<TH WIDTH="103" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 사용권자산 </TH>
<TH WIDTH="123" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 건설중인 자산 </TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 합 계 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> -당기 변동 </TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="103" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="83" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="103" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="123" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 기초 순장부금액 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">2,590,667</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">1,148,787</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">34,260</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">774,004</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">2,984,411</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">1,721,387</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">313,229</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">2,577,147</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">12,143,892</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 취득 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">291,371</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">709,401</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">33,419</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">621,753</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">1,826,758</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">3,482,703</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 감소 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">(520)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">(74,936)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(75,456)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 감가상각 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">(105,605)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(834,059)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(119,895)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">(429,914)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(1,489,473)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 기타(*) </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(2,590,667)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(1,148,787)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">(34,260)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">(536,573)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(728,709)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(1,405,020)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(6,444,016)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 당기말 순장부금액 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">422,677</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">2,131,044</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">229,891</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">430,132</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">4,403,905</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">7,617,650</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> - 당기말 현재 </TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="103" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="83" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="103" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="123" HEIGHT="30"></TD>
<TD VALIGN="MIDDLE" WIDTH="96" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 취득원가 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">895,806</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">6,537,182</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">778,313</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">824,973</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">5,270,905</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">14,307,179</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 감가상각누계액 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">(465,395)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(4,377,867)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(548,422)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">(394,841)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(5,786,525)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 정부보조금 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">(7,733)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(28,271)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">(867,000)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">(903,004)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="153" HEIGHT="30"> 당기말 순장부금액 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="83" HEIGHT="30">422,677</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">2,131,044</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">229,891</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="103" HEIGHT="30">430,132</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="123" HEIGHT="30">4,403,905</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="96" HEIGHT="30">7,617,650</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 기타의 금액은 당기중 종속회사에 대한 지배력 상실로 인해 장부에서 제거된 금액입니다. &cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="1046" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="286"></COL>
<COL WIDTH="742"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30" VALIGN="MIDDLE"><전기></TD>
<TD ALIGN="RIGHT" WIDTH="751" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1047">

<COLGROUP>
<COL WIDTH="125"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="93"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="88"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="92"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="134" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="102" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">토지</TH>
<TH WIDTH="102" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">건물</TH>
<TH WIDTH="102" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">차량운반구</TH>
<TH WIDTH="102" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비 품</TH>
<TH WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">연구설비</TH>
<TH WIDTH="97" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">시설장치</TH>
<TH WIDTH="98" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사용권자산</TH>
<TH WIDTH="108" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">건설중인 자산</TH>
<TH WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">기초 순장부금액</TD>
<TD WIDTH="102" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">2,590,667</TD>
<TD WIDTH="102" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">1,212,768</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">45,204</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">759,110</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,053,776</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,172,578</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,440,556</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,274,660</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">취득</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,550</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">292,274</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,837,982</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">222,820</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">798,268</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,136,591</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">4,296,484</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">감소</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(7,009)</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(19,640)</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(413)</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(36,360)</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(63,423)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">감가상각</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(63,981)</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(12,484)</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(257,740)</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(907,347)</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(673,597)</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(448,679)</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(2,363,828)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">당기말 순장부금액</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,590,667</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,148,787</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">34,261</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">774,004</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,984,411</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,721,387</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">313,229</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,577,147</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,143,892</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">- 당기말 현재</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">취득원가</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,590,667</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,559,253</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">60,478</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,706,067</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,056,568</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,056,063</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">761,907</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,577,147</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">21,368,150</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">감가상각누계액</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,410,466)</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(26,217)</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(932,064)</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(5,028,156)</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(1,334,676)</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(448,679)</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(9,180,257)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">정부보조금</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(44,001)</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(44,001)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="134" HEIGHT="30" VALIGN="MIDDLE">당기말 순장부금액</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,590,667</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,148,787</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">34,261</TD>
<TD WIDTH="102" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">774,004</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,984,411</TD>
<TD WIDTH="97" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,721,387</TD>
<TD WIDTH="98" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">313,229</TD>
<TD WIDTH="108" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,577,147</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,143,892</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(2) </SPAN>
<SPAN>당기</SPAN>
<SPAN>와 전기 감가상각비 전액은 영업비용에 포함되어 있습니다. </SPAN>
</P>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(3) 당기 중 적격자산인 유형자산에 대해 자본화된 차입원가는 46백만원 이며, 자본화가능차입원가를 산정하기 위해 사용된 자본화차입이자율은 4.85% 입니다. &cr;</SPAN>
</P>
<P>16. 리스&cr;&cr; (1) 사용권자산</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="630">

<COLGROUP>
<COL WIDTH="469"></COL>
<COL WIDTH="143"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="478" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="684" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="314"></COL>
<COL WIDTH="172"></COL>
<COL WIDTH="171"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="323" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기말</TH>
<TH WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" HEIGHT="30">부동산</TD>
<TD WIDTH="181" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">151,103</TD>
<TD WIDTH="180" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">164,197</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" HEIGHT="30">차량운반구</TD>
<TD WIDTH="181" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">279,029</TD>
<TD WIDTH="180" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">149,032</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합 계</TD>
<TD WIDTH="181" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">430,132</TD>
<TD WIDTH="180" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">313,229</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<P>한편, 당기와 전기에 인식된 사용권자산상각비가 포함된 항목은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="627">

<COLGROUP>
<COL WIDTH="618"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="627" HEIGHT="30" ALIGN="RIGHT">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="687" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="312"></COL>
<COL WIDTH="174"></COL>
<COL WIDTH="174"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="321" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계정명</TH>
<TH WIDTH="183" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="183" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="321" HEIGHT="30">판매비와관리비</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">429,914</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">448,679</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="321" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합 계</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">429,914</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">448,679</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(</SPAN>
<SPAN>2) 리스부채 </SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="630">

<COLGROUP>
<COL WIDTH="469"></COL>
<COL WIDTH="143"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="478" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="689" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="314"></COL>
<COL WIDTH="174"></COL>
<COL WIDTH="174"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="323" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="183" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기말</TH>
<TH WIDTH="183" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" HEIGHT="30">리스부채 - 유동</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">78,082</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">111,180</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" HEIGHT="30">리스부채 - 비유동</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">297,156</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">173,994</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="323" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합 계</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">375,238</TD>
<TD WIDTH="183" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">285,174</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>한편, 당기 리스부채에 대한 이자비용은 15,625천원이며 전액 차입원가 자본화되었습니다. 리스부채 상환 등을 통해서 당기에 지출된 총 현금유출액은 </SPAN>
<SPAN>412,395천원</SPAN>
<SPAN>(전기: 436,813천원)입니다. </SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>(3) 당기말 현재 리스계약에 의해 향후 지급할 최소리스료 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="992">

<COLGROUP>
<COL WIDTH="497"></COL>
<COL WIDTH="477"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="506" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD WIDTH="486" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="993">

<COLGROUP>
<COL WIDTH="133"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="117"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1년이하</TH>
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 1년 초과 ~ 2년 이하</TH>
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 2년 초과 ~ 3년 이하</TH>
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 3년 초과 ~ 4년 이하</TH>
<TH WIDTH="152" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 4년 초과 ~ 5년 이하</TH>
<TH WIDTH="126" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 5년 초과</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="142" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">최소리스료</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">206,833 </TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">78,660 </TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">64,273 </TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">42,112 </TD>
<TD WIDTH="152" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,432 </TD>
<TD WIDTH="126" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">-</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;17. 무형자산 &cr;</SPAN>
</P>
<P>(1) 보고기간말 현재 무형자산의 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="599" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="590"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="599" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="720">

<COLGROUP>
<COL WIDTH="231"></COL>
<COL WIDTH="231"></COL>
<COL WIDTH="231"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="240" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="240" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기말</TH>
<TH WIDTH="240" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="240" HEIGHT="30"> 산업재산권 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">808,697 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">671,232</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="240" HEIGHT="30"> 기타의 무형자산</TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">6,800,219 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">8,160,264</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="240" HEIGHT="30"> 회원권 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">540,993 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">100,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="240" HEIGHT="30" VALIGN="MIDDLE"> 소프트웨어 외 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">56,961</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="240" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">8,149,909 </TD>
<TD ALIGN="RIGHT" WIDTH="240" HEIGHT="30">8,988,457</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>(2) </SPAN>
<SPAN>기중 무형자산의 변동내역은 다음과 같습니다.</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="720" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="288"></COL>
<COL WIDTH="414"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="297" HEIGHT="30" VALIGN="MIDDLE"><당기>                                         </TD>
<TD ALIGN="RIGHT" WIDTH="423" HEIGHT="30" VALIGN="MIDDLE">  (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="719">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="104"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="150" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">구 분</TH>
<TH WIDTH="114" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">산업재산권</TH>
<TH WIDTH="114" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">고객관계</TH>
<TH WIDTH="109" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">회원권</TH>
<TH WIDTH="119" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">소프트웨어 외</TH>
<TH WIDTH="113" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">합  계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">기초순장부금액</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">671,233</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">8,160,263 </TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">100,000 </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">56,961 </TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">8,988,457 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">대체증가</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">267,894</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">440,993 </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">39,105 </TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">747,994 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">감소</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">(21,182)</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">(21,182)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">상각</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">(126,983)</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">(1,360,044)</TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">(17,923)</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">(1,504,951)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">기타(*1)</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">(3,447)</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">(56,961)</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">(60,408)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">기말 순장부금액</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">808,697</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">6,800,219 </TD>
<TD ALIGN="RIGHT" WIDTH="109" HEIGHT="30">540,993 </TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">8,149,909 </TD>
</TR>
</TBODY>
</TABLE>
<P>(*1) 당기 중 종속회사에 대한 지배력 상실로 종속회사 유형자산 장부금액이 장부에서 제거되었습니다.&cr;</P>

<TABLE ACLASS="NORMAL" WIDTH="716" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="288"></COL>
<COL WIDTH="410"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="297" HEIGHT="30" VALIGN="MIDDLE"><전기>                                         </TD>
<TD ALIGN="RIGHT" WIDTH="419" HEIGHT="30" VALIGN="MIDDLE">  (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="717">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="105"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="98"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="150" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">구 분</TH>
<TH WIDTH="114" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">산업재산권</TH>
<TH WIDTH="114" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">고객관계(*1)</TH>
<TH WIDTH="113" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">회원권</TH>
<TH WIDTH="119" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">기타의 무형자산</TH>
<TH WIDTH="107" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">합  계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">기초 순장부금액</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">589,269</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">9,520,307</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="107" HEIGHT="30">10,109,576</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">대체</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">186,167</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">100,000</TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">56,961</TD>
<TD ALIGN="RIGHT" WIDTH="107" HEIGHT="30">343,128</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">상각</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">(104,203)</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">(1,360,044)</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="107" HEIGHT="30">(1,464,247)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">손상차손</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">-</TD>
<TD ALIGN="RIGHT" WIDTH="107" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" HEIGHT="30">기말 순장부금액</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">671,232</TD>
<TD ALIGN="RIGHT" WIDTH="114" HEIGHT="30">8,160,263</TD>
<TD ALIGN="RIGHT" WIDTH="113" HEIGHT="30">100,000</TD>
<TD ALIGN="RIGHT" WIDTH="119" HEIGHT="30">56,961</TD>
<TD ALIGN="RIGHT" WIDTH="107" HEIGHT="30">8,988,456</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1)  2015년 12월 21일 주식회사 칸메드를 흡수합병함에 따라 발생하였으며, 영업권은 전기 이전에 전액 손상차손으로 처리하여 당기말 현재는 없습니다.&cr;</SPAN>
<SPAN>&cr;(3) 무형자산상각비의 포괄손익계산서의 계정과목별 내용은 다음과 같습니다.</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="602" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="288"></COL>
<COL WIDTH="296"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="297" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="305" HEIGHT="30" VALIGN="MIDDLE">  (단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="600">

<COLGROUP>
<COL WIDTH="190"></COL>
<COL WIDTH="189"></COL>
<COL WIDTH="194"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="199" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="198" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="203" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="199" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">판매비와관리비</TD>
<TD ALIGN="RIGHT" WIDTH="198" HEIGHT="30">1,504,951</TD>
<TD ALIGN="RIGHT" WIDTH="203" HEIGHT="30">1,464,573</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(4) 비용으로 인식한 연구와 개발 지출의 총액은 </SPAN>
<SPAN>54,204</SPAN>
<SPAN>백만원(전기: 16,711백만원)입니다. </SPAN>
</P>

<P>
<SPAN>&cr;18. 정부보조금&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>(1) 당사가 정부기관 등과 체결한 국책연구과제 및 이와 관련하여 수령한 정부보조금의 변동내역은 다음과 같습니다.</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1110">

<COLGROUP>
<COL WIDTH="473"></COL>
<COL WIDTH="619"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="482" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD WIDTH="628" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1116">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="335"></COL>
<COL WIDTH="158"></COL>
<COL WIDTH="65"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="63"></COL>
<COL WIDTH="68"></COL>
<COL WIDTH="56"></COL>
<COL WIDTH="60"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계정과목</TH>
<TH WIDTH="344" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">과  제 명</TH>
<TH WIDTH="167" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">시행기간</TH>
<TH WIDTH="74" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기초</TH>
<TH WIDTH="86" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수령액</TH>
<TH WIDTH="84" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지출액</TH>
<TH WIDTH="72" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">감면액</TH>
<TH WIDTH="77" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-10">유동성대체</TH>
<TH WIDTH="65" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">반납액</TH>
<TH WIDTH="69" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="78" HEIGHT="126" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">미지급금</TD>
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE"> 신규 항암치료제로써 DLK1을 표적하는 DLK1-ADC의 비임상 연구</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE"> 2017.09.01-2018.02.28 </TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">235,800 </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">235,800 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">삼중음성유방암 치료용 ADC 후보 물질의 GLP 독성시험 시료 생산을 위한 MCB 구축 및 ADC 제조 공정 확립</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2019-07-01-2019-12-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">140,000 </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">140,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="511" HEIGHT="28" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">375,800 </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">375,800 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="78" HEIGHT="371" ROWSPAN="11" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-10">장기&cr;미지급금</SPAN>
</TD>
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">그람음성균에효과적인새로운 항생제개발(바이오)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2009.05.01-2012.05.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">223,494 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">223,494 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">그람음성균에 효과적인 새로운 항생제의 개발(범부처)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2013.02.12-2014.06.11</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">49,598 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">49,598 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">신규경구용혈액응고인자 XIa억제제개발(바이오)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2011.06.01-2014.05.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">118,000 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">118,000 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">국제공동기술개발사업(한불과제)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2015.12.01-2017.11.30</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">98,894 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">98,894 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">새로운 옥사졸리디논계 항생제의 항결핵제 임상2상 개발</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017.04.10-2019.12.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">209,000 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">62,700 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">146,300 </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">EGFRVIII를 표적으로하는 ADC 후보 발굴</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017.06.30-2019.01.29</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">147,500 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">147,500 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">신규 항암치료제로써 DLK1을 표적하는 DLK1-ADC의 비임상 연구</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2017.09.01-2018.02.28</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">235,800 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">(235,800)</TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">사업화연계기술개발사업(BI연계형)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017.06.01-2018.05.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">36,000 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">36,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">삼중음성유방암 치료용 ADC 후보 물질의 GLP 독성시험 시료 생산을 위한 MCB 구축 및 ADC 제조 공정 확립</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2019-07-01-2019-12-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">140,000 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">(140,000)</TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">기존 PBD-ADC 기술 대비 항암 치료제로서 치료지수 2배 이상 확보 가능한 기술</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2019-06-01-2020-05-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">8,938 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">48,142 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">57,080 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="511" HEIGHT="28" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,267,224 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">48,142 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">552,686 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">(375,800)</TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">146,300 </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">240,580 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="78" HEIGHT="574" ROWSPAN="16" ALIGN="CENTER" VALIGN="MIDDLE">선수수익</TD>
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">GPCR을 타깃으로 하는 항암제로써 항체절편과 약물 접합체 개발 후보 발굴(한불과제)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2015.12.01-2017.11.30</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">신약타겟검증사업(TM4SF5)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2016.07.01-2018.03.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">BCMA를 표적으로 하는 다발성 골수종 치료용 항체약물접합체 개발</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2016.09.01-2018.01.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">새로운 옥사졸리디논계 항생제의 항결핵제 임상2상 개발(보건복지부371)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2017.04.10-2018.12.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">13,111 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">9,383 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">3,728 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">EGFRVIII를 표적으로하는 ADC 후보 발굴</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017.06.30-2019.01.29</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">179,638 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">179,638 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">신규 항암치료제로써 DLK1을 표적하는 DLK1-ADC의 비임상 연구</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2017.09.01-2018.12.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">545,193 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">545,193 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">ADC독성평가(ROR1)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017.06.01-2019.05.31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">삼중음성유방암 치료용 ADC 후보 물질의 GLP 독성시험 시료 생산 위한 MCB 구축 및 ADC 제조 공정 확립</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2019-07-01-2019-12-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">856,948 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">607,924 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">249,024 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="49" VALIGN="MIDDLE">기존 PBD-ADC 기술 대비 항암 치료제로서 치료지수 2배 이상 확보 가능한 기술</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE">2019-06-01-2020-05-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">190,247 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">190,247 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">질병관리본부(항생제)</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2019-02-21-2019-12-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">49,370 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">49,370 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE">신진석박사 연구인력 채용사업</TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE">2017-06-01-2020-05-31</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">31,043 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">47,500 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">46,251 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">32,292 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE"> 신진여성연구원 산업현장진출 지원사업 </TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE"> 2020-08-01-2021-01-31 </TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">10,000 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">8,333 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,667 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE"> 고용유지 상생협약 특별재정 지원사업 </TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE"> 2020-07-01-2020-12-31 </TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">12,000 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">12,000 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE"> 대전시지방이전투자유치보조금 </TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE"> 2020-12-15-2023-12-14 </TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,474,000 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">867,000 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">607,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="344" HEIGHT="28" VALIGN="MIDDLE"> 더존 그룹웨어 백업솔루션 지원사업 </TD>
<TD USERMARK="F-10" WIDTH="167" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE"> 2020-12-10-2021-12-09 </TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">8,000 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">8,000 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="511" HEIGHT="28" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">소계</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,625,933 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,791,117 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">2,523,339 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">893,711 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-10" WIDTH="589" HEIGHT="28" COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE">합계</TD>
<TD USERMARK="F-10" WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">2,893,157 </TD>
<TD USERMARK="F-10" WIDTH="86" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,839,259 </TD>
<TD USERMARK="F-10" WIDTH="84" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">2,523,339 </TD>
<TD USERMARK="F-10" WIDTH="72" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">552,686 </TD>
<TD USERMARK="F-10" WIDTH="77" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">- </TD>
<TD USERMARK="F-10" WIDTH="65" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">146,300 </TD>
<TD USERMARK="F-10" WIDTH="69" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE">1,510,09 </TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1062">

<COLGROUP>
<COL WIDTH="473"></COL>
<COL WIDTH="571"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="482" HEIGHT="30" VALIGN="MIDDLE"><전기></TD>
<TD WIDTH="580" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1062">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="339"></COL>
<COL WIDTH="154"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="78"></COL>
<COL WIDTH="65"></COL>
<COL WIDTH="65"></COL>
<COL WIDTH="71"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계정과목</TH>
<TH WIDTH="348" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">과  제 명</TH>
<TH WIDTH="163" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">시행기간</TH>
<TH WIDTH="76" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기초</TH>
<TH WIDTH="82" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수령액</TH>
<TH WIDTH="87" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지출액</TH>
<TH WIDTH="74" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">감면액</TH>
<TH WIDTH="74" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">반납액</TH>
<TH WIDTH="80" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" HEIGHT="371" ROWSPAN="11" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">장기&cr;미지급금</TD>
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">그람음성균에효과적인새로운 항생제개발(바이오)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2009.05.01-2012.05.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">223,494</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">223,494</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">그람음성균에 효과적인 새로운 항생제의 개발(범부처)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2013.02.12-2014.06.11</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">49,598</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">49,598</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">신규경구용혈액응고인자 XIa억제제개발(바이오)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2011.06.01-2014.05.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">118,000</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">118,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">국제공동기술개발사업(한불과제)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2015.12.01-2017.11.30</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">98,894</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">98,894</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">새로운 옥사졸리디논계 항생제의 항결핵제 임상2상 개발</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.04.10-2019.12.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">209,000</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">209,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">EGFRVIII를 표적으로하는 ADC 후보 발굴</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.06.30-2019.01.29</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">100,000</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">47,500</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">147,500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">신규 항암치료제로써 DLK1을 표적하는 DLK1-ADC의 비임상 연구</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.09.01-2018.02.28</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">135,800</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">100,000</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">235,800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">사업화연계기술개발사업(BI연계형)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.06.01-2018.05.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">36,000</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">36,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">삼중음성유방암 치료용 ADC 후보 물질의 GLP 독성시험 시료 생산을 위한 MCB 구축 및 ADC 제조 공정 확립</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2019-07-01-2019-12-31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">140,000</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">140,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">기존 PBD-ADC 기술 대비 항암 치료제로서 치료지수 2배 이상 확보 가능한 기술</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2019-06-01-2020-05-31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">8,938</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">8,938</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="511" HEIGHT="28" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">소계</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">970,786</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">296,438</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">　</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">　</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">　</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,267,224</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="78" HEIGHT="462" ROWSPAN="12" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">선수수익</TD>
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">GPCR을 타깃으로 하는 항암제로써 항체절편과 약물 접합체 개발 후보 발굴(한불과제)</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2015.12.01-2017.11.30</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">신약타겟검증사업(TM4SF5)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2016.07.01-2018.03.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">BCMA를 표적으로 하는 다발성 골수종 치료용 항체약물접합체 개발</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2016.09.01-2018.01.31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">새로운 옥사졸리디논계 항생제의 항결핵제 임상2상 개발(보건복지부371)</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.04.10-2018.12.31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">544,165</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">531,054</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">13,111</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">EGFRVIII를 표적으로하는 ADC 후보 발굴</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.06.30-2019.01.29</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">115,855</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">427,500</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">363,716</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">179,639</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">신규 항암치료제로써 DLK1을 표적하는 DLK1-ADC의 비임상 연구</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.09.01-2018.12.31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">5,536</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">900,000</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">360,343</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">545,193</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">ADC독성평가(ROR1)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017.06.01-2019.05.31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">100</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">100</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">삼중음성유방암 치료용 ADC 후보 물질의 GLP 독성시험 시료 생산 위한 MCB 구축 및 ADC 제조 공정 확립</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2019-07-01-2019-12-31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,260,000</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">403,052</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">856,948</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="49" VALIGN="MIDDLE" USERMARK="F-10">기존 PBD-ADC 기술 대비 항암 치료제로서 치료지수 2배 이상 확보 가능한 기술</TD>
<TD WIDTH="163" HEIGHT="49" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2019-06-01-2020-05-31</TD>
<TD WIDTH="76" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">35,754</TD>
<TD WIDTH="87" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">35,754</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="49" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">질병관리본부(항생제)</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2019-02-21-2019-12-31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">22,727</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">22,727</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="348" HEIGHT="28" VALIGN="MIDDLE" USERMARK="F-10">신진석박사 연구인력 채용사업</TD>
<TD WIDTH="163" HEIGHT="28" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">2017-06-01-2020-05-31</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">24,139</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">47,500</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">26,874</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">13,722</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">31,043</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="511" HEIGHT="28" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">소계</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">689,795</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">2,693,481</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,743,520</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">13,822</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,625,934</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="589" HEIGHT="28" COLSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-10">합계</TD>
<TD WIDTH="76" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,660,581</TD>
<TD WIDTH="82" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">2,989,919</TD>
<TD WIDTH="87" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">1,743,520</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">-</TD>
<TD WIDTH="74" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">13,822</TD>
<TD WIDTH="80" HEIGHT="28" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK="F-10">2,893,159</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(2) 상기 국책과제와 관련하여 수령한 정부보조금의 지출내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="593" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="584"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="593" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="642">

<COLGROUP>
<COL WIDTH="269"></COL>
<COL WIDTH="173"></COL>
<COL WIDTH="173"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="278" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="182" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="182" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="278" HEIGHT="30">비용상계</TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">1,648,339 </TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">1,743,520</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="278" HEIGHT="30">유형자산의 증가</TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">875,000 </TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="278" HEIGHT="30">반납액</TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">146,300 </TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">13,822</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="278" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합 계</TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">2,669,639 </TD>
<TD WIDTH="182" HEIGHT="30" ALIGN="RIGHT">1,757,342</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(3)</SPAN>
<SPAN> </SPAN>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 정부보조금의 미사용잔액의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="591" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="582"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="591" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="645">

<COLGROUP>
<COL WIDTH="270"></COL>
<COL WIDTH="174"></COL>
<COL WIDTH="174"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="279" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="183" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="183" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30"> 선수수익 </TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">893,711</TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">1,625,934</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30"> 장기미지급금(*1) </TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">240,580</TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">1,267,225</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30"> 미지급금 </TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">375,800</TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 합 계 </TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">1,510,091</TD>
<TD WIDTH="183" HEIGHT="30" ALIGN="RIGHT">2,893,159</TD>
</TR>
</TBODY>
</TABLE>
<P>(*1) 상환의무가 있는 정부보조금의 경우 장기미지급금으로 계상하고 있습니다.</P>
<P></P>
<P>(4) 보고기간 중 정부보조금으로 취득한 연구설비 등(주석15 참조)과 관련하여 계상된 감가상각비와 상계된 금액은 다음과 같습니다.                                  (단위:천원)</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="648">

<COLGROUP>
<COL WIDTH="207"></COL>
<COL WIDTH="207"></COL>
<COL WIDTH="207"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="216" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="216" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="216" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" HEIGHT="30" ALIGN="CENTER">비품</TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">267</TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" HEIGHT="30" ALIGN="CENTER">연구설비</TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">15,730</TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">15,730</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" HEIGHT="30" ALIGN="CENTER">합 계 </TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">15,997</TD>
<TD WIDTH="216" HEIGHT="30" ALIGN="RIGHT">15,730</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(5) 보고기간 중 사용한 정부보조금 중 자산의 차감항목으로 잔존하고 있는 정부보조금은 다음과 같습니다.                                                                        (단위:천원)</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="645">

<COLGROUP>
<COL WIDTH="206"></COL>
<COL WIDTH="206"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="215" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="215" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="215" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER"> 비품 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">7,733</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER"> 연구설비 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">28,271</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">44,001</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER"> 건설중인자산 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">867,000</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER"> 특허권 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">21,554</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">24,095</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 장기선급금 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">56,102</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">57,322</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="215" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 합 계 </TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">980,660</TD>
<TD WIDTH="215" HEIGHT="30" ALIGN="RIGHT">125,419</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>19.</SPAN>
<SPAN> 차입금&cr;&cr;</SPAN>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 당사의 장기차입금의 내역은 다음과 같습니다.</SPAN>
<SPAN>                                                                                                                                    (단위: 천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="697">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="108"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="171" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="2">구     분</TH>
<TH WIDTH="78" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">차입처</TH>
<TH WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">최장만기일</TH>
<TH WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">연이자율</TH>
<TH WIDTH="118" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="117" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2022-12-12</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">0.844%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,500,000</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,500,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2022-12-12</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">0.714%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">400,000</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">400,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2022-12-12</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">0.951%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">800,000</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2023-11-13</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">0.540%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">352,000</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2023-11-13</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">1.350%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">500</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="93" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">원화대출</TD>
<TD WIDTH="78" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">하나은행</TD>
<TD WIDTH="112" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">2023-11-13</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">0.540%</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">559,500</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="462" HEIGHT="30" VALIGN="MIDDLE" COLSPAN="5" ALIGN="CENTER"> 합  계</TD>
<TD WIDTH="118" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,612,000</TD>
<TD WIDTH="117" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,900,000</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>상기의 차입금과 관련하여 회사의 일부 </SPAN>
<SPAN>유형자산  및 정기예금이 담보로 제공되어 있으며, 대표이사로부터 지급보증을 제공</SPAN>
<SPAN>받고 있습니다</SPAN>
<SPAN>(주석 8, 37 참조).&cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>20. 기타금융부채 &cr;</SPAN>
</P>

<P>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 당사의 기타금융부채의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="595" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="586"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="595" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="592">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="187"></COL>
<COL WIDTH="187"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="200" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="196" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="196" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">유동:</TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">　</TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">  미지급금</TD>

<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">
<SPAN>5,733,881</SPAN>
</TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">4,922,680</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">  미지급비용</TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">221,964 </TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">364,322</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">  환불부채</TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">181,650 </TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">275,543</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="200" HEIGHT="30">소 계</TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">6,137,495 </TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">5,562,545</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">비유동:</TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">　</TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="200" HEIGHT="30">  장기미지급금</TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">240,580 </TD>
<TD WIDTH="196" HEIGHT="30" ALIGN="RIGHT">1,267,226</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="200" HEIGHT="30">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">6,378,075 </TD>
<TD ALIGN="RIGHT" WIDTH="196" HEIGHT="30">6,829,771</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;21.</SPAN>
<SPAN> 기타부채&cr;&cr;보</SPAN>
<SPAN>고기간말 현재 당사의 기타부채의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="594" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="585"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="594" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="592">

<COLGROUP>
<COL WIDTH="189"></COL>
<COL WIDTH="188"></COL>
<COL WIDTH="188"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="198" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="197" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="197" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30"> 예수금 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">306,464 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">212,443</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30"> 선수금 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">38,749 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">6,875</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30"> 선수수익 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">893,711 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">1,625,935</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30"> 과제예수금 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">- </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">213,184</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE"> 합 계 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">1,238,924 </TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">2,058,437</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN>22</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>. </SPAN>
<SPAN>확정급여부채&cr;</SPAN>
</P>

<P>
<SPAN>(1) </SPAN>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 </SPAN>
<SPAN>순확정급여부채</SPAN>
<SPAN> 산정내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="592" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="583"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="592" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="589">

<COLGROUP>
<COL WIDTH="286"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="138"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="295" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="147" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="147" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30">확정급여채무의 현재가치</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">4,766,196</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">3,981,633 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30">사외적립자산의 공정가치</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">(392,210)</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">(59,464)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">재무상태표상 부채</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">4,373,986</TD>
<TD ALIGN="RIGHT" WIDTH="147" HEIGHT="30">3,922,169 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<PGBRK></PGBRK>
<P>&cr;(2) 보고기간 중 확정급여채무의 변동내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="589" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="589" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="587">

<COLGROUP>
<COL WIDTH="357"></COL>
<COL WIDTH="102"></COL>
<COL WIDTH="101"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="366" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="111" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="110" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">기초금액</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">3,981,633</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">3,120,150</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">당기근무원가</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">690,151</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">719,201</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">이자비용</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">79,786</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">74,015</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">재측정요소</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">425,687</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">980,629</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">- 인구통계적가정의 변동으로 인한 보험수리적 손익</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">-　</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">60,637</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">- 재무적가정의 변동으로 인한 보험수리적 손익</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">(14,831)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">414,484</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">- 경험적조정으로 인한 보험수리적 손익</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">440,518</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">505,508</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">제도에서의 지급</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">(155,897)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">(912,363)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">기타(*)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">(255,163)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="366" HEIGHT="30">보고기간말 금액</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="111" HEIGHT="30">4,766,196</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="110" HEIGHT="30">3,981,633</TD>
</TR>
</TBODY>
</TABLE>
<P>(*) 당기 중 종속회사에 대한 지배력 상실로 종속회사 확정급여부채 장부금액이 장부에서 제거되었습니다.&cr;&cr;(3) 보고기간 중 사외적립자산의 변동내역은 다음과 같습니다.</P>

<TABLE WIDTH="624" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="615"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="624" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="623" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="254"></COL>
<COL WIDTH="171"></COL>
<COL WIDTH="171"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="263" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">기초</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">59,464</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">58,652</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">회사부담금</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">392,169</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">사외적립자산의 기대수익</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">1,124</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">1,392</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">사외적립자산에서 지급된 퇴직급여</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">(51,610)</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">재측정요소</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">(1,480)</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">(580)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">기타 (*)</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">(7,457)</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="263" HEIGHT="30">기말</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">392,210</TD>
<TD WIDTH="180" ALIGN="RIGHT" HEIGHT="30">59,464</TD>
</TR>
</TBODY>
</TABLE>
<P>(*) 당기 중 종속회사에 대한 지배력 상실로 종속회사 사외적립자산 장부금액이 장부에서 제거되었습니다.&cr;&cr;(4)  포괄손익계산서에 손익항목으로 반영된 금액은 다음과 같습니다</P>

<TABLE ACLASS="NORMAL" WIDTH="589" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="589" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="629">

<COLGROUP>
<COL WIDTH="270"></COL>
<COL WIDTH="166"></COL>
<COL WIDTH="166"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="279" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="175" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="175" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30">당기근무원가</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">690,151</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">719,201</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30">순이자원가</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">78,662</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">74,015</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="279" HEIGHT="30" VALIGN="MIDDLE">종업원급여에 포함된 총 비용(*) </TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">768,813</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">793,216</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) </SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>종업원급여 전액은 </SPAN>
<SPAN>영업비용에 포함되어 있습니다.</SPAN>
</P>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(5) 보고기간말 현재 보험수리적평가를 위하여 사용된 주요 추정은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="630">

<COLGROUP>
<COL WIDTH="272"></COL>
<COL WIDTH="166"></COL>
<COL WIDTH="165"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="281" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="175" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="174" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="281" HEIGHT="30">할인율</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">2.36%</TD>
<TD WIDTH="174" HEIGHT="30" ALIGN="RIGHT">2.32%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="281" HEIGHT="30">미래임금상승률</TD>
<TD WIDTH="175" HEIGHT="30" ALIGN="RIGHT">5.26%</TD>
<TD WIDTH="174" HEIGHT="30" ALIGN="RIGHT">5.26%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(</SPAN>
<SPAN>6) 보고기간중 주요 보험수리적 가정에 대한 민감도 분석 결과는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="589">

<COLGROUP>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="589" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="627">

<COLGROUP>
<COL WIDTH="286"></COL>
<COL WIDTH="157"></COL>
<COL WIDTH="157"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="295" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2" VALIGN="MIDDLE">구 분</TH>
<TH WIDTH="332" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="2">확정급여채무에 대한 영향</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="166" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1% 증가</TH>
<TH WIDTH="166" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">1% 감소</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30">할인율</TD>
<TD ALIGN="RIGHT" WIDTH="166" HEIGHT="30">4,477,000</TD>
<TD ALIGN="RIGHT" WIDTH="166" HEIGHT="30">5,104,874</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="295" HEIGHT="30">임금상승율</TD>
<TD ALIGN="RIGHT" WIDTH="166" HEIGHT="30">5,091,827</TD>
<TD ALIGN="RIGHT" WIDTH="166" HEIGHT="30">4,481,606</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>23. 자본금 &cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>당사가 발행할 주식의  총수는 보통주 50,000,000주(종류주식 10,000,000주 포함), 1주의 금액은 500원입니다. &cr;&cr;당사의 정관에 의하면 이익배당 및 주식의 상환에 관한 종류주식과 이익배당 및주식의 전환에 관한 종류주식을 발행할 수 있으며, 기간 만료시에 보통주식으로 전환되며, 발행가 기준으로 최소 연 0% 이상(이사회에서 우선배당율 정함)의 금전배당을 받을 수 있는 누적적 참가적 의결권 기명우선주식을 10,000,000주까지 발행할 수 있습니다. 종류주식의 주주는 종류주식 1주당 의결권 한 표를 갖습니다. &cr;</SPAN>
</P>

<P>
<SPAN>(1) </SPAN>
<SPAN>보</SPAN>
<SPAN>고기간말 현재 자본금의 구성요소는 다음과 같습니다.                   (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="629">

<COLGROUP>
<COL WIDTH="201"></COL>
<COL WIDTH="201"></COL>
<COL WIDTH="200"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="210" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="210" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="209" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="210" HEIGHT="30">보통주 자본금</TD>
<TD ALIGN="RIGHT" WIDTH="210" HEIGHT="30">11,841,903</TD>
<TD ALIGN="RIGHT" WIDTH="209" HEIGHT="30">5,360,970</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="210" HEIGHT="30">우선주 자본금</TD>
<TD ALIGN="RIGHT" WIDTH="210" HEIGHT="30">211,268</TD>
<TD ALIGN="RIGHT" WIDTH="209" HEIGHT="30">643,035</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="210" HEIGHT="30">합계</TD>
<TD ALIGN="RIGHT" WIDTH="210" HEIGHT="30">12,053,171</TD>
<TD ALIGN="RIGHT" WIDTH="209" HEIGHT="30">6,004,005</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(2</SPAN>
<SPAN>) 보고기간 중 유통주식수 및 납입자본의 변동은 다음과 같습니다.        (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="659">

<COLGROUP>
<COL WIDTH="145"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="154" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">구 분</TH>
<TH WIDTH="101" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">주식수&cr;(단위:주)</TH>
<TH WIDTH="101" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">보통주&cr;자본금</TH>
<TH WIDTH="101" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">우선주&cr;자본금</TH>
<TH WIDTH="101" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">주식발행&cr;초과금</TH>
<TH WIDTH="101" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="53">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">2019년 01월 01일</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,998,329</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,294,941</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">704,224</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">181,500,410</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">187,499,575</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">주식매수선택권 행사</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,680</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,840</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">346,746</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">351,586</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">우선주의 보통주전환</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">61,189</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(61,189)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(633)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(633)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">2019년 12월 31일</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,008,009</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,360,970</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">643,035</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">181,846,523</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">187,850,528</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">주식매수선택권 행사</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">45,162</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">22,581</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,793,029</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,815,610</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="60" ROWSPAN="2">우선주 보통주 전환</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,074,802</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">537,401</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(13,395)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">524,006</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,074,802)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(537,401)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(537,401)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">무상증자(*)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,053,171</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,920,951</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">105,634</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,069,799)</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(43,214)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="154" VALIGN="MIDDLE" HEIGHT="30">2020년 12월 31일</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">24,106,342</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,841,903</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">211,268</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">177,556,358</TD>
<TD WIDTH="101" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">189,609,529</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 2020년 6월 1일 무상증자를 결정하였고, 2020년 6월 17일 현재 주주명부에 등재된 주주에 대하여 신주를 배정하였으며 신주 배정비율은 1:1 입니다.&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>(3) 전환우선주 발행내역</SPAN>
</P>

<TABLE BORDER="1" WIDTH="588" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="185"></COL>
<COL WIDTH="385"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구  분 </TH>
<TH WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제3자배정 전환우선주(*2)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">우선주 발행주식수</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1,408,447주</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">보통주 전환 주식수</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1,197,179주</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">현재 잔액 주식수</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">211,268주 ( 신주배정비율 1:1 무상증자 후 422,536주)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">발행금액</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">주당 42,600원 ( 무상증자 후 21,300원)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">발행일</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2018년 11월 23일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">만기(*1)</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">5년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">배당금에 관한 사항 </TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항 없음.</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">전환에 관한 사항</TD>
<TD WIDTH="394" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">우선주 1주당 보통주 1주</TD>
</TR>
</TBODY>
</TABLE>
<P>(*1) 본건 우선주의 주주는 본건 우선주의 발행일 이후 1년이 경과한 날로부터 전환권 존속기간 전일까지 본건 우선주의 전부 또는 만주 단위 이상에 한해 분할하여 보통주로 전환할 수 있습니다.&cr;(*2) 당사는 금융감독원 질의회신 "회제이-00094"에 의하여 상기 전환우선주를 자본으로 인식하였습니다.</P>

<P>
<SPAN></SPAN>
<SPAN>(*3) 당사는 전환우선주 교부 후 2년이되는 날로부터 1년간 인수회사가 보유한 우선주 총수의 15%까지 당사가 지정하는 제3자에게 우선주 발행총액에 발행일로부터 연복리 3%를 가산한 금액으로 매도하여 줄 것을 청구할 수 있으며, 당기 중 동 권리에 따라 당사의 임직원 등에게 매도하여 줄 것을 청구하였습니</SPAN>
<SPAN>다. 이와 관련하여 당기중파생상품평가이익 20,045백만원과 주식보상비용 19,808백만원</SPAN>
<SPAN> 및 지급수수료 237백만원을</SPAN>
<SPAN> 인식하였습니다.&cr;&cr;</SPAN>
<SPAN>24. 자본잉여금 &cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 자본잉여금 구성요소는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="596" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="587"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="596" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="594">

<COLGROUP>
<COL WIDTH="189"></COL>
<COL WIDTH="189"></COL>
<COL WIDTH="189"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="198" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="198" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="198" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30">주식발행초과금</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">177,556,358</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">181,846,523</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30">기타자본잉여금</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">3,333,501</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">3,333,501</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합 계</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">180,889,859</TD>
<TD WIDTH="198" HEIGHT="30" ALIGN="RIGHT">185,180,024</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;25. 기타자본구성요소&cr;&cr;</SPAN>
<SPAN>보</SPAN>
<SPAN>고</SPAN>
<SPAN>기간말 현재 기타자본의 구성요소는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="594" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="585"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="594" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="593">

<COLGROUP>
<COL WIDTH="189"></COL>
<COL WIDTH="189"></COL>
<COL WIDTH="188"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="198" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="198" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="197" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="198" HEIGHT="30" ALIGN="CENTER">주식매수선택권</TD>
<TD ALIGN="RIGHT" WIDTH="198" HEIGHT="30">2,245,694</TD>
<TD ALIGN="RIGHT" WIDTH="197" HEIGHT="30">1,471,713</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>26. 주식매수선택권 &cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(1) 당사는 주주총회 결의에 의거 당사의 임직원에게 주식선택권을 부여하였는 바, 주요사항은 다음과 같습니다.&cr;&cr;ㆍ 주식선택권으로 발행한 주식의 종류 : 기명식 보통주식&cr;ㆍ 부여방법: 보통주 신주발행교부&cr;ㆍ 가득조건 및 행사가능시점: 부여일 이후 주주총회 결의일로부</SPAN>
<SPAN>터 2년 이상 재임하고 부여일로부터 3년이 경과한 날로부터 5년내에 행사가능함.&cr;</SPAN>
<SPAN>&cr;(2) 주식선택권의 수량과 가중평균행사가격의 변동은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="626">

<COLGROUP>
<COL WIDTH="89"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="123"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구 분</TH>
<TH COLSPAN="2" WIDTH="264" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">주식매수선택권 수량(단위: 주)</TH>
<TH COLSPAN="2" WIDTH="264" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">가중평균행사가격(단위: 원)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="132" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="132" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30">기초 잔여주</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">463,440 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">185,470</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,214 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">48,295</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30">부 여</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">127,350 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">107,500</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,579 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">48,371</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30">행 사</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(90,324)</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(9,680)</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,325 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">27,450</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30">소 멸</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(4,960)</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(51,570)</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,755 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">60,751</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="98" VALIGN="MIDDLE" HEIGHT="30">기말 잔여주</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">495,506 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">231,720</TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,102 </TD>
<TD WIDTH="132" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,428</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;보고기간말 현재 유효한 주식선택권의 만기와 행사가격은 아래와 같습니다.</P>

<TABLE BORDER="1" WIDTH="626" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="40"></COL>
<COL WIDTH="134"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="99"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="49" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="85">구분</TH>
<TH ROWSPAN="2" WIDTH="143" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="85">만 기</TH>
<TH COLSPAN="2" WIDTH="218" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="32">당기</TH>
<TH COLSPAN="2" WIDTH="216" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="32">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">주당 행사가격&cr;(단위: 원)</TH>
<TH WIDTH="109" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">주식수&cr;(단위: 주)</TH>
<TH WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">주당 행사가격&cr;(단위: 원)</TH>
<TH WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="53">주식수&cr;(단위: 주)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 10차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2021-02-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">13,725</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">9,496 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">27,450</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">8,390</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 11차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2021-05-10</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">15,925</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">31,850</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">3,640</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 12차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2021-06-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">16,575</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">33,150</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">2,240</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 13차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2021-10-04</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">21,150</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">42,300</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">690</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 14차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2021-11-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">17,500</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">35,000</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">900</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 15차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2022-02-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">16,500</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">12,180 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">33,000</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">40,140</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 16차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2022-08-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">17,350</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">4,460 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">34,700</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">2,230</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 17차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2022-11-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">15,650</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">31,300</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">1,010</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 18차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-02-01</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">28,200</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">85,440 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">56,400</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">42,720</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 19차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-03-27</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">30,650</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">10,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">61,300</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">5,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 20차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-04-30</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">31,200</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">62,400</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">0</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 21차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-05-14</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">26,000</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">4,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">52,000</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">2,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 22차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-07-16</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">20,625</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">3,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">41,250</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">1,500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 23차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2023-11-26</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">28,000</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">40,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">56,000</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">20,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 24차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-01-31</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">24,725</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">90,260 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">49,450</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">45,130</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 25차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-01-31</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">24,725</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">2,860 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">49,450</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">1,430</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 26차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-03-10</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">27,750</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">1,600 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">55,500</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 27차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-04-30</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">29,450</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">3,840 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">58,900</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">2,020</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 28차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-05-31</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">27,000</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">7,240 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">54,000</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">3,800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 29차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2024-09-11</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">22,575</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">96,160 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">45,150</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">48,080</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 30차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2025-02-03</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">23,425</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">47,080 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 31차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2025-03-25</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">20,850</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">40,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 32차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2025-03-25</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">22,200</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">22,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 33차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2025-03-25</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">26,850</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">3,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 34차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2020-07-24</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">51,700</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">7,050 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 35차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2020-08-03</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">57,600</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">2,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 36차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2020-09-10</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">54,900</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">1,840 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" ALIGN="CENTER" HEIGHT="30"> 37차</TD>
<TD WIDTH="143" ALIGN="CENTER" HEIGHT="30">2020-11-02</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">57,600</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">2,000 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="192" ALIGN="CENTER" HEIGHT="30"> 합계 </TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">495,506 </TD>
<TD WIDTH="108" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">231,720</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(3) 주식선택권의 보상원가는 이항옵션모형과 블랙-숄즈모형을 이용한 공정가액접근법을 적용하여 산정하였으며, 보상원가를 산정하기 위한 제반 가정 및 변수는 다음과 같습니다.</SPAN>
</P>

<TABLE WIDTH="1050" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="1041"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1050" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위:원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="1052" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="114"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="58"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="123" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">구 분</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">10차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">11차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">12차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">13차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">14차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">15차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">16차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">17차</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">18차</TH>
<TH WIDTH="67" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">19차</TH>
<TH WIDTH="67" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">20차</TH>
<TH WIDTH="67" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">21차</TH>
<TH WIDTH="67" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">22차</TH>
<TH WIDTH="67" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">23차</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">무위험이자율</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.53%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.41%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.44%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.28%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.45%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.685%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">1.73%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">2.14%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">2.27%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">2.24%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">2.201%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">2.286%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">2.105%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">1.914%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">주가</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">29,300</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30,300</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">34,600</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">40,050</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">31,300</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30,650</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">32,850</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">31,450</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">56,400</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">61,300</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">62,400</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">52,000</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">41,250</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">56,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">예상주가변동성</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">32.73%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">32.20%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">31.86%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30.25%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30.52%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30.48%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">30.57%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">31.64%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">34.81%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">35.74%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">35.32%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">35.72%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">34.89%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">32.51%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">기대배당수익률</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">0%</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">0%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">기대만기</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="66" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">4년</TD>
<TD WIDTH="67" ALIGN="RIGHT" HEIGHT="30">4년</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">공정가액</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,935</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,726</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,985</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,466</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,881</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,266</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,072</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,905</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,860</TD>
<TD WIDTH="67" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,253</TD>
<TD WIDTH="67" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">17,109</TD>
<TD WIDTH="67" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,921</TD>
<TD WIDTH="67" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,781</TD>
<TD WIDTH="67" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,769</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1047">

<COLGROUP>
<COL WIDTH="114"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="57"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="123" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">24차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">25차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">26차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">27차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">28차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">29차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">30차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">31차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">32차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">33차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">34차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">35차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">36차</TH>
<TH WIDTH="66" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">37차</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">무위험이자율</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.809%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.809%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.802%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.712%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.626%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.242%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.30%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.13%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">1.07%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.83%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.80%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.80%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.92%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.97%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">주가</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">49,450</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">49,450</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">55,500</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">58,900</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">54,000</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">45,150</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">46,850</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">41,700</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">44,400</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">53,700</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">51,700</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">57,600</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">54,900</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">57,600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">예상주가변동성</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">31.52%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">31.52%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">29.70%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">29.66%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">29.87%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">31.36%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">31.86%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">34.73%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">37.42%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">37.54%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">38..49%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">38.50%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">38.99%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">38.57%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">기대배당수익률</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">0.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">기대만기</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT">4년</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT"> 4년 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="123" HEIGHT="30">공정가액</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,045</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,045</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,996</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,588</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,131</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">11,232</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,732</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,787</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,102</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,910</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">20,580</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">17,912</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,457</TD>
<TD WIDTH="66" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,037</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>27. 기타포괄손익누계액&cr;</SPAN>
</P>
<P>(1)보고기간종료일 현재 당사의 기타포괄손익누계액의 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="599">

<COLGROUP>
<COL WIDTH="590"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="599" HEIGHT="30" ALIGN="RIGHT" VALIGN="BOTTOM">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="597" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="284"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="143"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="293" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="152" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="293" HEIGHT="30">기타포괄손익-공정가치측정금융자산(*1)</TD>
<TD WIDTH="152" ALIGN="RIGHT" HEIGHT="30">3,075,072</TD>
<TD WIDTH="152" ALIGN="RIGHT" HEIGHT="30">(94,895)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="293" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">계</TD>
<TD WIDTH="152" ALIGN="RIGHT" HEIGHT="30">3,075,072</TD>
<TD WIDTH="152" ALIGN="RIGHT" HEIGHT="30">(94,895)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1) 법인세 효과가 차감된 금액입니다.&cr;</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>(2) 당기의 기타포괄손익-공정가치측정금융자산 및 전기의 매도가능금융자산의 평가손익의 변동내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="599">

<COLGROUP>
<COL WIDTH="590"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="599" HEIGHT="30" ALIGN="RIGHT" VALIGN="BOTTOM">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="594">

<COLGROUP>
<COL WIDTH="185"></COL>
<COL WIDTH="191"></COL>
<COL WIDTH="191"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>구분</P>
</TH>

<TH WIDTH="200" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>당기</P>
</TH>

<TH WIDTH="200" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P>전기</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기초금액</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">(94,895)</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">468,289</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">평가손익</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">3,169,967</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">(1,689,644)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">금융자산의 제거</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">1,126,460</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">당기말</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">3,075,072</TD>
<TD WIDTH="200" ALIGN="RIGHT" HEIGHT="30">(94,895)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>28. 결손금처리계산서 &cr;&cr;</SPAN>
<SPAN>보고기간 중 당사의 결손금 처리 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE WIDTH="750" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="741"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="750" ALIGN="CENTER" HEIGHT="30">결 손 금 처 리 계 산 서</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="749" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="108"></COL>
<COL WIDTH="56"></COL>
<COL WIDTH="56"></COL>
<COL WIDTH="56"></COL>
<COL WIDTH="55"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="53"></COL>
<COL WIDTH="62"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="117" VALIGN="MIDDLE" HEIGHT="60">제15 (당)기</TD>
<TD WIDTH="65" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2020년</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">01월</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">01일</TD>
<TD WIDTH="64" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">부터</TD>
<TD ROWSPAN="2" WIDTH="115" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="60">제 14 (전)기</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2019년</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">01월</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">01일</TD>
<TD WIDTH="71" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">부터</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="65" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">2020년</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">12월</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">31일</TD>
<TD WIDTH="64" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">까지</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2019년</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">12월</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">31일</TD>
<TD WIDTH="71" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">까지</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="117" VALIGN="MIDDLE" HEIGHT="30">처리예정일</TD>
<TD WIDTH="65" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">2021년</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">03월</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" VALIGN="MIDDLE">31일</TD>
<TD WIDTH="64" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"></TD>
<TD WIDTH="115" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">처리확정일</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2020년</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">03월</TD>
<TD WIDTH="62" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">25일</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"></TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="748" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="316"></COL>
<COL WIDTH="414"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="325" VALIGN="BOTTOM" HEIGHT="30">주식회사 레고켐 바이오사이언스</TD>
<TD WIDTH="423" VALIGN="BOTTOM" ALIGN="RIGHT" HEIGHT="30">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="750" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="302"></COL>
<COL WIDTH="101"></COL>
<COL WIDTH="101"></COL>
<COL WIDTH="101"></COL>
<COL WIDTH="100"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="311" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">과 목</TH>
<TH COLSPAN="2" WIDTH="220" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제 15 (당) 기</TH>
<TH COLSPAN="2" WIDTH="219" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제 14 (전) 기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">미처리이익잉여금(결손금)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(86,137,612)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">(70,139,417)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   전기이월미처리이익잉여금(결손금)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(70,139,417)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(84,111,493)</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   당기순이익(손실)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(6,986,261)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">16,003,664</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   순확정급여부채의 재측정요소</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(333,190)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(905,128)</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   지분법자본변동</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(6,615)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   기타포괄손익-공정가치측정 금융자산제거</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(1,126,460)</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">   연결조정(*) </TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">(8,672,129)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">결손금처리액</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="109" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="311" HEIGHT="30">차기이월미처리이익잉여금(결손금)</TD>
<TD WIDTH="110" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="110" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(86,137,612)</TD>
<TD WIDTH="110" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="109" VALIGN="MIDDLE" HEIGHT="30" ALIGN="RIGHT">(70,139,417)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*) 당기 중 종속회사에 대한 지배력 상실로 인한 효과로써 연결대상 종속회사의 기초미처분이익잉여금과 관계회사 투자의 지분법회계처리 반영에 따른 기초 이익잉여금 조정분이 반영되었습니다. </SPAN>
<SPAN>&cr;&cr;29. 영</SPAN>
<SPAN>업비용&cr;&cr;보고기간 중 당사의 영업비용의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="642" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="633"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="642" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="647" BORDER="1" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="207"></COL>
<COL WIDTH="207"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="216" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계정과목</TH>
<TH WIDTH="216" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">제품매출원가</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,156,494</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">용역매출원가</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">590,804</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  상품매출원가</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,781,979 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">17,181,132</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  반품매출원가</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,996 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(239,376)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">상품 등 매출원가</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,828,975 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">22,689,054</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">연구개발비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">54,204,279 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,711,213</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">판매관리비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,122,209 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,683,029</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  직원급여</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,569,832 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,605,189</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  퇴직급여</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">185,996 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">276,452</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  복리후생비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">160,605 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">262,961</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  여비교통비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">113,363 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">259,100</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  감가상각비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">136,248 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">241,777</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  지급수수료</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,533,702 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,164,405</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  무형고정자산상각</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,504,951 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,464,573</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  대손상각비(환입)</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,462,501)</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,945,160</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  주식보상비</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,839,724 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">190,109</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">  기타</TD>
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">540,288 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,273,303</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합 계</TD>

<TD WIDTH="216" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<SPAN>79,155,463 </SPAN>
</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">49,083,296</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>30</SPAN>
<SPAN>.</SPAN>
<SPAN> 비용</SPAN>
<SPAN>의 성격별 분류 &cr;&cr;</SPAN>
<SPAN>보고기간 중 비용의 성격별 분류는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="596" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="587"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="596" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="646">

<COLGROUP>
<COL WIDTH="207"></COL>
<COL WIDTH="206"></COL>
<COL WIDTH="206"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="216" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="215" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="215" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">상품매입액</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,935,600 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,887,013 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">재고자산의 변동</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(106,624)</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,400,899)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">시약재료비</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,154,339 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">663,942 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">종업원급여</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,652,040 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,119,524 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">감가상각비, 무형자산 상각</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,994,425 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,862,030 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">지급수수료</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,911,529 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,919,332 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">여비교통비</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">188,426 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">395,849 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">대손상각비</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,462,501)</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,945,160 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">복리후생비</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">380,901 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">787,927 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">기술개발비</TD>

<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<SPAN>29,446,427</SPAN>
</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,702,800 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30">기타</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,060,901 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,200,619 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="216" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">영업비용 합계</TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">79,155,463 </TD>
<TD WIDTH="215" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">49,083,297 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>31. 기타수익 및 기타비용 &cr;&cr;보고기간 중 기타수익과 기타비용 내역은 다음과 같습니다. </SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="595" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="586"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="595" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="596">

<COLGROUP>
<COL WIDTH="264"></COL>
<COL WIDTH="153"></COL>
<COL WIDTH="152"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="273" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">계정과목</TH>
<TH WIDTH="162" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="161" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 수입임대료</TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 채무면제이익 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">552,687</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-   </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 잡이익 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,247</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,167</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기타수익 합계</TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">554,934</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,667</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 기부금 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,189</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">57,302</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 유형자산처분손실 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-   </TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">414</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 재고자산평가손실 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,726</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">204,878</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 유형자산폐기손실 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">520</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-   </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 무형자산손상차손 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,182</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-   </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 잡손실 </TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">413</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,181</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">기타비용 합계</TD>
<TD WIDTH="162" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">27,030</TD>
<TD WIDTH="161" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">263,776</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN>32. 종업원급여 &cr;&cr;보고기</SPAN>
<SPAN>간중</SPAN>
<SPAN> 종업원급여는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="593" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="584"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="593" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="594">

<COLGROUP>
<COL WIDTH="200"></COL>
<COL WIDTH="185"></COL>
<COL WIDTH="182"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="209" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="194" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="191" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="209" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">급 여</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,357,553 </TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9,327,701 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="209" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">퇴직급여</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">768,813 </TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">791,823 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="209" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">사회보장비용</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600,622 </TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">630,600 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="209" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">주식보상비용</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,925,051 </TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">545,501 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="209" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합 계</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">29,652,040 </TD>
<TD WIDTH="191" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,295,625 </TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<PGBRK></PGBRK>
<P>33. 금융수익 및 금융비용&cr;&cr;보고기간의 당사의 금융손익 내역은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="654" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="645"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="654" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="657">

<COLGROUP>
<COL WIDTH="264"></COL>
<COL WIDTH="183"></COL>
<COL WIDTH="183"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="273" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="192" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="192" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">금융수익</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 외환차익 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">963,786 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">136,600</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 외화환산이익 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,161 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">33,189</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 파생상품평가이익 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,045,108 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 당기손익인식금융자산평가이익</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,989,025</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">금융수익 합계</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,021,055 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,158,814</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">금융비용</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 외환차손 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,178,370 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">702,298</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 외화환산손실 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">411,355 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">53,574</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 이자비용</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,804</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 당기손익인식금융자산평가손실 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,546,875 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30"> 종속기업투자주식처분손실 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">260,816 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 금융비용 합계 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,397,415 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">781,676</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30"> 이자수익 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,001,397 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,498,903</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">리스이자수익</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">37,191 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">42,746</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="273" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">순금융손익</TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,662,228 </TD>
<TD WIDTH="192" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,918,786</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>34</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>. 법인세비용&cr;</SPAN>
</P>

<P>
<SPAN>(1) 보고기간 중 법인세비용 산출내역은 다음과 같습니다. </SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="626">

<COLGROUP>
<COL WIDTH="617"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="626" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="627">

<COLGROUP>
<COL WIDTH="309"></COL>
<COL WIDTH="146"></COL>
<COL WIDTH="145"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="318" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="155" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="154" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="318" VALIGN="MIDDLE" HEIGHT="30">당기손익에 대한 당기법인세</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> - </TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="318" VALIGN="MIDDLE" HEIGHT="30">   일시적차이로 인한 이연법인세 변동액</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,627,602)</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">467,164</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="318" VALIGN="MIDDLE" HEIGHT="30">   기타포괄손익에 직접 반영된 법인세비용</TD>

<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK=" 0X0000FF">
<SPAN USERMARK=" 0X000000">(798,251)</SPAN>
</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">158,847</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="318" VALIGN="MIDDLE" HEIGHT="30">   기타</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">585,352 </TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="318" VALIGN="MIDDLE" HEIGHT="30">법인세비용</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,840,501)</TD>
<TD WIDTH="154" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">626,011</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(2) 보고기간 중 법인세차감전순이익과 법인세비용간의 관계는 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="589">

<COLGROUP>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="589" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="584">

<COLGROUP>
<COL WIDTH="258"></COL>
<COL WIDTH="150"></COL>
<COL WIDTH="149"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="267" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="159" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="158" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">법인세비용차감전순이익(손실)</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(8,826,762)</TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,003,664</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">적용세율에 따른 법인세비용</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,007,888)</TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,520,806</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">조정사항</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">비공제비용</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">334 </TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,716</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">기타(이연법인세미인식효과 등)</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">167,053 </TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,907,511)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">법인세비용(수익)</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,840,501)</TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">626,011</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="267" VALIGN="MIDDLE" HEIGHT="30">평균유효세율</TD>
<TD WIDTH="159" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="158" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3.9%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(3) 보고기간중 주요 누적 일시적 차이 및 이연법인세자산과 부채의 변동은 다음과 같습니다.&cr;</SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="869">

<COLGROUP>
<COL WIDTH="284"></COL>
<COL WIDTH="567"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="293" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD WIDTH="576" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="882">

<COLGROUP>
<COL WIDTH="293"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="85"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="89"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="302" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구 분</TH>
<TH COLSPAN="3" WIDTH="284" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">차감할(가산할) 일시적차이</TH>
<TH COLSPAN="3" WIDTH="296" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">이연법인세자산(부채)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">증감액</TH>
<TH WIDTH="94" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
<TH WIDTH="99" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="99" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">증감액</TH>
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">- 손익에 영향이 있는 이연법인세변동액</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">퇴직급여충당부채</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,989,965</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">612,561</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,602,526</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">437,792</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">134,764</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">572,556</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">퇴직연금운용자산</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(52,007)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(340,203)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(392,210)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(11,441)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(74,845)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(86,286)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">미수수익</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(218,133)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">99,365</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(118,768)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(47,989)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,860</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(26,129)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">장기미지급금(미지급금 대체분 포함)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,267,226</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(650,846)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">616,380</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">278,790</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(143,186)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">135,604</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">국고보조금</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,964,538</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(90,167)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,874,371</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">432,198</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(19,836)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">412,362</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">미지급비용(연차수당)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">349,227</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(128,850)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">220,377</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">76,830</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(28,347)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">48,483</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">환불부채(순액)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,098</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,098</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,142</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,142</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">임대보증금(현할차)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">55,438</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">55,438</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,196</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,196</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">주식선택권</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,245,694</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,245,694</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">494,053</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">494,053</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">감가상각비(업무용자동차)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">45,911</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,976</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">67,887</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,100</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,835</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">14,935</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">기타의무형자산</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(8,260,263)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,460,044</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,800,219)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,817,258)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">321,210</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,496,048)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">사용권자산</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(313,229)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(116,904)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(430,133)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(68,910)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(25,719)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(94,629)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">리스부채</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">285,174</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">90,063</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">375,237</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">62,738</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">19,814</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">82,552</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">당기손익-공정가치측정 금융자산 평가손익</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(4,657,500)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,546,875</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(3,110,625)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,024,650)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">340,312</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(684,338)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">대손충당금</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">566,954</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">566,954</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">124,730</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">124,730</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">지분법이익</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,744,867)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,744,867)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(383,871)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(383,871)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">세액공제</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,501,375</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,321,368</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,501,375</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,321,368</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">이월결손금</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,381,577</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,975,033</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">60,356,610</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,203,947</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,074,507</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,278,454</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">소계</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">41,602,479</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">19,149,639</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">60,752,118</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,352,140</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,383,994</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,736,134</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">- 자본에 직접가감하는 이연법인세변동액</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">기타포괄-공정가치평가손익</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">121,660</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(4,064,060)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(3,942,400)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">26,765</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(894,093)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(867,328)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">보험수리적손익</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,736,504</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">427,166</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,163,670</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">382,031</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">93,977</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">476,008</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">지분법자본변동</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,481</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8,481</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,866</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,866</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">소계</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,858,164</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(3,628,413)</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,770,249)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">408,796</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(798,250)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(389,454)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">총계</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">43,460,643</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,521,226</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">58,981,869</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,760,936</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,585,744</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16,346,680</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">차감>실현가능성없는 이연법인세자산</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(14,641,681)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,958,142)</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(17,599,823)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="302" VALIGN="MIDDLE" HEIGHT="30">이연법인세자산(부채)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="94" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,880,745)</TD>
<TD WIDTH="99" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,627,602</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,253,143)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="887">

<COLGROUP>
<COL WIDTH="284"></COL>
<COL WIDTH="585"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="293" VALIGN="MIDDLE" HEIGHT="30"><전기></TD>
<TD WIDTH="594" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="868">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="296" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구 분</TH>
<TH COLSPAN="3" WIDTH="287" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">차감할(가산할) 일시적차이</TH>
<TH COLSPAN="3" WIDTH="285" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">이연법인세자산(부채)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="96" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">증감액</TH>
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">증감액</TH>
<TH WIDTH="95" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">- 손익에 영향이 있는 이연법인세변동액</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">퇴직급여충당부채</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,903,506 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(913,541)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,989,965 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">638,771 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(200,979)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">437,792 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">사외적립자산</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(51,322)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(684)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(52,007)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(11,291)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(151)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(11,441)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">미수수익</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(130,349)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(87,784)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(218,133)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(28,677)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(19,313)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(47,989)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">장기미지급금</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">970,787 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">296,438 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,267,226 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">213,573 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">65,216 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">278,790 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">정부보조금</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">837,038 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,127,499 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,964,538 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">184,148 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">248,050 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">432,198 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">미지급비용</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">122,835 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">226,392 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">349,227 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">27,024 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">49,806 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">76,830 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">감가상각비</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">51,129 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(5,218)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">45,911 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,248 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,148)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,100 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">무형자산(고객관계)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(9,520,307)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,260,044 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(8,260,263)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,094,468)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">277,210 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,817,258)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">사용권자산</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(313,229)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(68,910)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(68,910)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">리스부채</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">285,174 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">62,738 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">62,738 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">당기손익-공정가치평가손익</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(668,475)</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(4,657,500)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(147,065)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(877,586)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,024,650)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">세액공제</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,819,993 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">이월결손금</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,381,577 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">46,381,577 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,203,947 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,203,947 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">소계</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">43,716,413 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,903,146 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">41,602,479 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,817,205 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(465,064)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,352,140 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">- 자본에 직접가감하는 이연법인세변동액</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">기타포괄-공정가치평가손익</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">600,371 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(478,711)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">121,660 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(132,082)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">158,847 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">26,765 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">보험수리적손익</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">828,968 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">907,536 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,736,504 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">182,373 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">199,658 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">382,031 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">소계</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,429,339 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">428,825 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,858,164 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">50,291 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">358,505 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">408,796 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">합계</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">45,145,751 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,331,972 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">43,460,643 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,867,497 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(106,560)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,760,936 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">차감>실현가능성없는 이연법인세자산</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(14,281,078)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(360,603)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(14,641,681)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" VALIGN="MIDDLE" HEIGHT="30">이연법인세부채</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,413,581)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(467,164)</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,880,745)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>(4) 세무상 차감할일시적차이에 대한 이연법인세자산은 관련 세무상 혜택이 미래 과세소득을 통해 실현될 가능성이 높은 경우에 인식됩니다. 회사는 가산할 일시적차이의 한도 내에서 차감할 일시적차이를 인식하였으며, 세무상결손금 및 세액공제에 대하여는 실현가능성의 불확실성 때문에 이연법인세자산을 인식하지 않았습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>35. 주당순이익(손실)&cr;</SPAN>
</P>
<P>(1) 기본주당순이익(손실)</P>

<TABLE ACLASS="NORMAL" WIDTH="682" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="673"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="682" HEIGHT="30">(단위:원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE AFIXTABLE="N" WIDTH="687" BORDER="1" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="220"></COL>
<COL WIDTH="220"></COL>
<COL WIDTH="220"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="229" HEIGHT="30" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구     분</TH>
<TH ALIGN="CENTER" WIDTH="229" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH ALIGN="CENTER" WIDTH="229" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기(*2)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" HEIGHT="30">보통주당기순이익(손실)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">(6,986,261,219)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">13,586,123,504</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" HEIGHT="30">가중평균유통보통주식수(*1)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">22,752,996 </TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">21,209,313 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="229" HEIGHT="30">기본주당순이익(손실)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">(307)</TD>
<TD ALIGN="RIGHT" WIDTH="229" HEIGHT="30">641 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1) 당기 가중평균 유통보통주식수 = </SPAN>
<SPAN></SPAN>
<SPAN>8,327,596,598 ÷ 366 = 22,752,996</SPAN>
<SPAN>&cr;        전기 가중평균 유통보통주식수 =</SPAN>
<SPAN> 7,741,399,400 ÷ 365 =21,209,313&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(*2) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 기존주식에 무상증자분을 추가하여 작성하였습니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>(*) 가중평균 유통보통주식수의 계산내역&cr;&cr;</SPAN>
<SPAN>1) 당기 누적</SPAN>
</P>

<TABLE AFIXTABLE="N" WIDTH="761" BORDER="1" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="178"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="176"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="136"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="187" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH ALIGN="CENTER" WIDTH="126" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수(*1)</TH>
<TH ALIGN="CENTER" WIDTH="185" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기간</TH>
<TH ALIGN="CENTER" WIDTH="118" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">일수</TH>
<TH ALIGN="CENTER" WIDTH="145" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 적수 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="32">2020.01.01(전기이월)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="32">21,443,878 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="32">2020-01-01~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="32">366 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="32">7,848,459,348 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.02.13(스톡옵션행사)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">76,764 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-02-13~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">323 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">24,794,772 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.04.22(스톡옵션행사)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">13,560 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-04-22~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">254 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">3,444,240 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.05.07(보통주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">6,000 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-05-07~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">239 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">1,434,000 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.06.02(보통주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">79,810 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-06-02~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">213 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">16,999,530 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.06.04(보통주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">32,264 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-06-04~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">211 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">6,807,704 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.06.05(보통주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">1,790,456 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-06-05~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">210 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">375,995,760 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2020.06.09(보통주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">241,074 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2020-06-09~2020-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">206 </TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">49,661,244 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">23,683,806</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30"></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30"></TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">8,327,596,598 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>* 가중평균 유통보통주식수 = </SPAN>
<SPAN>8,327,596,598 ÷ 366 = 22,752,996&cr;</SPAN>
<SPAN>(*1) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 기존주식에 무상증자분을 추가하여 작성하였습니다.&cr;</SPAN>
<SPAN></SPAN>
</P>
<P>2) 전기 누적</P>

<TABLE AFIXTABLE="N" WIDTH="761" BORDER="1" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="178"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="176"></COL>
<COL WIDTH="109"></COL>
<COL WIDTH="136"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="187" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH ALIGN="CENTER" WIDTH="126" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수(*1)</TH>
<TH ALIGN="CENTER" WIDTH="185" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기간</TH>
<TH ALIGN="CENTER" WIDTH="118" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">일수</TH>
<TH ALIGN="CENTER" WIDTH="145" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 적수 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.01.01(전기이월)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">21,179,764 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2019-01-01~2019-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">365</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">7,730,613,860 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.03.20(스톡옵션행사)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">19,360 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2019-03-20~2019-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">287</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">5,556,320 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.12.10(우선주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">167,070 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2019-12-10~2019-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">22</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">3,675,540 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.12.12(우선주 전환)</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">77,684 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">2019-12-12~2019-12-31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">20</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">1,553,680 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="126" HEIGHT="30">21,443,878 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="185" HEIGHT="30">　</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="118" HEIGHT="30">　</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">7,741,399,400 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>* 가중평균 유통보통주식수 = 7,741,399,400 ÷ 365일 = 21,209,313&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(*1) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 전기분도 소급하여 기존주식에 무상증자분을 추가하여 작성하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN>(2) 희석주당순이익&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>1) 당사의 당기는 희석화증권의 희석화효과가 존재하지 않아 희석주당손실은기본주당손실과 동일합니다.</SPAN>
<SPAN></SPAN>
<SPAN>&cr;&cr;</SPAN>
<SPAN>2) 전기 누적</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="529" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="520"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="529" HEIGHT="30">(단위:원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE AFIXTABLE="N" WIDTH="528" BORDER="1" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="245"></COL>
<COL WIDTH="265"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="254" HEIGHT="60" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ROWSPAN="2">구     분</TH>
<TH ALIGN="CENTER" WIDTH="274" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="274" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">누적</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" HEIGHT="30">희석주당기순이익(손실)</TD>
<TD ALIGN="RIGHT" WIDTH="274" HEIGHT="30">13,586,123,504 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" HEIGHT="30">가중평균유통희석주식수(*1)</TD>
<TD ALIGN="RIGHT" WIDTH="274" HEIGHT="30">24,011,881 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="254" HEIGHT="30">희석주당순이익(손실)</TD>
<TD ALIGN="RIGHT" WIDTH="274" HEIGHT="30">566 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>&cr;(*) 가중평균 유통희석주식수의 계산내역</SPAN>
<SPAN>&cr;</SPAN>
</P>

<TABLE AFIXTABLE="N" WIDTH="761" BORDER="1" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="178"></COL>
<COL WIDTH="126"></COL>
<COL WIDTH="201"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="136"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="187" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구분</TH>
<TH ALIGN="CENTER" WIDTH="135" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주식수(*1)</TH>
<TH ALIGN="CENTER" WIDTH="210" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">기간</TH>
<TH ALIGN="CENTER" WIDTH="84" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">일수</TH>
<TH ALIGN="CENTER" WIDTH="145" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N"> 적수 </TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.1.1(전기이월)</TD>
<TD ALIGN="RIGHT" WIDTH="135" HEIGHT="30">23,996,658 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="210" HEIGHT="30">2019.01.01~2019.12.31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="84" HEIGHT="30">365</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">8,758,780,170 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30">2019.3.20(스톡옵션행사)</TD>
<TD ALIGN="RIGHT" WIDTH="135" HEIGHT="30">19,360 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="210" HEIGHT="30">2019.03.20~2019.12.31</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="84" HEIGHT="30">287</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">5,556,320 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="187" HEIGHT="30" VALIGN="MIDDLE" ALIGN="CENTER">합 계</TD>
<TD ALIGN="RIGHT" WIDTH="135" HEIGHT="30">24,016,018 </TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="210" HEIGHT="30">　</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="84" HEIGHT="30">　</TD>
<TD ALIGN="RIGHT" WIDTH="145" HEIGHT="30">8,764,336,490 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>* 가중평균 유통희석주식수 = 8,764,336,400 ÷ 365일 = 24,011,881주</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(*1) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 전기분도 소급하여 기존주식에 무상증자분을 추가하여 작성하였습니다.</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
</P>
<P>36. 영업활동으로부터 창출된 현금 &cr;&cr;(1) 보고기간의 영업으로부터 창출된 현금은 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="748" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="739"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="748" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="762">

<COLGROUP>
<COL WIDTH="245"></COL>
<COL WIDTH="245"></COL>
<COL WIDTH="245"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="254" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구  분</TH>
<TH WIDTH="254" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="254" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30" USERMARK=" B">당기순이익(손실)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(6,986,261)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12,475,508 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30" USERMARK=" B">조정:</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 감가상각비</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,489,473 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,400,192 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 무형자산상각비</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,504,951 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,464,573 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 대손상각비(환입)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,462,501)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,945,160 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 퇴직급여</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">768,813 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">791,823 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 법인세비용</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,840,501)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">626,011 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 주식보상비용</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,925,051 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">545,502 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 이자비용</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">25,803 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 유형자산폐기손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">520 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 유형자산처분손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">414 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 외화환산손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">411,355 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">53,574 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 재고자산폐기손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,726 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">204,879 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 지급수수료</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">237,200 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 무형자산손상차손</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,182 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 종속기업투자주식처분손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">260,816 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 당기손익인식금융자산평가손실</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,546,875 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 당기손익인식금융자산평가이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(3,989,025)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 파생상품평가이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(20,045,108)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 지분법이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,744,867)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 리스이자수익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(37,191)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(42,746)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 채무면제이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(552,687)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 이자수익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,001,397)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,498,903)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 외화환산이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(12,161)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(33,189)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 잡이익</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(890)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30" USERMARK=" B">순운전자본의 증감 :</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 매출채권의 감소(증가)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(8,776,487)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,682,135 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 매입채무의 증가(감소)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(658,188)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(567,255)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 재고자산의 감소(증가)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(106,624)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,471,549)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타유동금융자산의감소(증가)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">146,523 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(30,171)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타유동자산의감소(증가)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">590,657 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,587,160 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타비유동자산의감소(증가)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(205,102)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타유동금융부채의증가(감소)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">599,438 </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,598,677 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타비유동금융부채의증가(감소)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">296,438 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 기타유동부채의증가(감소)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(779,998)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,253,910 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30"> 퇴직급여채무의증가(감소)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(496,456)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(912,363)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="254" VALIGN="MIDDLE" HEIGHT="30" USERMARK=" B">영업으로부터 창출된 현금</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(15,994,737)</TD>
<TD WIDTH="254" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">23,201,456 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(2) 보고기간 중 현금의 유출입이 없는 중요한 거래내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="682" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="673"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="682" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="741">

<COLGROUP>
<COL WIDTH="344"></COL>
<COL WIDTH="185"></COL>
<COL WIDTH="185"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="353" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30"> 구  분</TH>
<TH WIDTH="194" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="194" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">무상증자</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6,026,586 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">주식매수선택권 행사</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">343,163 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">기타포괄손익-공정가치 측정 금융자산 평가이익</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,169,967 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,689,644</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">사용권자산의 취득으로 인한 증가</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">486,832 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">리스계약의 해지로 인한 사용권자산의 감소</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">74,936 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">장기선급비용 유동성대체</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">39,745 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30">장기선급금 유동성대체</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">404,347 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="353" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">계</TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">10,545,576 </TD>
<TD WIDTH="194" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,689,644</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(3) 재무활동에서 생기는 부채의 변동&cr;&cr;당기의 재무활동에서 생기는 주요 부채의 변동내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="714" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="405"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="300" HEIGHT="30"><당기></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="414" HEIGHT="30">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="721">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">구분</TD>
<TD ROWSPAN="2" WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">기초</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ROWSPAN="2" USERMARK=" BC0XD7D7D7">재무활동&cr;현금흐름</TD>
<TD COLSPAN="2" WIDTH="240" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">비현금 변동</TD>
<TD ROWSPAN="2" WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">당기말</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">전환</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">기타변동</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER"> 장기차입금 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,900,000</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,712,000</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,612,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER"> 리스부채 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">285,175</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(396,770)</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">486,832</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">375,237</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" WIDTH="717" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="408"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" WIDTH="300" HEIGHT="30"><전기></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="417" HEIGHT="30">(단위: 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="723">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">구분</TD>
<TD ROWSPAN="2" WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">기초</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ROWSPAN="2" USERMARK=" BC0XD7D7D7">재무활동&cr;현금흐름</TD>
<TD COLSPAN="2" WIDTH="240" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">비현금 변동</TD>
<TD ROWSPAN="2" WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">당기말</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">전환</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">기타변동</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">장기차입금</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,900,000</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,900,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="121" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">리스부채</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">436,813 </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(151,638)</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">285,175 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-GL11 B">        </SPAN>
</P>
<PGBRK></PGBRK>

<P>
<SPAN>37. 우발채무와 약정사항</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(1) 당기말 현재 당사의 금융기관 약정사항의 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="636">

<COLGROUP>
<COL WIDTH="627"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="636" HEIGHT="30" ALIGN="RIGHT">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="724">

<COLGROUP>
<COL WIDTH="172"></COL>
<COL WIDTH="172"></COL>
<COL WIDTH="172"></COL>
<COL WIDTH="172"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">거래처</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">내용</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">한도액</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">실행금액</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ROWSPAN="2" ALIGN="CENTER" WIDTH="181" HEIGHT="60">하나은행</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">일반자금</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,000,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">911,500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">일반자금</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,000,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">기업은행</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">수입신용장</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">USD 300,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">서울보증보험</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="181" HEIGHT="30">이행보증</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3,000,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,690,900</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" ROWSPAN="2" WIDTH="362" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60">합계</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,000,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2,602,900</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">USD 300,000</TD>
<TD WIDTH="181" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P>당사는 상기 금융기관 약정한도와 관련하여 당사의 대표이사로부터 연대보증을 제공받고 있습니다.&cr;</P>

<P>
<SPAN></SPAN>
<SPAN>(2) 당기말 현재 당사의 채무에 대하여 담보로 제공된 자산 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="630" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="621"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="630" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="671">

<COLGROUP>
<COL WIDTH="194"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="203" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">담보제공자산</TH>
<TH WIDTH="117" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">장부금액</TH>
<TH WIDTH="117" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">담보권자</TH>
<TH WIDTH="117" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">담보설정액</TH>
<TH WIDTH="117" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">관련 채무액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="203" HEIGHT="30">정기예금(*1)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">12,000,000</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="117" HEIGHT="30">하나은행</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">11,000,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="60" ROWSPAN="2">3,612,000</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="203" HEIGHT="30">토지분양대금 반환채권(*2)</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">3,539,380</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="117" HEIGHT="30">하나은행</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">3,240,000</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>(*1) 당사는 정기예금을 직원 대출에 대한 담보로 제공되어 있습니다 (주석 39(5) 참조)&cr;</SPAN>
<SPAN>(*2) 토지분양(대전시 유성구 둔곡동 1002-1)대금에 대한 담보 대출로 당기말 현재 건설중인자산으로 계상되어 있습니다. &cr;&cr;(3) 당사는 당기말 현재 현대해상화재보험에 당사 건물, 집기비품 및 시설에 대하여 화재보험에 가입(부보금액 6,850,262천원)하고 있으며 가스사고배상책임보험에 가입(부보금액 300,000천원)하고 있습니다. 또한 당사 업무용차량에 대하여 차량종합책임보험에 있습니다.&cr;&cr;(4) 당사는 당기말 현재 직원 스톡옵션행사에 대한 직원대출에 대해 하나은행에 765백만원의 보증을 제공하고 있습니다.&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>38. 영업부문 정보&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>영업부문은 최고영업의사결정자에게 보고되는 내부 보고자료와 동일한 방식으로 보고하고 있으며 당기와 전기 영업부문의 부문별 정보는 다음과 같습니다.</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>(1) 부문수익 및 이익&cr;보고기간 종료일 현재 보고부문별 수익 및 이익의 내용은 다음과 같습니다. </SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="612">

<COLGROUP>
<COL WIDTH="471"></COL>
<COL WIDTH="123"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="480" HEIGHT="30" VALIGN="MIDDLE">
<SPAN></SPAN>
<SPAN><당기></SPAN>
</TD>

<TD WIDTH="132" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>(단위: 천원)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" WIDTH="608" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="210"></COL>
<COL WIDTH="121"></COL>
<COL WIDTH="121"></COL>
<COL WIDTH="120"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="219" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구          분</TH>
<TH ALIGN="CENTER" WIDTH="130" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">신약연구개발</TH>
<TH ALIGN="CENTER" WIDTH="130" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">의약사업</TH>
<TH ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" VALIGN="MIDDLE">계</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="219" HEIGHT="30">영업수익</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">31,091,686 </TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">18,302,016 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">49,393,702 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="219" HEIGHT="30">영업비용</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">66,105,791 </TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">13,049,672 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">79,155,463 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="219" HEIGHT="30">영업이익(손실)</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">(35,014,105)</TD>
<TD WIDTH="130" HEIGHT="30" ALIGN="RIGHT">5,252,344 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">(29,761,761)</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="612">

<COLGROUP>
<COL WIDTH="471"></COL>
<COL WIDTH="123"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="480" HEIGHT="30" VALIGN="MIDDLE">
<SPAN></SPAN>
<SPAN><전기></SPAN>
</TD>

<TD WIDTH="132" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>(단위: 천원)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="609">

<COLGROUP>
<COL WIDTH="213"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="120"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="222" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구          분</TH>
<TH WIDTH="129" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">신약연구개발</TH>
<TH WIDTH="129" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">의약사업</TH>
<TH WIDTH="129" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="222" HEIGHT="30">영업수익</TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">31,788,865 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">25,711,274 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">57,500,139 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="222" HEIGHT="30">영업비용</TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">21,316,436 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">27,766,861 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT">49,083,297 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="222" HEIGHT="30">
<SPAN USERMARK="F-10"></SPAN>
<SPAN>영업이익(손실)</SPAN>
</TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">10,472,429 </TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(2,055,587)</TD>
<TD WIDTH="129" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,416,842 </TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;위에서 보고된 수익은 외부고객으로부터 발생한 수익입니다. 당기 및 전기에 기업내의 다른 영업부문과의 거래로 인한 수익은 없습니다. 한편, 의약사업은 전액 한 시점에 이전되는 재화(상품)의 매출이며, 신약연구개발은 각 계약별 특성에 따라 한 시점에 인식하거나, 기간에 걸쳐 수익을 인식합니다(주요 계약의 상세 내용 주석 40참조).</P>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN>(2) 부문자산 및 부채&cr;보고기간 종료일 현재 보고부문별 자산 및 부채의 내용은 다음과 같습니다. </SPAN>
<SPAN>&cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="667">

<COLGROUP>
<COL WIDTH="471"></COL>
<COL WIDTH="178"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="480" HEIGHT="30" VALIGN="MIDDLE">
<SPAN></SPAN>
<SPAN><당기></SPAN>
</TD>

<TD WIDTH="187" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>(단위: 천원)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="664">

<COLGROUP>
<COL WIDTH="187"></COL>
<COL WIDTH="147"></COL>
<COL WIDTH="147"></COL>
<COL WIDTH="147"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="196" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구     분</TH>
<TH WIDTH="156" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">신약연구개발</TH>
<TH WIDTH="156" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">의약사업</TH>
<TH WIDTH="156" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="30">유동자산</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">86,046,311 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">13,964,327 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">100,010,638 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="30">비유동자산</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">35,726,373 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">175,337 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">35,901,710 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="30">자산총계</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">121,772,684 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">14,139,664 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">135,912,348 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="196" HEIGHT="30">부채총계</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">16,800,872 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,985,292 </TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">23,786,164 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="661">

<COLGROUP>
<COL WIDTH="471"></COL>
<COL WIDTH="172"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="480" HEIGHT="30" VALIGN="MIDDLE">
<SPAN></SPAN>
<SPAN><전기></SPAN>
</TD>

<TD WIDTH="181" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">
<SPAN>(단위: 천원)</SPAN>
</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="660">

<COLGROUP>
<COL WIDTH="185"></COL>
<COL WIDTH="147"></COL>
<COL WIDTH="146"></COL>
<COL WIDTH="146"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="194" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구     분</TH>
<TH WIDTH="156" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">신약연구개발</TH>
<TH WIDTH="155" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">의약사업</TH>
<TH WIDTH="155" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" HEIGHT="30">유동자산</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">97,095,806</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT">14,323,467</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT">111,419,272</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" HEIGHT="30">비유동자산</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT">23,873,745</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT">6,184,435</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT">30,058,181</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" HEIGHT="30">자산총계</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">120,969,551</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">20,507,902</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">141,477,453</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="194" HEIGHT="30">부채총계</TD>
<TD WIDTH="156" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,885,140</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">9,682,968</TD>
<TD WIDTH="155" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">25,568,107</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(3) 보고기간 중 당사 매출액의 10%이상을 차지하는 외부고객은 다음과 같습니다.</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="593" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="584"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="593" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="610">

<COLGROUP>
<COL WIDTH="119"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="128" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60">구 분</TH>
<TH COLSPAN="2" WIDTH="242" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH COLSPAN="2" WIDTH="240" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">금액</TH>
<TH WIDTH="121" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">비율</TH>
<TH WIDTH="120" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">금액</TH>
<TH WIDTH="120" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">비율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">A사</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="121" HEIGHT="30">11,346,000 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">22.97%</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">B사</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="121" HEIGHT="30">10,335,300 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20.92%</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">C사</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="121" HEIGHT="30">7,018,975 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">14.21%</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,096,431</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8.86%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">D사</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="121" HEIGHT="30">4,860,305 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9.84%</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,978,357</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">8.66%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="128" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">E사</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="121" HEIGHT="30">4,804,542 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">9.73%</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">4,285,526</TD>
<TD WIDTH="120" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7.45%</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(4) 전기 말 선수금 잔액 중 당기 중 수익으로 인식한 금액은 없으며, 당기말 선수금 잔액 38,749천원은 1년내 수익으로 인식할 것으로 판단하고 있습니다.&cr;</P>

<P>
<SPAN></SPAN>
<SPAN>39. 특수관계자 거래</SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>&cr;(1) 보고기간말 현재 당사의 특수관계자현황은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="629">

<COLGROUP>
<COL WIDTH="203"></COL>
<COL WIDTH="121"></COL>
<COL WIDTH="121"></COL>
<COL WIDTH="148"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="212" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">회사명</TH>
<TH WIDTH="260" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">지분율</TH>
<TH WIDTH="157" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="130" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기말</TH>
<TH WIDTH="130" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="212" HEIGHT="53" VALIGN="MIDDLE">
<P>  바스칸바이오제약</P>
<P>    (구, (주)레고켐제약)</P>
</TD>
<TD WIDTH="130" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">32.52%</TD>
<TD WIDTH="130" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">68.52%</TD>
<TD WIDTH="157" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">관계회사</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P>
<SPAN></SPAN>
<SPAN>(2) 보고기간 중 특수관계자와의 손익 등 거래 내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="703" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="694"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" WIDTH="703" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="701">

<COLGROUP>
<COL WIDTH="107"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="99"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="116" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">특수관계구분</TH>
<TH WIDTH="152" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">회사명</TH>
<TH WIDTH="217" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="2">매입</TH>
<TH WIDTH="216" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">이자수익</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="109" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="108" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
<TH WIDTH="108" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="108" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="116" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">관계기업</TD>

<TD WIDTH="152" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">
<P>바스칸바이오제약</P>
<P>(구, (주)레고켐제약)</P>
</TD>
<TD WIDTH="109" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">1,628,029</TD>
<TD WIDTH="108" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">1,644,970</TD>
<TD WIDTH="108" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">4,022</TD>
<TD WIDTH="108" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE"> - </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(3) 보고기간</SPAN>
<SPAN>말</SPAN>
<SPAN> 현재 특수관계자에 대한 거래내역 및 채권ㆍ채무 잔액은 다음과 같습니다.</SPAN>
<SPAN>                                                                                                (단위:천원)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="938">

<COLGROUP>
<COL WIDTH="99"></COL>
<COL WIDTH="140"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
<COL WIDTH="76"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="108" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">특수관계구분</TH>
<TH WIDTH="149" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">회사명</TH>
<TH WIDTH="341" HEIGHT="30" COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">당기</TH>
<TH WIDTH="340" HEIGHT="30" COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">전기</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="86" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매입채무</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">단기대여금</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">미수수익</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">미수금</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매입채무</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">단기대여금</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">미수수익</TH>
<TH WIDTH="85" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">미수금</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="108" HEIGHT="53" ALIGN="CENTER" VALIGN="MIDDLE">관계기업</TD>

<TD WIDTH="149" HEIGHT="53" VALIGN="MIDDLE">
<P>바스칸바이오제약</P>
<P>(구, (주)레고켐제약)</P>
</TD>
<TD WIDTH="86" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">232,234</TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-   </TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE"> - </TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">-   </TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">    17,746</TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">500,000 </TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">2,079 </TD>
<TD WIDTH="85" HEIGHT="53" ALIGN="RIGHT" VALIGN="MIDDLE">958,545</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;</SPAN>
<SPAN>(4) 보고기간 중 특수관계자와의 자금거래내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="788" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="483"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD ALIGN="RIGHT" WIDTH="492" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="789">

<COLGROUP>
<COL WIDTH="97"></COL>
<COL WIDTH="140"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="79"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">특수관계구분</TH>
<TH WIDTH="149" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">회사명</TH>
<TH WIDTH="90" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">계정과목</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">대여</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">회수</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자전환</TH>
<TH WIDTH="88" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="106" HEIGHT="53">관계기업</TD>

<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="53">
<P>바스칸바이오제약</P>
<P>(구, (주)레고켐제약)</P>
</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="90" HEIGHT="53">단기대여금</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="89" HEIGHT="53">500,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="89" HEIGHT="53"> - </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="89" HEIGHT="53">500,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="89" HEIGHT="53"> - </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="88" HEIGHT="53">-</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>* 당기의 자금거래내역은 없습니다.&cr;</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="803" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="498"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><전기></TD>
<TD ALIGN="RIGHT" WIDTH="507" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="805">

<COLGROUP>
<COL WIDTH="97"></COL>
<COL WIDTH="101"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="88"></COL>
<COL WIDTH="78"></COL>
<COL WIDTH="96"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="106" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">특수관계구분</TH>
<TH WIDTH="110" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">회사명</TH>
<TH WIDTH="116" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">계정과목</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기초</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">대여</TH>
<TH WIDTH="97" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">회수</TH>
<TH WIDTH="87" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">출자전환</TH>
<TH WIDTH="105" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">기말</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="106" HEIGHT="30">종속기업</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="110" HEIGHT="30">㈜레고켐제약</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">단기대여금</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="92" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="92" HEIGHT="30">500,000</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="97" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="87" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="105" HEIGHT="30">500,000</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(5) 보고기간말 현재 당사가 특수관계자를 위하여 제공하고 있는 담보내역은 다음과 같습니다.</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="678">

<COLGROUP>
<COL WIDTH="669"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="678" HEIGHT="30" ALIGN="RIGHT">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="676">

<COLGROUP>
<COL WIDTH="118"></COL>
<COL WIDTH="129"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="128"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="127" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">담보제공자산</TH>
<TH WIDTH="138" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">담보제공액</TH>
<TH WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">담보권자</TH>
<TH WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">채무자</TH>
<TH WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">관련차입금</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="127" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">정기예금</TD>
<TD WIDTH="138" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,484,750</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">하나은행</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">임직원</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">828,991</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="127" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">정기예금</TD>
<TD WIDTH="138" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,685,250</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">국민은행</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">임직원</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">1,456,015</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="127" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE">합계</TD>
<TD WIDTH="138" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">3,170,000</TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="137" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">2,285,006</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>당기말 현재 당사는 상기 임직원 관련차입금에 대해 연대보증을 제공하고 있습니다.</SPAN>
<SPAN></SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN></SPAN>
<SPAN>(6) 주요경영진에 대한 보상&cr;</SPAN>
<SPAN>주요 경영진은 이사(등기 및 비등기), 이사회의 구성원, 재무책임자 및 내부감사책임자를 포함하고 있습니다. 종업원서비스의 대가로서 주요 경영진에게 지급되었거나 지급될 보상금액은 다음과 같습니다.</SPAN>
</P>

<TABLE WIDTH="678" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="669"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="678" ALIGN="RIGHT" HEIGHT="30">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="685">

<COLGROUP>
<COL WIDTH="220"></COL>
<COL WIDTH="219"></COL>
<COL WIDTH="219"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="229" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="228" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">당기</TH>
<TH WIDTH="228" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30">전기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">급            여</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">976,090</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,129,450</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">퇴  직  급  여</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">373,683</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">401,511</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">사회보장비용</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">67,627</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">60,081</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">주식보상비용</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">251,098</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">142,813</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="229" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합            계</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,668,497</TD>
<TD WIDTH="228" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,733,854</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN></SPAN>
<SPAN></SPAN>
</P>

<P>
<SPAN>40. 주요 기술이전계약&cr;&cr;(1) 2020년 중 당사가 신규로 체결한 4건의 주요 기술이전계약의 내용은 다음과 같습니다.&cr;&cr;</SPAN>
<SPAN>1)</SPAN>
<SPAN> 2020년 4월 14일자로 영국에 소재한 Iksuda Therapeutics Limited(이하"Iksuda")와 항체-약물 복합체(ADC) 원천기술 3타겟 대상으로 기술이전 계약을 체결하였습니다. 동 계약으로 인하여 Iksuda사는 전 세계에서 ADC원천기술 3타겟에 대한 개발 및 상업화에 대한 독점적 권리를 확보하였습니다. 당사는 반환조건 없는 계약금(Upfront payment) USD  750,000을 2021년 3월에 수령하였으며, 계약과 관련된 의무가 종결되는 기간까지 분할하여 수익으로 인식하였습니다. 또한, 당사는 계약조건과 규제당국의 허가 및 상업화에 성공할 경우 최대 USD 406,500,000 규모의 선급금 및 마일스톤 금액(Milestone payment)을 수령할 수 있습니다.&cr;&cr;2) 2020년 5월 13일자로 영국에 소재한 Iksuda사와  항체-약물 복합체(ADC) 원천기술 CD19 물질에 대한 기술이전 계약을 체결하였습니다. 동 계약으로 인하여 Iksuda사는 전 세계에서 CD19에 대한 개발 및 상업화에 대한 독점적 권리를 확보하였습니다. 당사는 반환조건 없는 계약금(Upfront payment)  USD 5,000,000을  2020년에 일시에 수령하였으며, 계약과 관련된 의무가 종료되는 기간까지 분할하여 수익으로 인식하였습니다. 또한, 당사는 규제당국의 허가 및 상업화에 성공할 경우 최대 USD 222,000,000 규모의 마일스톤 금액(Milestone payment)과 경상기술료 및 수익배분을 추가로 수령할 수 있습니다.&cr;&cr;3) 2020년 10월 28일자로 중국에 소재한 CStone Pharmaceuticals(이하"CStone")와  항체-약물 복합체(ADC) 원천기술 ROR1 물질에 대한 기술이전 계약을 체결하였습니다. 동 계약으로 인하여 CStone사는 한국을 제외한 전 세계에서 ROR1에 대한 개발 및 상업화에 대한 독점적 권리를 확보하였습니다. 당사는 반환조건 없는 계약금(Upfront payment) USD 10,000,000을  2020년에 일시에 수령하였으며, 계약과 관련된 의무가 종료되는 기간까지 분할하여 수익으로 인식하였습니다. 또한, 당사는 규제당국의 허가 및 상업화에 성공할 경우 최대 USD 353,500,000 규모의 마일스톤 금액(Milestone payment)과 경상기술료 및 수익배분을 추가로 수령할 수 있습니다.&cr;</SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>4) 2020년 12월 1일자로 미국에 소재한 Pyxis Oncology(이하"Pyxis")와  항체-약물 복합체(ADC) 원천기술 DLK1 물질에 대한 기술이전 계약을 체결하였습니다. 동 계약으로 인하여 Pyxis사는 한국을 제외한 전 세계에서 DLK1에 대한 개발 및 상업화에 대한 독점적 권리를 확보하였습니다. </SPAN>
<SPAN>회사는 반환조건 없는 계약금(Upfront payment) USD 9,500,000 중  1차 선급금 USD 500,000을 2020년에, 2차 선급금 USD 9,000,000은 2021년 3월에 수령</SPAN>
<SPAN>하였으며, 계약과 관련된 의무가 종료되는 기간까지 분할하여 수익으로 인식하였습니다. 또한, 회사는 규제당국의 허가 및 상업화에 성공할 경우 최대 USD 284,500,000 규모의 마일스톤 금액(Milestone payment)과 경상기술료 및 수익배분을 추가로 수령할 수 있습니다.</SPAN>
</P>
<P> </P>
<P>(2) 2017년 중 체결한 기술이전계약의 주요 변동내역은 다음과 같습니다. &cr;</P>

<P>
<SPAN>1) 2017년 브릿지바이오테라퓨틱스 주식회사와 체결하였던 ATX저해제 기술이전 계약과 관련하여 2019년 7월 브릿지바이오테라퓨틱스 주식회사가 베링거잉겔하임과 기술이전계약을 체결함에 따라 사전합의한 비율에 따른 이익 배분으로 전기 및 당기에 </SPAN>
<SPAN>EUR 14,502,955.08</SPAN>
<SPAN>을 수령하였습니다. 한편 당기 중 베링거잉겔하임에서 브릿지바이오테라퓨틱스와의 기술이전계약에 대한 권리반환을 결정하였으며, 본 건과 관련하여 브릿지바이오테라퓨틱스와의 이익 배분비율에 따라 레고켐이 기 수령한 계약금 </SPAN>
<SPAN>EUR 14,502,955.08</SPAN>
<SPAN>은 브릿지에 반환하지 않는 조건으로 계약이 종료되었습니다. 브릿지와 레고켐 간 2017년 기술이전 계약은 유효합니다.</SPAN>
<SPAN>  </SPAN>
</P>
<P></P>
<P>(3) 기술이전계약과 관련된 불확실성 및 기타사항&cr;&cr;당사의 향후 마일스톤 금액과 경상기술료 및 수익배분은 임상시험, 관계당국의 허가 등 개발의 성공여부에 따라 달라질 수 있으므로 발생가능성에 불확실성이 내포되어 있습니다. 또한 ADC 기술이전계약과 관련하여 항체 공급회사에게 일정 수수료를 지급하기로 약정하고 있습니다.</P>

<P>
<SPAN></SPAN>
</P>

<P>
<SPAN></SPAN>
<SPAN>41. 재무제표의 승인&cr;&cr;</SPAN>
<SPAN>당기 재무제표는 2021년 3월 23일 이사회에서 승인되어, 상법 제449조의2 및 당사 정관 제 54조 ⑥항에 따라 외부감사인의 적정의견 및 감사가 동의할 시 이사회에서 승인하고, 주주총회에는 보고로 변경되어 진행 될 수 있습니다. 따라서 2021년 3월 31일 주주총회에서 보고로 진행될 예정입니다.&cr;&cr;</SPAN>
<SPAN>42. 보고기간 후 사건&cr;&cr;2021년 2월 22일 이사회 결의에 따라 타법인인 브릿지바이오테라퓨틱스 주식회사의 주식 317,460주를 약5,000백만원에 취득하였습니다.</SPAN>
</P>
<P></P>
</SECTION-2>
</LIBRARY>
</INSERTION>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-3-6-0">6. 기타 재무에 관한 사항</TITLE>

<P>
<SPAN>가. 재무제표 재작성 등 유의사항</SPAN>
<SPAN>&cr;</SPAN>(1) 재무제표를 재작성한 경우 재작성사유, 내용 및 재무제표에 미치는 영향 - 해당사항은 없습니다. &cr;(2) 최근 3사업연도 중 합병, 분할, 자산양수도 또는 영업양수도 사항&cr; - 해당 사항은 없습니다.&cr;&cr;(3) 자산유동화와 관련한 자산매각의 회계처리 및 우발채무 등에 관한 사항&cr;- 해당 사항은 없습니다.&cr;
</P>
<P>(4) 재무제표 이용에 유의할 사항&cr;당사의 재무제표는 한국채택국제회계기준에 따라 작성되었습니다. 한국채택국제회계기준은 국제회계기준위원회("IASB")가 발표한 기준서와 해석서 중 대한민국이 채택한 내용을 의미합니다. &cr;한국채택국제회계기준은 재무제표 작성시 중요한 회계추정의 사용을 허용하고 있으며, 회계정책을 적용함에 있어 경영진의 판단을 요구하고 있습니다. 보다 복잡하고 높은 수준의 판단이 요구되는 부분이나 중요한 가정 및 추정이 요구되는 부분은 주석2에서 설명하고 있습니다. 기타 자세한 사항은 III.재무에 관한 사항 중 5. 재무제표 주석을 참고해 주시기 바랍니다.&cr;&cr;나. 대손충당금 설정 현황&cr;(1). 계정과목별 대손충당금 설정내역 </P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="626">

<COLGROUP>
<COL WIDTH="617"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="626" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="629">

<COLGROUP>
<COL WIDTH="82"></COL>
<COL WIDTH="82"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="102"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">구 분</TD>
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">계정과목</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">채권금액</TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">대손충당금</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">장부금액</TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">대손충당금&cr;설정률</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="120">제15기</TD>
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">매출채권</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,250 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(682)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">20,568 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3.2%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">미수금</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">868 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">868 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">미수수익</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">119 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">119 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">22,237 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(682)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,555 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">3.2%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="120">제14기</TD>
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">매출채권</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,277 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,157)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,120 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16.3%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">미수금</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">263 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">263 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">미수수익</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">216 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">216 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,756 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,157)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">11,599 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">16.3%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="4" WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">제13기</TD>
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">매출채권</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">17,879 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(212)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">17,667 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1.2%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">미수금</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">233 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">233 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="32">미수수익</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="32">133 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="32">　-</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="32">133 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="32">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="91" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,245 </TD>
<TD WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(212)</TD>
<TD WIDTH="112" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,033 </TD>
<TD WIDTH="111" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1.2%</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(2) 대손충당금 변동현황</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="623">

<COLGROUP>
<COL WIDTH="614"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="623" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="623" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="250"></COL>
<COL WIDTH="113"></COL>
<COL WIDTH="112"></COL>
<COL WIDTH="112"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">구 분</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제15기</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제14기</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제13기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">1. 기초 대손충당금 잔액합계</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,157)</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(212)</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(153)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">2. 순대손처리액(①－②±③)</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">12</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">① 대손처리액(상각채권액)</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">② 상각채권회수액</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">③ 기타증감액</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">6</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">3. 대손상각비 계상(환입)액</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1,463 </TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(1,945)</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(59)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">4. 환율변동차이</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">5. 연결범위변동</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="259" VALIGN="MIDDLE" HEIGHT="30">6. 기말 대손충당금 잔액합계</TD>
<TD WIDTH="122" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(682)</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(2,157)</TD>
<TD WIDTH="121" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(212)</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;(3) 매출채권관련 대손충당금 설정방침</P>
<P>- 당사는 재무상태표일 현재의 매출채권 등의 잔액에 대하여 개별분석 및 과거의 대손경험을 기초로 대손예상액을 추정하여 대손충당금을 설정하고 있습니다.&cr;- 기준금액 : 매출채권 잔액&cr;- 대손처리기준 : 과거의 대손경험률 및 장래의 대손추산액에 의해 적용</P>
<P>&cr;(4) 기준일 현재 경과기간별 매출채권잔액 현황</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="1049">

<COLGROUP>
<COL WIDTH="1040"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="1049" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 백만원, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1052">

<COLGROUP>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="87"></COL>
<COL WIDTH="86"></COL>
<COL WIDTH="86"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">구분</TD>
<TD COLSPAN="5" WIDTH="478" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기</TD>
<TD COLSPAN="5" WIDTH="478" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">전기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">3개월 이하</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">4~6개월</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">7~12개월</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">12개월 초과</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">합계</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">3개월 이하</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">4~6개월</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">7~12개월</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">12개월 초과</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">합계</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">매출채권</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,767 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,127 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">356 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,250 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,305</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,487</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">279</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">72</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,144</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">받을어음</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">133</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">133</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">합계</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">15,767 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,127 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">356 </TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">21,250 </TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">7,438</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">5,487</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">279</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">72</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">13,277</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">구성비율</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">74.20%</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">24.13%</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.00%</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">1.68%</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">100.00%</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">56.02%</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">41.33%</TD>
<TD WIDTH="96" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">2.10%</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">0.54%</TD>
<TD WIDTH="95" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">100.00%</TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;</P>

<P>
<SPAN>다. 재고자산 현황</SPAN>
<SPAN>&cr;</SPAN>(1) 재고자산의 보유현황
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="852">

<COLGROUP>
<COL WIDTH="843"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="852" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="853">

<COLGROUP>
<COL WIDTH="171"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="122"></COL>
<COL WIDTH="121"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">사업부문</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">계정과목</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제15기</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제14기</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제13기</TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="6" WIDTH="180" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="180">의약사업부문</TD>
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">상품</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">149,894 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">837,555 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            581,915 </TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">제품</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30"> 320,145 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">                     - </TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">원재료</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">605,712 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            164,853 </TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">부재료</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,585 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">                7,934 </TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">기타</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">135,552 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">239,376 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">                     - </TD>
<TD WIDTH="130" VALIGN="MIDDLE" HEIGHT="30">주)　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" HEIGHT="30" ALIGN="CENTER">합 계</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">285,447 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">        2,021,372 </TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">            754,702 </TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="330" VALIGN="MIDDLE" HEIGHT="53">총자산대비 재고자산 구성비율(%)&cr;[재고자산합계÷기말자산총계×100]</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">0.21%</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1.43%</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">0.62%</TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" WIDTH="330" VALIGN="MIDDLE" HEIGHT="53">재고자산회전율(회수)&cr;[연환산 매출원가÷{(기초재고+기말재고)÷2}]</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">11.99</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">16.35</TD>
<TD WIDTH="131" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">22.87</TD>
<TD WIDTH="130" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">-</TD>
</TR>
</TBODY>
</TABLE>
<P>주) 최근 3년간 반품율을 적용하여 산정한 반품자산입니다.&cr;&cr;(2) 재고자산의 실사현황&cr;&cr;재고자산의 취득원가는 매입원가, 전환원가 및 재고자산을 현재의 장소에 현재의 상태로 이르게 하는 데 발생한 기타 원가 모두를 포함하고 있으며, 재고자산의 단위원가는 선입선출법을 사용하여 결정하고 있습니다.  &cr;&cr;재고자산은 취득원가와 순실현가능가치 중 낮은 금액으로 측정하고 있습니다. 순실현가능가치는 정상적인 영업과정의 예상 판매가격에서 예상되는 추가 완성원가와 판매비용을 차감한 금액으로서  매 후속기간에 순실현가능가치를  재평가하고 있습니다. &cr;&cr;재고자산의 판매시 관련된 수익을 인식하는 기간에 재고자산의 장부금액을 비용으로인식하고 있으며 재고자산을 순실현가능가치로 감액한 평가손실과 모든 감모손실은 감액이나 감모가 발생한 기간에 비용으로 인식하며, 순실현가능가치의 상승으로 인한 재고자산 평가손실의 환입은 환입이 발생한 기간의 비용으로 인식된 재고자산 금액의 차감액으로 인식하고 있습니다. &cr;</P>

<P>재고자산이 담보로 제공된 경우는 없습니다.&cr;&cr;
<SPAN></SPAN>
<SPAN>- 재고실사일 : 2021년 1월 2일&cr;- 입회인 : 회계감사인, 창고별수불담당자, 회계담당자&cr;- 장기체화재고 등 현황 : 실사과정에서 장기체화재고, 진부화재고 또는 손상재고 등이 파악되거나, 그 시가가 취득원가보다 하락함으로 인해 재고자산의 저가법이 적용되는 경우 각 계정의 평가손실을 인식하며, 충당금으로써 재고자산의 차감계정으로 표시하고 상대계정으로 매출원가에 가산합니다. </SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="776">

<COLGROUP>
<COL WIDTH="767"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="776" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">(단위 : 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="780">

<COLGROUP>
<COL WIDTH="72"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="107"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="2" WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" USERMARK=" BC0XD7D7D7">구분</TD>
<TD COLSPAN="6" WIDTH="699" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">제 15기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="117" HEIGHT="30" USERMARK=" BC0XD7D7D7"> 취득원가</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="117" HEIGHT="30" USERMARK=" BC0XD7D7D7">보유금액</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="117" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기 폐기손실</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30" USERMARK=" BC0XD7D7D7">당기 평가손실</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30" USERMARK=" BC0XD7D7D7">기말잔액</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30" USERMARK=" BC0XD7D7D7">비고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">상품</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">153,621 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">153,621 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">3,726 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">149,894 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">제품</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">원재료</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">부재료</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">재공품</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">미착품</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">반품자산</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">135,552 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">135,552 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">135,552 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="81" HEIGHT="30">합 계</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">289,173 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">289,173 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">3,726 </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">- </TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="116" HEIGHT="30">285,447 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="116" HEIGHT="30">　</TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;
<SPAN></SPAN>
<SPAN>라. 공정가치평가 내역&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>(1) </SPAN>
<SPAN>공정가치 서열체계&cr;</SPAN>
<SPAN></SPAN>
<SPAN>공정가치로 측정되거나 공정가치가 공시되는 금융상품은 공정가치 서열체계에 따라 구분되며 정의된 수준들은 다음과 같습니다.&cr;&cr;- 동일한 자산이나 부채에 대한 활성시장의(조정되지 않은) 공시가격(수준 1)&cr;- 직접적으로(예: 가격) 또는 간접적으로(예: 가격에서 도출되어) 관측가능한, &cr;   자산이나 부채에 대한 투입변수. 단, 수준 1에 포함된 공시가격은 제외함(수준 2)&cr;- 관측가능한 시장자료에 기초하지 않은, 자산이나 부채에 대한 투입변수&cr;  (관측가능 하지 않은 투입변수)를 이용하여 산정한 공정가치(수준 3)&cr;&cr;</SPAN>
<SPAN></SPAN>
<SPAN>당</SPAN>
<SPAN>사의 공정가치로 측정되거나 공정가치가 공시되는 금융상품</SPAN>
<SPAN>은 다음과 같습니다.</SPAN>
</P>

<TABLE WIDTH="593" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="288"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><당기></TD>
<TD WIDTH="297" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="594" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="232"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="79"></COL>
<COL WIDTH="79"></COL>
<COL WIDTH="79"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="241" ALIGN="CENTER" VALIGN="MIDDLE" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="89" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 1</TH>
<TH WIDTH="88" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 2</TH>
<TH WIDTH="88" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 3</TH>
<TH WIDTH="88" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">당기손익-공정가치 금융자산</TD>
<TD WIDTH="89" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK=" 0X0000FF"></TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK=" 0X0000FF"></TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK=" 0X0000FF">　           </TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT" USERMARK=" 0X0000FF"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">  브릿지바이오테라퓨틱스(주)</TD>
<TD WIDTH="89" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">4,910,625 </TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">- </TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">- </TD>
<TD WIDTH="88" HEIGHT="30" VALIGN="MIDDLE" ALIGN="RIGHT">4,910,625 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">기타포괄손익-공정가치 금융자산</TD>
<TD WIDTH="89" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">　</TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">　</TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">　</TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">  (주)인투셀</TD>
<TD WIDTH="89" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">- </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">4,932,400 </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">- </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">4,932,400 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">  에스알파테라퓨틱스</TD>
<TD WIDTH="89" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">- </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">499,993 </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">- </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">499,993 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">합   계</TD>
<TD WIDTH="89" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">4,910,625 </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">5,432,393 </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">- </TD>
<TD WIDTH="88" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">10,343,018 </TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0X1814FF"></SPAN>
</P>

<TABLE WIDTH="593" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="287"></COL>
<COL WIDTH="288"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="296" HEIGHT="30" VALIGN="MIDDLE"><전기></TD>
<TD WIDTH="297" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE">(단위:천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="594">

<COLGROUP>
<COL WIDTH="232"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="78"></COL>
<COL WIDTH="79"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="241" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 1</TH>
<TH WIDTH="89" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 2</TH>
<TH WIDTH="87" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">수준 3</TH>
<TH WIDTH="88" HEIGHT="30" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">당기손익-공정가치 금융자산</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　           </TD>
<TD WIDTH="87" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">　           </TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">  브릿지바이오테라퓨틱스(주)</TD>

<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">6,457,500</SPAN>
</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="87" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">6,457,500</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">기타포괄손익-공정가치 금융자산</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="87" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE"></TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">  (주)인투셀</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">868,340</TD>
<TD WIDTH="87" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">868,340</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="241" HEIGHT="30">합   계</TD>

<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">6,457,500</SPAN>
</TD>
<TD WIDTH="89" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">868,340</TD>
<TD WIDTH="87" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">-</TD>
<TD WIDTH="88" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">7,325,840</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>&cr;(2)</SPAN>
<SPAN> 반복적인 공정가치 측정치의 수준3의 변동 내용&cr;</SPAN>
<SPAN>당사는 공정가치 서열체계의 수준 간 이동을 보고기간 말에 인식합니다. </SPAN>
<SPAN>당기 및 전기 중 </SPAN>
<SPAN></SPAN>
<SPAN>반복적인 측정치의 </SPAN>
<SPAN>수준 3에 해당하는 내역은 없습니다.</SPAN>
<SPAN></SPAN>
</P>
<P></P>
<P></P>

<INSERTION ABASISNUMBER="SE2" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『진행률적용 수주계약 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*진행률적용수주계약현황*.dsl</LIBRARYLIST>
</INSERTION>

<TABLE-GROUP ACLASS="SUB_PIS" ADELETETABLE="N">
<TITLE ATOC="N">채무증권 발행실적</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="747" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="445"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="147" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="454" HEIGHT="30" AUNIT="WONPERCENT" AUNITVALUE="1">(단위 : 원, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="748" BORDER="1">

<COLGROUP>
<COL WIDTH="60"></COL>
<COL WIDTH="60"></COL>
<COL WIDTH="61"></COL>
<COL WIDTH="61"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="67"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="69" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">발행회사</TH>
<TH WIDTH="69" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">증권종류</TH>
<TH WIDTH="70" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">발행방법</TH>
<TH WIDTH="70" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">발행일자</TH>
<TH WIDTH="80" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">권면(전자등록)총액</TH>
<TH WIDTH="73" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">이자율</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">평가등급&cr;(평가기관)</TH>
<TH WIDTH="84" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">만기일</TH>
<TH WIDTH="68" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">상환&cr;여부</TH>
<TH WIDTH="76" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">주관회사</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_CMPY">-</TE>
<TU WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_KNN" AUNITVALUE="-">-</TU>
<TU WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_STC" AUNITVALUE="-">-</TU>
<TU WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_DAT" AUNITVALUE="-">-</TU>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_MON">-</TE>
<TE WIDTH="73" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_RATE">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_LEV">-</TE>
<TU WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_LAS" AUNITVALUE="-">-</TU>
<TE WIDTH="68" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_REC">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_SUC">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_CMPY">-</TE>
<TU WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_KNN" AUNITVALUE="-">-</TU>
<TU WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_STC" AUNITVALUE="-">-</TU>
<TU WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_DAT" AUNITVALUE="-">-</TU>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_MON">-</TE>
<TE WIDTH="73" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_RATE">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_LEV">-</TE>
<TU WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUNIT="BSS_PIS_LAS" AUNITVALUE="-">-</TU>
<TE WIDTH="68" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_REC">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_SUC">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합  계</TD>
<TD WIDTH="69" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">-</TD>
<TD WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">-</TD>
<TD WIDTH="70" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">-</TD>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_MONT">-</TE>
<TE WIDTH="73" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_PIS_RATET">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_LEVT">-</TE>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">-</TD>
<TE WIDTH="68" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_RECT">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="BSS_PIS_SUCT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.</P>

<INSERTION ABASISNUMBER="LE0" AFREQUENCY="0" ADUPLICATION="Y">
<COMMENT>◆click◆ 『사채관리계약 주요내용 및 충족여부 등』 삽입</COMMENT>
<LIBRARYLIST>11011#*사채관리계약주요내용.dsl</LIBRARYLIST>
</INSERTION>
<P></P>

<TABLE-GROUP ACLASS="SUB_BLC" ADELETETABLE="N">
<TITLE ATOC="N">기업어음증권 미상환 잔액</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="820" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="514"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="523" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="820" BORDER="1">

<COLGROUP>
<COL WIDTH="45"></COL>
<COL WIDTH="43"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="106" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">잔여만기</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10일 이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10일초과&cr;30일이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">30일초과&cr;90일이하</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">90일초과&cr;180일이하</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">180일초과&cr;1년이하</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년초과&cr;2년이하</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">2년초과&cr;3년이하</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">3년 초과</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" AUPDATECONT="N" ROWSPAN="3">미상환 잔액</TD>
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">공모</TD>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA90">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA180">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA365">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA730">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA1095">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DA1111">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BL_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사모</TD>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA90">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA180">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA365">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA730">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA1095">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DA1111">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BC_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="52" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합계</TD>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA90">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA180">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA365">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA730">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA1095">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DA1111">-</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_BLC_DATT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.</P>

<TABLE-GROUP ACLASS="SUB_ELPN" ADELETETABLE="N">
<TITLE ATOC="N">단기사채 미상환 잔액</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="759" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="453"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="462" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="760" BORDER="1">

<COLGROUP>
<COL WIDTH="45"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="109" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">잔여만기</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10일 이하</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10일초과&cr;30일이하</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">30일초과&cr;90일이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">90일초과&cr;180일이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">180일초과&cr;1년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">합 계</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">발행 한도</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">잔여 한도</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" AUPDATECONT="N" ROWSPAN="3">미상환 잔액</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">공모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DA10">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DA30">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DA90">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DA180">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DA365">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_DATT">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_PUB">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EL_REM">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DA10">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DA30">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DA90">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DA180">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DA365">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_DATT">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_PUB">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_EP_REM">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합계</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DA10">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DA30">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DA90">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DA180">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DA365">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_DATT">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_PUB">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_ELP_REM">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.</P>

<TABLE-GROUP ACLASS="SUB_CNC" ADELETETABLE="N">
<TITLE ATOC="N">회사채 미상환 잔액</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="762" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="456"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="465" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="761" BORDER="1">

<COLGROUP>
<COL WIDTH="45"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="109" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">잔여만기</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년 이하</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년초과&cr;2년이하</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">2년초과&cr;3년이하</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">3년초과&cr;4년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">4년초과&cr;5년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">5년초과&cr;10년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10년초과</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" AUPDATECONT="N" ROWSPAN="3">미상환 잔액</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">공모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA1">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA2">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA3">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA4">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DA11">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CN_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA1">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA2">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA3">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA4">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DA11">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CC_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합계</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA1">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA2">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA3">-</TE>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA4">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DA11">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CNC_DATT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;</P>

<TABLE-GROUP ACLASS="SUB_NEF" ADELETETABLE="N">
<TITLE ATOC="N">신종자본증권 미상환 잔액</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="757" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="451"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="460" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="758" BORDER="1">

<COLGROUP>
<COL WIDTH="45"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="109" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">잔여만기</TH>
<TH WIDTH="82" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년 이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년초과&cr;5년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">5년초과&cr;10년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10년초과&cr;15년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">15년초과&cr;20년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">20년초과&cr;30년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">30년초과</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" AUPDATECONT="N" ROWSPAN="3">미상환 잔액</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">공모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA15">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA20">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA30">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DA31">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NE_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사모</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA15">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA20">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA30">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DA31">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NF_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합계</TD>
<TE WIDTH="82" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA5">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA10">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA15">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA20">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA30">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DA31">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_NEF_DATT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;</P>

<TABLE-GROUP ACLASS="SUB_CEF" ADELETETABLE="N">
<TITLE ATOC="N">조건부자본증권 미상환 잔액</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="912" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="606"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="615" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="912" BORDER="1">

<COLGROUP>
<COL WIDTH="45"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="109" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">잔여만기</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년 이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">1년초과&cr;2년이하</TH>
<TH WIDTH="81" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">2년초과&cr;3년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">3년초과&cr;4년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">4년초과&cr;5년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">5년초과&cr;10년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">10년초과&cr;20년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">20년초과&cr;30년이하</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">30년초과</TH>
<TH WIDTH="80" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">합 계</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="54" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" AUPDATECONT="N" ROWSPAN="3">미상환 잔액</TD>
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">공모</TD>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA2">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA3">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA4">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA5">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA20">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DA31">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CE_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사모</TD>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA2">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA3">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA4">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA5">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA20">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DA31">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CF_DATT">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="55" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">합계</TD>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA1">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA2">-</TE>
<TE WIDTH="81" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA3">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA4">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA5">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA10">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA20">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA30">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DA31">-</TE>
<TE WIDTH="80" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="BSS_CEF_DATT">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>☞ 본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;</P>
<P></P>
<PGBRK></PGBRK>
</SECTION-2>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-4-0-0">IV. 이사의 경영진단 및 분석의견</TITLE>
<P></P>

<P>1. 예측정보에 대한 주의사항 &cr;당사가 동 경영진단보고서에서 기재한 예측은 당해 공시서류 작성시점의 재무성과 에 대한 당사의 의견을 반영한 것입니다. 동 예측정보는 미래의 경영환경과 관련된 여러 가정에 근거하고 있으며 이러한 가정들은 결과적으로 부정확한 것으로 판명될 수도 있습니다. 또한 이러한 가정들은 예측치와 실제결과 간에 중요한 차이를 초래 할 수 있는 위험 및 기타요인을 포함하고 있습니다. 이러한 중요한 차이를 초래 할 수있는 요인에는 회사 경영성과 등 내부환경에 관련된 요인과 외부환경에 관한 요인 및기타요인이 포함되어 있습니다. 회사는 동 예측정보 작성시점 이후에 발생하는 위험 또는 불확실성을 반영하기 위하여 예측정보에 기재한 사항을 수정하는 정정보고서를공시할 의무는 없습니다. &cr;&cr;2. 개요 &cr;2020년 말 기준
<SPAN> 103명</SPAN>
<SPAN>으로</SPAN> 운영되고 있으며, 2012년 12월 코스닥 특례상장제도인 기술성 심사를 통과하고 2013년 5월 10일 상장을 완료하였습니다.
</P>
<P> </P>
<P>2020년 주요 경영실적을 요약하면 다음과 같습니다.</P>
<P> 당사의 핵심 사업모델은 신약개발의 적정단계에서 국내외 제약사에 기술이전을 통해 수익을 창출하는 것입니다. 창업초기에는 초기 자금부담 및 위험 분산을 위하여 후보물질이나 전임상 등의 초기단계에서 기술이전을 하였으나, 2013년 5월 상장을 통한 자금확보를 통해 점차 연구분야 확대 및 개발기능을 확충하면서 임상 1상이나 임상 2상까지 단독개발을 한 후 부가가치를 높여 기술이전 하는 전략을 추진하고 있습니다. </P>
<P>신약개발부문은 먼저 당사가 가장 역량을 집중하고 있는 ADC 분야에서 총 4건의 기술이전을 달성하였습니다. ADC분야에 탁월한 임상개발 능력을 보유한 영국의 익수다 테라퓨틱스사에 4월 ADC플랫폼기술이전(총 계약금액 4,963억원)에 이어 5월에 ADC프로덕트 기술이전(선급금 61억원, 총 계약금액 2,784억원)을 진행하였습니다. 또한, 10월에는 중국의 시스톤 파마수티컬스사(선급금 113억원, 총 계약금액 4,099억원)와 12월에는 미국의 픽시스 온콜로지사(선급금 105억원, 총계약금액 3,255억원)와 ADC프로덕트 기술이전계약을 체결하였으며, 2020년 한해 약 1.5조원의 마일스톤을 확보하였습니다. &cr;  </P>
<P>현재까지 당사의 기술이전 실적 및 공동연구, 기술용역/원료공급 계약, 의약사업부문의 상품매출 등을 요약하면 다음과 같으며 회계금액  기준으로 약 494억의 매출을 기록하고 있습니다.</P>

<P USERMARK=" 0X0000FF"> 
<SPAN></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="0" WIDTH="606">

<COLGROUP>
<COL WIDTH="597"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="606" HEIGHT="35" ALIGN="RIGHT">(단위: 건, 천원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="612">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="65"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="131"></COL>
<COL WIDTH="130"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="90">
<P USERMARK="F-BT">구 분</P>
</TH>

<TH ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="90">
<P USERMARK="F-BT">판 매 구 분</P>
</TH>

<TH COLSPAN="4" WIDTH="426" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">판  매  실  적</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH COLSPAN="2" WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">건   수</P>
</TH>

<TH COLSPAN="2" WIDTH="279" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">금    액</P>
</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">제15기</P>
</TH>

<TH WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">제14기</P>
</TH>

<TH WIDTH="140" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">제15기</P>
</TH>

<TH WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="30">
<P USERMARK="F-BT">제14기</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">상품매출</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">400 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">319</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,302,016 </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       23,371,346 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" 0X0000FF">
<P USERMARK="F-BT">　-</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">-</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">400 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">319</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">18,302,016 </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       23,371,346 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">제품매출</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">39</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">         1,539,578 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">　</TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">7</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">           345,758 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">46</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">         1,885,336 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">연구용역</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">3 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">1</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P>230,000 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">             57,000 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">4 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">2</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK=" 0X0000FF">
<P>904,707 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">           355,692 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">7 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">3</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK=" 0X0000FF">
<P>1,134,707 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">           412,692 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">용역</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">6</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">           459,792 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">-</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">                - </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">- </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">6</P>
</TD>
<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">- </TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">           459,792 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">기술이전</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">3 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">2</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P>1,256,704 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       26,920,657 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">5 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">3</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK=" 0X0000FF">
<P>28,700,275 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">         4,450,316 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">8 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">5</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" USERMARK=" 0X0000FF">
<P>29,956,979 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       31,370,973 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="3" WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90">
<P USERMARK="F-BT">합   계</P>
</TD>

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">내수</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">406 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">367</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P>19,788,720 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       52,348,373 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">수출</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">9 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">12</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P>29,604,982 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">         5,151,766 </P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">계</P>
</TD>
<TD WIDTH="74" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">415 </TD>

<TD WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<P USERMARK="F-BT">379</P>
</TD>

<TD WIDTH="140" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P>49,393,702 </P>
</TD>

<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">
<P USERMARK="F-BT">       57,500,139 </P>
</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0X0000FF">&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>3. 재</SPAN>
<SPAN>무상태 및 영업실적&cr;</SPAN>가. 영업실적
</P>

<TABLE ACLASS="NORMAL" WIDTH="852" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="843"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="852" HEIGHT="30" USERMARK="F-BT">(단위: 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="849">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="64"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="52"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="73"></COL>
<COL WIDTH="57"></COL>
<COL WIDTH="73"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="121" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">구  분</TH>
<TH COLSPAN="3" WIDTH="212" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">금액</TH>
<TH COLSPAN="2" WIDTH="149" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">제15기(전기대비)</TH>
<TH COLSPAN="2" WIDTH="137" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">제14기(전기대비)</TH>
<TH COLSPAN="3" WIDTH="230" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">매출액대비(%)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">과목</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">제15기</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">제14기</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">제13기</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">증감액</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">변동(%)</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">증감액</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">변동(%)</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">제15기</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">제14기</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">제13기</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">매출액</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">49,393 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">57,500 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">25,240 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(8,107)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">-14.10%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">32,260</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">127.80%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">　-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">-　</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-　</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">매출원가</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">13,828 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">22,689 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">19,332 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(8,861)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">-39.05%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">3,357</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">17.40%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">28.00%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">39.50%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">76.60%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">매출총이익</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">35,565 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">34,811 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">5,908 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">754 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">2.17%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">28,903</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">489.20%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">72.00%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">60.50%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">23.40%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT"> 연구개발비</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">54,204 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">16,711 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">15,505 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">37,493 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">224.36%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">1,206</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">7.80%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">109.74%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">29.10%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">61.40%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">판매비와관리비</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">11,123 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">9,683 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">6,381 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">1,440 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">14.87%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">3,302</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">51.70%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">22.52%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">16.80%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">25.30%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">영업이익</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(29,762)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">8,417 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(15,978)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(38,179)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">적자전환</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">24,395</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">흑자전환</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-60.26%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">14.60%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-63.30%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="121" HEIGHT="30" USERMARK="F-BT">당기순손익</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(6,987)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">12,476 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(26,073)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="73" HEIGHT="30" USERMARK="F-BT">(19,463)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">적자전환</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="61" HEIGHT="30" USERMARK="F-BT">38,548</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="76" HEIGHT="30" USERMARK="F-BT">흑자전환</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-14.15%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="66" HEIGHT="30" USERMARK="F-BT">21.70%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="82" HEIGHT="30" USERMARK="F-BT">-103.30%</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK=" 0X0000FF"> &cr;</SPAN>
<SPAN></SPAN>
<SPAN>당사의 전년대비 매출은 14.1% 하락한 약 494억원을 기록하였고, 영업손실은 298억원, 당기순손실은 70억으로 적자전환 하였습니다. &cr;</SPAN>
<SPAN>주요 적자전환 이유로는 지난해 후보물질 3건 기술이전에 따른 항체파트너사로의 기술료 지급과 임상개발지행에 따라 시료생산비용이 증가였으며, 신규 과제진행에 따른 연구개발비가 증가하였기 때문입니다. &cr;&cr;이와 별도로 영업손실이 2018년 11월 발행한 전환우선주의 콜옵션을 2020년 12월 전임직원에게 부여함에 따라 약 200억원의 일시적 비용이 발생하였으나, 이는 현금유출이 없는 비경상적인 회계처리비용이며 동일금액이 금융수익으로 계상되어 경상이익에는 영향을 주지 않았습니다.&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF">&cr;</SPAN>
<SPAN>매출원가는 의약사업부문만 해당되며 기술이전 매출액을 포함한 매출원가율은 &cr;39.5%입니다. &cr;연구개발비는 542억으로 전년대비 224.36% 증가하였으며, 이는 개발단계로 진입한 과제수의 증가로 인한 개발비가 증가되었기 때문입니다. &cr;</SPAN>
<SPAN USERMARK=" 0X0000FF"></SPAN>
</P>

<P>
<SPAN>나. 재무상태</SPAN>
<SPAN>(연결기준)</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="870" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="861"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="870" HEIGHT="30" USERMARK="F-BT">(단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="872">

<COLGROUP>
<COL WIDTH="156"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="165" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">　구  분</TH>
<TH COLSPAN="3" WIDTH="303" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">금액</TH>
<TH COLSPAN="2" WIDTH="202" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">제15기(전기대비)</TH>
<TH COLSPAN="2" WIDTH="202" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">제14기(전기대비)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">과목</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">제15기</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">제14기</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">제13기</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">증감액</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">변동(%)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">증감액</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">변동(%)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">유동자산</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">100,010 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">111,419</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">93,379</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(11,409)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-10.24%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">18,040</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">19.3%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">비유동자산</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">35,901 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">30,058</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">28,307</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">5,843 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">19.44%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">1,751</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">6.2%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">자산총계</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">135,911 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">141,477</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">121,686</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(5,566)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-3.93%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">19,791</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">16.3%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">유동부채</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">14,009 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">15,424</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">9,946</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(1,415)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-9.17%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">5,478</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">55.1%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">비유동부채</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">9,776 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">10,144</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">6,446</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(368)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-3.63%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">3,698</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">57.4%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">부채총계</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">23,785 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">25,568</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">16,392</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(1,783)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-6.97%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">9,177</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">56.0%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="165" HEIGHT="30" USERMARK="F-BT">자본총계</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">112,126 </TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">115,909</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">105,295</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">(3,783)</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">-3.26%</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">10,615</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="101" HEIGHT="30" USERMARK="F-BT">10.1%</TD>
</TR>
</TBODY>
</TABLE>

<P USERMARK=" 0X0000FF">&cr;
<SPAN USERMARK=" 0X000000">전기 대비하여 자산이 약 37억원 감소하였습니다. &cr;이는  신약개발부문의 연구개발비 증가가 주요 요인입니다. &cr;&cr;부채 총계는 전년대비 약 17억이 감소하였고, 이는 기술이전 매출 기간인식에 따른 선수금 감소 16억, 국책과제 기술료 감소 10억, 사옥보조금 수령에 따른 선수수익 증가 7억이 등이 주요인입니다.&cr;</SPAN>&cr;
<SPAN USERMARK=" 0X000000">자기자본은 38억이 감소되었고, 이는 기술개발비 증가로 인한 적자 전환이 주요요인입니다다.</SPAN>
<SPAN USERMARK=" 0X000000">&cr;</SPAN>
</P>

<P>
<SPAN>당사의 실적 및 자산현황과 관련한 자세한 사항은 본 사업보고서의 재무제표 및 첨부서류의 감사보고서 등을 참조하여주시기 바랍니다. &cr;</SPAN>
</P>

<P USERMARK=" 0X0000FF">
<SPAN USERMARK=" 0X000000"></SPAN>
<SPAN USERMARK=" 0X000000"></SPAN>
<SPAN USERMARK=" 0X000000">4</SPAN>
<SPAN USERMARK=" 0X000000">.유동성에 관한 분석</SPAN>
</P>

<TABLE WIDTH="589" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="580"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="589" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(단위:백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="588" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="138"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="138"></COL>
<COL WIDTH="138"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">과목</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">제15기</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">제14기</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">제13기</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">유동자산</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">100,010 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">111,419</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">93,379</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">비유동자산</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">35,901 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">30,058</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">28,307</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">자산총계</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">135,911 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">141,477</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">121,686</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">유동부채</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">14,009 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">15,424</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">9,946</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">비유동부채</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">9,776 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">10,144</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">6,446</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">부채총계</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">23,785 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">25,568</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">16,392</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">자본총계</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">112,126 </TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">115,909</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">105,295</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">유동비율</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">420.5%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">722.4%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">938.9%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">자기자본비율</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">82.5%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">81.9%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">86.5%</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">부채비율</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">21.2%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">22.1%</TD>
<TD WIDTH="147" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">15.6%</TD>
</TR>
</TBODY>
</TABLE>

<P USERMARK=" 0X0000FF">
<SPAN>&cr;</SPAN>
<SPAN USERMARK=" 0X000000">당사는 신약개발부문의 기술이전 계약건수 증가 및 개발단계 진척에 따라 받게 되는 마일스톤 수령에 따른 증가 및 국책과제 지원금 수령 등으로  2020년말 기준으로 현금성 자산 및 정기예금으로  약 768억원을 보유하고 있습니다.&cr;</SPAN>
<SPAN USERMARK=" 0X000000">당사의</SPAN>
<SPAN USERMARK=" 0X000000"> 20년 유동비율은 420.5% 자기자본비율 82.5%, 부채비율 21.2%로  재무건전성은 매우 우수한 편입니다.</SPAN>
</P>
<P USERMARK=" 0X0000FF"></P>

<P USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">5. 자금조달&cr;당사의 2019년말 사용가능한 기초 현금 잔액은 949억이었고, 2020년말 기준 현금 </SPAN>
<SPAN USERMARK=" 0X000000">유입액은 494억이며, 현금 유출액은  675억으로 사용 가능한 현금은 768억입니다.</SPAN>
<SPAN USERMARK=" 0X000000"> 2020년 현금 유입액 494억의 비중은 매출 86%, 증자,국책과제,차입금 9%, 예금이자 등 5%이며, 상세 내역은 아래와 같습니다.</SPAN>
</P>

<TABLE WIDTH="600" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="600" ALIGN="RIGHT" HEIGHT="30" USERMARK="F-BT">(단위:백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="600" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">구  분</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">금 액</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">비 중(%)</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">비  고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">매     출</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">42,290</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">86%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">증     자</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">1,474 </TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">3%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">정부보조금</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">1,474</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">3%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">차 입 금</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">1,712</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">3%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT BC0XD7D7D7">기     타</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">2,434</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">5%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주5)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT BC0XD7D7D7">계</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">49,385</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">100%</TD>
<TD WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">　</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN>주1) 매출은 입금 기준으로 부가세가 포함되어 있으며,기술이전 및 상품매출에 대한&cr;     매출채권 입금액입니다.&cr;</SPAN>
<SPAN>주2) 주식매수선택권 행사에 따른 증자입니다.&cr;</SPAN>
<SPAN></SPAN>
<SPAN>주3) 사옥건축 지방비 보조금입니다..&cr;주4) 사옥 신축용 토지분양대금에 대한 차입금 입니다.&cr;주5) 정기예금에 대한 이자수익, 부가세 등 세금 환급액, 고용지원금등입니다.</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>6. 부외부채의 사항&cr;당사는 사업보고서 제출일 향후 재무제표에 중대한 영향을 줄만한 채무보증, 특정거래에 관한 우발채무</SPAN>
<SPAN> 등의 부외거래가 없습니다.</SPAN>
<SPAN>&cr;&cr;7. 그 밖에 투자의사 결정에 필요한 사항&cr;가. 중요한 회계정책 및 추정에 관한 사항&cr;"중요한 회계정책 및 추정에 관한 사항"은 첨부하는 감사보고서를 참고하시기 바랍니다.&cr;&cr;나. 법규상의 규제에 관한 사항&cr;당사가 영위하는 업종에서 당사의 재무상태 및 영업실적에 중대한 영향을 미칠만한 법규상의 주요 규제 내용 등에 관해서는 해당사항이 없습니다. &cr;</SPAN>
</P>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-5-0-0">V. 감사인의 감사의견 등</TITLE>
<P></P>
<WARNING>※ 회계감사인의 감사(검토)의견, 회계감사인과의 감사/비감사 용역 체결현황이 있을 경우&cr;    아래 『회계감사인의 감사의견』단위서식을 클릭하여 삽입하신 후 입력하세요.</WARNING>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『회계감사인의 감사의견』 삽입</COMMENT>
<LIBRARYLIST>11011#*회계감사인의감사의견.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">25_회계감사인의감사의견</FILENAME>
<P>1. 회계감사인의 명칭 및 감사의견(검토의견 포함한다. 이하 이 조에서 같다)을 다음의 표에 따라 기재한다.</P>

<TABLE-GROUP ACLASS="AUD_OPN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="658" BORDER="1">

<COLGROUP>
<COL WIDTH="112"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="234"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="121" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">사업연도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">감사인</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">감사의견</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">강조사항 등</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="243" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">핵심감사사항</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="121" HEIGHT="30" ACODE="OPN_YEAR1" VALIGN="MIDDLE">제15기 (당기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_AUR1" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="OPN_CMT1" VALIGN="MIDDLE">적정</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_EMP1" VALIGN="MIDDLE">해당사항없음</TE>
<TE ALIGN="CENTER" WIDTH="243" HEIGHT="30" ACODE="OPN_POT1" VALIGN="MIDDLE">기술이전 수익인식의 적정성 평가</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="121" HEIGHT="30" ACODE="OPN_YEAR2" VALIGN="MIDDLE">제14기(전기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_AUR2" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="OPN_CMT2" VALIGN="MIDDLE">적정</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_EMP2" VALIGN="MIDDLE">해당사항없음</TE>
<TE ALIGN="CENTER" WIDTH="243" HEIGHT="30" ACODE="OPN_POT2" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="121" HEIGHT="30" ACODE="OPN_YEAR3" VALIGN="MIDDLE">제13기(전전기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_AUR3" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="OPN_CMT3" VALIGN="MIDDLE">적정</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="OPN_EMP3" VALIGN="MIDDLE">해당사항없음</TE>
<TE ALIGN="CENTER" WIDTH="243" HEIGHT="30" ACODE="OPN_POT3" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>2. 감사용역 체결현황은 다음의 표에 따라 기재한다.</P>

<TABLE-GROUP ACLASS="AUD_SIGK" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="813" BORDER="1">

<COLGROUP>
<COL WIDTH="117"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="348"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="39"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">사업연도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">감사인</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="357" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">내 용</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">감사계약내역</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">실제수행내역</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">보수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">시간</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">보수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">시간</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="126" HEIGHT="30" ACODE="SIGK_YEAR1" VALIGN="MIDDLE">제15기 (당기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SIGK_AUR1" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="357" HEIGHT="30" ACODE="SIGK_CNT1" VALIGN="MIDDLE">개별 반기검토 및 재무제표(K-IFRS) 감사</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_CPAY1" VALIGN="MIDDLE">80,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_CTIM1" VALIGN="MIDDLE">943</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_FPAY1" VALIGN="MIDDLE">80,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_FTIM1" VALIGN="MIDDLE">943</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="126" HEIGHT="30" ACODE="SIGK_YEAR2" VALIGN="MIDDLE">제14기 (전기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SIGK_AUR2" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="357" HEIGHT="30" ACODE="SIGK_CNT2" VALIGN="MIDDLE">별도 반기검토,별도 및 연결재무제표(K-IFRS) 감사</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_CPAY2" VALIGN="MIDDLE">75,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_CTIM2" VALIGN="MIDDLE">968</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_FPAY2" VALIGN="MIDDLE">75,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_FTIM2" VALIGN="MIDDLE">968</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="126" HEIGHT="30" ACODE="SIGK_YEAR3" VALIGN="MIDDLE">제13기 (전전기)</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SIGK_AUR3" VALIGN="MIDDLE">한울회계법인</TE>
<TE ALIGN="CENTER" WIDTH="357" HEIGHT="30" ACODE="SIGK_CNT3" VALIGN="MIDDLE">별도 반기검토,별도 및 연결재무제표(K-IFRS) 감사</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_CPAY3" VALIGN="MIDDLE">55,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_CTIM3" VALIGN="MIDDLE">858</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SIGK_FPAY3" VALIGN="MIDDLE">55,000</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="30" ACODE="SIGK_FTIM3" VALIGN="MIDDLE">858</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>3. 회계감사인과의 비감사용역 계약체결 현황은 다음의 표에 따라 기재한다.&cr;- 보고서 작성 기준일 현재 해당사항 없습니다.</P>

<TABLE-GROUP ACLASS="AUD_SIGL" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="600" BORDER="1">

<COLGROUP>
<COL WIDTH="138"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="70"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="147" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">사업연도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="101" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">계약체결일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">용역내용</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="115" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">용역수행기간</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">용역보수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="79" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="147" HEIGHT="60" ACODE="SIGL_YEAR1" VALIGN="MIDDLE" ROWSPAN="2">제15기 (당기)</TE>
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE1" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY1" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE1" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="147" HEIGHT="60" ACODE="SIGL_YEAR2" VALIGN="MIDDLE" ROWSPAN="2">제14기(전기)</TE>
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE2" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY2" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE2" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="147" HEIGHT="60" ACODE="SIGL_YEAR3" VALIGN="MIDDLE" ROWSPAN="2">제13기(전전기)</TE>
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE3" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="101" HEIGHT="30" ACODE="SIGL_CRT3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SIGL_CNT3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="115" HEIGHT="30" ACODE="SIGL_TIM3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="80" HEIGHT="30" ACODE="SIGL_PAY3" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="79" HEIGHT="30" ACODE="SIGL_NOTE3" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『내부감사기구가 회계감사인과 논의한 결과』 삽입</COMMENT>
<LIBRARYLIST>11011#*회계감사인과논의한결과.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">46_회계감사인과논의한결과</FILENAME>
<P>4. 재무제표 중 이해관계자의 판단에 상당한 영향을 미칠 수 있는 사항에 대해 내부감사기구가 회계감사인과 논의한 결과를 다음의 표에 따라 기재한다.</P>

<TABLE-GROUP ACLASS="DIS_CUS" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="777" BORDER="1">

<COLGROUP>
<COL WIDTH="74"></COL>
<COL WIDTH="121"></COL>
<COL WIDTH="172"></COL>
<COL WIDTH="123"></COL>
<COL WIDTH="242"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="83" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">구분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="130" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">일자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="181" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">참석자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="132" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">방식</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="251" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주요 논의 내용</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="83" HEIGHT="122" ACODE="DIS_DIV" VALIGN="MIDDLE">1</TE>
<TU ALIGN="CENTER" WIDTH="130" HEIGHT="122" AUNIT="DIS_DATE" AUNITVALUE="20200724" VALIGN="MIDDLE">2020년 07월 24일</TU>
<TE ALIGN="CENTER" WIDTH="181" HEIGHT="122" ACODE="DIS_ATT" VALIGN="MIDDLE">회사측: 감사, 재무이사 &cr;감사인측: 업무수행이사</TE>
<TE ALIGN="CENTER" WIDTH="132" HEIGHT="122" ACODE="DIS_WAY" VALIGN="MIDDLE">대면회의</TE>
<TE WIDTH="251" HEIGHT="122" ACODE="DIS_CONT" VALIGN="MIDDLE">- 연간 회계감사 수행계획&cr;- 핵심감사항목의 예비 선정 및 &cr;   유의적 위험 논의&cr;- 경영진 및 감사인의 책임에 대한    사항 설명</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="83" HEIGHT="76" ACODE="DIS_DIV" VALIGN="MIDDLE">2</TE>
<TU ALIGN="CENTER" WIDTH="130" HEIGHT="76" AUNIT="DIS_DATE" AUNITVALUE="20210217" VALIGN="MIDDLE">2021년 02월 17일</TU>
<TE ALIGN="CENTER" WIDTH="181" HEIGHT="76" ACODE="DIS_ATT" VALIGN="MIDDLE">회사측: 감사, 재무이사 감사인측: 업무수행이사</TE>
<TE ALIGN="CENTER" WIDTH="132" HEIGHT="76" ACODE="DIS_WAY" VALIGN="MIDDLE">대면회이</TE>
<TE WIDTH="251" HEIGHT="76" ACODE="DIS_CONT" VALIGN="MIDDLE">- 회계감사 결과 &cr;- 핵심감사사항 논의 &cr;- 감사인의 독립성</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<P>
<SPAN>5. 회계감사인의 변경</SPAN>
<SPAN>&cr;&cr;</SPAN>
<SPAN> 당사는 제15기(2020년)부터 제17기(2022년)까지 3년간 한울회계법인과 외부감사인 계약을 체결하였으나, 2019년 11월 주식회사 등의 외부감사에 관한 법률 제11조에 의거 주기적지정제에 해당되어 증권선물위원회로부터 제16기(2021년)부터 3년간 외부감사인(삼화회계법인)을 지정받아 선임하였습니다.&cr; &cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>6</SPAN>
<SPAN>. 내부통제에 관한 사항&cr;&cr;감사인은 첨부된 주식회사 레고켐 바이오사이언스의 2020년 12월 31일 현재의 내부회계관리제도의 운영실태보고서에 대하여 검토를 실시하였습니다. 내부회계관리제도를 설계, 운영하고 그에 대한 운영실태보고서를 작성할 책임은 주식회사 레고켐 바이오사이언스의 경영진에게 있으며, 감사인의 책임은 동 보고내용에 대하여 검토를 실시 하고 검토결과를 보고하는데 있습니다. 회사의 경영진은 첨부된 내부회계관리제도 운영실태보고서에서 "내부회계관리제도 운영실태 평가결과, 2020년 12월 31일 현재 당사의 내부회계관리제도는 내부회계관리제도 모범규준에 근거하여 볼 때, 중요성 의 관점에서 중요한 취약점이 발견되지 아니하였습니다"라고 기술하고 있습니다.&cr;감사인은 내부회계관리제도 검토기준에 따라 검토를 실시하였습니다. 이 기준은 감사인이 중요성의 관점에서 경영진이 제시한 내부회계관리제도의 운영실태보고서에 대하 여 회계감사보다는 낮은 수준의 확신을 얻을 수 있도록 검토절차를 계획하고 실시할 것을 요구하고 있습니다. 검토는 회사의 내부회계관리제도를 이해하고 경영진의 내부회계관리제도의 운영실태보고내용에 대한 질문 및 필요하다고 판단되는 경우 제한적 범위 내에서 관련 문서의 확인 등의 절차를 포함하고 있습니다. 그러나 회사는 상장중소기업으로서 경영자의 내부회계관리제도 구축과 운영, 그리고 이에 대한 운영 실태평가보고는 내부회계관리제도 모범규준 제5장 '중소기업에 대한 적용'의 규정에 따라 상장대기업보다는 현저하게 완화된 방식으로 이루어졌습니다. 따라서 우리는 내부회계관리제도 검토기준 중 '14. 중소기업 등에 대한 검토특례'에 따라 검토를 실시하였습니다. &cr;회사의 내부회계관리제도는 신뢰할 수 있는 회계정보의 작성 및 공시를 위하여 기업 회계기준에 따라 작성한 재무제표의 신뢰성에 대한 합리적인 확신을 줄 수 있도록 제정한 내부회계관리규정과 이를 관리ㆍ운영하는 조직을 의미합니다. 그러나 내부회계 관리제도는 내부회계관리제도의 본질적인 한계로 인하여 재무제표에 대한 중요한 왜곡표시를 적발하거나 예방하지 못할 수 있습니다. 또한, 내부회계관리제도의 운영실 태보고 내용을 기초로 미래기간의 내용을 추정시에는 상황의 변화 혹은 절차나 정책 이 준수되지 않음으로써 내부회계관리제도가 부적절하게 되어 미래기간에 대한 평가 및 추정내용이 달라질 위험에 처할 수 있다는 점을 고려하여야 합니다. &cr;경영진의 내부회계관리제도 운영실태보고서에 대한 감사인의 검토결과, 상기 경영진의 운영실태보고 내용이 중요성의 관점에서 내부회계관리제도 모범규준 제5장 '중소기 업에 대한 적용'의 규정에 따라 작성되지 않았다고 판단하게 하는 점이 발견되지 아니하였습니다. &cr;감사인의 검토는 2020년 12월 31일 현재의 내부회계관리제도를 대상으로 하였으며 2020년 12월 31일 이후의 내부회계관리제도는 검토하지 않았습니다. 본 검토보고서 는 주식회사등의외부감사에관한법률에 근거하여 작성된 것으로서 기타 다른 목적이나 다른 이용자를 위하여는 적절하지 않을 수 있습니다.&cr;</SPAN>
</P>
</LIBRARY>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『조정협의회내용 및 재무제표 불일치정보』 삽입</COMMENT>
<LIBRARYLIST>11011#*조정협의회내용및재무제표불일치정보.dsl</LIBRARYLIST>
</INSERTION>
<P></P>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y">VI. 이사회 등 회사의 기관에 관한 사항</TITLE>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-6-1-0">1. 이사회에 관한 사항</TITLE>

<P>
<SPAN USERMARK=" B">가 . 이사회 구성 개요&cr;</SPAN>
<SPAN USERMARK=" 0X0000FF B"></SPAN>
<SPAN USERMARK=" 0XFF0016 B"></SPAN>
<SPAN USERMARK=" 0XFF0016 B"></SPAN>
<SPAN USERMARK=" 0XFF0016 B"></SPAN>사업보고서 작성 제출일 현재 당사의 이사회는 사내이사 4명, 사외이사 2명, 상근 감사 1명으로 구성되어 있으며 이사회내에 별도의 위원회를 두고 있지 않습니다.&cr;
</P>
<P>이사회 의장을 겸직하고 있는 대표이사(김용주)는 회사를 대표하고 업무를 총괄하고 있으며, 이사는 대표이사를 보좌하고 이사회에서 정하는 바에 따라 회사의 업무를 분장 집행하고 있습니다.&cr;대표이사의 이사회 의장 선임 사유는 당사의 정관에 따른 것입니다. </P>

<TABLE BORDER="1" WIDTH="600" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="600" HEIGHT="237">
<P>제 41 조 (이사회의 구성과 소집)</P>
<P>① 이사회는 이사로 구성한다.</P>
<P>② 이사회는 대표이사(사장) 또는 이사회에서 따로 정한 이사가 있을 때에는 그 이사가 회일 7일 전에 각 이사 및 감사에게 통지하여 소집한다.</P>
<P>③ 제2항의 규정에 의하여 소집권자로 지정되지 않은 다른 이사는 소집권자인 이사에게 이사회 소집을 요구할 수 있다. 소집권자인 이사가 정당한 이유 없이 이사회 소집을 거절하는 경우에는 다른 이사가 이사회를 소집할 수 있다.</P>
<P>④ 이사 및 감사 전원의 동의가 있을 때에는 제2항의 소집절차를 생략할 수 있다.</P>
<P>⑤ 이사회의 의장은 제2항 및 제3항의 규정에 의한 이사회의 소집권자로 한다.</P>
<P>⑥ 이사는 3개월에 1회 이상 업무의 집행상황을 이사회에 보고하여야 한다.</P>
</TD>
</TR>
</TBODY>
</TABLE>
<P>이사의 주요 이력 및 인적사항은 본 보고서 「Ⅷ. 임원 및 직원 등에 관한 사항」을 참조하시기 바랍니다.</P>

<P>
<SPAN USERMARK=" 0XFF0016 B"></SPAN>
<SPAN></SPAN>&cr;
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" 0X1814FF"></SPAN>
<SPAN USERMARK=" B">나. 이사회의 중요 의결 사항</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="1454">

<COLGROUP>
<COL WIDTH="40"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="499"></COL>
<COL WIDTH="77"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="103"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT12" WIDTH="49" HEIGHT="137" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">회차</TH>
<TH USERMARK="F-BT12" WIDTH="107" HEIGHT="137" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">개최일자</TH>
<TH USERMARK="F-BT12" WIDTH="508" HEIGHT="137" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">의안내용 </TH>
<TH USERMARK="F-BT12" WIDTH="86" HEIGHT="137" ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">가결 여부</TH>
<TH USERMARK="F-BT12" WIDTH="704" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="6">이사의 성명</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="120" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사내이사&cr;김용주&cr;(출석율: 100%)</TH>
<TH WIDTH="120" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사내이사&cr;박세진&cr;(출석율: 100%)</TH>
<TH WIDTH="112" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사내이사&cr;조영락&cr;(출석율: 91%)</TH>
<TH WIDTH="112" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사내이사&cr;이창선&cr;(출석율: 91%)</TH>
<TH WIDTH="120" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사외이사&cr;맹필재&cr;(출석율: 100%)</TH>
<TH WIDTH="120" HEIGHT="76" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">사외이사&cr;송락경&cr;(출석율: 100%)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="704" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" COLSPAN="6">참석 및 찬반여부</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">1</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-03</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">불참</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">불참</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">2</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-10</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="55" VALIGN="MIDDLE">- 제14기 감사 전 별도 재무제표 승인의 건&cr;- 제14기 내부회계 관리제도 운영실태 평가보고</TD>

<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>가결</SPAN>
</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="55" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">3</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-10</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 타법인 주식 취득 결정의 건</TD>
<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">4</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-11</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 제14기 감사 전 연결 재무제표 승인의 건</TD>
<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">5</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-13</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 직원 대출분 정기예금 담보제공(근질권설정 계약)의 건</TD>
<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">6</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-02-24</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 직원 대출분 정기예금 담보제공(근질권설정 계약)의 건</TD>
<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT12" WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">7</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-03-04</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 제14기 정기주주총회 소집의 관한 건</TD>

<TD USERMARK="F-BT12" WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>가결</SPAN>
</TD>

<TD USERMARK="F-BT12" WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">8</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-03-16</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 제14기 별도 및 연결 재무제표 확정 승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">
<SPAN USERMARK="F-BT12">찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">9</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-03-31</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- (지분) 투자회사 정기주총 안건 및 결과 보고의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>

<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">
<SPAN>찬성</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">10</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-03-31</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 2020년 1분기 주식매수선택권 부여 취소의 건 </TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">11</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-04-01</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결 </TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">12</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-04-01</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 이사 및 감사 보수 결정의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">13</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-01</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자) 승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">14</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-01</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">15</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-02</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">16</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-04</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">17</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-05</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 기업시설일반자금 대출 차입에 관한건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">불참</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">불참</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">18</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-05</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">19</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-06-09</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">20</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-07-24</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">21</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-07-27</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- (신규시설투자) (둔곡지구) 사옥 신축 신규 투자 결정의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">22</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-08-03</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">23</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-09-10</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">24</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-11-02</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">25</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-11-06</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 기업시설일반자금대출 차입에 관한건.</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">26</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-12-30</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 전환우선주의 매도청구권(Call-Option)부여의 건.</TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="49" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">27</TD>
<TD USERMARK="F-BT12" WIDTH="107" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">2020-12-30</TD>
<TD USERMARK="F-BT12" WIDTH="508" HEIGHT="31" VALIGN="MIDDLE">- 2020년 4분기 주식매수선택권 부여 취소의 건 </TD>
<TD WIDTH="86" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE">가결</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="112" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
<TD WIDTH="120" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK="F-BT12">찬성</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11">&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK=" B">다.</SPAN>
<SPAN USERMARK=" B"> 이사회에서의 사외이사 주요 활동내역</SPAN>
<SPAN USERMARK="F-11"></SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="611">

<COLGROUP>
<COL WIDTH="44"></COL>
<COL WIDTH="146"></COL>
<COL WIDTH="291"></COL>
<COL WIDTH="94"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">회 차</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">개최일자</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">사외이사 참석인원</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">비 고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">1</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-03</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-10</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">3</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-10</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">4</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-11</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">5</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-13</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">6</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-02-24</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">7</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-03-04</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">8</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-03-16</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK=" 0X1814FF">
<SPAN USERMARK=" 0X000000">가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">9</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-03-31</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">10</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-03-31</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">11</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-04-01</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">12</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-04-01</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">13</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-01</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">14</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-01</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">15</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-02</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">16</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-04</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">17</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-05</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">18</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-05</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">19</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-06-09</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">20</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-07-24</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">21</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-07-27</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">
<SPAN>맹필재, 송락경</SPAN>
</TD>

<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<SPAN>가결</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">22</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-08-03</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">23</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-09-10</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">24</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-11-02</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">
<SPAN>맹필재, 송락경</SPAN>
</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">25</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-11-06</TD>

<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">
<SPAN>맹필재, 송락경</SPAN>
</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">26</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-12-30</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">27</TD>
<TD WIDTH="155" VALIGN="MIDDLE" ALIGN="CENTER" USERMARK="F-BT12" HEIGHT="31">2020-12-30</TD>
<TD WIDTH="300" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT12">맹필재, 송락경</TD>
<TD WIDTH="103" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">가결</TD>
</TR>
</TBODY>
</TABLE>

<P USERMARK=" B">
<SPAN USERMARK="F-11 !B">&cr;</SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>라. 이사회내 위원회 구성 현황과 활동 내역&cr;</SPAN>
<SPAN USERMARK=" !B"></SPAN>
<SPAN USERMARK=" !B"></SPAN>
<SPAN USERMARK=" !B">당사는 이사회내 위원회가 구성되어 있지 않습니</SPAN>
<SPAN USERMARK=" !B">다.&cr;</SPAN>
<SPAN>&cr;</SPAN>
<SPAN>마. 이사의 독립성</SPAN>
</P>
<P>본 보고서 작성 기준일 현재 당사의 이사회는 대표이사 1인, 사내이사  3인, 사외이사 2인으로 총 6인으로 구성되어 있으며, 회사의 중요한 의사결정과 업무집행은 이사회의 심의 및 결정을 통해 이루어지고 있습니다. &cr;&cr;당사는 이사의 독립성 강화를 위해 이사 선임시 주주총회 전이사에 대한 모든 정보를 투명하게 공개하여 추천인, 회사와의 거래, 최대주주와의 관계 등에 대하여 외부에 공시하고 있습니다.</P>
<P></P>
<P>사외이사 및 그 변동현황</P>

<TABLE-GROUP ACLASS="OUT_DIR" ADELETETABLE="N">

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="300" HEIGHT="30" AUPDATECONT="N" VALIGN="MIDDLE"></TD>
<TD WIDTH="300" HEIGHT="30" AUPDATECONT="N" VALIGN="MIDDLE" ALIGN="RIGHT">(단위 : 명)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="121"></COL>
<COL WIDTH="120"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="100"></COL>
<COL WIDTH="113"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="130" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">이사의 수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="129" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">사외이사 수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="340" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="3">사외이사 변동현황</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="109" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">선임</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="109" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">해임</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="122" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">중도퇴임</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="RIGHT" WIDTH="130" HEIGHT="30" ACODE="DIR_NUM" VALIGN="MIDDLE">6</TE>
<TE ALIGN="RIGHT" WIDTH="129" HEIGHT="30" ACODE="ODIR_NUM" VALIGN="MIDDLE">2</TE>
<TE ALIGN="RIGHT" WIDTH="109" HEIGHT="30" ACODE="ODIR_PRE" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="109" HEIGHT="30" ACODE="ODIR_DIS" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="122" HEIGHT="30" ACODE="ODIR_RET" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『사외이사 교육실시 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*_사외이사_교육_*.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">40_02_사외이사_교육_미실시내역</FILENAME>
<P>사외이사 교육 미실시 내역</P>

<TABLE-GROUP ACLASS="ODRT_EDU_NOT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="714" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="505"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="200" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">사외이사 교육 실시여부</TH>
<TH WIDTH="514" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">사외이사 교육 미실시 사유</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="200" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168" AUPDATECONT="N">미실시</TD>
<TE WIDTH="514" HEIGHT="168" ACODE="ODRT_EDU_NOT_DTL">- 당사는 공시대상기간 중 이사를 대상으로 교육을 실시하거나 위탁교육 등 외부기관이 제공하는 교육을 이수하도록 한 바 없습니다.&cr;- 당사는 이사가 업무 수행함에 있어 전문적인 직무수행이 가능하도록 보조하고 있습니다. &cr;관련 내용을 충분히 검토할 수 있도록 사전에 자료를 제공하고기타 주요 현안에 대해서도 수시로 정보를 제공하고 있습니다.&cr;향후 직무관련 교육의 기회가 있으면 적극적으로 참여할 계획입니다.</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-6-2-0">2. 감사제도에 관한 사항</TITLE>

<P>
<SPAN USERMARK=" B">가. 감사위원회(감사) 설치 여부&cr;</SPAN>당사는 본 보고서 제출일 현재 감사위원회를 별도로 설치하고 있지 아니하며, 정기주주총회 결의에 의하여 선임된 상근 감사 1명(박두원)이 감사업무를 수행하고 있습니다. &cr;&cr;
<SPAN></SPAN>
<SPAN USERMARK=" B">나. 감사의 독립성&cr;</SPAN>감사는 이사회에 참석하여 독립적으로 이사의 업무를 감독할 수 있으며, 제반업무와 관련하여 관련 장부 및 관계서류를 해당 부서에 제출을 요구할 수 있습니다. 또한, 필요시 회사로부터 연구개발 및 영업에 관한 사항을 보고 받을 수 있으며, 적절한 방법으로 경영정보에 접근할 수 있습니다. &cr;&cr;
<SPAN USERMARK=" B">다. 감사의 인적사항</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="600" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="78"></COL>
<COL WIDTH="383"></COL>
<COL WIDTH="112"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="87" HEIGHT="31" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT12">성 명</TH>
<TH ALIGN="CENTER" WIDTH="392" HEIGHT="31" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT12">주요 경력</TH>
<TH ALIGN="CENTER" WIDTH="121" HEIGHT="31" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" USERMARK="F-BT12">비 고</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="87" HEIGHT="127" USERMARK="F-BT12">박두원</TD>

<TD WIDTH="392" HEIGHT="127">
<P USERMARK="F-BT12">한양대 공과대학 공업화학과 졸업</P>
<P USERMARK="F-BT12">충남대 경영대학원 회계학 석사</P>
<P USERMARK="F-BT12">전 LG 화학 부장</P>
<P USERMARK="F-BT12">전 ㈜한국기술연구소 대표이사</P>
<P USERMARK="F-BT12">현 화일약품㈜ 사외이사</P>
</TD>
<TD WIDTH="121" HEIGHT="127" USERMARK="F-BT12" VALIGN="MIDDLE" ALIGN="CENTER">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<P USERMARK=" B">라
<SPAN></SPAN>
<SPAN>. 감사의 주요 활동내역</SPAN>
</P>

<TABLE ACLASS="NORMAL" WIDTH="663" BORDER="1" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="98"></COL>
<COL WIDTH="499"></COL>
<COL WIDTH="39"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" WIDTH="107" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">개최일자</TH>
<TH ALIGN="CENTER" WIDTH="508" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">주 요 내 용 </TH>
<TH ALIGN="CENTER" WIDTH="48" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비고</TH>
</TR>
</THEAD>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12">2020-02-03</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="55" USERMARK="F-BT12">2020-02-10</TD>
<TD WIDTH="508" HEIGHT="55" USERMARK="F-BT12">- 제14기 감사 전 별도 재무제표 승인의 건&cr;- 제14기 내부회계 관리제도 운영실태 평가보고</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="55">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-02-10</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 타법인 주식 취득 결정의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-02-11</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 제14기 감사 전 연결 재무제표 승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-02-13</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 직원 대출분 정기예금 담보제공(근질권설정 계약)의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-02-24</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 직원 대출분 정기예금 담보제공(근질권설정 계약)의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-03-04</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 제14기 정기주주총회 소집의 관한 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-03-16</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 제14기 별도 및 연결 재무제표 확정 승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-03-31</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- (지분) 투자회사 정기주총 안건 및 결과 보고의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-03-31</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 2020년 1분기 주식매수선택권 부여 취소의 건 </TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-04-01</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-04-01</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 이사 및 감사 보수 결정의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-01</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자) 승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-01</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-02</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-04</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-05</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 기업시설일반자금 대출 차입에 관한건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-05</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-06-09</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 준비금(주식발행초과금)의 자본전입(무상증자)관한 정정  승인의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-07-24</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-07-27</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- (신규시설투자) (둔곡지구) 사옥 신축 신규 투자 결정의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-08-03</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-09-10</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-11-02</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 주식매수선택권 부여의 건</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-11-06</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 기업시설일반자금대출 차입에 관한건.</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-12-30</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 전환우선주의 매도청구권(Call-Option)부여의 건.</TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="107" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">2020-12-30</TD>
<TD WIDTH="508" HEIGHT="31" USERMARK="F-BT12" VALIGN="MIDDLE">- 2020년 4분기 주식매수선택권 부여 취소의 건 </TD>
<TD ALIGN="CENTER" WIDTH="48" HEIGHT="31" VALIGN="MIDDLE">-</TD>
</TR>
</TBODY>
</TABLE>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="Y">
<COMMENT>◆click◆『감사위원회 위원의 인적사항 및 사외이사 여부』 삽입</COMMENT>
<LIBRARYLIST>11011#*감사위원현황.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="E1" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『감사위원회(감사) 교육실시 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*_감사*_교육_*.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">41_04_감사_교육_미실시내역</FILENAME>
<P>감사 교육 미실시 내역</P>

<TABLE-GROUP ACLASS="ADT_EDU_NOT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="709" BORDER="1">

<COLGROUP>
<COL WIDTH="191"></COL>
<COL WIDTH="500"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="200" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">감사 교육 실시여부</TH>
<TH WIDTH="509" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">감사 교육 미실시 사유</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="200" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="168" AUPDATECONT="N">미실시</TD>
<TE WIDTH="509" HEIGHT="168" ACODE="ADT_EDU_NOT_DTL">- 당사는 공시대상기간 중 감사를 대상으로 교육을 실시하거나 위탁교육 등 외부기관이 제공하는 교육을 이수하도록 한 바 없습니다.&cr;- 당사는 감사가 업무 수행함에 있어 전문적인 직무수행이 가능하도록 보조하고 있습니다. &cr;관련 내용을 충분히 검토할 수 있도록 사전에 자료를 제공하고기타 주요 현안에 대해서도 수시로 정보를 제공하고 있습니다.&cr;향후 직무관련 교육의 기회가 있으면 적극적으로 참여할 계획입니다.</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P></P>

<INSERTION ABASISNUMBER="E1" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『감사위원회(감사) 지원조직 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*_감사*_지원조직_*.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">42_02_감사_지원조직_현황</FILENAME>
<P>감사 지원조직 현황</P>

<TABLE-GROUP ACLASS="ADT_OGN" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="723" BORDER="1">

<COLGROUP>
<COL WIDTH="84"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="258"></COL>
<COL WIDTH="264"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="93" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">부서(팀)명</TH>
<TH WIDTH="90" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">직원수(명)</TH>
<TH WIDTH="267" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">직위(근속연수)</TH>
<TH WIDTH="273" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">주요 활동내역</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="ADT_OGN_NM">경영관리팀</TE>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="ADT_OGN_CNT">3</TE>
<TE WIDTH="267" VALIGN="MIDDLE" HEIGHT="53" ACODE="ADT_OGN_PST" ALIGN="CENTER">이사1명, 부장1명, 과장1명(평균 7년)</TE>
<TE WIDTH="273" VALIGN="MIDDLE" HEIGHT="53" ACODE="ADT_OGN_DTL">재무제표, 이사회 등 경영전반에 관한 &cr;감사직무 수행지원</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
</LIBRARY>
</INSERTION>

<P>
<SPAN USERMARK=" B">마. 준법지원인 지원조직 현황&cr;</SPAN>
<SPAN>당사는 보고서 제출일 현재 해당사항 없습니다.</SPAN>
</P>

<INSERTION ABASISNUMBER="E1" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『준법지원인 등 지원조직 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*_준법지원인등_지원조직_*.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">43_02_준법지원인등_지원조직_해당사항없음</FILENAME>

<INSERTION ABASISNUMBER="E0" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>지원조직이 없는 경우에는 그 사실을 기재한다.</COMMENT>
<LIBRARYLIST></LIBRARYLIST>
</INSERTION>
</LIBRARY>
</INSERTION>
<P></P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-6-3-0">3. 주주의 의결권 행사에 관한 사항</TITLE>

<P>가. 투표제도&cr;
<SPAN>(1) 집중투표제의 채택여부</SPAN>
</P>
<P>당사는 본 보고서 작성 기준일 현재 집중투표제를 채택하고 있지 않습니다. </P>
<P>&cr;(2) 서면투표제 또는 전자투표제의 채택여부</P>
<P>당사는 본 보고서 작성 기준일 현재 서면투표제 또는 전자투표제를 채택하고 있지 않습니다. </P>
<P>  </P>
<P>나. 소수주주권의 행사여부</P>
<P>당사는 본 보고서 작성 기준일 현재 해당사항 없습니다. &cr;</P>

<P>
<SPAN>다. 경영권 경쟁 여부&cr;</SPAN>당사는 본 보고서 작성 기준일 현재 경영권과 관련하여 경쟁이 발생한 사실이 없으므로 해당사항이 없습니다.
</P>
<P></P>
<PGBRK></PGBRK>
</SECTION-2>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-7-0-0">VII. 주주에 관한 사항</TITLE>
<P></P>
<P USERMARK="F-16">최대주주 및 특수관계인의 주식소유 현황</P>

<TABLE-GROUP ACLASS="BSH_SPCL" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="653" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="333"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="SH5_CUR_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="342" HEIGHT="30" AUNIT="STOCKPERCENT" AUNITVALUE="1">(단위 : 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="653" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="59"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="120"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">성 명</TH>
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">관 계</TH>
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식의&cr;종류</TH>
<TH COLSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="310" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">소유주식수 및 지분율</TH>
<TH ROWSPAN="3" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="129" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="163" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기 초</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="147" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기 말</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="100" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">지분율</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="84" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">지분율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김용주</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">본인 </TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">1,239,514</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">10.29</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">2,479,028</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">10.28</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">대표이사</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">박세진</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">등기임원</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">230,764</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">1.92</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">461,528</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">1.91</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">수석부사장/CFO</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">조영락</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">등기임원</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">3,430</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.02</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">6,860</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.03</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">이법표</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">등기임원</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">20,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.17</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">0</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">주1)</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김용만 </TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">6,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.05</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">12,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.05</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김용근</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">15,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.12</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">30,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.12</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김홍규</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">7,800</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.06</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">15,600</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.06</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김용운</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">3,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.02</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">6,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.02</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김태형</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">4,500</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.04</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">9,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.04</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">황태원</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_RET" VALIGN="MIDDLE">친인척</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="68" HEIGHT="30" ACODE="STK_KND">보통주 </TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="SH5_BGN_CNT" VALIGN="MIDDLE">1,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_BGN_RT" VALIGN="MIDDLE">0.01</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_END_CNT" VALIGN="MIDDLE">2,000</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="SH5_END_RT" VALIGN="MIDDLE">0.01</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE5" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ROWSPAN="2" COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="146" HEIGHT="60" AUPDATECONT="N">계</TD>
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_STK_KNDT" VALIGN="MIDDLE">보통주</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="STK_CNT_BIML" VALIGN="MIDDLE">1,531,008</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="STK_RATE_BIML" VALIGN="MIDDLE">12.74</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="STK_CNT_GIML" VALIGN="MIDDLE">3,022,016</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="STK_RATE_GIML" VALIGN="MIDDLE">12.54</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE4" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="68" HEIGHT="30" ACODE="SH5_STK_KNDT" VALIGN="MIDDLE">우선주</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="30" ACODE="STK_CNT_BIML" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="STK_RATE_BIML" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="STK_CNT_GIML" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="63" HEIGHT="30" ACODE="STK_RATE_GIML" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="129" HEIGHT="30" ACODE="NOTE4" VALIGN="MIDDLE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P USERMARK="F-11">주1) 이법표 부사장은 3월4일 일신상의 이유로 사임하였습니다.</P>

<P>
<SPAN USERMARK="F-11">주2) 기초와 기말의 지분율 변동사유는 신규 상장에 의한 지분율 변동입니다. &cr;주3) 위의 표 기말 지분율은 발행주식 총수 기준 (24,106,342주)으로 작성하였습니다.&cr;</SPAN>
</P>
<P USERMARK="F-16">최대주주의 주요경력 및 개요</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="782">

<COLGROUP>
<COL WIDTH="83"></COL>
<COL WIDTH="63"></COL>
<COL WIDTH="231"></COL>
<COL WIDTH="369"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH USERMARK="F-BT12" WIDTH="92" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">직위</TH>
<TH USERMARK="F-BT12" WIDTH="72" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">성명</TH>
<TH USERMARK="F-BT12" WIDTH="240" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">학력</TH>
<TH USERMARK="F-BT12" WIDTH="378" HEIGHT="31" ALIGN="CENTER" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">경력</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD USERMARK="F-BT" WIDTH="92" HEIGHT="151" ALIGN="CENTER" VALIGN="MIDDLE">대표이사&cr;(상근/등기)</TD>
<TD USERMARK="F-BT" WIDTH="72" HEIGHT="151" ALIGN="CENTER" VALIGN="MIDDLE">김용주</TD>

<TD WIDTH="240" HEIGHT="151">
<P USERMARK="F-BT">1983.02 한국과학원 화학과 &cr;           (유기화학) 이학박사</P>
<P USERMARK="F-BT">1980.02 한국과학원 화학과 &cr;           (유기화학) 이학석사</P>
<P USERMARK="F-BT">1978.02 서울대학교 자연과학대학           화학과 학사 </P>
</TD>

<TD WIDTH="378" HEIGHT="151">
<P USERMARK="F-BT"> 83.01 ~ 97.11 ㈜LG화학 기술연구원 연구위원&cr; 97.12 ~ 00.08 ㈜LG화학기술연구원연구소장, &cr;                       LG BMI 법인장&cr; 00.08 ~ 06.04 ㈜LG생명과학기술연구원&cr;                     신약연구소장/연구위원&cr; 06.05 ~ 현재  ㈜레고켐 바이오사이언스 대표이사</P>
</TD>
</TR>
</TBODY>
</TABLE>

<INSERTION ABASISNUMBER="LE0" AFREQUENCY="0" ADUPLICATION="Y">
<COMMENT>◆복수click가능◆『최대주주가 법인 또는 투자조합 등 단체인 경우』 삽입</COMMENT>
<LIBRARYLIST>11011#*최대주주가단체인경우.dsl</LIBRARYLIST>
</INSERTION>

<P>
<SPAN>2. 최대주주 변동 현황&cr;</SPAN>
<SPAN>당사는 설립일 이후부터 현재까지 대표이사이며 최대주주인 김용주 대표이사의  변동 사실이 없습니다.&cr;&cr;</SPAN>
<SPAN>3</SPAN>
<SPAN>. 주식 분</SPAN>
<SPAN>포현황&cr;</SPAN>
<SPAN USERMARK="F-16"></SPAN>
<SPAN>가. 5% 이상 주주와 우리사</SPAN>
<SPAN>주조합 등의 주식 소유현황 </SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK="F-16 B"></SPAN>
<SPAN>본 보고서 작성 기준일 현재 최대주주 겸 대표이사 김용주를 제외하고 5%이상 지분을 보유하고 있는 주주는 조</SPAN>
<SPAN>긍수 주주이며 7.00%를 보유중입니다.&cr;</SPAN>
</P>
<P USERMARK="F-16">최대주주의 최대주주(법인 또는 단체)의 개요</P>

<INSERTION ABASISNUMBER="LE0" AFREQUENCY="0" ADUPLICATION="Y">
<COMMENT>◆복수click가능◆『최대주주의 최대주주(최대출자자)가 법인 또는 단체인 경우』 삽입</COMMENT>
<LIBRARYLIST>11011#*최대주주의최대출자자가단체인경우.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『최대주주 변동내역』 삽입</COMMENT>
<LIBRARYLIST>11011#*최대주주변동내역.dsl</LIBRARYLIST>
</INSERTION>
<P>주식 소유현황</P>

<TABLE-GROUP ACLASS="SH5_PRE_STT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="601" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="63"></COL>
<COL WIDTH="290"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="72" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="299" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="98"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="107"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="163"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="107" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">구분</TH>
<TH WIDTH="115" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">주주명</TH>
<TH WIDTH="116" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">소유주식수</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">지분율</TH>
<TH WIDTH="172" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ROWSPAN="2" AUPDATECONT="N">5% 이상 주주</TD>
<TE WIDTH="115" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="SH5_NM">김용주</TE>
<TE WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_TOT_CNT">2,479,028</TE>
<TE WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_TOT_RT">10.28</TE>
<TD WIDTH="172" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="115" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="SH5_NM">조긍수</TE>
<TE WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_TOT_CNT">1,687,399</TE>
<TE WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_TOT_RT">7.00</TE>
<TD WIDTH="172" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="222" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" COLSPAN="2" AUPDATECONT="N">우리사주조합</TD>
<TE WIDTH="116" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_WOO_CNT">-</TE>
<TE WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH5_WOO_RT">-</TE>
<TD WIDTH="172" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<P>
<SPAN USERMARK="F-11">주) 위의 표 지분율은 발행주식 총수</SPAN>
<SPAN USERMARK="F-11"> 기준 </SPAN>
<SPAN USERMARK="F-11"> (24,106,342주)으</SPAN>
<SPAN USERMARK="F-11">로 작성하였습니다.</SPAN>
</P>
<P USERMARK="F-11"></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『소액주주현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*소액주주현황.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">10_소액주주현황</FILENAME>

<TABLE-GROUP ACLASS="SH4_PRE_STT" ADELETETABLE="N">
<TITLE ATOC="N">소액주주현황</TITLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="550" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="244"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="253" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="551" BORDER="1">

<COLGROUP>
<COL WIDTH="69"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="44"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="78" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="83" ROWSPAN="2">구 분</TH>
<TH WIDTH="181" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" COLSPAN="3">주주</TH>
<TH WIDTH="239" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" COLSPAN="3">소유주식</TH>
<TH WIDTH="53" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="83" ROWSPAN="2">비 고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="63" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">소액&cr;주주수</TH>
<TH WIDTH="63" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">전체&cr;주주수</TH>
<TH WIDTH="55" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">비율&cr;(%)</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">소액&cr;주식수</TH>
<TH WIDTH="92" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">총발행&cr;주식수</TH>
<TH WIDTH="55" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">비율&cr;(%)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">소액주주</TD>
<TE WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_JJ_CNT">42,357</TE>
<TE WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_JJ_CNTT">42,367</TE>
<TE WIDTH="55" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_JJ_RT">99.97</TE>
<TE WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_BB_CNT">15,535,615</TE>
<TE WIDTH="92" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_BB_CNTT">24,106,342</TE>
<TE WIDTH="55" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="SH4_BB_RT">64.45</TE>
<TE WIDTH="53" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<P>
<SPAN USERMARK="F-11">주) 위의 표는 기준일 당시 발행주식 총수 기준으로 작성하였습니다.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK=" B">4. 주식 사무</SPAN>
<SPAN USERMARK=" 0X0000FF BI"></SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>

<TABLE BORDER="1" WIDTH="708" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="130"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="72"></COL>
<COL WIDTH="26"></COL>
<COL WIDTH="319"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="766" USERMARK="F-BT">정관상&cr; 신주인수권의&cr; 내용</TD>

<TD COLSPAN="4" WIDTH="569" HEIGHT="766">
<P USERMARK="F-BT">제 10 조 (신주인수권)&cr;</P>
<P USERMARK="F-BT">①주주는 그가 소유한 주식의 수에 비례하여 신주의 배정을 받을 권리를 갖는다.</P>
<P USERMARK="F-BT">②회사는 제1항의 규정에도 불구하고 다음 각 호의 어느 하나에 해당하는 경우 이사회의 결의로 특정한 자(당 회사의 주식을 소유한 자를 포함한다)에게 신주를 배정할 수 있다.</P>
<P USERMARK="F-BT">1.발행주식총수의 100 분의 50을 초과하지 않는 범위 내에서 자본시장과 금융투자업에 관한 법률 제 165 조의 6에 따라 일반공모증자 방식으로 신주를 발행하는 경우</P>
<P USERMARK="F-BT">2.상법 제 542 조의 3에 따른 주식매수선택권의 행사로 인하여 신주를 발행하는 경우</P>
<P USERMARK="F-BT">3.우리사주조합원에게 주식을 배정하는 경우</P>
<P USERMARK="F-BT">4. 발행주식총수의 100분의 50을 초과하지 않는 범위 내에서 사업상 중요한 기술도입, 연구개발, 생산·판매·자본제휴를 위하여 그 상대방에게 신주를 발행하는 경우5. 주권을 코스닥 시장 또는 유가증권시장에 신규 상장하기 위하여 신주를 모집하거나 인수인에게 인수하게 하는 경우</P>
<P USERMARK="F-BT">6. 자본시장과 금융투자업에 관한 법률 제 165 조의 16에 의하여 아사회의 결의로 외국주식예탁증권(DR)발행에 따라 신주를 발행하는 경우</P>
<P USERMARK="F-BT">7. 발행주식총수의 100분의 50을 초과하지 않는 범위 내에서 긴급한 자금조 달을 위하여 국내외 금융기관 또는 기관투자자에게 신주를 발행하는 경우</P>
<P USERMARK="F-BT">8. 발행주식총수의 100분의 50을 초과하지 않는 범위 내에서 임상실험 등 회사 전략상 필요한 자금의 조달을 위하여 국내외 법인에 신주를 발행하 는 경우.</P>
<P USERMARK="F-BT">9. 발행주식총수의 100분의 50을 초과하지 않는 범위 내에서 전략적 제휴상 의 필요로 그 제휴회사에 신주를 발행하는 경우</P>
<P USERMARK="F-BT">10. 「근로복지기본법」 제39조의 규정에 의한 우리사주매수선택권의 행사로 인하여 신주를 발행하는 경우&cr;③ 신주인수권의 포기 또는 상실에 따른 주식과 신주배정에서 발생한 단주에 대한 처리방법은 이사회의 결의로 정한다.</P>
<P USERMARK="F-BT">④ 제2항 각 호 중 어느 하나의 규정에 의해 신주를 발행할 경우 발행할 주식의 종류와 수 및 발행가격 등은 이사회 결의로 정한다.</P>
<P USERMARK="F-BT">⑤ 제2항에 따라 주주 외의 자에게 신주를 배정하는 경우 회사는 상법 제 416조 제1호, 제2호, 제2호의2, 제3호 및 제4호에서 정하는 사항을 그 납입기일의 2주 전까지 주주에게 통지하거나 공고하여야 한다. 다만, 금 융위원회에 제출한 주요사항보고서가 금융위원회와 거래소에 공시된 경우에는 적용하지 아니한다.</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">결산일</TD>

<TD WIDTH="125" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">
<SPAN USERMARK="F-BT">매년</SPAN>
<SPAN USERMARK="F-BT"> 12월 31일</SPAN>
</TD>
<TD COLSPAN="2" WIDTH="116" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">정기주주총회</TD>
<TD WIDTH="328" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">매 사업연도 종료 후 3개월 이내</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="35" USERMARK="F-BT">주주명부폐쇠시기</TD>
<TD COLSPAN="4" WIDTH="569" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="35" USERMARK="F-BT">매년 1월 1일부터 1월 15일까지</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주권의 종류</TD>
<TD COLSPAN="4" WIDTH="569" HEIGHT="30" USERMARK="F-BT"> 일주권, 오주권, 일십주권, 오십주권, 일백주권, 오백주권, 일천주권, 일만주권(8종)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31" USERMARK="F-BT">명의개서대리인</TD>

<TD COLSPAN="4" WIDTH="569" VALIGN="MIDDLE" HEIGHT="31">
<SPAN USERMARK="F-BT"> 한국예탁결제원 </SPAN>
<SPAN USERMARK="F-BT">증권대행부</SPAN>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="139" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">주주의 특전</TD>
<TD WIDTH="125" VALIGN="MIDDLE" HEIGHT="122" USERMARK="F-BT"> 해당사항 없음</TD>
<TD WIDTH="81" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122" USERMARK="F-BT">공고게재</TD>
<TD COLSPAN="2" WIDTH="363" VALIGN="MIDDLE" HEIGHT="122" USERMARK="F-BT">회사의 인터넷 홈페이지(www.legochembio.com)에 한다. 다만, 전산장애 또는 그 밖의 부득이한 사유로 회사의 인터넷 홈페이지에 공고를 할 수 없는 때에는서울특별시내에서 발행하는 일간 매일경제신문에 게재한다. </TD>
</TR>
</TBODY>
</TABLE>
<P> </P>

<P>
<SPAN USERMARK=" B">5</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B">. 주가 및 주식 거래 실적</SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN USERMARK=" B"></SPAN>
<SPAN>&cr;한국거래소 코스닥 시장 - 보통주(141080)                                      (단위:원, 천주)</SPAN>
</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="693">

<COLGROUP>
<COL WIDTH="49"></COL>
<COL WIDTH="44"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
<COL WIDTH="92"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="111" HEIGHT="30" COLSPAN="2" ALIGN="CENTER" USERMARK=" BC0XD7D7D7">구   분</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 07월</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 08월</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 09월</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 10월</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 11월</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="CENTER" VALIGN="MIDDLE" USERMARK=" BC0XD7D7D7">2020년 12월</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="58" HEIGHT="60" ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE">주  가</TD>
<TD WIDTH="53" HEIGHT="30" ALIGN="CENTER">최 고</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">67,400</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">59,200</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">71,600</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">64,600</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">58,000</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">74,900</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="53" HEIGHT="30" ALIGN="CENTER">최 저</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">42,100</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">46,050</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">49,350</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">50,300</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">50,200</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">54,800</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="111" HEIGHT="30" COLSPAN="2" ALIGN="CENTER">월간 거래량</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">39,443</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">15,567</TD>
<TD WIDTH="93" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">38,847</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">12,622</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">8,821</TD>
<TD WIDTH="101" HEIGHT="30" ALIGN="RIGHT" VALIGN="MIDDLE">30,019</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
</LIBRARY>
</INSERTION>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y">VIII. 임원 및 직원 등에 관한 사항</TITLE>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-8-1-0">1. 임원 및 직원 등의 현황</TITLE>
<P></P>
<P>임원 현황</P>

<TABLE-GROUP ACLASS="SH5_DRCT_STT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="931" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="582"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="108" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="591" HEIGHT="30" AUNIT="STOCK" AUNITVALUE="1">(단위 : 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1053" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="54"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="83"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">성명</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">성별</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">출생년월</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">직위</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">등기임원&cr;여부</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">상근&cr;여부</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">담당&cr;업무</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주요경력</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="167" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">소유주식수</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최대주주와의&cr;관계</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">재직기간</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">임기&cr;만료일</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="84" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">의결권&cr;있는 주식</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="83" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">의결권&cr;없는 주식</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">김용주</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="195605" VALIGN="MIDDLE">1956.05</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">대표이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="1" VALIGN="MIDDLE">상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">회사총괄</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">2,479,028</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">본인</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">14년 7개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20210330" VALIGN="MIDDLE">2021.03.30</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">박세진</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="196203" VALIGN="MIDDLE">1962.03</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">사내이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="1" VALIGN="MIDDLE">상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">경영관리총괄</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">461,528</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">14년 7개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20210330" VALIGN="MIDDLE">2021.03.30</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">조영락</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="196602" VALIGN="MIDDLE">1966.02</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">사내이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="1" VALIGN="MIDDLE">상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">개발본부장</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">6,860</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">14년 7개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20210330" VALIGN="MIDDLE">2021.03.30</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">이창선</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="196604" VALIGN="MIDDLE">1966.04</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">사내이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="1" VALIGN="MIDDLE">상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">신약연구소장</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">2년 1개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20220326" VALIGN="MIDDLE">2022.03.26</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">송락경</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="195707" VALIGN="MIDDLE">1957.07</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">사외이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="2" VALIGN="MIDDLE">비상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">사외이사</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">1년 11개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20220326" VALIGN="MIDDLE">2022.03.26</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">맹필재</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="195503" VALIGN="MIDDLE">1955.03</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">사외이사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="2" VALIGN="MIDDLE">비상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">사외이사</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">1년 11개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20220326" VALIGN="MIDDLE">2022.03.26</TU>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="63" HEIGHT="30" ACODE="SH5_NM_T" VALIGN="MIDDLE">박두원</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="30" AUNIT="SH5_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_BIH" AUNITVALUE="195502" VALIGN="MIDDLE">1955.02</TU>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_LEV" VALIGN="MIDDLE">감사</TE>
<TU ALIGN="CENTER" WIDTH="78" HEIGHT="30" AUNIT="SH5_REG_DRCT" AUNITVALUE="1" VALIGN="MIDDLE">등기임원</TU>
<TU ALIGN="CENTER" WIDTH="63" HEIGHT="30" AUNIT="SH5_FUL" AUNITVALUE="1" VALIGN="MIDDLE">상근</TU>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_OBJ" VALIGN="MIDDLE">상근감사</TE>
<TE ALIGN="CENTER" WIDTH="78" HEIGHT="30" ACODE="SH5_SKL" VALIGN="MIDDLE">아래참조</TE>
<TE ALIGN="RIGHT" WIDTH="84" HEIGHT="30" ACODE="SH5_STK_VOTY" VALIGN="MIDDLE">-</TE>
<TE ALIGN="RIGHT" WIDTH="83" HEIGHT="30" ACODE="SH5_STK_VOTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="30" ACODE="SH5_RLTN" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="92" HEIGHT="30" ACODE="SH5_PER" VALIGN="MIDDLE">1년 11개월</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="30" AUNIT="SH5_FIH" AUNITVALUE="20220326" VALIGN="MIDDLE">2022.03.26</TU>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『등기임원후보자 및 해임대상자』 삽입</COMMENT>
<LIBRARYLIST>11011#*등기임원후보자및해임대상자.dsl</LIBRARYLIST>
</INSERTION>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11">주1) 보고서 제출일 현재 사내이사 4명, 사외이사 2명, 상근감사 1명임.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK="F-11 0X0000FF"></SPAN>☞ 임원 약력
</P>
<P>(1) 김용주 &cr;  78.02 서울대학교 화학과 이학사 &cr;  80.02 한국과학원 (유기화학) 이학석사&cr;  83.02 한국과학원 (유기화학) 이학박사&cr;  83.01 ~ 97.11 ㈜LG화학 기술연구원 연구위원&cr;  97.12 ~ 00.08 ㈜LG화학기술연구원연구소장.LG BMI 법인장&cr;  00.08 ~ 06.04 ㈜LG생명과학기술연구원 신약연구소장 &cr;  06.05 ~ 현재 ㈜레고켐 바이오사이언스 대표이사&cr;&cr;(2) 박세진&cr;  87.02 고려대학교 경제학과&cr;  20.02  연세대 경영대학원MBA(경영학)</P>
<P>  87.01 ~ 96.06 ㈜LG화학기술연구원 기획, 인사팀장</P>
<P>  96.07 ~ 99.02 ㈜LG BMI(San Diego) 관리</P>
<P>  99.03 ~ 03.02 ㈜LG화학기술연구원 전략기획팀장</P>
<P>  03.01 ~ 06.06 ㈜LG화학 영상소재사업부 팀장</P>
<P>  06.07 ~ 현재 ㈜레고켐 바이오사이언스 수석부사장</P>
<P>&cr;(3) 조영락&cr;  90.02 연세대학교 화학과 이학사&cr;  94.08 연세대학교 (유기화학) 이학석사&cr;  99.02 연세대학교 (유기화학) 이학박사&cr;  99.04 ~ 00.09 The Scripps Research Institute (La Jolla, CA, USA) PostDoc.&cr;  00.10 ~ 01.10 The Salk Institute (La Jolla, CA, USA) PostDoc.</P>
<P>  01.10 ~ 06.04 ㈜LG생명과학 선임연구원&cr;  06.05 ~ 현재 ㈜레고켐 바이오사이언스 신약연구소 개발본부장</P>

<P>&cr;(4) 이창선&cr;
<SPAN> </SPAN>
<SPAN> 89 서울대 화학과 이학사&cr;  91 서울대 화학과 이학석사</SPAN>
</P>
<P>  01 Yale 대 유기화학 이학박사</P>
<P>  91 ~ 96 LG생명과학 연구원</P>
<P>  01 ~ 03 Oregon State University Postdoc/Staff Scientist (연구교수)</P>
<P>  06 ~ 16 PTC Therapeutics(연구위원) </P>
<P>  16 ~ 17 RaND Biosciences Inc. CTO </P>
<P>  18 ~ 18.10 ㈜한독 상무이사 </P>
<P>  18.11 ~ 현재 ㈜레고켐 바이오CTO</P>
<P>&cr;(5) 송락경&cr;  81.02 서울대 기계설계학과</P>
<P>  92.08 서강대 경영대학원MBA(인사관리전공)</P>
<P>  83.10~99.12  KTB네트워크 벤처투융자 센터장&cr;  00.01~05.09  KTB인큐베이팅㈜ 대표이사</P>
<P>  05.09~08.12  대덕연구개발특구지원본부 사업단장&cr;  14.03~15.01  대전창조경제혁신센터 센터장 </P>
<P>  09.01~현재    KAIST 기술경영학과 교수. KAIST 이노베이션 센터 소장&cr;</P>
<P>(6) 맹필재&cr;  78.02 서울대 자연과학대학 미생물학과 학사</P>
<P>  80.02 서울대 대학원 미생물학과 석사</P>
<P>  86.02 서울대 대학원 미생물학과 박사 </P>
<P>  86.09 ~ 88.02 미국 MIT 응용생물학과 Post-Doc</P>
<P>  09.03 ~ 11.03 충남대 생명시스템과학대학 학장</P>
<P>  09.06 ~ 12.05 충남대 의약바이오 인재양성센터 센터장</P>
<P>  88.03 ~ 현재 충남대 미생물·분자생명과학과 교수</P>
<P>  97.03 ~ 현재 (학교법인)혜화학원(대전대) 이사</P>
<P>  16.01 ~ 현재 (사)바이오헬스케어협회 회장</P>
<P>&cr;(7) 박두원&cr;  79.02 한양대 공과대학 공업화학과 졸업</P>
<P>  04.08 충남대 경영대학원 회계학 석사</P>
<P>  81.07 ~ 07.07 전 LG 화학 부장</P>
<P>  09.05 ~ 11.03 전 ㈜한국기술연구소 대표이사</P>
<P>  13010 ~ 현재 화일약품㈜ 사외이사&cr;</P>
<P>* 당해 임원의 타회사 임원 겸임 현황   </P>

<TABLE BORDER="1" WIDTH="524" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="54"></COL>
<COL WIDTH="156"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="96"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">성 명</TD>
<TD WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">겸임 회사명</TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">직급,직책</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">최초선임시기</TD>
<TD WIDTH="105" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">담당업무</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" ALIGN="CENTER" HEIGHT="53">박세진</TD>
<TD WIDTH="165" ALIGN="CENTER" HEIGHT="53">(주)바스칸바이오제약&cr;(구.레고켐 제약)</TD>
<TD WIDTH="83" ALIGN="CENTER" HEIGHT="53">이사</TD>
<TD WIDTH="108" ALIGN="CENTER" HEIGHT="53">2015.11</TD>
<TD WIDTH="105" ALIGN="CENTER" HEIGHT="53">이사(비상근)</TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11">주) (주)바스칸바이오제약(구.레고켐 제약)은 당사가 지분 32.52%를 소유하고 있는 관계기업임.&cr;</SPAN>
</P>

<P>
<SPAN USERMARK="F-11"></SPAN>
</P>
<P>직원 등 현황</P>

<TABLE-GROUP ACLASS="EMPLOYEE" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="907" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="540"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="126" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="549" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="909" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="99"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="60"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="60"></COL>
<COL WIDTH="44"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="62"></COL>
<COL WIDTH="24"></COL>
<COL WIDTH="24"></COL>
<COL WIDTH="24"></COL>
<COL WIDTH="39"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="762" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="10">직원</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="99" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="3">소속 외&cr;근로자</TH>
<TH ROWSPAN="4" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="189" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="108" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">사업부문</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">성별</TH>
<TH COLSPAN="5" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="365" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">직 원 수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">평 균&cr;근속연수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">연간급여&cr;총 액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="71" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">1인평균&cr;급여액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="33" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">남</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="33" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">여</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="33" HEIGHT="136" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="3">계</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="195" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">기간의 정함이&cr;없는 근로자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="117" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">기간제&cr;근로자</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="53" HEIGHT="106" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">합 계</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">전체</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="69" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">(단시간&cr;근로자)</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">전체</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="69" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">(단시간&cr;근로자)</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="35" ACODE="EMP_OPR" VALIGN="MIDDLE">신약연구개발</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="35" AUNIT="EMP_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="35" ACODE="EMP_REO" VALIGN="MIDDLE">                45</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_REOS" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="35" ACODE="EMP_COC" VALIGN="MIDDLE">
<P>3</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_COCS" VALIGN="MIDDLE">
<P>-</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="53" HEIGHT="35" ACODE="EMP_CN" VALIGN="MIDDLE">48 </TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="35" ACODE="EMP_AVY" VALIGN="MIDDLE">3년 8개월</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="35" ACODE="EMP_AIC" VALIGN="MIDDLE">3,361</TE>
<TE ALIGN="RIGHT" WIDTH="71" HEIGHT="35" ACODE="EMP_VIC" VALIGN="MIDDLE">70</TE>
<TE ALIGN="RIGHT" WIDTH="33" HEIGHT="175" ACODE="EMP_MAN" VALIGN="MIDDLE" ROWSPAN="5">-</TE>
<TE ALIGN="RIGHT" WIDTH="33" HEIGHT="175" ACODE="EMP_WOM" VALIGN="MIDDLE" ROWSPAN="5">-</TE>
<TE ALIGN="RIGHT" WIDTH="33" HEIGHT="175" ACODE="EMP_MW_TOTAL" VALIGN="MIDDLE" ROWSPAN="5">-</TE>

<TE ALIGN="CENTER" WIDTH="48" HEIGHT="35" ACODE="NOTE" VALIGN="MIDDLE">
<P>-</P>
</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="35" ACODE="EMP_OPR" VALIGN="MIDDLE">신약연구개발</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="35" AUNIT="EMP_SEX" AUNITVALUE="2" VALIGN="MIDDLE">여</TU>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="35" ACODE="EMP_REO" VALIGN="MIDDLE">                 40</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_REOS" VALIGN="MIDDLE">
<P>-</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="35" ACODE="EMP_COC" VALIGN="MIDDLE">7</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_COCS" VALIGN="MIDDLE">
<P>-</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="53" HEIGHT="35" ACODE="EMP_CN" VALIGN="MIDDLE">47 </TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="35" ACODE="EMP_AVY" VALIGN="MIDDLE">3년 9개월</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="35" ACODE="EMP_AIC" VALIGN="MIDDLE">2,606</TE>
<TE ALIGN="RIGHT" WIDTH="71" HEIGHT="35" ACODE="EMP_VIC" VALIGN="MIDDLE">55</TE>

<TE ALIGN="CENTER" WIDTH="48" HEIGHT="35" ACODE="NOTE" VALIGN="MIDDLE">
<P>-</P>
</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="35" ACODE="EMP_OPR" VALIGN="MIDDLE">의약사업부문</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="35" AUNIT="EMP_SEX" AUNITVALUE="1" VALIGN="MIDDLE">남</TU>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="35" ACODE="EMP_REO" VALIGN="MIDDLE">                2 </TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_REOS" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="35" ACODE="EMP_COC" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_COCS" VALIGN="MIDDLE">
<P>-</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="53" HEIGHT="35" ACODE="EMP_CN" VALIGN="MIDDLE">2 </TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="35" ACODE="EMP_AVY" VALIGN="MIDDLE">2년 11개월</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="35" ACODE="EMP_AIC" VALIGN="MIDDLE">191</TE>
<TE ALIGN="RIGHT" WIDTH="71" HEIGHT="35" ACODE="EMP_VIC" VALIGN="MIDDLE">95</TE>

<TE ALIGN="CENTER" WIDTH="48" HEIGHT="35" ACODE="NOTE" VALIGN="MIDDLE">
<P>-</P>
</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="108" HEIGHT="35" ACODE="EMP_OPR" VALIGN="MIDDLE">의약사업부문</TE>
<TU ALIGN="CENTER" WIDTH="48" HEIGHT="35" AUNIT="EMP_SEX" AUNITVALUE="2" VALIGN="MIDDLE">여</TU>
<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="35" ACODE="EMP_REO" VALIGN="MIDDLE">                   2 </TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_REOS" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="35" ACODE="EMP_COC" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_COCS" VALIGN="MIDDLE">
<P>-</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="53" HEIGHT="35" ACODE="EMP_CN" VALIGN="MIDDLE">2 </TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="35" ACODE="EMP_AVY" VALIGN="MIDDLE">1년 11개월</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="35" ACODE="EMP_AIC" VALIGN="MIDDLE">33</TE>
<TE ALIGN="RIGHT" WIDTH="71" HEIGHT="35" ACODE="EMP_VIC" VALIGN="MIDDLE">16</TE>

<TE ALIGN="CENTER" WIDTH="48" HEIGHT="35" ACODE="NOTE" VALIGN="MIDDLE">
<P>-</P>
</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="156" HEIGHT="35" AUPDATECONT="N" COLSPAN="2" VALIGN="MIDDLE">합 계</TD>

<TE ALIGN="RIGHT" WIDTH="126" HEIGHT="35" ACODE="EMP_REOT" VALIGN="MIDDLE">
<P>     89</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_REOST" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="48" HEIGHT="35" ACODE="EMP_COCT" VALIGN="MIDDLE">
<P>10</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="69" HEIGHT="35" ACODE="EMP_COCST" VALIGN="MIDDLE">
<P>-</P>
</TE>

<TE ALIGN="RIGHT" WIDTH="53" HEIGHT="35" ACODE="EMP_CNT" VALIGN="MIDDLE">
<P> 99</P>
</TE>
<TE ALIGN="RIGHT" WIDTH="92" HEIGHT="35" ACODE="EMP_AVYT" VALIGN="MIDDLE">3년 8개월</TE>
<TE ALIGN="RIGHT" WIDTH="78" HEIGHT="35" ACODE="EMP_AICT" VALIGN="MIDDLE">6,191</TE>
<TE ALIGN="RIGHT" WIDTH="71" HEIGHT="35" ACODE="EMP_VICT" VALIGN="MIDDLE">62</TE>

<TE ALIGN="CENTER" WIDTH="48" HEIGHT="35" ACODE="NOTET" VALIGN="MIDDLE">
<P>-</P>
</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<INSERTION ABASISNUMBER="E0" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>* 직원 현황 표는 미등기임원을 포함하여 작성한다</COMMENT>
<LIBRARYLIST></LIBRARYLIST>
</INSERTION>

<P>
<SPAN USERMARK="F-11">주1) 연간급여총액란에 기재된 수치는 퇴직자의 급여를 포함한 제15기(2020.1.1~2020.12.31) 12개월 급여총액이며, 1인평균 급여액란에 기재된 수치는 기준일 재직자 수로   간급여 총액을 나눈 금액입니다. &cr;주2) 평균 근속년수는 </SPAN>
<SPAN USERMARK="F-11">2020년 12월 31일 현재 근무 중인</SPAN>
<SPAN USERMARK="F-11">직원을 기준으로 산출 하였습니다</SPAN>
<SPAN USERMARK="F-11">.&cr;</SPAN>
<SPAN USERMARK="F-11"></SPAN>
</P>
<P>미등기임원 보수 현황</P>

<TABLE-GROUP ACLASS="UNRESISTER" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="787" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="420"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="126" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="429" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="786" BORDER="1">

<COLGROUP>
<COL WIDTH="110"></COL>
<COL WIDTH="110"></COL>
<COL WIDTH="156"></COL>
<COL WIDTH="155"></COL>
<COL WIDTH="210"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="119" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="119" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">인원수</TH>
<TH WIDTH="165" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">연간급여 총액</TH>
<TH WIDTH="164" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">1인평균 급여액</TH>
<TH WIDTH="219" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="119" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">미등기임원</TD>
<TE WIDTH="119" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="URT_CNT">12</TE>
<TE WIDTH="165" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="URT_PAY_TOT">1,502</TE>
<TE WIDTH="164" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="URT_PAY_AVR">125</TE>
<TE WIDTH="219" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="URT_NOTE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<P>
<SPAN USERMARK="F-11">주) 연간급여총액란에 기재된 수치는 15기(2020.1.1~2020.12.31)까지 12개월 급여총액이며, 1인평균 급여액란에 기재된 수치는 1인평균 12개월 총 급여액입니다. &cr;주1) 평균 근속년수는 2020년 12월 31일 기준 근무중인 미등기임원을 기준으로 산출 하였습니다.&cr;</SPAN>
</P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-0-8-2-0">2. 임원의 보수 등</TITLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="600" HEIGHT="30" AUPDATECONT="N"><이사ㆍ감사 전체의 보수현황></TD>
</TR>
</TBODY>
</TABLE>
<P>1. 주주총회 승인금액</P>

<TABLE-GROUP ACLASS="SUB_CMP" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="169"></COL>
<COL WIDTH="78"></COL>
<COL WIDTH="199"></COL>
<COL WIDTH="120"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="178" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="87" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">인원수</TH>
<TH WIDTH="208" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">주주총회 승인금액</TH>
<TH WIDTH="129" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="PRT_PAY_SUB">등기이사(사외이사포함)</TE>
<TE WIDTH="87" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="PRT_PAY_NUM"> 6</TE>
<TE WIDTH="208" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="PRT_PAY_KMY">5,000</TE>
<TE WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="178" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="PRT_PAY_SUB">감사</TE>
<TE WIDTH="87" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="PRT_PAY_NUM">1</TE>
<TE WIDTH="208" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="PRT_PAY_KMY">100</TE>
<TE WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>2. 보수지급금액</P>
<P>2-1. 이사ㆍ감사 전체</P>

<TABLE-GROUP ACLASS="SUB_CMPT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="142"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="151" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">인원수</TH>
<TH WIDTH="151" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">보수총액</TH>
<TH WIDTH="150" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">1인당 평균보수액</TH>
<TH WIDTH="150" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE WIDTH="151" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="TRT_PAY_NUM">7 </TE>
<TE WIDTH="151" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="TRT_PAY_SUM">1,044</TE>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="TRT_PAY_VIC">149</TE>
<TE WIDTH="150" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE5">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>2-2. 유형별</P>

<TABLE-GROUP ACLASS="SUB_CMPP" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="236"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
<COL WIDTH="80"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="245" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">구 분</TH>
<TH WIDTH="90" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">인원수</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">보수총액</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">1인당&cr;평균보수액</TH>
<TH WIDTH="89" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="53">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="245" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">등기이사&cr;(사외이사, 감사위원회 위원 제외)</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="RRT_PAY_NUM">4</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="RRT_PAY_SUM">956</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="RRT_PAY_VIC">239</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="NOTE1">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="245" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">사외이사&cr;(감사위원회 위원 제외)</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="ORT_PAY_NUM">2</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="ORT_PAY_SUM">40</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="ORT_PAY_VIC">20</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="NOTE2">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="245" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">감사위원회 위원</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="GRT_PAY_NUM">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="GRT_PAY_SUM">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="GRT_PAY_VIC">-</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE3">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="245" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">감사</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="AUD_PAY_NUM">1</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="AUD_PAY_SUM">48</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="AUD_PAY_VIC">48</TE>
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE4">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="600" HEIGHT="30" AUPDATECONT="N"><보수지급금액 5억원 이상인 이사ㆍ감사의 개인별 보수현황></TD>
</TR>
</TBODY>
</TABLE>
<P>1. 개인별 보수지급금액</P>

<TABLE-GROUP ACLASS="SUB_CMPK" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="85"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="157"></COL>
<COL WIDTH="257"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="94" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">이름</TH>
<TH WIDTH="76" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">직위</TH>
<TH WIDTH="166" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">보수총액</TH>
<TH WIDTH="266" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">보수총액에 포함되지 않는 보수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="94" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_NM">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_LEV">-</TE>
<TE WIDTH="166" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_PAY">-</TE>
<TE WIDTH="266" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_NOTPAY">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="94" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_NM">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_LEV">-</TE>
<TE WIDTH="166" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_PAY">-</TE>
<TE WIDTH="266" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_NOTPAY">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>2. 산정기준 및 방법</P>

<TABLE BORDER="0" WIDTH="602" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR>
<TD WIDTH="300" HEIGHT="30" VALIGN="BOTTOM"></TD>
<TD WIDTH="302" HEIGHT="30" ALIGN="RIGHT" VALIGN="BOTTOM">(단위 : 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="600" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="111"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="140"></COL>
</COLGROUP>

<THEAD>

<TR>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="120" HEIGHT="30">이름</TH>
<TH COLSPAN="2" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="214" HEIGHT="30">보수의 종류</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="117" HEIGHT="30">총액</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="149" HEIGHT="30">산정기준 및 방법</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="6" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="120" HEIGHT="203"></TD>
<TD ROWSPAN="4" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="99" HEIGHT="143">근로소득</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">급여</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">상여</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="53">주식매수선택권&cr; 행사이익</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="53">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">기타 근로소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="214" HEIGHT="30">퇴직소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="214" HEIGHT="30">기타소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<TABLE ACLASS="NORMAL" AFIXTABLE="Y" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="591"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="600" HEIGHT="30" AUPDATECONT="N"><보수지급금액 5억원 이상 중 상위 5명의 개인별 보수현황></TD>
</TR>
</TBODY>
</TABLE>
<P>- 당사는 개인별 지급한 보수총액이 5억원 미만이므로 해당사항이 없습니다.&cr;1. 개인별 보수지급금액</P>

<TABLE-GROUP ACLASS="SUB_CMPK_HIGH" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="85"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="157"></COL>
<COL WIDTH="257"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="94" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">이름</TH>
<TH WIDTH="76" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">직위</TH>
<TH WIDTH="166" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">보수총액</TH>
<TH WIDTH="266" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">보수총액에 포함되지 않는 보수</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="94" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_NM">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_LEV">-</TE>
<TE WIDTH="166" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_PAY">-</TE>
<TE WIDTH="266" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_NOTPAY">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="94" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_NM">-</TE>
<TE WIDTH="76" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="CMPK_LEV">-</TE>
<TE WIDTH="166" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_PAY">-</TE>
<TE WIDTH="266" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="CMPK_NOTPAY">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P></P>
<P>2. 산정기준 및 방법</P>

<TABLE BORDER="0" WIDTH="602" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR>
<TD WIDTH="300" HEIGHT="30" VALIGN="BOTTOM"></TD>
<TD WIDTH="302" HEIGHT="30" ALIGN="RIGHT" VALIGN="BOTTOM">(단위 : 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="600" ACLASS="NORMAL">

<COLGROUP>
<COL WIDTH="111"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="106"></COL>
<COL WIDTH="108"></COL>
<COL WIDTH="140"></COL>
</COLGROUP>

<THEAD>

<TR>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="120" HEIGHT="30">이름</TH>
<TH COLSPAN="2" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="214" HEIGHT="30">보수의 종류</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="117" HEIGHT="30">총액</TH>
<TH VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" WIDTH="149" HEIGHT="30">산정기준 및 방법</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ROWSPAN="6" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="120" HEIGHT="203"></TD>
<TD ROWSPAN="4" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="99" HEIGHT="143">근로소득</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">급여</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">상여</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="53">주식매수선택권&cr; 행사이익</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="53">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="53">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="115" HEIGHT="30">기타 근로소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="214" HEIGHT="30">퇴직소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD COLSPAN="2" VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="214" HEIGHT="30">기타소득</TD>
<TD VALIGN="MIDDLE" ALIGN="RIGHT" WIDTH="117" HEIGHT="30">-</TD>
<TD VALIGN="MIDDLE" ALIGN="CENTER" WIDTH="149" HEIGHT="30">-</TD>
</TR>
</TBODY>
</TABLE>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『주식매수선택권의 부여 및 행사현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*주식매수선택권의부여및행사현황.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">14_주식매수선택권의부여및행사현황</FILENAME>
<P><주식매수선택권의 부여 및 행사현황></P>
<P><표1></P>

<TABLE-GROUP ACLASS="SUB_SOPT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="602" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="293"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="302" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="602" BORDER="1">

<COLGROUP>
<COL WIDTH="127"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="232"></COL>
<COL WIDTH="126"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="136" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">구 분</TH>
<TH WIDTH="90" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">인원수</TH>
<TH WIDTH="241" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">주식매수선택권의 공정가치 총액</TH>
<TH WIDTH="135" VALIGN="MIDDLE" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30">비고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="136" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">등기이사</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="RRT_PAY_NUM">4</TE>
<TE WIDTH="241" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="RRT_PAY_SUMT">761</TE>
<TE WIDTH="135" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE1" USERMARK=" U">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="136" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">사외이사</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ORT_PAY_NUM">2</TE>
<TE WIDTH="241" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="ORT_PAY_SUMT">-</TE>
<TE WIDTH="135" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE2" USERMARK=" U">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="136" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" AUPDATECONT="N">감사위원회 위원 또는 감사</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="GRT_PAY_NUM">1</TE>
<TE WIDTH="241" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53" ACODE="GRT_PAY_SUMT">-</TE>
<TE WIDTH="135" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53" ACODE="NOTE3" USERMARK=" U">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="136" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">계</TD>
<TE WIDTH="90" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="TRT_PAY_NUM">7</TE>
<TE WIDTH="241" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="TRT_PAY_SUMT">761</TE>
<TE WIDTH="135" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE4" USERMARK=" U">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>

<P>
<SPAN USERMARK="F-11">주) 주식매수선택권 공정가치 산정방법 : 공정가액접근법&cr;      (옵션가격결정모형중 Black-Scholes Model 적용) &cr;   - 공정가치 산정 가정 : 권리부여 전일종가, 행사가격, 기대행사기간은 4년 적용                무위험이자율은 최근 3년 만기 국고채 유통수익률 적용, 예상주가변동성 고려하여 &cr;      산정함.&cr;</SPAN>
</P>
<P><표2></P>

<TABLE-GROUP ACLASS="SOPT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="1076" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="144"></COL>
<COL WIDTH="682"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="SH5_CUR_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="153" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="691" HEIGHT="30" AUNIT="WONSTOCK" AUNITVALUE="1">(단위 : 원, 주)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1078" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="110"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="169"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="54"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">부여&cr;받은자</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">관 계</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">부여일</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">부여방법</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">주식의&cr;종류</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">최초&cr;부여&cr;수량</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="111" HEIGHT="46" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">당기변동수량</TH>
<TH COLSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="126" HEIGHT="46" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">총변동수량</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">기말&cr;미행사수량</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">행사기간</TH>
<TH ROWSPAN="2" ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">행사&cr;가격</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">행사</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="48" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">취소</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">행사</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">취소</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">조영락외 4명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20060526">2006.05.26</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">40,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">24,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">16,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2009.05.26&cr;∼&cr;2013.05.26</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">500</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">이대연외 7명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20100323">2010.03.23</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">33,750</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">31,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">2,250</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2013.03.23&cr;∼&cr;2015.03.23</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">2,333</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">송호영외 2명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20110715">2011.07.15</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">27,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">27,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2014.07.15&cr;∼&cr;2016.07.15</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">3,333</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">이향숙외8명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20120229">2012.02.29</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">15,480</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">14,468</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">1,012</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2015.02.29&cr;∼&cr;2017.02.29</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">8,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">박태교</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="-">-</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20120229">2012.02.29</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2015.02.29&cr;∼&cr;2017.02.29</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">8,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">박세진</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20120229">2012.02.29</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2015.02.29&cr;∼&cr;2017.02.29</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">8,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">우성호</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="-">-</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20120229">2012.02.29</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2015.02.29&cr;∼&cr;2017.02.29</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">8,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="76" ACODE="SH5_NM">김선영외11명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="76" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" AUNIT="SH5_GV_DT" AUNITVALUE="20130325">2013.03.25</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="76" ACODE="SH5_MTH">신주발행</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_START_CNT">25,006</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="76" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_EXE_CNT">19,108</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_CNL_CNT">5,898</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="76" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="76" ACODE="SH5_PER">2016.03.25&cr;∼&cr;2018.03.25</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="76" ACODE="SH5_PRC">12,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">장혜경외1명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20130927">2013.09.27</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">15,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">5,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2016.09.27&cr;∼&cr;2018.09.27</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">13,700</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">조영락외11명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20140328">2014.03.28</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">16,720</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">13,380</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">3,340</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2017.03.28&cr;∼&cr;2019.03.28</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">24,650</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20141230">2014.12.30</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">4,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">4,500</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2017.12.30&cr;~ &cr;2019.12.30</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">18,050</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20150203">2015.02.03</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2018.2.3&cr;~&cr;2020.2.3</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">19,150</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">이대연외11명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20150203">2015.02.03</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">16,890</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">11,100</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">5,790</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2018.2.3&cr;~&cr;2020.2.3</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">19,150</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20160201">2016.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">9,780</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">9,780</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.2.1&cr;~&cr;2021.2.1</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">27,450</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">조영락</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20160201">2016.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">1,930</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">1,930</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.2.1&cr;~&cr;2021.2.1</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">27,450</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">송호영외15명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20160201">2016.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">26,978</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">3,642</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">11,392</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">6,090</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">9,496</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.2.1&cr;~&cr;2021.2.1</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">13,725</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20160510">2016.05.10</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">3,640</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">3,640</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">3,640</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.5.10&cr;~&cr;2021.5.10</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">31,850</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20160601">2016.06.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">2,240</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">2,240</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">2,240</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.6.1&cr;~&cr;2021.6.1</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">33,150</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20161004">2016.10.04</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">690</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">690</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">690</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.10.4&cr;~&cr;2021.10.4</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">42,300</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20161101">2016.11.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">900</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">900</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">900</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2019.11.1&cr;~&cr;2021.11.1</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">35,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">송호영외 33명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20170201">2017.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">57,580</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">34,050</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">34,050</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">11,350</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">12,180</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2020.02.01&cr;~&cr;2022.02.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">16,500</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20170801">2017.08.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">4,460</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">4,460</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2020.08.01&cr;~&cr;2022.08.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">17,350</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20171101">2017.11.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">1,010</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">1,010</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2020.11.01&cr;~&cr;2022.11.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">31,300</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">조영락</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180201">2018.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">22,020</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">22,020</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.02.01&cr;~&cr;2023.02.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">28,200</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">송호영외 19명 </TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180201">2018.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">64,250</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">830</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">63,420</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.02.01&cr;~&cr;2023.02.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">28,200</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180327">2018.03.27</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">40,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">40,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.03.27&cr;~&cr;2023.03.27</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">61,300</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">이법표</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180327">2018.03.27</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">10,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">10,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.03.27&cr;~&cr;2023.03.27</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">30,650</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180430">2018.04.30</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">5,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">5,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">-</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.04.30&cr;~&cr;2023.04.30</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">62,400</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo외1명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180514">2018.05.14</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">4,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">4,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.05.14&cr;~&cr;2023.05.14</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">26,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20180716">2018.07.16</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">3,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">3,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.07.16&cr;~&cr;2023.07.16</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">20,625</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">이창선</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20181126">2018.11.26</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">40,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">40,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2021.11.26&cr;~&cr;2023.11.26</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">28,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo외 31명 </TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190201">2019.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">91,170</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">910</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">90,260</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.02.01&cr;~&cr;2024.01.31</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">24,725</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190201">2019.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">2,860</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">2,860</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.02.01&cr;~&cr;2024.01.31</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">24,725</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190311">2019.03.11</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">1,600</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">1,600</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.03.11&cr;~&cr;2024.03.10</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">27,750</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190430">2019.04.30</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">9,190</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">5,350</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">3,840</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.04.30&cr;~&cr;2024.04.29</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">29,450</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190531">2019.05.31</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">7,780</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">540</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">7,240</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.05.31&cr;~&cr;2024.05.30</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">27,000</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20190911">2019.09.11</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">96,160</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">96,160</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2022.09.11&cr;~&cr;2024.09.10</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">22,575</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200203">2020.02.03</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">48,720</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">1,640</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">47,080</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.02.03&cr;~&cr;2025.02.02</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">23,425</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">이창선</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="1">등기임원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200325">2020.03.25</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">40,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">40,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.03.25&cr;~&cr;2025.03.24</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">20,850</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200401">2020.04.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">22,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">22,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.04.01&cr;~&cr;2025.03.31</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">22,200</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200601">2020.06.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">3,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">3,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.06.01&cr;~&cr;2025.05.31</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">26,850</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo외 10명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200724">2020.07.24</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">7,050</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">7,050</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.07.24&cr;~&cr;2025.07.23</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">51,700</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200803">2020.08.03</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">2,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">2,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.08.03&cr;~&cr;2025.08.02</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">57,600</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20200910">2020.09.10</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">1,840</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">1,840</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.09.10&cr;~&cr;2025.09.09</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">54,900</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20201102">2020.11.02</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">2,000</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">2,000</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2023.11.02&cr;~&cr;2025.11.01</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">57,600</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="122" ACODE="SH5_NM">ooo외 42명</TE>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="78" HEIGHT="122" AUNIT="SH5_RLT" AUNITVALUE="3">직원</TU>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" AUNIT="SH5_GV_DT" AUNITVALUE="20210201">2021.02.01</TU>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="178" HEIGHT="122" ACODE="SH5_MTH">(1)신주발행&cr;(2)자기주식&cr;(3)행사가와 시가차액을&cr;현금또는&cr;자기주식</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_STK_KNDD">보통주</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_START_CNT">43,940</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_MEXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="48" HEIGHT="122" ACODE="SH5_MCNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_EXE_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_CNL_CNT">-</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="93" HEIGHT="122" ACODE="SH5_NEXE_CNT">43,940</TE>
<TE ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="122" ACODE="SH5_PER">2024.02.01&cr;~&cr;2026.01.31</TE>
<TE ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="63" HEIGHT="122" ACODE="SH5_PRC">63,200</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주1) 2020년 06월 01일 1주당 1주 무상증자결정에 따라 무상증자 대상인 &cr;      미행사수량에 대해서 부여주식 추가 및 행사가액을 조정하여 작성하였습니다. </P>
</LIBRARY>
</INSERTION>
<P></P>
<PGBRK></PGBRK>
</SECTION-2>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-9-0-0">IX. 계열회사 등에 관한 사항</TITLE>

<P>
<SPAN>1. 계열회사의 현황&cr;</SPAN>당사의 출자에 따라 독점규제 및 공정거래에 관한 법률 제2조 제2호에 정하는 기업집단을 형성하고 있으며 기업집단의 대표회사는 당사입니다. 그러나 규모상 공정거래법 규정의 상호출자제한, 출자총액제한 및 채무보증제한 기업집단 등에는 해당하지 않습니다. 계열회사의 내역은 다음과 같습니다.
</P>

<TABLE WIDTH="615" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="606"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="615" ALIGN="RIGHT" HEIGHT="30">[단위: 백만원, %]</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="615" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="156"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="67"></COL>
<COL WIDTH="56"></COL>
<COL WIDTH="52"></COL>
<COL WIDTH="126"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="165" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">회사명</TD>
<TD WIDTH="113" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">소재지</TD>
<TD WIDTH="76" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">설립일</TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">자본금</TD>
<TD WIDTH="61" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">지분율</TD>
<TD WIDTH="135" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">비 고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="165" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">(주)바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="113" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">경기도 안성시</TD>
<TD WIDTH="76" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">1986.03 </TD>
<TD WIDTH="65" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">16,298</TD>
<TD WIDTH="61" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">32.52%</TD>
<TD WIDTH="135" HEIGHT="53" VALIGN="MIDDLE" ALIGN="CENTER">관계기업*</TD>
</TR>
</TBODY>
</TABLE>

<TABLE WIDTH="616" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="607"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="616" HEIGHT="30" USERMARK="F-BT">☞ 지분율은 공시서류 작성기준일 현재 회사가 출자한 지분율입니다.</TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK="F-11">※ 당사는 당기 중 ㈜바스칸바이오제약에 대한 지배력을 상실하여, 해당 기업을 연결대상 종속기업에서 제외하였으며, 관계기업으로 분류하였습니다.&cr;</P>
<P>회사와 계열회사간 임원 겸직 현황은 다음과 같습니다. </P>

<TABLE BORDER="1" WIDTH="612" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="54"></COL>
<COL WIDTH="156"></COL>
<COL WIDTH="74"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="184"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">성 명</TD>
<TD WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">겸임 회사명</TD>
<TD WIDTH="83" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">직급,직책</TD>
<TD WIDTH="108" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">최초선임시기</TD>
<TD WIDTH="193" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK=" BC0XD7D7D7">담당업무</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="63" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">박세진</TD>
<TD WIDTH="165" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">(주)바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="83" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">이사</TD>
<TD WIDTH="108" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">2015.11</TD>
<TD WIDTH="193" ALIGN="CENTER" HEIGHT="53" VALIGN="MIDDLE">이사(비상근)</TD>
</TR>
</TBODY>
</TABLE>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『타법인출자 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*타법인출자현황.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">6_타법인출자현황</FILENAME>
<P>타법인출자 현황</P>

<TABLE-GROUP ACLASS="INV_PRT" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="1154" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="204"></COL>
<COL WIDTH="700"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="213" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="709" HEIGHT="30" AUNIT="WONSTOCKPERCENT" AUNITVALUE="7">(단위 : 백만원, 주, %)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1157" BORDER="1">

<COLGROUP>
<COL WIDTH="200"></COL>
<COL WIDTH="128"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="99"></COL>
<COL WIDTH="55"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="41"></COL>
<COL WIDTH="55"></COL>
<COL WIDTH="39"></COL>
<COL WIDTH="47"></COL>
<COL WIDTH="55"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="48"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="54"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="3" WIDTH="209" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="113" AUPDATECONT="N">법인명</TH>
<TH ROWSPAN="3" WIDTH="137" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="113" AUPDATECONT="N">최초취득일자</TH>
<TH ROWSPAN="3" WIDTH="48" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="113" AUPDATECONT="N">출자&cr;목적</TH>
<TH ROWSPAN="3" WIDTH="108" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="113" AUPDATECONT="N">최초취득금액</TH>
<TH COLSPAN="3" WIDTH="177" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="53" AUPDATECONT="N">기초잔액</TH>
<TH COLSPAN="3" WIDTH="168" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="53" AUPDATECONT="N">증가(감소)</TH>
<TH COLSPAN="3" WIDTH="184" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="53" AUPDATECONT="N">기말잔액</TH>
<TH COLSPAN="2" WIDTH="126" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="53" AUPDATECONT="N">최근사업연도&cr;재무현황</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ROWSPAN="2" WIDTH="64" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">수량</TH>
<TH ROWSPAN="2" WIDTH="63" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">지분율</TH>
<TH ROWSPAN="2" WIDTH="50" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">장부&cr;가액</TH>
<TH COLSPAN="2" WIDTH="112" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N">취득(처분)</TH>
<TH ROWSPAN="2" WIDTH="56" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">평가&cr;손익</TH>
<TH ROWSPAN="2" WIDTH="64" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">수량</TH>
<TH ROWSPAN="2" WIDTH="63" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">지분율</TH>
<TH ROWSPAN="2" WIDTH="57" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">장부&cr;가액</TH>
<TH ROWSPAN="2" WIDTH="63" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">총자산</TH>
<TH ROWSPAN="2" WIDTH="63" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="60" AUPDATECONT="N">당기&cr;순손익</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="64" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N">수량</TH>
<TH WIDTH="48" ALIGN="CENTER" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" VALIGN="MIDDLE" HEIGHT="30" AUPDATECONT="N">금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE WIDTH="209" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PRM" USERMARK="F-10">(주)인투셀 주1)&cr;(비상장)</TE>
<TU WIDTH="137" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" AUNIT="INV_GET" AUNITVALUE="20150424">2015년 04월 24일</TU>
<TE WIDTH="48" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_OBJ" USERMARK="F-10">투자</TE>
<TE WIDTH="108" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_GTM" USERMARK="F-10">990 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTN" USERMARK="F-10">11,000 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BPR" USERMARK="F-10">4.32 </TE>
<TE WIDTH="50" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTM" USERMARK="F-10">868 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTN" USERMARK="F-10">429,000 </TE>
<TE WIDTH="48" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTM" USERMARK="F-10">0 </TE>
<TE WIDTH="56" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PPM" USERMARK="F-10">4,064 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTN" USERMARK="F-10">440,000 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LPR" USERMARK="F-10">4.29 </TE>
<TE WIDTH="57" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTM" USERMARK="F-10">4,932 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_NTM" USERMARK="F-10">46,810</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_TPM" USERMARK="F-10">-6,904</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="209" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PRM" USERMARK="F-10">브릿지바이오테라퓨틱스(주) 주2)&cr;(코스닥 상장)</TE>
<TU WIDTH="137" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" AUNIT="INV_GET" AUNITVALUE="20170629">2017년 06월 29일</TU>
<TE WIDTH="48" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_OBJ" USERMARK="F-10">투자</TE>
<TE WIDTH="108" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_GTM" USERMARK="F-10">1,800 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTN" USERMARK="F-10">112,500 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BPR" USERMARK="F-10">1.81 </TE>
<TE WIDTH="50" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTM" USERMARK="F-10">6,458 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTN" USERMARK="F-10">225,000 </TE>
<TE WIDTH="48" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTM" USERMARK="F-10">0 </TE>
<TE WIDTH="56" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PPM" USERMARK="F-10">-1,547</TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTN" USERMARK="F-10">337,500 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LPR" USERMARK="F-10">1.76 </TE>
<TE WIDTH="57" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTM" USERMARK="F-10">4,911 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_NTM" USERMARK="F-10">63,510</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_TPM" USERMARK="F-10">-19,232</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE WIDTH="209" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PRM" USERMARK="F-10">(주)에스알파테라퓨틱스&cr;(비상장)</TE>
<TU WIDTH="137" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" AUNIT="INV_GET" AUNITVALUE="20200211">2020년 02월 11일</TU>
<TE WIDTH="48" ALIGN="CENTER" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_OBJ" USERMARK="F-10">투자</TE>
<TE WIDTH="108" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_GTM" USERMARK="F-10">500</TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTN" USERMARK="F-10">38,461</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BPR" USERMARK="F-10">7.65 </TE>
<TE WIDTH="50" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_BTM" USERMARK="F-10">500</TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTN" USERMARK="F-10">0 </TE>
<TE WIDTH="48" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PTM" USERMARK="F-10">0 </TE>
<TE WIDTH="56" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_PPM" USERMARK="F-10">0 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTN" USERMARK="F-10">38,461 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LPR" USERMARK="F-10">6.70 </TE>
<TE WIDTH="57" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_LTM" USERMARK="F-10">500 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_NTM" USERMARK="F-10">2,814</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="49" VALIGN="MIDDLE" ACODE="INV_TPM" USERMARK="F-10">-1,548</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD COLSPAN="4" WIDTH="502" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N" VALIGN="MIDDLE">합 계</TD>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_BTNT" USERMARK="F-10">-</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_BPRT" USERMARK="F-10">-</TE>
<TE WIDTH="50" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_BTMT" USERMARK="F-10">7,326 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_PTNT" USERMARK="F-10">-</TE>
<TE WIDTH="48" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_PTMT" USERMARK="F-10">-</TE>
<TE WIDTH="56" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_PPMT" USERMARK="F-10">2,517 </TE>
<TE WIDTH="64" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_LTNT" USERMARK="F-10">-</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_LPRT" USERMARK="F-10">-</TE>
<TE WIDTH="57" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_LTMT" USERMARK="F-10">10,343 </TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_NTMT" USERMARK="F-10 0X1814FF">-</TE>
<TE WIDTH="63" ALIGN="RIGHT" HEIGHT="30" VALIGN="MIDDLE" ACODE="INV_TPMT" USERMARK="F-10 0X1814FF">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P USERMARK="F-11">주1) (주)인투셀 취득수량에는 액면분할(액면가 5,000원 -> 500원)  및 &cr;    무상증자 1주당 3주 수량을 반영한 것입니다.&cr;주2) 브릿지바이오테라퓨틱스(주)는 무상증자 1주당 2주 수량을 반영한 것입니다.&cr;</P>
</LIBRARY>
</INSERTION>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-10-0-0">X. 이해관계자와의 거래내용</TITLE>
<P>1. 대주주 등(특수관계인 포함)에 대한 신용공여&cr;- 해당사항 없습니다.&cr;&cr;2. 대주주(특수관계인 포함)와의 자산양수도 등&cr;- 해당사항 없습니다.&cr;&cr;3. 대주주(특수관계인 포함)와의 영업거래&cr;- 해당사항 없습니다.&cr;</P>

<P>
<SPAN>4.</SPAN>
<SPAN> 대주주 이외의 이해관계자와의 거래</SPAN>
</P>

<TABLE WIDTH="751" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="168"></COL>
<COL WIDTH="565"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="177" HEIGHT="30">(기준일 : 2020.12.31)</TD>
<TD WIDTH="574" ALIGN="RIGHT" HEIGHT="30">(단위 : 천원, %)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="753" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="156"></COL>
<COL WIDTH="104"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="62"></COL>
<COL WIDTH="84"></COL>
<COL WIDTH="75"></COL>
<COL WIDTH="54"></COL>
<COL WIDTH="57"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">이해관계자명</TH>
<TH ROWSPAN="2" WIDTH="113" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">회사와의 관계</TH>
<TH ROWSPAN="2" WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">거래종류</TH>
<TH COLSPAN="3" WIDTH="248" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제 15기</TH>
<TH COLSPAN="2" WIDTH="129" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">소유지분(%)</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="71" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매출</TH>
<TH WIDTH="93" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">용역수수료</TH>
<TH WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매입</TH>
<TH WIDTH="63" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">피출자</TH>
<TH WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">출자</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="165" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">(주)바스칸바이오제약&cr;(구.레고켐제약)</TD>
<TD WIDTH="113" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">관계기업</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">의약품 제조</TD>
<TD WIDTH="71" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">200,000</TD>
<TD WIDTH="93" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">243,000</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">1,628,029</TD>
<TD WIDTH="63" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="53">-</TD>
<TD WIDTH="66" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="53">32.52%</TD>
</TR>
</TBODY>
</TABLE>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y" AASSOCNOTE="D-0-11-0-0">XI. 그 밖에 투자자 보호를 위하여 필요한 사항</TITLE>

<P>
<SPAN USERMARK=" B">&cr;1. 공시내용의 진행 ·변경상황 및 주주총회 현황&cr;</SPAN>
</P>
<P>가. 공시사항의 진행 ·변경상황&cr;- 해당사항 없습니다.&cr;&cr;나. 주주총회 의사록 요약</P>

<TABLE BORDER="1" WIDTH="717" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="98"></COL>
<COL WIDTH="416"></COL>
<COL WIDTH="98"></COL>
<COL WIDTH="69"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">주총일자</TD>
<TD WIDTH="425" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">안          건</TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">결의내용</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">비  고</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="260">제9기&cr;정기주총&cr;(2015.03.30)</TD>

<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="260">
<P> 제1호 의안 : 정관 일부 개정 승인의 건&cr;제2호 의안 : 주식매수선택권 부여 승인의 건&cr;제3호 의안 : 이사 선임 승인의 건&cr;    (사내이사3명, 사외이사1명, 기타비상무이사1명 총5명)&cr;- 제3-1호의안:김용주 사내이사 재선임의 건.&cr;- 제3-2호의안:박세진 사내이사 재선임의 건.&cr;- 제3-3호의안:오영수 사내이사 신규선임의 건&cr;- 제3-4호의안:유성은 사외이사 신규선임의 건&cr;- 제3-5호의안:박태교 기타비상무이사신규선임의건&cr;제4호 의안 : 이사 보수한도액 결정의 건&cr;제5호 의안 : 감사 보수한도액 결정의 건</P>
</TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="260">  원안대로 승인</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="260">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">제10기&cr;임시주총&cr;(2015.11.16)</TD>

<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="214">
<P> 제1호 의안 : 합병계약서 승인의 건&cr;(1) 존속법인 : 주식회사 레고켐 바이오사이언스&cr;(2) 피합병법인 : 주식회사 칸메드&cr;제2호 의안 : 정관 일부 변경의 건&cr;(1) 정관 제02조 : 목적 사항 추가 변경&cr;(2) 정관 제35조 : 이사의 수 변경&cr;제3호 의안 : 신규 이사 선임의 건&cr;3-1호 의안 : 사내이사 이법표(상근) 신규 선임의건&cr;3-2호 의안 : 기타비상무이사 박용호(비상근) 신규 선임의 건 </P>
</TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">  원안대로 승인</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">제10기&cr;정기주총&cr;(2016.03.28)&cr;</TD>
<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="122">제1호 의안 : 정관 일부 개정 승인의 건&cr;제2호 의안 : 주식매수선택권 부여 승인의 건&cr;제3호 의안 : 감사 선임 승인의 건(재선임건, 감사1명)&cr;제4호 의안 : 이사 보수한도액 결정의 건&cr;제5호 의안 : 감사 보수한도액 결정의 건 </TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">  원안대로 승인</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">제11기&cr;정기주총&cr;(2017.03.27)&cr;</TD>
<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="145">제1호 의안 : 정관 일부 변경 승인의 건&cr;제2호 의안 : (이사회 부여) 주식매수선택권 부여 승인의 건&cr;제3호 의안 : 사외이사 (신규)선임 승인의 건&cr;제4호 의안 : 이사 보수한도 승인의 건&cr;제5호 의안 : 감사 보수한도 승인의 건&cr;</TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">원안대로&cr;승인&cr;</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="145">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">제12기&cr;정기주총&cr;(2018.03.27)&cr;</TD>
<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="214">제1호 의안: (이사회부여분) 주식매수선택권 부여 승인의 건제2호 의안: (주총부여분) 주식매수선택권 부여 승인의 건&cr;제3호 의안 : 이사 신규 및 중임 승인의 건 (사내이사 4명)&cr;3-1호 의안 : 사내이사(김용주) 선임의 건(중임)&cr;3-2호 의안 : 사내이사(박세진) 선임의 건(중임)&cr;3-3호 의안 : 사내이사(조영락) 선임의 건(신규선임)&cr;3-4호 의안 : 사내이사(이법표) 선임의 건(신규선임)&cr;제4호 의안 : 이사 보수한도액 승인의 건&cr;제5호 의안 : 감사 보수한도액 승인의 건 </TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">원안대로&cr;승인&cr;</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="214">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="237">제13기&cr;정기주총&cr;(2019.03.26)&cr;</TD>
<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="237">제1호 의안: 정관변경의 건&cr;제2호 의안: (이사회부여분) 주식매수선택권 부여 승인의 건제3호 의안 : 이사 신규 및 중임 승인의 건 (사내이사 1명, 사외이사 2명)&cr;3-1호 의안 : 사내이사(이창선) 선임의 건(신규선임)&cr;3-2호 의안 : 사외이사(송락경) 선임의 건(신규선임)&cr; 3-3호 의안 : 사외이사(맹필재) 선임의 건(신규선임)&cr;제4호 의안 : 감사(박두원) 선임의 건(신규선임)&cr;제5호 의안 : 이사 보수한도액 승인의 건&cr;제6호 의안 : 감사 보수한도액 승인의 건 </TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="237">원안대로&cr;승인&cr;</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="237">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">제14기&cr;정기주총&cr;(2020.03.25)&cr;</TD>
<TD WIDTH="425" VALIGN="MIDDLE" HEIGHT="122">제1호 의안: (주주총회부여분) 주식매수선택권 부여 승인의 건&cr;제2호 의안: (이사회부여분) 주식매수선택권 부여 승인의 건&cr;제3호 의안 : 이사 보수한도액 승인의 건&cr;제4호 의안 : 감사 보수한도액 승인의 건 &cr;</TD>
<TD WIDTH="107" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">원안대로&cr;승인&cr;</TD>
<TD WIDTH="78" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="122">-</TD>
</TR>
</TBODY>
</TABLE>
<P> </P>

<P>
<SPAN USERMARK=" B">2. 우발채무 등&cr;</SPAN>가. 중요한 소송사건&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;&cr;나. 견질 또는 담보용 어음ㆍ수표 현황&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;
</P>
<P>견질 또는 담보용 어음ㆍ수표 현황</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="291"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30">(기준일 : )</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="300" HEIGHT="30">(단위 : )</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="600" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
<COL WIDTH="141"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">제 출 처</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">매 수</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">금 액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="150" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">비 고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE">은 행</TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE">금융기관(은행제외)</TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE">법 인</TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE">기타(개인)</TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="150" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>
</TBODY>
</TABLE>
<P>&cr;다. 채무보증 현황&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.</P>
<P>&cr;라. 채무인수약정 현황&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;&cr;마. 그 밖의 우발부채 등&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;&cr;바. 자본으로 인정되는 채무증권의 발행&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;</P>

<P>
<SPAN USERMARK=" B">3. 제재현황 등 그 밖의 상황&cr;&cr;</SPAN>가. 제재현황&cr;
</P>
<P>본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;&cr;나. 작성기준일 이후 발생한 주요사항&cr;본 보고서 작성 기준일 현재 해당사항 없습니다.&cr;&cr;다. 중소기업기준 검토표</P>

<IMAGE>
<IMG WIDTH="600" HEIGHT="856" ALIGN="CENTER" HSPACE="0">2020년귀속 중소기업 등 기준검토표_페이지_1.jpg</IMG>
<IMG-CAPTION ATOC="N">2020년귀속 중소기업 등 기준검토표_페이지_1</IMG-CAPTION>
</IMAGE>

<IMAGE>
<IMG WIDTH="600" HEIGHT="856" ALIGN="CENTER" HSPACE="0">2020년귀속 중소기업 등 기준검토표_페이지_2.jpg</IMG>
<IMG-CAPTION ATOC="N">2020년귀속 중소기업 등 기준검토표_페이지_2</IMG-CAPTION>
</IMAGE>
<P>&cr;</P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『신용보강 제공 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*신용보강제공현황.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『장래매출채권 유동화 현황 및 채무비중』 삽입</COMMENT>
<LIBRARYLIST>11011#*장래매출채권유동화현황및채무비중.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『단기매매차익 미환수 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*단기매매차익미환수현황.dsl</LIBRARYLIST>
</INSERTION>
<P>라. 직접금융 자금의 사용</P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="N">
<COMMENT>◆click◆『공모자금의 사용내역』 삽입</COMMENT>
<LIBRARYLIST>11011#*공모자금의사용내역.dsl</LIBRARYLIST>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『사모자금의 사용내역』 삽입</COMMENT>
<LIBRARYLIST>11011#*사모자금의사용내역.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">19_사모자금의사용내역</FILENAME>
<P>&cr;사모자금의 사용내역</P>

<TABLE-GROUP ACLASS="FUND_SA" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="1122" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="59"></COL>
<COL WIDTH="813"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="68" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="822" HEIGHT="30" AUNIT="WON" AUNITVALUE="2">(단위 : 천원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="1124" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="91"></COL>
<COL WIDTH="40"></COL>
<COL WIDTH="83"></COL>
<COL WIDTH="198"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="193"></COL>
<COL WIDTH="91"></COL>
<COL WIDTH="265"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="100" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">구 분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="49" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">회차</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="92" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">납입일</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="307" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">주요사항보고서의&cr; 자금사용 계획</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="302" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">실제 자금사용&cr; 내역</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="274" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">차이발생 사유 등</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="207" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">사용용도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="100" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">조달금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="202" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">내용</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="100" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="100" HEIGHT="53" ACODE="PO_TYPE" VALIGN="MIDDLE" USERMARK="F-BT">제3자배정&cr;유상증자</TE>
<TE ALIGN="CENTER" WIDTH="49" HEIGHT="53" ACODE="MO_SEQ" VALIGN="MIDDLE">27회</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="53" AUNIT="PYM_DT" VALIGN="MIDDLE" AUNITVALUE="20160907">2016.09.07</TU>
<TE ALIGN="RIGHT" WIDTH="207" HEIGHT="53" ACODE="PLA_USE" VALIGN="MIDDLE" USERMARK="F-BT"> 개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="PLA_AMT" VALIGN="MIDDLE" USERMARK="F-BT">  24,499,845</TE>
<TE ALIGN="CENTER" WIDTH="202" HEIGHT="53" ACODE="BRK_CON" VALIGN="MIDDLE" USERMARK="F-BT">개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="BRK_AMT" VALIGN="MIDDLE" USERMARK="F-BT">  24,499,845</TE>
<TE ALIGN="CENTER" WIDTH="274" HEIGHT="53" ACODE="PS_AMT_PL" VALIGN="MIDDLE" USERMARK="F-BT">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="100" HEIGHT="53" ACODE="PO_TYPE" VALIGN="MIDDLE" USERMARK="F-BT">전환사채&cr;발행</TE>
<TE ALIGN="CENTER" WIDTH="49" HEIGHT="53" ACODE="MO_SEQ" VALIGN="MIDDLE">5회</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="53" AUNIT="PYM_DT" VALIGN="MIDDLE" AUNITVALUE="20160907">2016.09.07</TU>
<TE ALIGN="RIGHT" WIDTH="207" HEIGHT="53" ACODE="PLA_USE" VALIGN="MIDDLE" USERMARK="F-BT"> 개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="PLA_AMT" VALIGN="MIDDLE" USERMARK="F-BT">10,500,000</TE>
<TE ALIGN="CENTER" WIDTH="202" HEIGHT="53" ACODE="BRK_CON" VALIGN="MIDDLE" USERMARK="F-BT">개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="BRK_AMT" VALIGN="MIDDLE" USERMARK="F-BT">10,500,000</TE>
<TE ALIGN="CENTER" WIDTH="274" HEIGHT="53" ACODE="PS_AMT_PL" VALIGN="MIDDLE" USERMARK="F-BT">-</TE>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TE ALIGN="CENTER" WIDTH="100" HEIGHT="53" ACODE="PO_TYPE" VALIGN="MIDDLE" USERMARK="F-BT">제3자배정&cr;유상증자</TE>
<TE ALIGN="CENTER" WIDTH="49" HEIGHT="53" ACODE="MO_SEQ" VALIGN="MIDDLE">35회</TE>
<TU ALIGN="CENTER" WIDTH="92" HEIGHT="53" AUNIT="PYM_DT" VALIGN="MIDDLE" AUNITVALUE="20181123">2018.11.23</TU>
<TE ALIGN="RIGHT" WIDTH="207" HEIGHT="53" ACODE="PLA_USE" VALIGN="MIDDLE" USERMARK="F-BT"> 개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="PLA_AMT" VALIGN="MIDDLE" USERMARK="F-BT">59,999,842</TE>
<TE ALIGN="CENTER" WIDTH="202" HEIGHT="53" ACODE="BRK_CON" VALIGN="MIDDLE" USERMARK="F-BT">개발비 및 연구비 운영에 &cr;소요되는 제반경비 등</TE>
<TE ALIGN="RIGHT" WIDTH="100" HEIGHT="53" ACODE="BRK_AMT" VALIGN="MIDDLE" USERMARK="F-BT"> 59,022,236</TE>
<TE WIDTH="274" HEIGHT="53" ACODE="PS_AMT_PL" VALIGN="MIDDLE" USERMARK="F-BT">- 잔여분 977,606천원&cr;  -> 보통예금 예치: 977,606천원</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>&cr;마. 미사용자금의 운용내역</P>
</LIBRARY>
</INSERTION>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="N">
<COMMENT>◆click◆『미사용자금의 운용내역』 삽입</COMMENT>
<LIBRARYLIST>11011#*미사용자금의운용내역.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">53_미사용자금의운용내역</FILENAME>
<P>미사용자금의 운용내역</P>

<TABLE-GROUP ACLASS="UNS_HIY" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="598" BORDER="0">

<COLGROUP>
<COL WIDTH="71"></COL>
<COL WIDTH="143"></COL>
<COL WIDTH="117"></COL>
<COL WIDTH="231"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="80" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="BOTTOM" WIDTH="152" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="BOTTOM" WIDTH="126" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="240" HEIGHT="30" AUNIT="WON" AUNITVALUE="2">(단위 : 천원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="599" BORDER="1">

<COLGROUP>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="111"></COL>
<COL WIDTH="110"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">종류</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금융상품명</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">운용금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="120" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">계약기간</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="119" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">실투자기간</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="N">
<TU ALIGN="CENTER" WIDTH="120" HEIGHT="30" AUNIT="UNS_KND" AUNITVALUE="A" VALIGN="MIDDLE">예ㆍ적금</TU>
<TE ALIGN="CENTER" WIDTH="120" HEIGHT="30" ACODE="UNS_NAM" VALIGN="MIDDLE">보통예금</TE>
<TE ALIGN="RIGHT" WIDTH="120" HEIGHT="30" ACODE="UNS_MNY" VALIGN="MIDDLE">977,606</TE>
<TU ALIGN="CENTER" WIDTH="120" HEIGHT="30" AUNIT="UNS_PER" AUNITVALUE="-" VALIGN="MIDDLE">-</TU>
<TE ALIGN="CENTER" WIDTH="119" HEIGHT="30" ACODE="UNS_TRM" VALIGN="MIDDLE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="240" HEIGHT="30" VALIGN="MIDDLE" COLSPAN="2" AUPDATECONT="N">계</TD>
<TE ALIGN="RIGHT" WIDTH="120" HEIGHT="30" ACODE="UNS_MNY_SUM" VALIGN="MIDDLE">977,606</TE>
<TD ALIGN="CENTER" WIDTH="239" HEIGHT="30" VALIGN="MIDDLE" COLSPAN="2" AUPDATECONT="N">-</TD>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P></P>
<P>외국지주회사의 자회사 현황</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="700" BORDER="0">

<COLGROUP>
<COL WIDTH="291"></COL>
<COL WIDTH="391"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD VALIGN="BOTTOM" WIDTH="300" HEIGHT="30">(기준일 : )</TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="400" HEIGHT="30">(단위 : )</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" WIDTH="701" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="134"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="71"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="Y" ADELETE="Y">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="143" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">구 분</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">A지주회사</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">B법인</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">C법인</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">D법인</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="80" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">...</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="79" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">연결조정</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="79" HEIGHT="53" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">연결 후&cr;금액</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">매출액</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">  내부 매출액</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">-</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">  순 매출액</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">영업손익</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">계속사업손익</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">당기순손익</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">자산총액</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">  현금및현금성자산</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">  유동자산</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">  단기금융상품</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">부채총액</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">자기자본</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">자본금</TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">(     )</TD>
<TD ALIGN="RIGHT" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">감사인</TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">감사ㆍ검토 의견</TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE">-</TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="143" HEIGHT="30" VALIGN="MIDDLE">비  고</TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="80" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
<TD ALIGN="CENTER" WIDTH="79" HEIGHT="30" VALIGN="MIDDLE"></TD>
</TR>
</TBODY>
</TABLE>

<P>&cr;&cr;
<SPAN USERMARK=" B">4. 합병 등의 사후정보&cr;</SPAN>가. 합병에 관한 사항&cr;1) 합병당사자
</P>
<P>(1) 합병회사(존속법인): 주식회사 레고켐 바이오사이언스</P>
<P>(2) 피합병회사(소멸법인): 주식회사 칸메드&cr;</P>
<P>2) 합병목적 &cr;- 주식회사 레고켐 바이오사이언스와 주식회사 칸메드는 사업다각화와 경영효율성 증대를 통하여 양사의 주주가치 극대화&cr;</P>
<P>3) 합병방법&cr;- 본 합병은 합병법인인 주식회사 레고켐 바이오사이언스(이하 "레고켐 바이오사이언스")가 피합병법인 주식회사 칸메드(이하 "칸메드")를 흡수합병하는 방식입니다. 따라서 레고켐 바이오사이언스는 존속하고 주식회사 칸메드는 소멸되어 해산합니다.</P>
<P></P>
<P>4) 합병상대회사의 내용</P>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="591">

<COLGROUP>
<COL WIDTH="64"></COL>
<COL WIDTH="133"></COL>
<COL WIDTH="367"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="31">
<P>구분</P>
</TH>

<TH WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" HEIGHT="31">
<P>피합병법인</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>법인명</P>
</TD>

<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>주식회사 칸메드</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>합병 후 존속여부</P>
</TD>

<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>소멸</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>대표이사</P>
</TD>

<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>이법표</P>
</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD ROWSPAN="2" WIDTH="73" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="62">
<P>주소</P>
</TD>

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>본사</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">서울 마포구 마포대로 109, 101동 3101호</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="142" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>연락처</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">02-706-9163</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>설립년월일</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">2013년 10월 22일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>납입자본금</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">보통주 자본금 500,000,000원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>자산총액(주1)</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">7,293,226,910원</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>결산기</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">12월 31일</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">
<P>종업원수</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="31">22 명</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD COLSPAN="2" WIDTH="215" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="42">
<P>발행주식의 종류 및 수</P>
</TD>
<TD WIDTH="376" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="42">보통주 1,000,000주(액면 500원)</TD>
</TR>
</TBODY>
</TABLE>
<P>(주1)  2014년 12월 31일 현재 일반회계기준에 의한 개별재무제표 상의 금액입니다. </P>
<P></P>
<P>5) 합병비율 및 산출근거</P>

<TABLE WIDTH="672" BORDER="0" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="663"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="672" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30">(단위: 원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE BORDER="1" WIDTH="673" ACLASS="NORMAL" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="216"></COL>
<COL WIDTH="215"></COL>
<COL WIDTH="215"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">

<TH WIDTH="225" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>구분</P>
</TH>

<TH WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>합병법인</P>
</TH>

<TH WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N">
<P>피합병법인</P>
</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>가. 기준주가(주1)</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">22,693 </TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항없음</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>나. 본질가치(주2)</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항없음</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">30,949 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>다. 자산가치</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2,641 </TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">2,423 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>라. 수익가치</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항없음</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">49,967 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>마. 상대가치(주3)</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항없음</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">해당사항없음</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>바. 합병가액/1주(주4)</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">22,693 </TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">30,949 </TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">

<TD WIDTH="225" HEIGHT="30">
<P>사. 합병비율</P>
</TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1 </TD>
<TD WIDTH="224" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30">1.363813 </TD>
</TR>
</TBODY>
</TABLE>
<P USERMARK="F-11">(주1) '자본시장과금융투자업에관한법률시행령 제176조의5'에 의하여 주권상장법인인 합병법인의 기준주가를 산정하고, 주권비상장법인인 피합병법인의 기준주가는 주권비상장법인이므로 산정하지 아니하였습니다. </P>
<P USERMARK="F-11">(주2) '증권의발행및공시등에관한규정 시행세칙 제4조 내지 제6조'에 따라 자산가치와 수익가치를 각각 1과 1.5의 비율로 가중산술평균한 가액으로 산정하였습니다. </P>
<P USERMARK="F-11">(주3) 주권비상장법인인 피합병법인의 유사회사 선정기준을 충족시키는 유사한 주권상장법인이 없으므로 상대가치를 산정하지 아니합니다.&cr;(주4) '자본시장과금융투자업에관한법률시행령 제176조의5'에 의하여 주권상장법인인 합병법인의 합병가액은 기준주가로 산정하고, 주권비상장법인인 피합병법인의 합병가액은 본질가치로 산정하였습니다.&cr;</P>
<P>6) 합병으로 인하여 발행하는 신주의 종류 및 수</P>
<P>- 피합병법인 주주에게 교부할 주식의 총수는 1,363,813주입니다.</P>
<P></P>
<P>7) 합병교부금</P>
<P>- 별도의 합병교부금 없습니다.</P>
<P>&cr;8) 합병일정</P>
<P>(1) 합병계약일: 2015년 10월 1일</P>
<P>(2) 합병승인주주총회일: 2015년 11월 16일</P>
<P>(3) 합병기일: 2015년 12월 21일</P>
<P>(4) 합병등기일: 2015년12월21일</P>
<P></P>
<P>9) 채권자보호절차</P>
<P>(1) 채권자이의제출 시작일: 2015년11월17일</P>
<P>(2) 채권자이의제출 종료일: 2015년12월18일&cr;</P>
<P>10) 신주권 교부 및 상장일</P>
<P>(1) 신주권 교부일 : 2015년 12월 29일</P>

<P>(2) 신주권 상장일 : 2015년 12월 30일&cr;&cr;11
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN></SPAN>
<SPAN>) 합병 등 전후의 재무사항 비교표</SPAN>
</P>

<INSERTION ABASISNUMBER="LE0" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『합병등 전후의 재무사항 비교표』 삽입</COMMENT>
<LIBRARYLIST>11011#*합병등전후의재무사항비교표.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">15_합병등전후의재무사항비교표</FILENAME>
<P>합병등 전후의 재무사항 비교표</P>
<P>* 합병등(합병, 중요한 영업ㆍ자산양수도, 주식의 포괄적교환ㆍ이전, 분할)</P>

<TABLE-GROUP ACLASS="MGR_FIC" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="722" BORDER="0">

<COLGROUP>
<COL WIDTH="352"></COL>
<COL WIDTH="352"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="BOTTOM" WIDTH="361" HEIGHT="30" AUPDATECONT="N"></TD>
<TU ALIGN="RIGHT" VALIGN="BOTTOM" WIDTH="361" HEIGHT="30" AUNIT="WON" AUNITVALUE="3">(단위 : 백만원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="721" BORDER="1">

<COLGROUP>
<COL WIDTH="80"></COL>
<COL WIDTH="81"></COL>
<COL WIDTH="65"></COL>
<COL WIDTH="60"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="70"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="69"></COL>
<COL WIDTH="76"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="89" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" ROWSPAN="3">대상회사</TH>
<TH WIDTH="90" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" ROWSPAN="3">계정과목</TH>
<TH WIDTH="143" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">예측</TH>
<TH WIDTH="314" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="4">실적</TH>
<TH WIDTH="85" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="90" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" ROWSPAN="3">비고</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="74" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" ROWSPAN="2">1차연도</TH>
<TH WIDTH="69" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="60" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" ROWSPAN="2">2차연도</TH>
<TH WIDTH="158" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">1차연도</TH>
<TH WIDTH="156" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" COLSPAN="2">2차연도</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">실적</TH>
<TH WIDTH="79" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">괴리율</TH>
<TH WIDTH="78" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">실적</TH>
<TH WIDTH="78" VALIGN="MIDDLE" AUPDATECONT="N" ALIGN="CENTER" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N">괴리율</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TE WIDTH="89" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="90" ACODE="MGR_FIC_CMY" ROWSPAN="3">(주)칸메드</TE>
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">매출액</TD>
<TE WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_PR1">20,306</TE>
<TE WIDTH="69" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_PR2">28,246</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_AT1">16,101 </TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_RT1">-21</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_AT2">18,813</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_SAL_RT2">-33</TE>
<TE WIDTH="85" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">영업이익</TD>
<TE WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_PR1">3,257</TE>
<TE WIDTH="69" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_PR2">4,714</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_AT1">684 </TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_RT1">-79</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_AT2">316</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_BUS_RT2">-93</TE>
<TE WIDTH="85" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE1">-</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD WIDTH="90" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" AUPDATECONT="N">당기순이익</TD>
<TE WIDTH="74" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_PR1">2,563</TE>
<TE WIDTH="69" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_PR2">3,699</TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_AT1">682 </TE>
<TE WIDTH="79" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_RT1">-73</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_AT2">284</TE>
<TE WIDTH="78" VALIGN="MIDDLE" ALIGN="RIGHT" HEIGHT="30" ACODE="MGR_PRO_RT2">-92</TE>
<TE WIDTH="85" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" ACODE="NOTE2">-</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
<P>주1) 1차연도(2016년말)와 2차연도(2017년말) 예측치는, 2015년 10월1일자 공시 주요사항보고서(합병결정)에 첨부된 외부평가기관의 평가의견서 내용 중 [수익가치세부추정내역〕을 참고하였습니다. 2015년 12월 21일자(합병등기일)로 합병을 완료하여 1차연도는 2016년말, 2차연도는 2017년말을 기준으로 하였습니다.&cr;주2) 1차연도(2016년 12월 31일) 매출액의 괴리율에 대한 원인을 유형별로 분석하면 다음과 같습니다.</P>
<P></P>

<TABLE ACLASS="NORMAL" WIDTH="617" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="608"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="617" HEIGHT="30" USERMARK="F-BT">( 단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="620">

<COLGROUP>
<COL WIDTH="233"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="75"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="242" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT">구분</TH>
<TH COLSPAN="4" WIDTH="378" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">2016년</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">예측</TH>
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">실적</TH>
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">괴리율</TH>
<TH WIDTH="84" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비 고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">나누리병원 향 의료기기  </TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">11,680</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">14,387</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">23%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">의약품</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">7,408</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">967</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-87%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">척추 관련 MASS제품</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">317</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">439</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">39%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="34" USERMARK="F-BT">RF 카테터</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="34" USERMARK="F-BT">110</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="34" USERMARK="F-BT">-　</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="34" USERMARK="F-BT">-100%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="34" USERMARK="F-BT">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">지혈제</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">585</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-7</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-101%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주5)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">기타매출</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">207</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">315</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">53%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주6)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT" ALIGN="CENTER">합계</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">20,306</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">16,101</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-21%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11"></SPAN>
<SPAN USERMARK="F-11">주</SPAN>
<SPAN USERMARK="F-11">1) 나누리병원 향 의료기기 : 나누리병원의 전체적인 매출 확대와 주안병원의&cr;                                            조기 안정으로 매출실적이 23% 증가함.&cr;주2) 의약품 : 전문의약품 및 일반의약품에 대한 매출로, 초기 타사 상품 도입을 통한 매출에서 자사 생산 변경에 따른 매출 지연으로 감소 하였음.</SPAN>
<SPAN USERMARK="F-11"> </SPAN>
<SPAN USERMARK="F-11">자회사인 레고켐 제약의 리노베이션 및 생산개시 시점이 당초 예상보다 지연되어 계획에 차질이 생겼으나, 2017년부터는 가동율이 제고 되면서 매출과 손익이 개선될 것임.</SPAN>
<SPAN USERMARK="F-11"> 또한 수탁사업도 활발히 진행되고 </SPAN>
<SPAN USERMARK="F-11">있음.</SPAN>
</P>

<P>
<SPAN USERMARK="F-11">주3) 척추 관련 MASS제품 : 백조이(상품명)의 홈쇼핑 및 백화점 판매 등으로 39% 증가됨.&cr;주4) RF 카테터: 의료기기 자사 허가를 통한 시장 진입을 준비 하였으나, RF카테터 시장                          악화로 잠정 보류 상태임. &cr;주5) 지혈제 : &cr;      - 16년 식약처의 정책 변화를 기대하고 사업 진입을 준비 하였으나 예상 보다 정책             변화 시점이 지연되고 있는 상황임&cr;      - 16년 12월 제네웰사의 신제품에 대한 판권을 취득하였고 2017년 2분기 부터&cr;        본격적인 판매가 시작 될 것임&cr;      -  17년 하반기 기존 산정 불가 였던 의료기기 지혈제의 별도 산정이 예상되며,&cr;         이에 따른 당사의 전략 변화도 진행 중임&cr;주6) 기타매출 : </SPAN>
<SPAN USERMARK="F-11">기존 계획대비 53% 증가함.&cr;</SPAN>
<SPAN USERMARK="F-11">      </SPAN>
<SPAN USERMARK="F-11">- 엘티몰의 경우 용역 계약에 따른 판매 수수료 매출 전략에서 자사 허가 제품</SPAN>
<SPAN USERMARK="F-11"> 판매를        통한 매출로 변경 되었고 해당 제품의 매출은 의약품 매출에 포함되어 있음&cr;       -16년 신규 판매를 진행한 하이배리(의료기기 나누리 외 판매)의 매출이 확대 됨.&cr;</SPAN>
</P>
<P>주3) 2차연도(2017년 12월 31일) 매출액의 괴리율에 대한 원인을&cr;      유형별로 분석하면 다음과 같습니다.</P>

<TABLE ACLASS="NORMAL" WIDTH="617" BORDER="0" AFIXTABLE="N">

<COLGROUP>
<COL WIDTH="608"></COL>
</COLGROUP>

<TBODY ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TD ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="617" HEIGHT="30" USERMARK="F-BT">( 단위 : 백만원)</TD>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="NORMAL" AFIXTABLE="N" BORDER="1" WIDTH="620">

<COLGROUP>
<COL WIDTH="233"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="89"></COL>
<COL WIDTH="75"></COL>
</COLGROUP>

<THEAD ALIGN="LEFT" VALIGN="TOP">

<TR ACOPY="Y" ADELETE="Y">
<TH ROWSPAN="2" WIDTH="242" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="60" USERMARK="F-BT">구분</TH>
<TH COLSPAN="4" WIDTH="378" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">2017년</TH>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">예측</TH>
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">실적</TH>
<TH WIDTH="98" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">괴리율</TH>
<TH WIDTH="84" VALIGN="MIDDLE" ACOPYCOL="Y" ADELETECOL="Y" AMOVECOL="N" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">비 고</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">나누리병원 향 의료기기  </TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">13,863</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">15,203</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">10%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주1)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">의약품</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">12,630</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">2,815</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-78%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주2)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">척추 관련 MASS제품</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">586</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-5</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-101%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주3)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">RF 카테터</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">251</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-100%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주4)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">지혈제</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">674</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">101</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-85%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주5)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT">기타매출</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">238</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">699</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">194%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">주6)</TD>
</TR>

<TR ACOPY="Y" ADELETE="Y">
<TD WIDTH="242" VALIGN="MIDDLE" HEIGHT="30" USERMARK="F-BT" ALIGN="CENTER">합계</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">28,246</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">18,813</TD>
<TD WIDTH="98" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT">-33%</TD>
<TD WIDTH="84" VALIGN="MIDDLE" ALIGN="CENTER" HEIGHT="30" USERMARK="F-BT"></TD>
</TR>
</TBODY>
</TABLE>

<P>
<SPAN USERMARK="F-11">주</SPAN>
<SPAN USERMARK="F-11">1) 나누리병원 향 의료기기 : </SPAN>
<SPAN USERMARK="F-11">나누리병원 및 의료재단의 전체적인 매출 확대로 매출실적이 증가함.&cr;</SPAN>
<SPAN USERMARK="F-11">주2) 의약품 : 전문의약품 및 일반의약품에 대한 매출로, </SPAN>
<SPAN USERMARK="F-11">16년 하반기부터 신제품 허가 등록 및 본격적인 생산라인 가동하에 매출이 증가 하고 있으나 시장 경쟁 상황 악화로 인해 계획대비 실적이 저조한 상황임.&cr;</SPAN>
<SPAN USERMARK="F-11">주3) 척추 관련 MASS제품 : </SPAN>
<SPAN USERMARK="F-11">백조이(브랜드명)제</SPAN>
<SPAN USERMARK="F-11">품의 경쟁 심화 및 사업성 악화로 사업 철수 하였음&cr;</SPAN>
<SPAN USERMARK="F-11">주4) RF 카테터: 의료기기 자사 허가를 통한 시장 진입을 준비 하였으나, RF카테터 시장                          악화로 잠정 보류 상태임. &cr;주5) 지혈제 : &cr;      - 16년 식약처의 정책 변화를 기대하고 사업 진입을 준비 하였으나 예상 보다 정책             변화 시점이 지연되고 있는 상황임&cr;      - 16년 12월 제네웰사의 신제품에 대한 판권을 취득하였고 2017년 2분기 부터&cr;       </SPAN>
<SPAN USERMARK="F-11"> 판매가 시작 되었으며, 2018년 안정적인 매출 궤도에 진입할 것으로 판단됨&cr;</SPAN>
<SPAN USERMARK="F-11">     </SPAN>
<SPAN USERMARK="F-11"> - 18년 하반기 기존 산정 불가 였던 자사 판권보유 의료기기 지혈제의 별도 산정이 &cr;        예상되며, 이에 따른 당사의 전략 변화도 진행 중임&cr;주6) 기타매출 : &cr;</SPAN>
<SPAN USERMARK="F-11">      - 신규 판매를 진행한 의료기기 등의 매출이 확대 되었음.&cr;      - 의약품 포장수탁 용역매출이 증대 되었음.&cr;</SPAN>
<SPAN USERMARK="F-11">      - 엘티몰의 경우 용역 계약에 따른 판매 수수료 매출 전략에서 자사 허가 제품 판매를&cr;        통한 매출로 변경 되었고 해당 제품(레티몰)의 매출은 의약품 매출에 포함되어 있음&cr;&cr;</SPAN>
<SPAN USERMARK=" B">5. 보호예수 현황&cr;</SPAN>
<SPAN USERMARK=" B"> </SPAN>
<SPAN>- 해당 사항이 없습니다.</SPAN>
<SPAN USERMARK=" B"></SPAN>
</P>
</LIBRARY>
</INSERTION>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="0" ADUPLICATION="Y">
<COMMENT>◆click◆『보호예수 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*보호예수현황.dsl</LIBRARYLIST>
</INSERTION>
<P></P>

<INSERTION ABASISNUMBER="SE1" AFREQUENCY="1" ADUPLICATION="Y">
<COMMENT>◆click◆『특례상장기업 관리종목 지정유예 현황』 삽입</COMMENT>
<LIBRARYLIST>11011#*특례상장기업관리종목지정유예현황.dsl</LIBRARYLIST>

<LIBRARY>
<FILENAME ATYPE="dsl">52_특례상장기업관리종목지정유예현황</FILENAME>
<P>특례상장기업 관리종목 지정유예 현황</P>

<TABLE-GROUP ACLASS="SPE_MAG" ADELETETABLE="N">

<TABLE ACLASS="EXTRACTION" AFIXTABLE="Y" WIDTH="711" BORDER="0">

<COLGROUP>
<COL WIDTH="70"></COL>
<COL WIDTH="142"></COL>
<COL WIDTH="58"></COL>
<COL WIDTH="405"></COL>
</COLGROUP>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD VALIGN="MIDDLE" WIDTH="79" HEIGHT="30" AUPDATECONT="N">(기준일 : </TD>
<TU ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="151" HEIGHT="30" AUNIT="BASE_DT" AUNITVALUE="20201231">2020년 12월 31일</TU>
<TD VALIGN="MIDDLE" WIDTH="67" HEIGHT="30" AUPDATECONT="N">)</TD>
<TU ALIGN="RIGHT" VALIGN="MIDDLE" WIDTH="414" HEIGHT="30" AUNIT="WON" AUNITVALUE="1">(단위 : 원)</TU>
</TR>
</TBODY>
</TABLE>

<TABLE ACLASS="EXTRACTION" AFIXTABLE="N" WIDTH="711" BORDER="1" FRAME="BORDER" RULES="ALL">

<COLGROUP>
<COL WIDTH="154"></COL>
<COL WIDTH="116"></COL>
<COL WIDTH="90"></COL>
<COL WIDTH="114"></COL>
<COL WIDTH="42"></COL>
<COL WIDTH="46"></COL>
<COL WIDTH="86"></COL>
</COLGROUP>

<THEAD>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="163" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">관리종목 지정요건</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="347" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="3">요건별 회사 현황</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="106" HEIGHT="53" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" COLSPAN="2">관리종목&cr;지정유예 여부</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="95" HEIGHT="83" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N" ROWSPAN="2">항목별&cr;지정유예 &cr;종료시점</TH>
</TR>

<TR ACOPY="N" ADELETE="N">
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="125" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">항목</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="99" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">사업연도</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="123" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">금액</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="51" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">해당</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE" WIDTH="55" HEIGHT="30" ACOPYCOL="N" ADELETECOL="N" AMOVECOL="N" AUPDATECONT="N">미해당</TH>
</TR>
</THEAD>

<TBODY>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="53" VALIGN="MIDDLE" AUPDATECONT="N">최근 사업연도말&cr;매출액 30억미만</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="53" VALIGN="MIDDLE" AUPDATECONT="N">최근 사업연도말 매출액(별도)</TD>
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="53" ACODE="SPE_LAT_YER" VALIGN="MIDDLE">2020</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="53" ACODE="SPE_LAT_AMO" VALIGN="MIDDLE">49,393,701,591</TE>
<TE ALIGN="CENTER" WIDTH="51" HEIGHT="53" ACODE="SPE_LAT_ISY" VALIGN="MIDDLE">-</TE>
<TE ALIGN="CENTER" WIDTH="55" HEIGHT="53" ACODE="SPE_LAT_ISN" VALIGN="MIDDLE">O</TE>
<TU ALIGN="CENTER" WIDTH="95" HEIGHT="53" AUNIT="SPE_LAT_OFF" AUNITVALUE="20151231" VALIGN="MIDDLE">2015년 12월 31일</TU>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="120" VALIGN="MIDDLE" AUPDATECONT="N" ROWSPAN="4">최근 4사업연도 연속 영업손실 발생</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="120" VALIGN="MIDDLE" AUPDATECONT="N" ROWSPAN="4">최근 4사업연도 &cr;각 영업손익&cr;(별도)</TD>
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="30" ACODE="SPE_FOR_YER1" VALIGN="MIDDLE">2020</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="30" ACODE="SPE_FOR_AMO1" VALIGN="MIDDLE">-29,761,761,146</TE>
<TE ALIGN="CENTER" WIDTH="51" HEIGHT="120" ACODE="SPE_FOR_ISY" VALIGN="MIDDLE" ROWSPAN="4">-</TE>
<TE ALIGN="CENTER" WIDTH="55" HEIGHT="120" ACODE="SPE_FOR_ISN" VALIGN="MIDDLE" ROWSPAN="4">O</TE>
<TU ALIGN="CENTER" WIDTH="95" HEIGHT="120" AUNIT="SPE_FOR_OFF" AUNITVALUE="-" VALIGN="MIDDLE" ROWSPAN="4">-</TU>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="30" ACODE="SPE_FOR_YER2" VALIGN="MIDDLE">2019</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="30" ACODE="SPE_FOR_AMO2" VALIGN="MIDDLE">8,416,841,998</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="30" ACODE="SPE_FOR_YER3" VALIGN="MIDDLE">2018</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="30" ACODE="SPE_FOR_AMO3" VALIGN="MIDDLE">-15,977,963,887</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="30" ACODE="SPE_FOR_YER4" VALIGN="MIDDLE">2017</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="30" ACODE="SPE_FOR_AMO4" VALIGN="MIDDLE">-8,099,205,818</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TD ALIGN="CENTER" WIDTH="163" HEIGHT="168" VALIGN="MIDDLE" AUPDATECONT="N" ROWSPAN="3">자기자본 50%이상(10억원 이상에 한함)의 법인세차감전계속사업손실이 최근 3년간 2회 이상 및 최근 사업연도 법인세차감전계속사업손실 발생</TD>
<TD ALIGN="CENTER" WIDTH="125" HEIGHT="168" VALIGN="MIDDLE" AUPDATECONT="N" ROWSPAN="3">최근&cr;3사업연도&cr;각 법인세차감전&cr; 계속사업손익&cr;(연결)</TD>
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="45" ACODE="SPE_LOS_YER1" VALIGN="MIDDLE">2020</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="45" ACODE="SPE_LOS_AMO1" VALIGN="MIDDLE">-8,826,761,782</TE>
<TE ALIGN="CENTER" WIDTH="51" HEIGHT="168" ACODE="SPE_LOS_ISY" VALIGN="MIDDLE" ROWSPAN="3">-</TE>
<TE ALIGN="CENTER" WIDTH="55" HEIGHT="168" ACODE="SPE_LOS_ISN" VALIGN="MIDDLE" ROWSPAN="3">O</TE>
<TU ALIGN="CENTER" WIDTH="95" HEIGHT="168" AUNIT="SPE_LOS_OFF" AUNITVALUE="20151231" VALIGN="MIDDLE" ROWSPAN="3">2015년 12월 31일</TU>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="56" ACODE="SPE_LOS_YER2" VALIGN="MIDDLE">2019</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="56" ACODE="SPE_LOS_AMO2" VALIGN="MIDDLE">13,101,518,704</TE>
</TR>

<TR ACOPY="N" ADELETE="N">
<TE ALIGN="CENTER" WIDTH="99" HEIGHT="67" ACODE="SPE_LOS_YER3" VALIGN="MIDDLE">2018</TE>
<TE ALIGN="RIGHT" WIDTH="123" HEIGHT="67" ACODE="SPE_LOS_AMO3" VALIGN="MIDDLE">-26,426,772,928</TE>
</TR>
</TBODY>
</TABLE>
</TABLE-GROUP>
</LIBRARY>
</INSERTION>
<P></P>
<P></P>
<PGBRK></PGBRK>
</SECTION-1>

<SECTION-1 ACLASS="MANDATORY" APARTSOURCE="SOURCE">
<TITLE ATOC="Y">【 전문가의 확인 】</TITLE>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-3-0-1-0">1. 전문가의 확인</TITLE>
<P>해당사항 없음.&cr;</P>
</SECTION-2>

<SECTION-2 ACLASS="MANDATORY">
<TITLE ATOC="Y" AASSOCNOTE="D-3-0-2-0">2. 전문가와의 이해관계</TITLE>
<P>해당사항 없음.&cr;</P>
</SECTION-2>
</SECTION-1>
</BODY>
</DOCUMENT>